

000137479-24-03502710-Q FITLIFE BRANDS, INC. 2024111420241114073026073026073026 0 000137479-24-035027 10-Q 59 20240930 20241114 20241114 FITLIFE BRANDS, INC. 0001374328 2833 0000000000 NV 1231 10-Q 34 001-41803 24145702 5214 S. 136TH STREET OMAHA NE 68137 402-884-1894 5214 S. 136TH STREET OMAHA NE 68137 BOND LABORATORIES, INC. 200606831 10-Q 1 flf20240930 10q.htm FORM 10-Q flf20240930 10q.htm Q3 2024 -12-31 false 0001374328 False False False 0 0 0 0 http://fasb.org/us-gaap/2024#SecuredOvernightFinancingRateSoftMember 2 1 1 0 0 00013743282024-01-012024-09-30 thunderdome:item iso4217:USD 0001374328flf:AssetsOfMusclepharmCorporationMember2023-10-10 0001374328flf:AssetsOfMusclepharmCorporationMember2023-10-102023-10-10 0001374328flf:AssetsOfMusclepharmCorporationMember2023-10-10 0001374328flf:AssetsOfMusclepharmCorporationMember2023-10-102023-10-10 0001374328flf:MimisRockCorpMember2023-01-012023-09-30 0001374328flf:MimisRockCorpMember2024-01-012024-09-30 0001374328flf:MimisRockCorpMember2023-07-012023-09-30 0001374328flf:MimisRockCorpMember2024-07-012024-09-30 iso4217:USDxbrli:shares 0001374328flf:MimisRockCorpMember2023-02-28 0001374328flf:MimisRockCorpMember2023-02-282023-02-28 00013743282024-09-30 0001374328us-gaap:EmployeeStockOptionMember2023-01-012023-09-30 0001374328us-gaap:EmployeeStockOptionMember2024-01-012024-09-30 0001374328us-gaap:EmployeeStockOptionMember2023-07-012023-09-30 0001374328us-gaap:EmployeeStockOptionMember2024-07-012024-09-30 xbrli:pure 0001374328us-gaap:EmployeeStockOptionMember2024-08-012024-08-31 utr:Y 00013743282024-08-012024-08-31 00013743282024-08-31 xbrli:shares 0001374328flf:RangeTwoMember2024-09-30 0001374328flf:RangeOneMember2024-09-30 0001374328flf:RangeOneMember2024-01-012024-09-30 00013743282023-01-012023-12-31 00013743282023-12-31 0001374328flf:ShareRepurchaseProgramMember2024-09-30 0001374328flf:ShareRepurchaseProgramMember2024-01-012024-06-03 0001374328flf:ShareRepurchaseProgramMember2023-01-012023-09-30 utr:M 0001374328flf:ShareRepurchaseProgramMember2023-03-172023-03-17 0001374328flf:ShareRepurchaseProgramMember2023-03-17 0001374328us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-09-30 0001374328us-gaap:RestrictedStockUnitsRSUMember2023-07-012023-09-30 00013743282021-02-012021-02-28 0001374328us-gaap:RevolvingCreditFacilityMember2023-12-31 0001374328flf:TermLoanMember2023-12-31 0001374328flf:TermLoanMember2024-09-30 0001374328flf:TermLoansMember2023-10-10 0001374328flf:TermLoanMember2023-10-10 0001374328us-gaap:RevolvingCreditFacilityMember2023-02-232023-02-23 0001374328flf:TermLoanMember2024-01-012024-03-31 0001374328flf:TermLoanBMember2023-10-102023-10-10 0001374328flf:TermLoanAMember2023-10-102023-10-10 00013743282023-10-102023-10-10 0001374328flf:TermLoansMember2023-10-102023-10-10 0001374328flf:TermLoanBMember2023-12-31 0001374328flf:TermLoanBMember2024-09-30 0001374328flf:TermLoanAMember2023-12-31 0001374328flf:TermLoanAMember2024-09-30 00013743282023-01-012023-09-30 00013743282023-07-012023-09-30 00013743282024-07-012024-09-30 0001374328srt:MaximumMember2024-09-30 0001374328srt:MinimumMember2024-09-30 0001374328us-gaap:AssetPledgedAsCollateralMemberflf:FinancingArrangementsMember2024-09-30 0001374328flf:InventoryrelatedPurchasesMemberus-gaap:SupplierConcentrationRiskMemberflf:VendorTwoMember2024-01-012024-09-30 0001374328flf:InventoryrelatedPurchasesMemberus-gaap:SupplierConcentrationRiskMemberflf:VendorOneMember2023-01-012023-12-31 0001374328flf:InventoryrelatedPurchasesMemberus-gaap:SupplierConcentrationRiskMemberflf:TwoVendorsMember2024-01-012024-09-30 0001374328flf:InventoryrelatedPurchasesMemberus-gaap:SupplierConcentrationRiskMemberflf:TwoVendorsMember2023-01-012023-09-30 0001374328us-gaap:AccountsPayableMemberus-gaap:SupplierConcentrationRiskMemberflf:VendorOneMember2024-01-012024-09-30 0001374328us-gaap:AccountsPayableMemberus-gaap:SupplierConcentrationRiskMemberflf:VendorTwoMember2023-01-012023-12-31 0001374328us-gaap:AccountsPayableMemberus-gaap:CustomerConcentrationRiskMemberflf:OneVendorMember2023-01-012023-12-31 0001374328us-gaap:AccountsPayableMemberus-gaap:CustomerConcentrationRiskMemberflf:OneVendorMember2024-01-012024-09-30 0001374328us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberflf:GNCMember2023-01-012023-12-31 0001374328us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberflf:GNCMember2024-01-012024-09-30 0001374328us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberflf:GNCMember2023-01-012023-09-30 0001374328us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberflf:GNCMember2024-01-012024-09-30 0001374328us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberflf:GNCMember2023-07-012023-09-30 0001374328us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberflf:GNCMember2024-07-012024-09-30 0001374328flf:MusclePharmMember2024-01-012024-09-30 0001374328flf:MusclePharmMember2024-07-012024-09-30 0001374328flf:MRCMember2023-01-012023-09-30 0001374328flf:MRCMember2024-01-012024-09-30 0001374328flf:MRCMember2023-07-012023-09-30 0001374328flf:MRCMember2024-07-012024-09-30 0001374328flf:LegacyFitLifeMember2023-01-012023-09-30 0001374328flf:LegacyFitLifeMember2024-01-012024-09-30 0001374328flf:LegacyFitLifeMember2023-07-012023-09-30 0001374328flf:LegacyFitLifeMember2024-07-012024-09-30 0001374328us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMembercountry:US2023-01-012023-09-30 0001374328us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMembercountry:US2024-01-012024-09-30 0001374328us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMembercountry:US2023-07-012023-09-30 0001374328us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMembercountry:US2024-07-012024-09-30 0001374328us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberflf:WholesaleSalesMember2023-01-012023-09-30 0001374328us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberflf:WholesaleSalesMember2024-01-012024-09-30 0001374328us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberflf:OnlineSalesMember2023-01-012023-09-30 0001374328us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberflf:OnlineSalesMember2024-01-012024-09-30 0001374328us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberflf:WholesaleSalesMember2024-07-012024-09-30 0001374328us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberflf:WholesaleSalesMember2023-07-012023-09-30 0001374328us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberflf:OnlineSalesMember2023-07-012023-09-30 0001374328us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberflf:OnlineSalesMember2024-07-012024-09-30 0001374328us-gaap:SeriesAPreferredStockMember2024-09-30 00013743282023-09-3

FITLIFE BRANDS, INC.'S CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2024 AND 2023 (In thousands, except per share data) (Unaudited)

	Three months ended September 30, 2024	Nine months ended September 30, 2024	Three months ended September 30, 2023	Nine months ended September 30, 2023
Revenue	\$15,977	\$49,456	\$39,401	\$119,444
Cost of goods sold	(8,976)	(27,588)	(8,206)	(25,588)
Gross profit	7,001	21,868	16,069	49,456
Advertising and marketing	(1,093)	(3,647)	(3,359)	(10,341)
Selling, general and administrative	(2,645)	(8,187)	(2,645)	(8,187)
Depreciation and amortization	(22)	(85)	(64)	(248)
Total operating expense	(3,819)	(11,920)	(3,819)	(11,920)
Operating income	3,182	9,948	3,182	9,948
Other expense (income)	(19)	(119)	(41)	(269)
Interest income	(19)	(119)	(41)	(269)
Interest expense	326	249	326	249
Foreign exchange (gain) loss	(21)	(26)	93	286
Total other expense, net	286	340	1,018	422
Income before income tax provision	2,896	9,220	5,306	17,176
Income tax provision	(213)	(614)	(213)	(614)
Net income	\$2,126	\$6,914	\$5,093	\$16,562
Basic weighted average common shares	4,598	14,446	4,598	14,446
Diluted weighted average common shares	4,943	14,901	4,943	14,901
Basic earnings per share	\$0.46	\$0.48	\$1.11	\$1.15
Diluted earnings per share	\$0.43	\$0.46	\$1.03	\$1.11
Comprehensive income	\$2,126	\$6,914	\$5,093	\$16,562
Foreign currency translation adjustment	35	(318)	(136)	(49)
Comprehensive income	\$2,161	\$6,778	\$4,957	\$16,513

The accompanying notes are an integral part of these condensed consolidated financial statements.

-2- A FITLIFE BRANDS, INC. CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2024 AND 2023 (In thousands) (Unaudited)

	Common Stock	Additional paid-in	Retained earnings	Total
Balance at January 1, 2024	4,598	\$46	\$3,104	\$3,194
Net income	2,126	-	6,914	9,040
Stock-based compensation	21	-	21	42
Foreign currency translation adjustment	35	-	(318)	(283)
Balance at September 30, 2024	6,780	\$46	\$10,012	\$16,838
Balance at January 1, 2023	4,598	\$46	\$3,104	\$3,194
Net income	5,093	-	16,562	21,655
Stock-based compensation	21	-	21	42
Foreign currency translation adjustment	35	-	(49)	(14)
Balance at September 30, 2023	9,747	\$46	\$19,628	\$29,419

NOTE 1 - DESCRIPTION OF BUSINESS Summary FitLife Brands, Inc. (the "Company") is a provider of innovative and proprietary nutritional supplements and wellness products for health-conscious consumers marketed under the following brand names: (i) NDS Nutrition, PMR Sports, SirenLabs, Core Active, Nutrology, and Metis Nutrition (together, "NDS Products"); (ii) iSatori, BioGenetics Laboratories, and Energize (together, the "iSatori Products"); (iii) Dr. Tobias, All Natural Advice, and Maritime Naturals (together, the "MRC Products"); and (iv) MusclePharm. The Company distributes the NDS Products principally through franchised General Nutrition Centers, Inc. ("GNC") stores located both domestically and internationally and, with the launch of Metis Nutrition, through corporate GNC stores in the U.S. The iSatori Products are sold through retail locations, which include specialty and mass, as well as online directly to the end consumer. The Company distributes the MRC Products primarily online through e-commerce platforms, such as Amazon, directly to the end consumer. MusclePharm's products are sold to both wholesale customers as well as online through various e-commerce platforms directly to the end consumer. A FitLife Brands is headquartered in Omaha, Nebraska. For more information on the Company, please go to www.fitlifebands.com. The Company's common stock, par value \$0.01 per share ("Common Stock"), trades under the symbol "FITLF" on the Nasdaq Capital Market.

NOTE 2 - BASIS OF PRESENTATION The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation are included. Operating results for the three- and nine-month periods ended September 30, 2024 are not necessarily indicative of the results that may be expected for the year ending December 31, 2024. Although management of the Company believes the disclosures presented herein are adequate and not misleading, these interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the footnotes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Securities and Exchange Commission (the "SEC") on March 29, 2024.

NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The Company prepares its financial statements in accordance with accounting principles generally accepted in the U.S. ("GAAP"). Significant accounting policies are as follows:

- A Principles of Consolidation The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. Intercompany accounts and transactions have been eliminated in the condensed consolidated financial statements.
- A Foreign Currency Translation The functional currency of the Company is the U.S. dollar ("USD"). The functional currency of the Company's Canadian subsidiaries is the Canadian dollar ("CAD"). The assets and liabilities of the Company's foreign subsidiaries are translated into U.S. dollars using end-of-period exchange rates. Changes in reported amounts of assets and liabilities of foreign subsidiaries that occur as a result of changes in exchange rates between foreign subsidiaries' functional currencies and the U.S. dollar are included in foreign currency translation adjustment. Foreign currency translation adjustment is included as a component of stockholders' equity in the accompanying condensed consolidated balance sheets. Revenue and expense transactions use an average rate prevailing during the period of the related transaction. Transaction gains and losses that arise from exchange rate fluctuations denominated in a currency other than the functional currency of each subsidiary are included in the results of operations as incurred.
- A Use of Estimates and Assumptions The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect (i) the reported amounts of assets and liabilities, (ii) the disclosure of contingent assets and liabilities known to exist as of the date the financial statements are published, and (iii) the reported amount of net sales and expense recognized during the periods presented. Those estimates and assumptions include estimates for reserves of uncollectible accounts receivable, allowance for inventory obsolescence, product returns, depreciable lives of property and equipment, allocation of purchase price from business combinations, analysis of impairment of goodwill, realization of deferred tax assets, accruals for potential liabilities and assumptions made in valuing stock instruments issued for services. Management evaluates these estimates and assumptions on a regular basis. Actual results could differ from those estimates.
- A Revenue Recognition The Company's revenue is comprised of sales of nutritional supplements and wellness products to consumers. The Company accounts for revenue in accordance with FASB ASC 606, Revenue from Contracts with Customers ("ASC 606"). The underlying principle of ASC 606 is to recognize revenue to depict the transfer of goods or services to customers at the amount expected to be collected. ASC 606 creates a five-step model that requires entities to exercise judgment when considering the terms of contract(s), which includes (1) identifying the contract(s) or agreement(s) with a customer, (2) identifying our performance obligations in the contract or agreement, (3) determining the transaction price, (4) allocating the transaction price to the separate performance obligations, and (5) recognizing revenue as each performance obligation is satisfied. Under ASC 606, revenue is recognized when performance obligations under the terms of a contract are satisfied, which occurs for the Company upon shipment or delivery of products to our customers based on written sales terms. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring the products to a customer. All products sold by the Company are distinct individual products and consist of nutritional supplements and wellness products. The products are offered for sale solely as finished goods, and there are no performance obligations required post-shipment for customers to derive the expected value from them. The Company's products are also sold on e-commerce platforms including Amazon. For these transactions, the Company evaluated principal versus agent considerations to determine appropriateness of recording distribution and platform fees paid to third-party e-commerce companies as an expense or as a reduction of revenue. The Company records distribution and platform fees to cost of goods sold in the condensed consolidated statements of income and comprehensive income. Distribution and platform fees are not recorded as a reduction of revenue because the Company (1) owns the goods before they are transferred to the customer, (2) can direct Amazon, similar to other third-party logistics providers ("Logistic Providers"), to return the Company's inventory to any location specified by the Company, (3) has the responsibility to make customers whole following any returns made by customers directly to Logistic Providers and the Company retains the back-end inventory risk, (4) is subject to credit risk (i.e., credit card chargebacks), (5) establishes prices of its products, (6) can determine who fulfills the goods to the customer (Amazon or the Company) and (7) can limit quantities or stop selling the goods at any time. Based on these considerations, the Company is the principal in this arrangement. Advertising fees paid to Amazon are recorded in advertising and marketing expense in the condensed consolidated statements of income and comprehensive income. The Company disaggregates revenue into distribution channels, geographical regions, and collections of brands (Legacy FitLife and recently acquired brands). The Company determines that disaggregating revenue into these categories achieves the disclosure objective to depict how the nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factors. A Online revenue during the three months ended September 30, 2024 and 2023 was approximately 68% of net revenue for both periods, compared to 32% for the wholesale channel for the same periods. Online revenue during the nine months ended September 30, 2024 and 2023 was approximately 66% and 62% of net revenue, compared to 34% and 38% for the wholesale channel for the same period.
- A Sales to customers in the U.S. were approximately 95% and 93% during the three months ended September 30, 2024 and 2023, respectively, with the balance of sales for the same respective periods being to customers primarily in Canada. Sales to customers in

[illegible]

\$ 4.57 Á Á -12- Á Á The closing stock price for the Companyâ€™s stock on September 30, 2024 was \$32.74, resulting in an intrinsic value of outstanding options of \$12,554. Á In August 2024, the Company granted stock options to purchase 10 shares of common stock to employees. The stock options are exercisable at \$33.20 per share. The stock options expire in five years and vest (i) one fourth immediately on the date of grant, and (ii) in three equal annual installments thereafter. The total fair value of these options at grant date was approximately \$146, which was determined using a Black-Scholes option pricing model with the following assumptions: stock price of \$33.20 per share, expected term of 5 years, volatility of 45%, dividend rate of 0%, and risk-free interest rate of 3.38%. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of measurement corresponding with the expected term of the share option award. The expected term represents the weighted-average period of time that share option awards granted are expected to be outstanding giving consideration to vesting schedules and historical participant exercise behavior. The expected volatility is based upon historical volatility of the Companyâ€™s Common Stock. The expected dividend yield is based on the fact that the Company has not paid dividends in the past and does not expect to pay dividends in the future. Á During the three-month periods ended September 30, 2024 and 2023, the Company recognized stock-based compensation of \$141 and \$21, respectively, related to stock options. During the nine-month periods ended September 30, 2024 and 2023, the Company recognized stock-based compensation of \$344 and \$63, respectively, related to stock options. As of September 30, 2024 there is \$542 of unamortized stock-based compensation related to stock options. Á Á NOTE 8 â€” ACQUISITION OF MIMIÁ€™S ROCK CORP Á On February 28, 2023, the Company acquired all the equity interests of MimiÁ€™s Rock Corp. (“MRC”) for the purchase price of \$17,099. MRC is headquartered in Oakville, Ontario, Canada. Á The Company accounted for the acquisition as a business combination under ASC 805, Business CombinationsÁ (â€œASCÁ 805â€). Á As a result of the MRC acquisition, the Company recorded intangible assets â€” brands of \$7,630 and goodwill of \$12,764. The goodwill recognized is primarily attributable to anticipated synergies from future growth. The intangible assets, which consist of brands, is not amortized but will be tested for impairment on an annual basis. Goodwill is also not amortized but will be tested for impairment on an annual basis. Á The purchase was intended to augment and diversify the Companyâ€™s product offerings and lineup. Key factors that contributed to the recorded intangible assets and goodwill were the opportunity to complement existing operations of the Company and the opportunity to generate future synergies within the nutritional supplement and wellness business. Á Pro Forma Condensed Combined Financial Information (Unaudited, in thousands) Á The following presents the Companyâ€™s unaudited pro forma financial information for the nine months ended September 30, 2023, giving effect to the acquisition of MRC as if it had occurred at January 1, 2023. Included in the pro forma information are adjustments to (1) remove non-recurring transaction-related costs related to the acquisition of MRC,Á (2) remove the interest costs from MRCâ€™s debt prior to the closing of the acquisition, and (3) recognize interest expense based on the projected balance of the Term Loan Á for the respective periods presented for this pro forma. Á Á Nine months ended Á Á September 30, 2023 Á Á Á Á Revenue Á \$ 44,455 Á Á Á Á Net income Á \$ 5,419 Á Á Á Á Diluted net income per share Á \$ 1.09 Á Á The pro forma adjustments do not reflect adjustments for anticipated operating efficiencies that the Company expects to achieve as a result of this acquisition. The pro forma financial information is for informational purposes only and does not purport to present what the Companyâ€™s results would actually have been had the transaction actually occurred on the dates presented or to project the combined companyâ€™s results of operations or financial position for any future period. Á MRC revenue for the three months ended September 30, 2024 and 2023 was \$7,210 and \$7,202, respectively. MRC revenue for the nine months ended September 30, 2024 was \$22,164 and was \$17,468 for the period from February 28, 2023 (the acquisition date) to September 30, 2023. Á Á NOTE 9. ACQUISITION OF MUSCLEPHARM ASSETS Á On October 10, 2023, the Company acquired substantially all of the assets and assumed none of the liabilities other than de minimus cure costs relating to certain assumed contracts of MusclePharm through an asset purchase transaction under Section 363 of the U.S. Bankruptcy Code. Total consideration for the acquisition, including legal expense, amounted to \$18,788. Á The Company accounted for the transaction as an asset acquisition under Accounting Standards Codification (â€œASCÁ 805). The assets acquired consisted of indefinite life intellectual property â€” brands of \$18,593 and inventory of \$195. The intangible asset is not amortized and will be tested for impairment on an annual basis. Á -13- Á Á The Company accounted for the transaction as an asset acquisition under Á ASCÁ 805. The assets acquired consist of indefinite life intellectual property â€” brands with an estimated value of \$18,593 â€” and inventory of \$195. The intangible assets, which consist of brands, are not amortized but will be tested for impairment on an annual basis. Á Á NOTE 10 â€” COMMITMENTS AND CONTINGENCIES Á We currently are not involved in any litigation that we believe could have a material adverse effect on our financial condition or results of operations. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of the Company or any of its subsidiaries, threatened against or affecting the Company, our Common Stock, any of our subsidiaries or of the Companyâ€™s or our subsidiariesâ€™ officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect. Á Á NOTE 11 â€” SUBSEQUENT EVENTS Á The Company evaluated subsequent events for their potential impact on the condensed consolidated financial statements and disclosures through the date the condensed consolidated financial statements were issued and determined that no subsequent events occurred that were reasonably expected to impact the condensed consolidated financial statements presented herein. Á -14- Á Á Á Á ITEM 2.Á MANAGEMENTâ€™S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Á The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements and the related notes appearing elsewhere in this Quarterly Report on Form 10-Q (this “Quarterly Report”). This discussion and analysis may contain forward-looking statements based on assumptions about our future business. Unless otherwise stated, all dollar amounts are in thousands, except per share data. Á Overview Á FitLife Brands, Inc. (the “Company”) is a provider of innovative and proprietary nutritional supplements and wellness products for health-conscious consumers marketed under the following brand names: (i) NDS Nutrition, PMD Sports, SirenLabs, Core Active, Nutrology, and Metis Nutrition (together, “NDS Products”); (ii) iSatori, BioGenetic Laboratories, and Energize (together, the “iSatori Products”); (iii) Dr. Tobias, All Natural Advice, and Maritime Naturals (together, the “MRC Products”); and (iv) MusclePharm. Á The Company distributes the NDS Products principally through franchised General Nutrition Centers, Inc. (â€œGNC”) stores located both domestically and internationally and, with the launch of Metis Nutrition, through corporate GNC stores in the U.S. The iSatori Products are sold through retail locations, which include specialty, mass, and online. The Company distributes the MRC Products primarily online. MusclePharmâ€™s products are sold to wholesale customers as well as online directly to the end consumer. Á FitLife Brands is headquartered in Omaha, Nebraska. For more information on the Company, please go to www.fitlifebrands.com. The Companyâ€™s common stock, par value \$0.01 per share (â€œCommon Stock”), trades under the symbol Á FTLFÁ on the Nasdaq Capital Market. Á Recent Acquisitions Á Acquisition of MimiÁ€™s Rock Corp Á On December 4, 2022, the Company entered into an Arrangement Agreement with MimiÁ€™s Rock Corp. (â€œMRC”), pursuant to which the Company agreed to acquire MRC. On February 28, 2023, the Company completed the acquisition of MRC. Total consideration for the acquisition of MRC was \$17,099, of which \$12,500 was funded using proceeds from a term loan provided by First Citizens Bank with the remainder funded from the Companyâ€™s available cash. See Note 8 to the financial statements for additional disclosure regarding the acquisition of MRC. Á Acquisition of MusclePharm Assets Á On October 10, 2023, the Company acquired substantially all of the assets of MusclePharm Corporation (â€œMusclePharm”) through an asset purchase transaction under Section 363 of the U.S. Bankruptcy Code. The Company acquired substantially all of the assets and assumed none of the liabilities of MusclePharm other than de minimus cure costs relating to certain assumed contracts. Á Total consideration for the acquisition was approximately \$18,500. Á Of this amount, \$10,000 was funded using proceeds from a new term loan provided by First Citizens Bank, with the remainder funded from the Companyâ€™s available cash balances. See Note 9 for additional disclosure regarding the acquisition of the MusclePharm assets. Á -15- Á Á Results of Operations Á Comparison of the three months ended September 30, 2024 to the three months ended September 30, 2023 Á Á Three months ended Á Á Á Á Á Á Á Á September 30, 2024 Á Á September 30, 2023 Á Á Change (\$) Á Á Change (%) Á Á (Unaudited) Á Á Á Á Á Á Revenue Á \$ 15,977 Á Á \$ 13,902 Á Á \$ 2,075 Á Á 15 % Cost of goods sold Á \$ 8,976 Á Á \$ 8,206 Á Á \$ 770 Á Á 9 % Gross profit Á \$ 7,001 Á Á \$ 5,696 Á Á \$ 1,305 Á Á 23 % Gross margin Á Á 43.8 % Á Á 41.0 % Á Á n/m Á Á 2.8 % Advertising and marketing Á \$ 1,093 Á Á \$ 1,275 Á Á \$ (182) Á Á (14) % Selling, general and administrative (â€œSG&A”) Á \$ 2,645 Á Á \$ 1,897 Á Á \$ 748 Á Á 39 % Merger and acquisition related Á \$ 59 Á Á \$ 32 Á Á \$ 27 Á Á 84 % Depreciation and amortization Á \$ 22 Á Á \$ 22 Á Á \$ - Á Á - % Total operating expense Á \$ 3,819 Á Á \$ 3,226 Á Á \$ 593 Á Á 18 % Operating income Á \$ 3,182 Á Á \$ 2,470 Á Á \$ 712 Á Á 29 % Other expense (income), net Á \$ 286 Á Á \$ 340 Á Á \$ (54) Á Á (16) % Provision for income tax Á \$ 770 Á Á \$ 434 Á Á \$ 336 Á Á 77 % Net income Á \$ 2,126 Á Á \$ 1,696 Á Á \$ 430 Á Á 25 % Revenue Á Revenue for the three months ended September 30, 2024 increased 15% to \$15,977 as compared to \$13,902 for the three months ended September 30, 2023. The increase in revenue for the three months ended September 30, 2024 compared to the prior period is primarily due to the acquisition of the MusclePharm assets, which were acquired on October 10, 2023, partially offset by a decline in Legacy FitLife revenue. Á Legacy FitLife revenue for the three months ended September 30, 2024 was \$6,302, a 6% decrease compared to the previous year, driven by a 12% decline in wholesale revenue partially offset by a 4% increase in online revenue. Á MRC revenue for the three months ended September 30, 2024 was \$7,210, which was approximately flat compared to the previous year. Á During the three months ended September 30, 2024, MusclePharm generated revenue of \$2,465, of which approximately half was generated from wholesale customers and half from online sales. Á Online revenue and wholesale revenue for the quarter ended September 30, 2024 were approximately 68% and 32% of total net revenue, respectively, consistent with the online and wholesale revenue percentages for the same period of 2023. Á Sales to customers in the U.S. were approximately 95% and 93% during the quarters ended September 30, 2024 and 2023, respectively, with the balance of sales to customers primarily in Canada. Á Cost of Goods Sold Á Cost of goods sold for the three months ended September 30, 2024 increased to \$8,976 as compared to \$8,206 for the three months ended September 30, 2023. This 9% increase is primarily due to an increase in revenue attributable to the acquisition of the MusclePharm assets, partially offset by lower Legacy FitLife sales. Á Gross Profit Á Gross profit for the three months ended September 30, 2024 increased to \$7,001 as compared to \$5,696 for the three months ended September 30, 2023. The increase in gross profit is attributable to higher gross profit from both MRC and Legacy FitLife as well as incremental gross profit from MusclePharm. Á Gross Margin. Gross margin for the three months ended September 30, 2024 increased to 43.8% from 41.0% for the comparable prior period. The increase in gross margin is primarily attributable to higher margins from both MRC and Legacy FitLife. Á Advertising and Marketing. Advertising and marketing expense for the three months ended September 30, 2024 decreased to \$1,093 as compared to \$1,275 for the same period of the prior year. The 14% decrease is the result of targeted efforts to rationalize the Companyâ€™s advertising spend on less effective advertising campaigns. Á -16- Á Á SG&A. SG&A expense for the three months ended September 30, 2024 increased to \$2,645 as compared to \$1,897 for the three months ended September 30, 2023. The increase was primarily due to higher personnel costs (including salaries, benefits, and stock compensation) and higher professional fees. In addition, the Company incurred non-recurring severance costs of \$184. Á Merger and Acquisition Related. Merger and acquisition related expense increased to \$59 during the quarter ended September 30, 2024 compared to \$32 for the same period of 2023. Á Net Income Á We generated net income of \$2,126 for the three months ended September 30, 2024 as compared to net income of \$1,696 for the three months ended September 30, 2023. The increase in net income for the three months ended September 30, 2024 compared to the same period in 2023 was primarily attributable to incremental revenue and gross profit from MusclePharm, higher gross profit from MRC and Legacy FitLife, as well as reduced advertising and marketing expense. Á Comparison of the nine months ended September 30, 2024 to the nine months ended September 30, 2023 Á Á Nine months ended Á Á Á Á Á Á Á Á September 30, 2024 Á Á September 30, 2023 Á Á Change (\$) Á Á Change (%) Á Á (Unaudited) Á Á Á Á Á Á Revenue Á \$ 49,456 Á Á \$ 39,401 Á Á \$ 10,055 Á Á 26 % Cost of goods sold Á \$ 27,588 Á Á \$ 23,332 Á Á \$ 4,256 Á Á 18 % Gross profit Á \$ 21,868 Á Á \$ 16,069 Á Á \$ 5,799 Á Á 36 % Gross margin Á Á 44.2 % Á Á 40.8 % Á Á n/m Á Á 3.4 % Advertising and marketing Á \$ 3,647 Á Á \$ 3,359 Á Á \$ 288 Á Á 9 % Selling, general and administrative (â€œSG&A”) Á \$ 7,681 Á Á \$ 5,399 Á Á \$ 2,282 Á Á 42 % Merger and acquisition related Á \$ 217 Á Á \$ 1,519 Á Á \$ (1,302) Á Á (86) % Depreciation and amortization Á \$ 85 Á Á \$ 64 Á Á \$ 21 Á Á 33 % Total operating expense Á \$ 11,630 Á Á \$ 10,341 Á Á \$ 1,289 Á Á 12 % Operating income Á \$ 10,238 Á Á \$ 5,728 Á Á \$ 4,510 Á Á 79 % Other expense, net Á \$ 1,018 Á Á \$ 422 Á Á \$ 596 Á Á 141 % Provision for income tax Á \$ 2,306 Á Á \$ 1,490 Á Á \$ 816 Á Á 55 % Net income Á \$ 6,914 Á Á \$ 3,816 Á Á \$ 3,098 Á Á 81 % Revenue Á Revenue for the nine months ended September 30, 2024 increased 26% to \$49,456 as compared to \$39,401 for the nine months ended September 30, 2023. The increase in revenue for the nine months ended September 30, 2024 compared to the prior period is due to the acquisition of MRC and the MusclePharm assets, partially offset by a decline in Legacy FitLife revenue. MRC was acquired February 28, 2023, and as such only seven months of MRC revenue were included in the Companyâ€™s financial statements for the nine months ended September 30, 2023. MusclePharm was acquired on October 10, 2023. Á Legacy FitLife revenue for the nine months ended September 30, 2024 was \$20,065, a 9% decrease compared to the previous year, driven by a 15% decline in wholesale revenue partially offset by a 5% increase in online revenue. Á MRC revenue for the nine months ended September 30, 2024 was \$22,164. MRC revenue for the period from February 28, 2023 to September 30, 2023 was \$17,468. Á During the nine months ended September 30, 2024, MusclePharm generated revenue of \$7,227, of which approximately half was generated from wholesale customers and half from online sales. Á Online revenue and wholesale revenue for the nine months ended September 30, 2024 were approximately 66% and 34% of total net revenue, respectively. Á Online revenue and wholesale revenue for the nine months ended September 30, 2023 were approximately 62% and 38% of net revenue, respectively. Á Sales to customers in the U.S. were approximately 96% and 94% during the nine months ended September 30, 2024 and 2023, respectively, with the balance of sales to customers primarily in Canada. Á -17- Á Á Cost of Goods Sold Á Cost of goods sold for the nine months ended September 30, 2024 increased to \$27,588 as compared to \$23,332 for the nine months ended September 30, 2023. This 18% increase is due to an increase in revenue attributable to the acquisitions of MRC and the MusclePharm assets. Á Gross Profit Á Gross profit for the nine months ended September 30, 2024 increased to \$21,868 as compared to \$16,069 for the nine months ended September 30, 2023. The increase in gross profit is principally attributable to higher MRC gross profit as well as incremental gross profit from MusclePharm. Á Gross Margin. Gross margin for the nine months ended September 30, 2024 increased to 44.2% from 40.8% for the comparable prior period. The increase in gross margin is primarily attributable to higher margins from MRC and Legacy FitLife as well as the amortization of the fair value step-up to MRC inventory acquired in the first quarter of 2023. Excluding the \$323 impact of the step-up amortization, gross margin would have been 41.6% during the nine months ended September 30, 2023. Á Advertising and Marketing. Advertising and marketing expense for the nine months ended September 30, 2024 increased to \$3,647 as compared to \$3,359 for the same period of the prior year. The 9% increase is primarily due to the full-period impact of MRC advertising and marketing as well as incremental advertising and marketing expense following the acquisition of the MusclePharm assets. Á SG&A. SG&A expense for the nine months ended September 30, 2024 increased to \$7,681 as compared to \$5,399 for the nine months ended September 30, 2023. The increase was primarily due to the full-period impact of MRC SG&A as well as higher personnel costs (including salaries, benefits and stock compensation) and higher professional fees. In addition, the Company incurred non-recurring severance costs of \$184. Á Merger and Acquisition Related. Merger and acquisition related expense decreased to \$217 during the nine months ended September 30, 2024 compared to \$1,519 for the same period of 2023, driven primarily by transaction costs related to the MRC acquisition in 2023. Á Net Income Á We generated net income of \$6,914 for the nine months ended September 30, 2024 as compared to net income of \$3,816 for the nine months ended September 30, 2023. The increase in net income for the nine months ended September 30, 2024 compared to the same period in 2023 was primarily attributable to higher revenue and gross profit for MRC, incremental revenue and gross profit from MusclePharm, as well as a reduction in acquisition-related expense due to the MRC acquisition that closed during 2023, partially offset by incremental SG&A expense. Á Supplemental Discussion of Performance of Acquired Brands Á Management frequently receives questions from investors regarding the performance of brands subsequent to their acquisition by the Company. In an effort to be responsive to these questions, the Company is providing additional disclosure herein. Management intends to provide this level of disclosure for no more than two years following a transaction, after which the performance of acquired brands will be reported as part of Legacy FitLife results. Á One of the primary metrics used by management to evaluate the performance of the Companyâ€™s brands is contribution, a non-GAAP financial measure which management defines as gross profit less advertising and marketing expenditures. Á Other companies may also report contribution as a performance metric, but their definition or calculation of contribution may differ from the Companyâ€™s. Á Management believes that contribution, as defined by the Company, is a particularly relevant performance metric since it incorporates the gross profit associated with a specific brand or collection of brands as well as the advertising and marketing expenditures associated with the same brand or brands. Á With limited exceptions, other operating expenses incurred by the Company are generally not allocable to a specific brand or collection of brands. Á -18- Á Á Other than for MusclePharm, the numbers in the contribution tables presented below represent the performance of a collection of brands. Legacy

[illegible]

expected to be collected. ASC 606 creates a five-step model that requires entities to exercise judgment when considering the terms of contract(s), which includes (1) identifying the contract(s) or agreement(s) with a customer, (2) identifying our performance obligations in the contract or agreement, (3) determining the transaction price, (4) allocating the transaction price to the separate performance obligations, and (5) recognizing revenue as each performance obligation is satisfied. Under ASC 606, revenue is recognized when performance obligations under the terms of a contract are satisfied, which occurs for the Company upon shipment or delivery of products to our customers based on written sales terms. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring the products to a customer. All products sold by the Company are distinct individual products and consist of nutritional supplements and wellness products. The products are offered for sale solely as finished goods, and there are no performance obligations required post-shipment for customers to derive the expected value from them. The Company's products are also sold on e-commerce platforms including Amazon. For these transactions, the Company evaluated principal versus agent considerations to determine appropriateness of recording distribution and platform fees paid to third-party e-commerce companies as an expense or as a reduction of revenue. The Company records distribution and platform fees to cost of goods sold in the condensed consolidated statements of income and comprehensive income. Distribution and platform fees are not recorded as a reduction of revenue because the Company (1) owns the goods before they are transferred to the customer, (2) can direct Amazon, similar to other third-party logistics providers (Logistics Providers), to return the Company's inventory to any location specified by the Company, (3) has the responsibility to make customers whole following any returns made by customers directly to Logistics Providers and the Company retains the back-end inventory risk, (4) is subject to credit risk (i.e., credit card chargebacks), (5) establishes prices of its products, (6) can determine who fulfills the goods to the customer (Amazon or the Company) and (7) can limit quantities or stop selling the goods at any time. Based on these considerations, the Company is the principal in this arrangement. Advertising fees for Amazon are recorded in advertising and marketing expense in the condensed consolidated statements of income and comprehensive income.

-24- The Company disaggregates revenue into geographical regions and distribution channels. The Company determines that disaggregating revenue into these categories achieves the disclosure objective to depict how the nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factors. A Online revenue during the three months ended September 30, 2024 and 2023 was approximately 68% of net revenue for both periods, compared to 32% for the wholesale channel for the same periods. A Online revenue during the nine months ended September 30, 2024 and 2023 was approximately 66% and 62% of net revenue, compared to 34% and 38% for the wholesale channel for the same period. A Sales to customers in the U.S. were approximately 95% and 93% during the three months ended September 30, 2024 and 2023, respectively, with the balance of sales for the same respective periods being to customers primarily in Canada. A Sales to customers in the U.S. were approximately 96% and 94% during the nine months ended September 30, 2024 and 2023, respectively, with the balance of sales for the same respective periods being to customers primarily in Canada. A Control of products we sell transfers to customers upon shipment from our facilities or delivery to our customers, and the Company's performance obligations are satisfied at that time. Shipping and handling activities are performed before the customer obtains control of the goods and therefore represent a fulfillment activity rather than promised goods to the customer. Payments for sales are generally made by check, credit card, or wire transfer. Historically the Company has not experienced any significant payment delays from customers. A For direct-to-consumer sales, the Company allows for returns within 30 days of purchase. Our wholesale customers, such as GNC, may return purchased products to the Company under certain circumstances, which include expired or soon-to-be-expired products located in GNC corporate stores or at any of its distribution centers, and products that are subject to a recall or that contain an ingredient or ingredients that are subject to a recall by the FDA. A Right of return does not represent a separate performance obligation, but because customers are allowed to return products, the consideration to which the Company expects to be entitled is variable. Upon evaluation of returns, the Company determined that product returns are immaterial, and therefore believes it is probable that such returns will not cause a significant reversal of revenue in the future. We assess our contracts and the reasonableness of our conclusions on a quarterly basis. A Recent Accounting Pronouncements A See Note 3 of the Condensed Consolidated Financial Statements included in this Quarterly Report for a description of recent accounting pronouncements believed by management to have a material impact on our present or future financial statements. A ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK A Our business is conducted principally in the U.S. A However, due to the MRC acquisition in 2023, the Company now has more exposure to fluctuations in foreign currencies. A As a result, our financial results may be materially affected by factors such as changes in foreign currency exchange rates or economic conditions in foreign markets. A Foreign Currency A In January 2023, the Company entered into a foreign currency hedging transaction to mitigate the risk of adverse changes in the USD/CAD exchange rate with respect to the pending acquisition of MRC. The Company entered into a forward contract to purchase CAD \$25.0 million, as the Company anticipated providing additional working capital funding beyond the CAD \$23.2 million purchase price for MRC. As the geographical scope of our business broadens, we may engage in additional foreign currency hedging transactions in the future. The Company has not entered into any foreign currency hedging transactions during the nine months ended September 30, 2024. A -25- A Interest Rates A Our exposure to risk for changes in interest rates relates primarily to borrowings under the Amended Credit Agreement (which includes the Term Loans as well as our Line of Credit), and our investments in short-term financial instruments. As of September 30, 2024, the Company had \$14,250 outstanding on the Term Loans and \$0 under its Line of Credit. A Investments of our cash balances in both fixed-rate and floating-rate interest-earning instruments carry some interest rate risk. The fair value of fixed-rate securities may fall due to a rise in interest rates, while floating-rate securities may produce less income than expected if interest rates fall. Partly as a result of this, our future interest income will vary due to changes in interest rates and we may suffer losses in principal if we are forced to sell securities that have fallen in estimated fair value due to changes in interest rates. However, as substantially all of our cash equivalents consist of bank deposits and short-term money market instruments, we do not expect any material change with respect to our net income as a result of an interest rate change. A ITEM 4. CONTROLS AND PROCEDURES A a. Evaluation of disclosure controls and procedures. A Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, an evaluation of the effectiveness of the design and operations of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), as of September 30, 2024 was completed. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer believe that our disclosure controls and procedures are effective to ensure that information required to be disclosed in the reports submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, including to ensure that information required to be disclosed by the Company is accumulated and communicated to management, including the principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. A b. Changes in Internal Control Over Financial Reporting A There were no additional changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the three months ended September 30, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. A c. Inherent Limitations on the Effectiveness of Controls A Management does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control systems are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in a cost-effective control system, no evaluation of internal control over financial reporting can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been or will be detected. A These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of a simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures. A -26- A PART II OTHER INFORMATION A ITEM 1. LEGAL PROCEEDINGS A We currently are not involved in any litigation that we believe could have a material adverse effect on our financial condition or results of operations. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of the Company or any of its subsidiaries, threatened against or affecting the Company, our Common Stock, any of our subsidiaries or of the Company's or our subsidiaries' directors or officers in their capacities as such, in which an adverse decision could have a material adverse effect. A ITEM 1A. RISK FACTORS A Our results of operations and financial condition are subject to numerous risks and uncertainties described in our comprehensive Annual Report on Form 10-K for our fiscal year ended December 31, 2023, filed with the SEC on March 29, 2024. Management is not aware of any material changes to the risk factors discussed in Part 1, Item 1A, of the Annual Report on Form 10-K for the year ended December 31, 2023. A You should carefully consider these risk factors in conjunction with the other information contained in this Quarterly Report. Should any of these risks materialize, our business, financial condition and future prospects could be negatively impacted. A ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS A None. A ITEM 3. DEFAULTS UPON SENIOR SECURITIES A There were no defaults upon senior securities during the three-month period ended September 30, 2024. A ITEM 5. OTHER INFORMATION A In the three months ended September 30, 2024, no directors or officers adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement, as each term is defined in Item 408(a) of Regulation S-K. A A ITEM 6. EXHIBITS A 31.1 Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act. 31.2 Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act. 32.1 Certification of Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act. 32.2 Certification of Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act. 101.INS Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. 101.SCH Inline XBRL Taxonomy Extension Schema Document 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document 101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document and included in Exhibit 101) A -27- A SIGNATURES A Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934 the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. A Registrant FitLife Brands, Inc. A A Date: November 14, 2024 By: /s/ Dayton Judd A A Dayton Judd A A Chief Executive Officer and Chair (Principal Executive Officer) A A Registrant FitLife Brands, Inc. A A Date: November 14, 2024 By: /s/ Jakob York A A Jakob York A A Chief Financial Officer (Principal Financial Officer) A A -28- EX-31.1 2 ex 741593.htm EXHIBIT 31.1 Exhibit 31.1 Certification pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 and pursuant to Rule 13a-14(a) and Rule 15d-14 under the Securities Exchange Act of 1934 A I, Dayton Judd, Chief Executive Officer of the Company, certify that: A 1. I have reviewed this Quarterly Report on Form 10-Q of FitLife Brands, Inc.; A 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; A 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; A 4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: A a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; A b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; A c. Evaluated the effectiveness of the registrant's disclosure and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluations; and A d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and A 5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): A a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and A b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. A Registrant FitLife Brands, Inc. A A Date: November 14, 2024 By: /s/ Dayton Judd A Dayton Judd A Chief Executive Officer and Chair (Principal Executive Officer) A EX-31.2 3 ex 741594.htm EXHIBIT 31.2 Exhibit 31.2 Certification pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 and pursuant to Rule 13a-14(a) and Rule 15d-14 under the Securities Exchange Act of 1934 A I, Jakob York, Chief Financial Officer of the Company, certify that: A 1. I have reviewed this Quarterly Report on Form 10-Q of FitLife Brands, Inc.; A 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; A 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; A 4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: A a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; A b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; A c. Evaluated the effectiveness of the registrant's disclosure and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluations; and A d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and A 5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): A a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and A b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. A Registrant FitLife Brands, Inc. A A Date: November 14, 2024 By: /s/ Jakob York A Jakob York A Chief Financial Officer (Principal Financial Officer) A EX-32.1 4 ex 741595.htm EXHIBIT 32.1 Exhibit 32.1 CERTIFICATIONS PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (18 U.S.C. SECTION 1350) A In connection with the Quarterly Report of FitLife Brands, Inc. (the "Company") on Form 10-Q for the period ending September 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Dayton Judd, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, that: A (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and A (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of

operations of the Company. [A Registrant](#) [FitLife Brands, Inc.](#) [A](#) [Date: November 14, 2024](#) [By: *A/s/* Dayton Judd *A*](#) [Dayton Judd *A*](#) [Chief Executive Officer and Chair \(Principal Executive Officer\)](#) [A](#) [EX-32.2](#) [5 ex 741596.htm EXHIBIT 32.2 Exhibit 32.2](#) [A](#) [CERTIFICATIONS PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 \(18 U.S.C. SECTION 1350\)](#) [A](#) [In connection with the Quarterly Report of FitLife Brands, Inc. \(the "Company"\) on Form 10-Q for the period ending September 30, 2024, as filed with the Securities and Exchange Commission on the date hereof \(the "Report"\), I, *A* Jakob York, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, that:](#) [A](#) [\(1\) The Report fully complies with the requirements of Section 13\(a\) or 15\(d\) of the Securities Exchange Act of 1934, as amended; and](#) [A](#) [\(2\) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.](#) [A Registrant](#) [FitLife Brands, Inc.](#) [A](#) [Date: November 14, 2024](#) [By: *A/s/* Jakob York *A*](#) [Jakob York *A*](#) [Chief Financial Officer \(Principal Financial Officer\)](#) [A](#) [EX-101.SCH 6](#) [ftlf-20240930.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document](#) [And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Condensed Consolidated Balance Sheets \(Current Period Unaudited\) link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Condensed Consolidated Balance Sheets \(Current Period Unaudited\) \(Parentheticals\) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Condensed Consolidated Statements of Income and Comprehensive Income \(Unaudited\) link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Condensed Consolidated Statement of Stockholders' Equity \(Unaudited\) link:calculationLink link:definitionLink link:presentationLink 005 - Statement - Condensed Consolidated Statements of Cash Flows \(Unaudited\) link:calculationLink link:definitionLink link:presentationLink 006 - Disclosure - Note 1 - Description of Business link:calculationLink link:definitionLink link:presentationLink 007 - Disclosure - Note 2 - Basis of Presentation link:calculationLink link:definitionLink link:presentationLink 008 - Disclosure - Note 3 - Summary of Significant Accounting Policies link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note 4 - Inventories link:calculationLink link:definitionLink link:presentationLink 010 - Disclosure - Note 5 - Property and Equipment link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Note 6 - Notes Payable link:calculationLink link:definitionLink link:presentationLink 012 - Disclosure - Note 7 - Equity link:calculationLink link:definitionLink link:presentationLink 013 - Disclosure - Note 8 - Acquisition of Mimi's Rock Corp link:calculationLink link:definitionLink link:presentationLink 014 - Disclosure - Note 9 - Acquisition of Musclempharm Assets link:calculationLink link:definitionLink link:presentationLink 015 - Disclosure - Note 10 - Commitments and Contingencies link:calculationLink link:definitionLink link:presentationLink 016 - Disclosure - Note 11 - Subsequent Events link:calculationLink link:definitionLink link:presentationLink 995462 - Disclosure - Significant Accounting Policies \(Policies\) link:calculationLink link:definitionLink link:presentationLink 995463 - Disclosure - Note 3 - Summary of Significant Accounting Policies \(Tables\) link:calculationLink link:definitionLink link:presentationLink 995464 - Disclosure - Note 4 - Inventories \(Tables\) link:calculationLink link:definitionLink link:presentationLink 995465 - Disclosure - Note 5 - Property and Equipment \(Tables\) link:calculationLink link:definitionLink link:presentationLink 995466 - Disclosure - Note 6 - Notes Payable \(Tables\) link:calculationLink link:definitionLink link:presentationLink 995467 - Disclosure - Note 7 - Equity \(Tables\) link:calculationLink link:definitionLink link:presentationLink 995468 - Disclosure - Note 8 - Acquisition of Mimi's Rock Corp \(Tables\) link:calculationLink link:definitionLink link:presentationLink 995469 - Disclosure - Note 1 - Description of Business \(Details Textual\) link:calculationLink link:definitionLink link:presentationLink 995470 - Disclosure - Note 3 - Summary of Significant Accounting Policies \(Details Textual\) link:calculationLink link:definitionLink link:presentationLink 995471 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Disaggregation of Revenue \(Details\) link:calculationLink link:definitionLink link:presentationLink 995472 - Disclosure - Note 3 - Summary of Significant Accounting Policies - Basic and Diluted Income \(Loss\) Per Share \(Details\) link:calculationLink link:definitionLink link:presentationLink 995473 - Disclosure - Note 4 - Inventories \(Details Textual\) link:calculationLink link:definitionLink link:presentationLink 995474 - Disclosure - Note 4 - Inventories - Summary of Inventory \(Details\) link:calculationLink link:definitionLink link:presentationLink 995475 - Disclosure - Note 5 - Property and Equipment \(Details Textual\) link:calculationLink link:definitionLink link:presentationLink 995476 - Disclosure - Note 5 - Property and Equipment - Property and Equipment \(Details\) link:calculationLink link:definitionLink link:presentationLink 995477 - Disclosure - Note 6 - Notes Payable \(Details Textual\) link:calculationLink link:definitionLink link:presentationLink 995478 - Disclosure - Note 6 - Notes Payable - Debt Obligations \(Details\) link:calculationLink link:definitionLink link:presentationLink 995479 - Disclosure - Note 7 - Equity \(Details Textual\) link:calculationLink link:definitionLink link:presentationLink 995480 - Disclosure - Note 7 - Equity - Stock Option Activity \(Details\) link:calculationLink link:definitionLink link:presentationLink 995481 - Disclosure - Note 7 - Equity - Exercise Price Range \(Details\) link:calculationLink link:definitionLink link:presentationLink 995482 - Disclosure - Note 8 - Acquisition of Mimi's Rock Corp \(Details Textual\) link:calculationLink link:definitionLink link:presentationLink 995483 - Disclosure - Note 8 - Acquisition of Mimi's Rock Corp - Pro Forma Information \(Details\) link:calculationLink link:definitionLink link:presentationLink 995484 - Disclosure - Note 9 - Acquisition of Musclempharm Assets \(Details Textual\) link:calculationLink link:definitionLink link:presentationLink EX-101.DEF 7](#) [ftlf-20240930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 8](#) [ftlf-20240930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE](#) [Document](#) [And Entity Information](#) [Fair Value Measurement, Policy \[Policy Text Block\] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate](#) [Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate](#) [us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill](#) [Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill](#) [Note To Financial Statement](#) [Details](#) [Textual](#) [Significant Accounting Policies](#) [Share-Based Payment Arrangement, Option, Exercise Price Range \[Table Text Block\]](#) [Note 3 - Summary of Significant Accounting Policies](#) [us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate](#) [Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate](#) [Note 4 - Inventories](#) [Accrued expense and other liabilities](#) [Amount of accrued expense and liabilities classified as other, due within one year or the normal operating cycle, if longer.](#) [Note 5 - Property and Equipment](#) [Note 6 - Notes Payable](#) [Note 7 - Equity](#) [Note 8 - Acquisition of Mimi's Rock Corp](#) [Stock-based compensation](#) [us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims](#) [Note 2 - Summary of Significant Accounting Policies - Disaggregation of Revenue \(Details\)](#) [Note 3 - Summary of Significant Accounting Policies - Basic and Diluted Income \(Loss\) Per Share \(Details\)](#) [Note 4 - Inventories - Summary of Inventory \(Details\)](#) [Product returns](#) [ftlf_OperatingLeaseRightofuseAssetNetOfAmortizationAndLeaseLiability](#) [Right-of-use asset](#) [Amount of right-of-use asset net of amortization and lease liability from operating lease.](#) [Note 5 - Property and Equipment - Property and Equipment \(Details\)](#) [Foreign Currency Transactions and Translations Policy \[Policy Text Block\]](#) [Note 6 - Notes Payable - Debt Obligations \(Details\)](#) [us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate](#) [Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate](#) [Note 7 - Equity - Stock Option Activity \(Details\)](#) [us-gaap_LiabilitiesCurrent](#) [Total current liabilities](#) [Lessee, Leases \[Policy Text Block\]](#) [Note 7 - Equity - Exercise Price Range \(Details\)](#) [Note 8 - Acquisition of Mimi's Rock Corp - Pro Forma Information \(Details\)](#) [Schedule of Debt \[Table Text Block\]](#) [Notes To Financial Statements](#) [Business Combinations Policy \[Policy Text Block\]](#) [Notes To Financial Statements \[Abstract\]](#) [Earnings Per Share, Policy \[Policy Text Block\]](#) [us-gaap_BusinessCombinationConsiderationTransferred](#) [1 Business Combination, Consideration Transferred](#) [us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptions](#) [VestedInPeriodTotalFairValue](#) [Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Income Tax, Policy \[Policy Text Block\]](#) [us-gaap_IndefinitelyLivedIntangibleAssetsAcquired](#) [Indefinite-Lived Intangible Assets Acquired](#) [Share-Based Payment Arrangement, Option, Activity \[Table Text Block\]](#) [Foreign currency translation adjustment](#) [us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent](#) [us-gaap_LesseeOperatingLeaseTermOfContract](#) [Lessee, Operating Lease, Term of Contract](#) [us-gaap_Depreciation](#) [Depreciation](#) [us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptions](#) [GrantsInPeriod](#) [Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period](#) [Depreciation and amortization](#) [us-gaap_DepreciationDepletionAndAmortization](#) [Diluted net income per share \(in dollars per share\)](#) [us-gaap_BusinessAcquisitionProFormaEarningsPerShare](#) [Diluted](#) [us-gaap_LongTermDebtCurrent](#) [Current Term loan](#) [" current portion](#) [Comprehensive income](#) [us-gaap_AssetsCurrent](#) [Total current assets](#) [Net income](#) [us-gaap_BusinessAcquisitionsProFormaNetIncome](#) [Loss](#) [us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDate](#) [Actual Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual Equity \[Text Block\]](#) [Business Acquisition, Pro Forma Information \[Table Text Block\]](#) [Revenue](#) [us-gaap_BusinessAcquisitionsProFormaRevenue](#) [Outstanding, weighted average remaining life \(Year\)](#) [us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstanding](#) [IntrinsicValue](#) [Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value](#) [Common stock, \\$0.01 par value, 60,000 shares authorized; 4,598 issued and outstanding as of June 30, 2024 and December 31, 2023](#) [Adjustments to reconcile net income to net cash provided by operating activities:](#) [us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstanding](#) [WeightedAverageExercisePrice](#) [Outstanding, weighted average exercise price \(in dollars per share\)](#) [Outstanding, weighted average exercise price \(in dollars per share\)](#) [Common stock, shares authorized \(in shares\)](#) [Common Stock, Shares Authorized \(in shares\)](#) [Forfeited, weighted average exercise price \(in dollars per share\)](#) [Common stock, shares issued \(in shares\)](#) [Common Stock, Shares, Issued](#) [Common stock, par value \(in dollars per share\)](#) [Common Stock, Par or Stated Value](#) [Per Share Issued, weighted average exercise price \(in dollars per share\)](#) [Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Exercised, weighted average exercise price \(in dollars per share\)](#) [Income taxes payable](#) [Statistical Measurement \[Domain\]](#) [Maximum \[Member\]](#) [Minimum \[Member\]](#) [Accounts payable](#) [Product and Service \[Axis\]](#) [Revolving Credit Facility \[Member\]](#) [us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstanding](#) [Number Outstanding, number of options \(in shares\)](#) [Outstanding, number of options \(in shares\)](#) [Product and Service \[Domain\]](#) [Statistical Measurement \[Axis\]](#) [Credit Facility \[Axis\]](#) [Preferred stock, \\$0.01 par value, 10,000 shares authorized, none outstanding as of June 30, 2024 and December 31, 2023](#) [Credit Facility \[Domain\]](#) [Shares surrendered by former employee](#) [Amount of shares surrendered by former employee.](#) [Goodwill and Intangible Assets, Intangible Assets, Policy \[Policy Text Block\]](#) [Cash paid for interest, net of amounts capitalized](#) [us-gaap_PolicyTextBlockAbstract](#) [Accounting Policies](#) [Geographical \[Axis\]](#) [Property, Plant and Equipment](#) [Disclosure \[Text Block\]](#) [Geographical \[Domain\]](#) [Property, Plant and Equipment \[Table Text Block\]](#) [Preferred stock, shares authorized \(in shares\)](#) [Goodwill and Intangible Assets, Goodwill, Policy \[Policy Text Block\]](#) [Inventories, net of allowance for obsolescence of \\$69 and \\$162, respectively](#) [Total Inventory, Net Preferred stock, par value \(in dollars per share\)](#) [Preferred Stock, Par or Stated Value](#) [Per Share](#) [Dilutive effect of outstanding warrants and stock options \(in shares\)](#) [Range One \[Member\]](#) [Information related to range one.](#) [Revenue](#) [Range Two \[Member\]](#) [Information related to range two.](#) [Indefinite-Lived Intangible Assets \[Axis\]](#) [Foreign currency translation adjustment](#) [Allowance for obsolescence](#) [Inventory Valuation Reserves](#) [Allowance for obsolescence](#) [Indefinite-Lived Intangible Assets, Major Class Name \[Domain\]](#) [us-gaap_PaymentsToAcquirePropertyPlantAndEquipment](#) [Purchase of property and equipment](#) [Brands \[Member\]](#) [In reference to brands associated with the company.](#) [us-gaap_ForeignCurrencyTransactionGainLossBeforeTax](#) [Foreign exchange \(gain\) loss](#) [Finished goods](#) [Non-cash investing and financing activities](#) [ftlf_DebtInstrumentCovenantCashFlowLeverageThreshold](#) [Debt Instrument, Covenant, Cash Flow Leverage Threshold](#) [Rate of cash flow leverage threshold under covenant of the debt instrument.](#) [Customer \[Axis\]](#) [us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriod](#) [Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period](#) [Customer \[Domain\]](#) [Assets of MusclePharm Corporation \[Member\]](#) [Represents the assets of MusclePharm Corporation.](#) [ftlf_DebtInstrumentCovenantCashFlowLeverageThreshold](#) [PercentageOfExcessCashFlow](#) [Debt Instrument, Covenant, Cash Flow Leverage Threshold, Percentage of Excess Cash Flow](#) [Percentage of excess cash flow for rate of cash flow leverage threshold under the covenant of the debt instrument.](#) [Term Loans \[Member\]](#) [In reference to the Term Loans.](#) [Cash paid for income taxes](#) [Term Loan A \[Member\]](#) [In relation](#) [Term Loan A Financing Arrangements \[Member\]](#) [Represents financing arrangements.](#) [CURRENT LIABILITIES: Term Loan B \[Member\]](#) [Represents term loan B.](#) [Lease liability](#) [Components](#) [us-gaap_Assets](#) [TOTAL ASSETS](#) [Supplemental cash flow disclosure](#) [us-gaap_EmployeeService](#) [ShareBasedCompensationNonvestedAwardsTotalCompensationCost](#) [NotYetRecognized](#) [StockOptions](#) [Share-Based Payment Arrangement, Nonvested Award, Option, Cost](#) [Not yet Recognized, Amount CASH FLOWS FROM OPERATING ACTIVITIES: Amortization of deferred financing costs](#) [In reference to the amortization of deferred finance costs.](#) [Revenue \[Policy Text Block\]](#) [Statement \[Line Items\]](#) [Allowance of doubtful accounts](#) [us-gaap_DebtInstrumentVariableInterestRateType](#) [ExtensibleEnumeration](#) [Debt Instrument, Variable Interest Rate, Type \[Extensible Enumeration\]](#) [Accounts receivable, net of allowance of doubtful accounts of \\$18 and \\$17, respectively](#) [Additional paid-in capital](#) [Deferred tax asset](#) [Wholesale Sales \[Member\]](#) [Related to Wholesale Sales.](#) [STOCKHOLDERS' EQUITY: ftlf_DebtInstrumentAdditionalInterestRate](#) [Default Debt Instrument, Additional Interest Rate, Default](#) [The percent additional interest rate of debt instrument in the event of default.](#) [ftlf_FixedChargeCoverageRatio](#) [Fixed Charge Coverage Ratio](#) [The fixed charge coverage ratio.](#) [ftlf_FundedDebtToEBITDARatio](#) [Funded Debt to EBITDA Ratio](#) [The Funded Debt to EBITDA Ratio.](#) [us-gaap_PaymentsForOtherDeposits](#) [Cash deposit paid for the acquisition of MusclePharm assets](#) [us-gaap_NonoperatingIncomeExpense](#) [Total other expense, net Term Loan \[Member\]](#) [Related to term loan.](#) [Award Type \[Domain\]](#) [OTHER EXPENSE \(INCOME\) NET INCOME](#) [NET INCOME Award Type \[Axis\]](#) [Intangibles](#) [amortization](#) [Intangibles, net of amortization of \\$93 and \\$72, respectively \(provisional\)](#) [us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations](#) [CASH, BEGINNING OF PERIOD](#) [CASH AND RESTRICTED CASH, END OF PERIOD](#) [Foreign currency impact on cash](#) [us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect](#) [CHANGE IN CASH AND RESTRICTED CASH](#) [Restricted Stock Units \(RSUs\) \[Member\]](#) [us-gaap_Liabilities](#) [TOTAL LIABILITIES](#) [us-gaap_NetCashProvidedByUsedInFinancingActivities](#) [Net cash provided by \(used in\) financing activities](#) [us-gaap_OperatingIncomeLoss](#) [OPERATING INCOME](#) [us-gaap_NetCashProvidedByUsedInOperatingActivities](#) [Net cash provided by operating activities](#) [Share-Based Payment Arrangement, Option \[Member\]](#) [Prepaid expense and other current assets](#) [us-gaap_NetCashProvidedByUsedInInvestingActivities](#) [Net cash used in investing activities](#) [us-gaap_GrossProfit](#) [Gross profit](#) [Cost of goods sold](#) [Deferred tax liability](#) [Allowance for inventory obsolescence](#) [Commitments and Contingencies](#) [Disclosure \[Text Block\]](#) [us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment](#) [Accumulated depreciation](#) [Business Combination](#) [Disclosure \[Text Block\]](#) [Property and equipment, net](#) [Total Goodwill](#) [Goodwill](#) [Equipment](#) [Concentration Risk, Credit Risk, Policy \[Policy Text Block\]](#) [us-gaap_InterestAndOtherIncome](#) [Interest income](#) [Accumulated Foreign Currency Adjustment](#) [Attributable to Noncontrolling Interest \[Member\]](#) [us-gaap_NetCashProvidedByUsedInInvestingActivities](#) [Abstract](#) [Net Cash Provided by \(Used in\) Investing Activities \[Abstract\]](#) [Retained Earnings \[Member\]](#) [Unamortized debt issuance costs](#) [Additional Paid-in Capital \[Member\]](#) [Common Stock \[Member\]](#) [PROVISION FOR INCOME TAXES](#) [Equity Components \[Axis\]](#) [Equity Component \[Domain\]](#) [Vendor One \[Member\]](#) [Related to vendor one.](#) [Total debt](#) [us-gaap_LongTermDebt](#) [Long-Term Debt](#) [Vendor Two \[Member\]](#) [Related to vendor two.](#) [us-gaap_IncreaseDecreaseInAccountsPayable](#) [Accounts payable](#) [us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest](#) [INCOME BEFORE INCOME TAX](#) [PROVISION](#) [us-gaap_OperatingExpenses](#) [Total operating expense](#) [Restricted cash](#) [Restricted Cash](#) [us-gaap_LineOfCredit](#) [Long-Term Line of Credit](#) [Cash and cash equivalents](#) [Interest expense](#) [Disaggregation of Revenue \[Table Text Block\]](#) [us-gaap_AllocatedShareBasedCompensationExpense](#) [Share-Based Payment Arrangement, Expense](#) [us-gaap_RepaymentsOfLongTermDebt](#) [Payments on term loans](#) [Cash and Cash Equivalents, Policy \[Policy Text Block\]](#) [Document](#) [Quarterly Report](#) [Entity Incorporation, State or Country Code](#) [Amendment](#) [Flag](#) [Accounting Policies \[Abstract\]](#) [us-gaap_ComprehensiveIncomeNetOfTax](#) [Comprehensive income](#) [Significant Accounting Policies \[Text Block\]](#) [Document](#) [Transition Report](#) [dei_CityAreaCode](#) [City Area Code](#) [Use of Estimates, Policy \[Policy Text Block\]](#) [dei_EntityInteractiveData](#) [Current Entity Interactive Data](#) [Current](#) [ftlf_NumberOfVendors](#) [Number of Vendors](#) [The number of vendors.](#) [Sales tax receivable](#) [The amount of sales taxes receivable.](#) [Accrued expense, other liabilities and income taxes payable](#) [us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities](#) [Reclassification, Comparability Adjustment \[Policy Text Block\]](#) [One Vendor \[Member\]](#) [Related to one vendor.](#) [us-gaap_DebtInstrumentPeriodicPayment](#) [Principal Debt Instrument, Periodic Payment, Principal](#) [us-gaap_TreasuryStockSharesAcquired](#) [Treasury Stock, Shares, Acquired \(in shares\)](#) [us-gaap_SharesOutstanding](#) [Balance \(in shares\)](#) [Balance \(in shares\)](#) [us-gaap_IncreaseDecreaseInContractWithCustomerLiability](#) [Product returns](#) [dei_SecurityExchangeName](#) [Security Exchange](#)

Name Common stock, shares outstanding (in shares) Preferred stock, shares outstanding (in shares) dei_Security12bTitle Number of 12(b) Security Current Fiscal Year End Date us-gaap_ProceedsFromIssuanceOfLongTermDebt Borrowings on term loans us-gaap_DebtInstrumentBasisSpreadOnVariableRate1 Debt Instrument, Basis Spread on Variable Rate Inventory-related Purchases [Member] Related to inventory related purchases. Two Vendors [Member] Related to two vendors. Basis of Accounting [Text Block] Document Fiscal Period Focus Document Fiscal Year Focus us-gaap_IncreaseDecreaseInDeferredIncomeTaxes Deferred tax asset Consolidation, Policy [Policy Text Block] dei_DocumentPeriodEndDate Document Period End Date Addition to right-of-use assets from new operating lease liabilities us-gaap_IncreaseDecreaseInPrepaidExpense Prepaid expense, other current assets and sales tax receivable dei_EntityFileNumber Entity File Number Entity Emerging Growth Company us-gaap_DebtInstrumentFaceAmount Debt Instrument, Face Amount dei_DocumentType Document Type Entity Small Business dei_EntityShellCompany Entity Shell Company Merger and acquisition related Document Information [Line Items] Document Information [Table] Entity Filer Category Debt Instrument [Axis] dei_EntityCurrentReportingStatus Entity Current Reporting Status Debt Instrument, Name [Domain] Segments [Axis] Segments [Domain] Pledging Purpose [Domain] us-gaap_SharePrice Share Price Diluted weighted average common shares (in shares) Weighted average common shares - diluted (in shares) us-gaap_IncreaseDecreaseInAccountsReceivable Accounts receivable us-gaap_ConcentrationRiskPercentage1 Concentration Risk, Percentage Entity Tax Identification Number Pledging Purpose [Axis] Entity Central Index Key Depreciation and amortization Entity Registrant Name Product Concentration Risk [Member] Entity [Domain] Customer Concentration Risk [Member] Share Repurchase Program [Member] Information related to the Share Repurchase Program. Legal Entity [Axis] filf_StockRepurchaseProgramExpirationPeriod Stock Repurchase Program Expiration Period Expiration period for the purchase of an entity's own shares under a stock repurchase plan. Statement [Table] dei_EntityAddressAddressLine1 Entity Address, Address Line One Statement of Financial Position [Abstract] Diluted (in dollars per share) Supplier Concentration Risk [Member] Basic weighted average common shares (in shares) Weighted average common shares - basic (in shares) ecd_NonRule10b51ArrTrmndFlag Non-Rule 10b5-1 Arrangement Terminated [Flag] dei_EntityAddressCityOrTown Entity Address, City or Town Geographic Concentration Risk [Member] ecd_Rule10b51ArrTrmndFlag Rule 10b5-1 Arrangement Terminated [Flag] us-gaap_EffectiveIncomeTaxRateContinuingOperations Effective Income Tax Rate Reconciliation, Percent ecd_Rule10b51ArrAdoptedFlag Rule 10b5-1 Arrangement Adopted [Flag] dei_EntityAddressPostalZipCode Entity Address, Postal Zip Code Accounts Payable [Member] Basic (in dollars per share) Business Acquisition [Axis] dei_EntityAddressStateOrProvince Entity Address, State or Province Concentration Risk Type [Axis] Business Acquisition, Acquiree [Domain] ecd_NonRule10b51ArrAdoptedFlag Non-Rule 10b5-1 Arrangement Adopted [Flag] Concentration Risk Type [Domain] Material Terms of Trading Arrangement [Text Block] Statement of Cash Flows [Abstract] dei_EntityCommonStockSharesOutstanding Entity Common Stock, Shares Outstanding (in shares) Statement of Stockholders' Equity [Abstract] Income Statement [Abstract] Advertising and marketing Revenue Benchmark [Member] Accounts Receivable [Member] us-gaap_RepaymentsOfDebt Repayments of Debt us-gaap_IncreaseDecreaseInInventories Inventories dei_TradingSymbol Trading Symbol Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Nature of Operations [Text Block] dei_LocalPhoneNumber Local Phone Number Muscle Pharm [Member] Relating to Muscle Pharm. us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Exercised, number of options (in shares) us-gaap_TableTextBlock Notes Tables MRC [Member] Relating to MRC. GNC [Member] Information related to GNC. Online Sales [Member] Information related to online sales. Legacy FitLife [Member] Relating to Legacy FitLife. us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity Line of Credit Facility, Maximum Borrowing Capacity Asset Acquisition [Axis] srt_StockRepurchaseProgramAuthorizedAmount1 Share Repurchase Program, Authorized, Amount us-gaap_AssetAcquisitionConsiderationTransferred Asset Acquisition, Consideration Transferred Share Repurchase Program [Domain] Inventory Intangible Assets [Member] Relating to inventory intangible assets. Share Repurchase Program [Axis] Selling, general and administrative Allowance for doubtful accounts Stock-based compensation us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Net Cash Provided by (Used in) Financing Activities [Abstract] Issued, number of options (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Forfeited, number of options (in shares) Asset Acquisition [Domain] us-gaap_LiabilitiesAndStockholdersEquity TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY Asset Acquisition [Text Block] UNITED STATES Asset Pledged as Collateral [Member] Retained earnings (accumulated deficit) Series A Preferred Stock [Member] Debt Disclosure [Text Block] Pledged Status [Domain] Pledged Status [Axis] us-gaap_StockholdersEquity TOTAL STOCKHOLDERS' EQUITY Balance Balance us-gaap_DisclosureTextBlockAbstract Notes to Financial Statements Long-term lease liability, net of current portion Inventory Disclosure [Text Block] Class of Stock [Axis] Supplier [Axis] Schedule of Inventory, Current [Table Text Block] Class of Stock [Domain] Supplier [Domain] Long term Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] us-gaap_PaymentsToAcquireBusinessesGross Cash paid for acquisition of Mimiæ™s Rock Corp. Lease liability - current portion Term loan, net of current portion and unamortized deferred finance costs Shares surrendered by former employee (in shares) Represents the number of shares forfeited during period. Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price Mimiæ™s Rock Corp [Member] Relating to Mimiæ™s Rock Corp. Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable Subsequent Events [Text Block] Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price Right of use asset Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding Exercise Price Range [Axis] Exercise Price Range [Domain] Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit EX-101.PRE 9 filf-20240930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EX-101.CAL 10 filf-20240930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.24.3 Document And Entity Information - shares 9 Months Ended Sep. 30, 2024 Nov. 13, 2024 Document Information [Line Items] Â Â Document Type 10-Q Â Document Quarterly Report true Â Document Period End Date Sep. 30, 2024 Â Document Transition Report false Â Entity File Number 000-52369 Â Entity Registrant Name FITLIFE BRANDS, INC. Â Entity Incorporation, State or Country Code NV Â Entity Tax Identification Number 20-3464383 Â Entity Address, Address Line One 5214 S. 136th Street Â Entity Address, City or Town Omaha Â Entity Address, State or Province NE Â Entity Address, Postal Zip Code 68137 Â City Area Code 402 Â Local Phone Number 991-5618 Â Title of 12(b) Security Common Stock, par value \$0.01 per share Â Trading Symbol FTLF Â Security Exchange Name NASDAQ Â Entity Current Reporting Status Yes Â Entity Interactive Data Current Yes Â Entity Filer Category Non-accelerated Filer Â Entity Small Business true Â Entity Emerging Growth Company false Â Entity Shell Company false Â Entity Common Stock, Shares Outstanding (in shares) Â 4,598,241 Entity Central Index Key 0001374328 Â Current Fiscal Year End Date --12-31 Â Document Fiscal Year Focus 2024 Â Document Fiscal Period Focus Q3 Â Amendment Flag false Â X - Definition Boolean flag that is true when the XBRL content amends previously-filed or accepted submission. + References No definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - Definition Area code of city + References No definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - Definition End date of current fiscal year in the format --MM-DD. + References No definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - Definition Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + References No definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - Definition This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + References No definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details Name: dei_DocumentInformationLineItems Namespace Prefix: dei_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + References No definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - Definition Boolean flag that is true only for a form used as an quarterly report. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - Definition Boolean flag that is true only for a form used as a transition report. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - Definition The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + References No definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_Data Type: dei:submissionItemType Balance Type: na Period Type: duration X - Definition Address Line 1 such as Attn, Building Name, Street Name + References No definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - Definition Name of the City or Town + References No definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - Definition Code for the postal or zip code + References No definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - Definition Name of the state or province. + References No definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - Definition A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - Definition Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + References No definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Definition Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + References No definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - Definition Indicate if registrant meets the emerging growth company criteria. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - Definition Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + References No definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - Definition Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - Definition Two-character EDGAR code representing the state or country of incorporation. + References No definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - Definition Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - Definition The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - Definition Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - Definition Indicates that the company is a Smaller Reporting Company (SRC). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - Definition The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_Data Type: dei:employerIdItem Balance Type: na Period Type: duration X - Definition Local phone number for entity. + References No definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - Definition Title of a 12(b) registered security. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - Definition Name of the Exchange on which a security is registered. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - Definition Trading symbol of an instrument as listed on an exchange. + References No definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration XML 13 R2.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD (\$) \$ in Thousands Sep. 30, 2024 Dec. 31, 2023 Cash and cash equivalents \$ 4,664 \$ 1,139 Restricted cash \$ 5,759 Accounts receivable, net of allowance of doubtful accounts of \$18 and \$17, respectively 2,008 2,046 Inventories, net of allowance for obsolescence of \$69 and \$162, respectively 10,371 9,091 Sales tax receivable 58 1,019 Prepaid expense and other current assets 942 639 Total current assets 18,099 14,693 Property and equipment, net 91 137 Right of use asset 431 121 Intangibles, net of amortization of \$93 and \$72, respectively (provisional) 26,314 26,309 Goodwill 13,130 13,294 Deferred tax asset 522 792 TOTAL ASSETS 58,587 55,346 CURRENT LIABILITIES: Â Â Accounts payable 4,078 3,261 Accrued expense and other liabilities 957 1,026 Income taxes payable 1,861 892 Product returns 570 571 Term loan æ current portion 4,500 4,500 Lease liability - current portion 89 87 Total current liabilities 12,055 10,337 Term loan, net of current portion and unamortized deferred finance costs 9,664 15,509 Long-term lease liability, net of current portion 352 51 Deferred tax liability 2,358 2,413 TOTAL LIABILITIES 24,429 28,310 STOCKHOLDERS'æ EQUITY: Â Â Preferred stock, \$0.01 par value, 10,000 shares authorized, none outstanding as of June 30, 2024 and December 31, 2023 0 0 Common stock, \$0.01 par value, 60,000 shares authorized; 4,598 issued and outstanding as of June 30, 2024 and December 31, 2023 46 Additional paid-in capital 31,043 30,699 Retained earnings (accumulated deficit) 3,497 (3,417) Foreign currency translation adjustment (428) (292) TOTAL STOCKHOLDERS' EQUITY 34,158 27,036 TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY \$ 58,587 \$ 55,346 X - Definition Amount of accrued expense and

liabilities classified as other, due within one year or the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: ftfl AccruedExpenseAndOtherLiabilitiesCurrent Namespace Prefix: ftfl Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe amount of sales taxes receivable. + ReferencesNo definition available. + Details Name: ftfl SalesTaxesReceivable Namespace Prefix: ftfl Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 - SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(19\)\(a\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 - SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: <http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10> + Details Name: us-gaap AccountsPayableCurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2> + Details Name: us-gaap AccountsReceivableNetCurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-03\(15\)\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1) + Details Name: us-gaap AccruedIncomeTaxesCurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(18\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1)Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(30\)\(a\)\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) + Details Name: us-gaap AdditionalPaidInCapital Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48>Reference 2: <http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(ee\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 5: [http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 6: <http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22>Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(bb\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25](http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(iii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 12: <http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 13: <http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12>Reference 14: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(12\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(8\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(18\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 19: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 20: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 21: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 22: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 23: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 24: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 25: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 26: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 27: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 28: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7)Reference 29: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30)Reference 30: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-03\(11\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1) + Details Name: us-gaap Assets Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(bb\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25](http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(iii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 6: <http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1>Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(9\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 11: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 17:

Paragraph 6 - Publisher FASB -URI <https://asc.fasb.org/1943274/2147482525/740-10-45-6> + Details Name: us-gaap_DeferredIncomeTaxAssetsNet Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - Definition Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(15\)\(b\)\(2\)\)](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(15)(b)(2))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6> + Details Name: us-gaap_DeferredIncomeTaxLiabilitiesNet Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - Definition Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49>Reference 2: <http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24>Reference 3: [http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100](http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100)Reference 4: <http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(15\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 6: <http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1>Reference 7: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1)Reference 8: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(h\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-03\(10\)\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1) + Details Name: us-gaap_Goodwill Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - Definition Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2)Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2)Reference 3: <http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1> + Details Name: us-gaap_IntangibleAssetsNetExcludingGoodwill Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - Definition Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 2: [http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1](http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(6\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) + Details Name: us-gaap_InventoriesNet Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - Definition Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(22\)\) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(24\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 4: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(19\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 5: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(25\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 6: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(26\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 7: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(23\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 8: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(21\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25](http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(bb\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(iii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 15: <http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12>Reference 16: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(14\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 18: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 19: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 20: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 21: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 22: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 23: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 24: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 25: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 26: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 27: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7)Reference 28: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7)Reference 29: [http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30](http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30) + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - Definition Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(25\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1)Reference 3: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 4: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 5: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 6: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-03\(23\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1)Reference 7: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(32\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - Definition Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-0](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)

Type: duration X - DefinitionCarrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap LoansPayableCurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap LongTermLoansPayable Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: <http://www.xbrli.org/2003/role/disclosureRef> -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479041/842-20-45-1> + Details Name: us-gaap OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: <http://www.xbrli.org/2003/role/disclosureRef> -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479041/842-20-45-1> + Details Name: us-gaap OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: <http://www.xbrli.org/2003/role/disclosureRef> -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479041/842-20-45-1> + Details Name: us-gaap OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://www.xbrli.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 3: <http://www.xbrli.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1> + Details Name: us-gaap PreferredStockValue Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: <http://www.xbrli.org/2009/role/commonPracticeRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482099/360-10-50-1>Reference 2: <http://www.xbrli.org/2003/role/disclosureRef> -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478964/842-20-50-7A>Reference 3: <http://www.xbrli.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 4: <http://www.xbrli.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1>Reference 5: <http://www.xbrli.org/2003/role/disclosureRef> -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478451/942-360-50-1> + Details Name: us-gaap PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: <http://www.xbrli.org/2009/role/commonPracticeRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1>Reference 2: <http://www.xbrli.org/2009/role/commonPracticeRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: <http://www.xbrli.org/2009/role/commonPracticeRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482913/230-10-50-8>Reference 4: <http://www.xbrli.org/2009/role/commonPracticeRef> -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)(a)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478546/942-210-S99-1> + Details Name: us-gaap RestrictedCash Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://www.xbrli.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 3: <http://www.xbrli.org/2003/role/disclosureRef> -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480016/944-40-65-2>Reference 4: <http://www.xbrli.org/2003/role/disclosureRef> -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480016/944-40-65-2>Reference 5: <http://www.xbrli.org/2003/role/disclosureRef> -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480990/946-20-50-11>Reference 6: <http://www.xbrli.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1>Reference 7: <http://www.xbrli.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1>Reference 8: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480008/505-10-S99-1> + Details Name: us-gaap RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 4: <http://www.xbrli.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 5: <http://www.xbrli.org/2003/role/exampleRef> -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479168/946-830-55-12>Reference 6: <http://www.xbrli.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1>Reference 7: <http://www.xbrli.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-2>Reference 8: <http://www.xbrli.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 9: <http://www.xbrli.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 10: <http://www.xbrli.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 11: <http://www.xbrli.org/2009/role/commonPracticeRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 12: <http://www.xbrli.org/2009/role/commonPracticeRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3>Reference 13: <http://www.xbrli.org/2009/role/commonPracticeRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28>Reference 14: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480418/310-10-S99-2> + Details Name: us-gaap StockholdersEquity Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap StockholdersEquityAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cumulative translation gain (loss), after tax, from translating foreign currency financial statements into the reporting currency. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-11>Reference 2: <http://www.xbrli.org/2009/role/commonPracticeRef> -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481694/830-30-45-20> + Details Name: us-gaap TranslationAdjustmentFunctionalToReportingCurrencyNetOfTax Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 14 R3.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD \$(shares in Thousands, \$ in Thousands Sep. 30, 2024 Mar. 31, 2024 Dec. 31, 2023 Allowance of doubtful accounts \$ 19 Å \$ 17 Allowance for obsolescence \$ 86 Å 162 Intangibles amortization Å \$ 143 \$ 113 Preferred stock, par value (in dollars per share) \$ 0.01 Å \$ 0.01 Preferred stock, shares authorized (in shares) 10,000 Å 10,000 Preferred stock, shares outstanding (in shares) 0 Å 0 Common stock, par value (in dollars per share) \$ 0.01 Å \$ 0.01 Common stock, shares authorized (in shares) 60,000 Å 60,000 Common stock, shares outstanding (in shares) 4,598 Å 4,598 Common stock, shares issued (in shares) 4,598 Å 4,598 X - DefinitionAmount of allowance for credit loss on accounts receivable, classified as current. + ReferencesReference 1: <http://www.xbrli.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(4)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://www.xbrli.org/2003/role/disclosureRef> -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479344/326-20-45-1>Reference 3: <http://www.xbrli.org/2003/role/disclosureRef> -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481962/310-10-50-4> + Details Name: us-gaap AllowanceForDoubtfulAccountsReceivableCurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://www.xbrli.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: <http://www.xbrli.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1> + Details Name: us-gaap CommonStockSharesAuthorized Namespace Prefix: us-gaap Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap CommonStockSharesIssued Namespace Prefix: us-gaap Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI <https://asc.fasb.org/1943274/214748112/505-10-50-2>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: <http://www.xbrli.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-2>Reference 4: <http://www.xbrli.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 5: <http://www.xbrli.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3> + Details Name: us-gaap CommonStockSharesOutstanding Namespace Prefix: us-gaap Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAccumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: <http://www.xbrli.org/2003/role/exampleRef> -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482640/350-30-55-40>Reference 2: <http://www.xbrli.org/2003/role/disclosureRef> -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480265/350-10-S45-1>Reference 3: <http://www.xbrli.org/2003/role/disclosureRef> -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482665/350-30-50-2>Reference 4: <http://www.xbrli.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(16)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap FiniteLivedIntangibleAssetsAccumulatedAmortization Namespace Prefix: us-gaap Data Type:

xbrl:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of valuation reserve for inventory. + ReferencesReference 1:

Paragraph 1 -Publisher FASB -URI

Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32): [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33): <http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34>: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35>: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36): [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37):

Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23>: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32): [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33): <http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34>: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35>: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37): [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04\(22\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax and reclassification adjustments of other comprehensive income \(loss\). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax and reclassification adjustments of other comprehensive income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2): <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 3>: <http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 4>: <http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-1Reference 5>: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(19\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 6](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 6): <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4Reference 7>: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 8>: <http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 9>: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(21\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 10](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 10): [http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04\(23\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 11](http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 11): [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 12](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 12): <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 55 -Paragraph 15 -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15Reference 13>: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued which are neither cancelled nor held in the treasury. + ReferencesNo definition available. + Details Name: us-gaap_SharesOutstanding Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemBalance Type: na Period Type: instant X - DefinitionValue, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan \(ESOP\). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(28\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued which are neither cancelled nor held in the treasury. + ReferencesNo definition available. + Details Name: us-gaap_SharesOutstanding Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemBalance Type: na Period Type: instant X - DefinitionValue, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2): [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3): [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.3-04\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 4](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 4): [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph \(d\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity \(deficit\) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2): [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(30\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3): <http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5>: <http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6>: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(19\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-599-1Reference 7](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-599-1Reference 7): [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.6-05\(4\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8): [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(4\)\(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9): [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(6\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10): [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(7\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11): [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12): [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13): [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14): [http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML Flows FROM OPERATING ACTIVITIES: A Net Income $ 6,914 $ 3,816 Adjustments to reconcile net income to net cash provided by operating activities: A us-gaap_DepreciationDepletionAndAmortization 85,646 Allowance for doubtful accounts 2,177 Allowance for inventory obsolescence (76) 35 Stock-based compensation 344 94 Amortization of deferred financing costs 31 8 Accounts receivable 18 (498) Inventories (1,223) 2,534 Deferred tax asset 270 709 Prepaid expense, other current assets and sales tax receivable 793 (471) Right-of-use asset 72 60 Accounts payable 827 (3,570) Lease liability (82) (60) Accrued expense, other liabilities and income taxes payable 680 71 Product returns (2) (3) Net cash provided by operating activities 8,653 2,772 Amortization of deferred financing costs 31 8 Accounts receivable 18 (498) Inventories (1,223) 2,534 Deferred tax asset 270 709 Prepaid expense, other current assets and sales tax receivable 793 (471) Right-of-use asset 72 60 Accounts payable 827 (3,570) Lease liability (82) (60) Accrued expense, other liabilities and income taxes payable 680 71 Product returns (2) (3) Net cash provided by operating activities 8,653 2,772 us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract A Purchase of property and equipment (10) (60) Cash paid for acquisition of Mimiá™s Rock Corp. 0 (17,099) Cash deposit paid for the acquisition of MusclePharm assets 0 (1,825) Net cash used in investing activities (10) (18,984) us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract A Borrowings on term loans 0 12,500 Payments on term loans (5,875) (1,250) Net cash provided by (used in) financing activities (5,875) 11,250 Foreign currency impact on cash 54 (3) CHANGE IN CASH AND RESTRICTED CASH 2,822 (4,965) CASH, BEGINNING OF PERIOD 1,898 13,277 CASH AND RESTRICTED CASH, END OF PERIOD 4,720 8,312 Supplemental cash flow disclosure A Cash paid for income taxes 1,105 993 Cash paid for interest, net of amounts capitalized 1,083 475 Non-cash investing and financing activities A Addition to right-of-use assets from new operating lease liabilities $ 386 $ 0 X - DefinitionIn reference to the amortization of deferred finance costs. + ReferencesNo definition available. + Details Name: fltf_AmortizationOfDeferredFinanceCosts Namespace Prefix: fltf_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of right-of-use asset net of amortization and lease liability from operating lease. + ReferencesNo definition available. + Details Name: fltf_OperatingLeaseRightOfUseAssetNetOfAmortizationAndLeaseLiability Namespace Prefix: fltf_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemBalance Type: na Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2): <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2>: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase \(decrease\) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2):

rates. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 230 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1> + Details Name: us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 23 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22>Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 230 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2> + Details Name: us-gaap_IncomeTaxesPaidNet Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap_IncreaseDecreaseInAccountsPayable Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap_IncreaseDecreaseInAccountsReceivable Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in accrued expenses, and obligations classified as other. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 912 -SubTopic 310 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478345/912-310-45-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 912 -SubTopic 310 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478345/912-310-45-1)Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap_IncreaseDecreaseInContractWithCustomerLiability Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap_IncreaseDecreaseInDeferredIncomeTaxes Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap_IncreaseDecreaseInInventories Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in obligation for operating lease. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28)Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(g\)\(1\) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4](http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4) + Details Name: us-gaap_IncreaseDecreaseInOperatingLeaseLiability Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap_IncreaseDecreaseInPrepaidExpense Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17](http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph \(e\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25](http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25)Reference 3: <http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2> + Details Name: us-gaap_InterestPaidNet Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483080/330-10-50-2> + Details Name: us-gaap_InventoryWriteDown Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionFair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(b\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24> + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24> + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(g\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2)Reference 5: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-50-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-50-2)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-50-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 9: <http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 11: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(b\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 13: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8>Reference 14: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 16: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 17: <http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10>Reference 18: <http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7>Reference 19: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(18\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-50-19](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-50-19)Reference 20: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-07\(9\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-50-19](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-50-19)Reference 21: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(1\)\(d\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-50-19](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-50-19)Reference 22: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-50-1)Reference 23: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-50-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-50-1)Reference 24: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-50-1)Reference 25: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-50-1)Reference 26: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-50-1)Reference 27: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-50-1)Reference 28: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-50-1)Reference 29: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-50-1)Reference 30: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-50-1)Reference 31: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-50-1)

[http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04\(22\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1) + Details Name: us-gaap NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap NoncashInvestingAndFinancingItemsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash outflow for deposits classified as other. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13) + Details Name: us-gaap PaymentsForOtherDeposits Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(b\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13](http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13) + Details Name: us-gaap PaymentsToAcquireBusinessesGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13) + Details Name: us-gaap PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-03\(i\)\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14) + Details Name: us-gaap ProceedsFromIssuanceOfLongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of expense (reversal of expense) for expected credit loss on accounts receivable. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2) + Details Name: us-gaap ProvisionForDoubtfulAccounts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-03\(i\)\(2\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3) + Details Name: us-gaap RepaymentsOfLongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase in right-of-use asset obtained in exchange for operating lease liability. + ReferencesReference 1: [http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(g\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4](http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4) + Details Name: us-gaap RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap SupplementalCashFlowInformationAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DescriptionOf Business 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Á Nature of Operations [Text Block] NOTE 1 - DESCRIPTION OF BUSINESS Á Summary Á FitLife Brands, Inc. (the Company) is a provider of innovative and proprietary nutritional supplements and wellness products for health-conscious consumers marketed under the following brand names: (i) NDS Nutrition, PMD Sports, SirenLabs, Core Active, Nutrology, and Metis Nutrition (together, NDS Products); (ii) iSatori, BioGenetic Laboratories, and Energize (together, the iSatori Products); (iii) Dr. Tobias, All Natural Advice, and Maritime Naturals (together, the MRC Products); and (iv) MusclePharm. Á The Company distributes the NDS Products principally through franchised General Nutrition Centers, Inc. (GNC) stores located both domestically and internationally and, with the launch of Metis Nutrition, through corporate GNC stores in the U.S. The iSatori Products are sold through retail locations, which include specialty and mass, as well as online directly to the end consumer. The Company distributes the MRC Products primarily online through e-commerce platforms, such as Amazon, directly to the end consumer. MusclePharms products are sold to both wholesale customers as well as online through various e-commerce platforms directly to the end consumer. Á FitLife Brands is headquartered in Omaha, Nebraska. For more information on the Company, please go to www.fitlifebrands.com. The Companys common stock, par value \$0.01 per share (Common Stock), trades under the symbol FTLF on the Nasdaq Capital Market. Á X - ReferencesNo definition available. + Details Name: us-gaap DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the nature of an entitys business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 275 -Publisher FASB -URI https://asc.fasb.org/275/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 275 -Publisher FASB -URI https://asc.fasb.org/275/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1) + Details Name: us-gaap NatureOfOperations Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 19 R8.htm IDEA: XBRL DOCUMENT v3.24.3 Note 2 - Basis of Presentation 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Á Basis of Accounting [Text Block] NOTE 2 - BASIS OF PRESENTATION Á The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation are included. Operating results for the three- and nine-month periods ended September 30, 2024 are not necessarily indicative of the results that may be expected for the year ending December 31, 2024. Although management of the Company believes the disclosures presented herein are adequate and not misleading, these interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the footnotes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Securities and Exchange Commission (the SEC) on March 29, 2024. Á X - DefinitionThe entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent> + Details Name: us-gaap BasisOfAccounting Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 20 R9.htm IDEA: XBRL DOCUMENT v3.24.3 Note 3 - Summary of Significant Accounting Policies 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Á Significant Accounting Policies [Text Block] NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Á The Company prepares its financial statements in accordance with accounting principles generally accepted in the U.S. (GAAP). Significant accounting policies are as follows: Á Principles of Consolidation Á The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. Intercompany accounts and transactions have been eliminated in the condensed consolidated financial statements. Á Foreign Currency Translation Á The functional currency of the Company is the U.S. dollar (USD). The functional currency of the Companys Canadian subsidiaries is the Canadian dollar (CAD). The assets and liabilities of the Companys foreign subsidiaries are translated into U.S. dollars using end-of-period exchange rates. Changes in reported amounts of assets and liabilities of foreign subsidiaries that occur as a result of changes in exchange rates between foreign subsidiaries functional currencies and the U.S. dollar are included in foreign currency translation adjustment. Foreign currency translation adjustment is included as a component of stockholders equity in the accompanying condensed consolidated balance sheets. Revenue and expense transactions use an average rate prevailing during the period of the related transaction. Transaction gains and losses that arise from exchange rate fluctuations denominated in a currency other than the functional currency of each subsidiary are included in the results of operations as incurred. Á Use of Estimates and Assumptions Á The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect (i) the reported amounts of assets and liabilities, (ii) the disclosure of contingent assets and liabilities known to exist as of the date the financial statements are published, and (iii) the reported amount of net sales and expense recognized during the periods presented. Á Those estimates and assumptions include estimates for reserves of uncollectible accounts receivable, allowance for inventory obsolescence, product returns, depreciable lives of property and equipment, allocation of purchase price from business combinations, analysis of impairment of goodwill, realization of deferred tax assets, accruals for potential liabilities and assumptions made in valuing stock instruments issued for services. Management evaluates these estimates and assumptions on a regular basis. Actual results could differ from those estimates. Á Revenue Recognition Á The Companys revenue is comprised of sales of nutritional supplements and wellness products to consumers. Á The Company accounts for revenue in accordance with FASB ASC 606, Revenue from Contracts with Customers (ASC 606). The underlying principle of ASC 606 is to recognize revenue to depict the transfer of goods or services to customers at the amount expected to be collected. ASC 606 creates a five-step model that requires entities to exercise judgment when considering the terms of contract(s), which includes (1) identifying the contract(s) or agreement(s) with a customer, (2) identifying our performance obligations in the contract or agreement, (3) determining the transaction price, (4) allocating the transaction price to the separate performance obligations, and (5) recognizing revenue as each performance obligation is satisfied. Under ASC 606, revenue is recognized when performance obligations under the terms of a contract are satisfied, which occurs for the Company upon shipment or delivery of products to our customers based on written sales terms. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring the products to a customer. Á All products sold by the Company are distinct individual products and consist of nutritional supplements and wellness products. The products are offered for sale solely as finished goods, and there are no performance obligations required post-shipment for customers to derive the expected value from them. Á The Companys products are also sold on e-commerce platforms including Amazon. For these transactions, the Company evaluated principal versus agent considerations to determine appropriateness of recording distribution and platform fees paid to third-party e-commerce companies as an expense or as a reduction of revenue. The Company records distribution and platform fees to cost of goods sold in the condensed consolidated statements of income and comprehensive income. Distribution and platform fees are not recorded as a reduction of revenue because the Company (1) owns the goods before they are transferred to the customer, (2) can direct Amazon, similar to other third-party logistics providers (Logistic Providers), to return the Companys inventory to any location specified by the Company, (3) has the responsibility to make customers whole following any returns made by customers directly to Logistic Providers and the Company retains the back-end inventory risk, (4) is subject to credit risk (i.e., credit card chargebacks), (5) establishes prices of its products, (6) can determine who fulfills the goods to the customer (Amazon or the Company) and (7) can limit quantities or stop selling the goods at any time. Based on these considerations, the Company is the principal in this arrangement. Advertising fees paid to Amazon are recorded in advertising and marketing expense in the condensed consolidated statements of income and comprehensive income. Á The Company disaggregates revenue into distribution channels, geographical regions, and collections of brands (Legacy FitLife and recently acquired brands). The Company determines that disaggregating revenue into these categories achieves the disclosure objective to depict how the nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factors. Á Online revenue during the three months ended September 30, 2024 and 2023 was approximately 68% of net revenue for both periods, compared to 32% for the wholesale channel for the same periods. Online revenue during the nine months ended September 30, 2024 and 2023 was approximately 66% and 62% of net revenue, compared to 34% and 38% for the wholesale channel for the same period. Á Á Sales to customers in the U.S. were approximately 95% and 93% during the three months ended September 30, 2024 and 2023, respectively, with the balance of sales for the same respective periods being to customers primarily in Canada. Sales to customers in the U.S. were approximately 96% and 94% during the nine months ended September 30, 2024 and 2023, respectively, with the balance of sales for the same respective periods being to customers primarily in Canada. Á The Company provides limited financial performance metrics for three collections of brands Legacy FitLife (consists of nine brands), MRC (consists of three brands), and MusclePharm (one brand). These collections of brands do not meet the definition of operating segments and are not managed as such. Á Á Three months ended September 30, Á Á Nine months ended September 30, Á Á Á 2024 Á Á 2023 Á Á 2024 Á Á 2023 Á Legacy FitLife Á \$ 6,302 Á Á \$ 6,700 Á Á \$ 20,065 Á Á \$ 21,933 Á MRC Á \$ 7,210 Á Á \$ 7,202 Á Á \$ 22,164 Á Á \$ 17,468 Á MusclePharm Á \$ 2,465 Á Á \$ 2,727 Á Á \$ 2,727 Á Á \$ 2,727 Á Á \$ 2,727 Á Revenue Á \$ 15,977 Á Á \$ 13,902 Á Á \$ 49,456 Á Á \$ 39,401 Á Control of products we sell transfers to customers upon shipment from our facilities or delivery to our customers, and the Companys performance obligations are satisfied at that time. Shipping and handling activities are performed before the customer obtains control of the goods and therefore represent a fulfillment activity rather than promised goods to the customer. Payments for sales are generally made by check, credit card, or wire transfer. Historically the Company has not experienced any significant payment delays from customers. Á For direct-to-consumer sales, the Company allows for returns within 30 days of purchase. Our wholesale customers, such as GNC, may return purchased products to the Company under certain circumstances, which include expired or soon-to-be-expired products located in GNC corporate stores or at any of its distribution centers, and products that are subject to a recall or that contain an ingredient or ingredients that are subject to a recall by the U.S. Food and Drug Administration (FDA). Á A right of return does not represent a separate performance obligation, but because customers are allowed to return products, the consideration to which the Company expects to be entitled is variable. Upon evaluation of returns, the Company determined that product returns are immaterial, and therefore believes it is probable that such returns will not cause a significant reversal of revenue in the future. We assess our contracts and the reasonableness of our conclusions on a quarterly basis. Á Customer and Vendor Concentration Á Net sales to GNC during the three-month periods ended September 30, 2024 and 2023 represent 23% and 30% of total net revenue, respectively. Net sales to GNC during the nine-month periods ended September 30, 2024 and 2023 represent 24% and 34% of total net revenue, respectively. Gross accounts receivable attributable to GNC represented 28% and 30% of the Companys total accounts receivable balance as of September 30, 2024 and December 31, 2023, respectively. Á As of September 30, 2024 and December 31, 2023, there was one vendor that accounted for more than 10% of the Companys consolidated accounts payable. During the nine months ended September 30, 2024 and 2023, there were two vendors that each accounted for over 10% of the Companys inventory-related purchases. Á Cash and Cash Equivalents Á The Company considers all highly liquid investments with an original maturity from the date of purchase of three months or less to be cash equivalents. The Company has approximately \$56 in short-term interest-earning accounts pledged as collateral for financing arrangements at September 30, 2024, currently limited to business credit cards. Á Leases Á We lease certain corporate office space and office equipment under lease agreements with monthly payments over a period of 36 to 84 months. We determine if an arrangement is a lease at inception. Leased assets are presented as operating lease right-of-use assets and the related liabilities are presented as lease liabilities in our condensed consolidated balance sheets. Á Goodwill Á The Company has determined that it has a single reporting unit for purposes of performing its goodwill impairment test. The Company reviews goodwill for impairment on an annual basis or whenever events or changes in circumstances indicate the carrying value may not be recoverable. The Company first assesses

qualitative factors to determine whether it is more-likely-than-not that the fair value of the reporting unit is less than the carrying amount as a basis for determining whether it is necessary to perform an impairment test. If the qualitative assessment warrants further analysis, the Company compares the fair value of the reporting unit to its carrying value. The fair value of the reporting unit is determined using the market approach. The Company determines the amount of a potential goodwill impairment by comparing the fair value of the reporting unit with its carrying amount. To the extent the carrying value of a reporting unit exceeds its fair value, a goodwill impairment charge is recognized. As the Company uses the market approach to determine fair value of the reporting unit, the price of its Common Stock is an important component of the fair value calculation. If the Company's stock price experiences significant price fluctuations, this will impact the fair value of the reporting unit, which can lead to potential impairment in future periods. Management determined there were no indicators of impairment at September 30, 2024 or December 31, 2023. The Company will perform its next impairment analysis in December 2024. Intangible Assets The Company has certain intangible assets that were recorded at their fair value at the time of acquisition. The finite-lived intangible assets consist of client relationships, formulations, and website. Intangible assets with finite useful lives are amortized using the straight-line method over their estimated useful life. Intangible assets with indefinite lives, which consist of brands and trademarks, are not amortized but are tested for impairment annually or when indicators of impairment exist. Factors that management considers in this assessment include macroeconomic conditions, industry and market considerations, overall financial performance (both current and projected), changes in management and strategy, and changes in the composition and carrying amounts of net assets. If this qualitative assessment indicates that it is more likely than not that the fair value of a reporting unit is less than its carrying value, a quantitative assessment is then performed. The Company noted no indicators of impairment for intangible assets as of September 30, 2024, and December 31, 2023. Acquisitions and Business Combinations The Company allocates the fair value of purchase consideration to the tangible assets acquired, liabilities assumed, and separately identified intangible assets acquired based on their estimated fair values. The excess of the fair value of purchase consideration over the fair values of these identifiable assets and liabilities is recorded as goodwill. Such valuations require management to make significant estimates and assumptions, especially with respect to intangible assets. Significant estimates in valuing certain intangible assets include, but are not limited to, future expected cash flows from acquired trademarks and trade names, useful lives, and discount rates. Management's estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. During the measurement period, which is the period needed to gather all information necessary to make the purchase price allocation, not to exceed one year from the acquisition date, we may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period, any subsequent adjustments are recorded to earnings. Income Taxes Provision for income taxes consists of current and deferred tax expense. Current tax expense is the expected tax payable on the taxable income for the year using tax rates enacted in the countries where the Company and its subsidiaries operate and generate taxable income. The Company accounts for income taxes using the asset and liability method, whereby deferred tax assets are recognized for deductible temporary differences and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets may also result from unused losses and other deductions carried forward. An assessment of the probability that a deferred tax asset will be recovered is made prior to any deferred tax asset being recognized. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized, or that future deductibility is uncertain. The income tax provision for interim periods is determined using an estimate of the annual effective tax rate, adjusted for discrete items, if any, that are taken into account in the relevant period. Each quarter, the estimate of the annual effective tax rate is updated, and if the estimated effective tax rate changes, a cumulative adjustment is made. There is potential for volatility of the effective tax rate due to several factors, including changes in the mix of the pre-tax income and the jurisdictions to which it relates. The effective income tax rate was 25% and 28% for the nine months ended September 30, 2024 and 2023, respectively. Net Income Per Share Our computation of earnings per share (EPS) includes basic and diluted EPS. Basic EPS is measured as the income available to common stockholders divided by the weighted average common shares outstanding for the period. Diluted EPS reflects the potential dilution, using the treasury stock method, that could occur if securities or other contracts to issue Common Stock were exercised or converted into Common Stock or resulted in the issuance of Common Stock that then shared in the income of the Company as if they had been converted at the beginning of the periods presented, or issuance date, if later. In computing diluted EPS, the treasury stock method assumes that outstanding options and warrants are exercised, and the proceeds are used to purchase Common Stock at the average market price during the period. Options and warrants may have a dilutive effect under the treasury stock method only when the average market price of the Common Stock during the period exceeds the exercise price of the options and warrants. Potential common shares that have an antidilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS. Three months ended September 30, Nine months ended September 30, 2024 2023 2024 2023 Net income available to common shareholders \$ 2,126 \$ 1,696 \$ 6,914 \$ 3,816 Weighted average common shares - basic 4,598 4,446 4,598 4,458 Dilutive effect of outstanding warrants and stock options 367 445 345 443 Weighted average common shares - diluted 4,965 4,891 4,943 4,901 Net income per common share: Basic \$ 0.46 \$ 0.38 \$ 1.50 \$ 0.86 Diluted \$ 0.43 \$ 0.35 \$ 1.40 \$ 0.78 Fair Value Measurements The Company uses various inputs in determining the fair value of its investments and measures these assets on a recurring basis. Financial assets recorded at fair value in the balance sheets are categorized by the level of objectivity associated with the inputs used to measure their fair value. FASB ASC Topic 820, Fair Value, establishes a three-level valuation hierarchy for the use of fair value measurements based upon the transparency of inputs to the valuation of an asset or liability as of the measurement date: Level 1—Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities; Level 2—Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means; Level 3—Inputs that are both significant to the fair value measurement and unobservable. These inputs rely on management's own assumptions about the assumptions that market participants would use in pricing the asset or liability. The unobservable inputs are developed based on the best information available in the circumstances and may include the Company's own data. The carrying amounts of financial assets and liabilities, such as cash and cash equivalents, restricted cash, accounts receivable and accounts payable, approximate their fair values because of the short maturity of these instruments. The carrying value of our notes payable approximate their fair value based on the market interest rates of these notes. Segment The Company operates in one segment, providing nutritional supplements and wellness products to health-conscious consumers. The Company's chief operating decision maker is the Chief Executive Officer, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company. Reclassifications Certain reclassifications have been made in the Company's financial statements. Advertising and marketing expense for the three and nine months ended September 30, 2023 were previously reported as part of selling, general and administrative expense. Advertising and marketing expense is now segregated and reported separately in the accompanying statement of income and comprehensive income to conform to current period presentation. These reclassifications had no impact on earnings or stockholders' equity. Recently Adopted Accounting Pronouncements In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosure (ASC 280A), which is intended to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expense categories that are regularly provided to the chief operating decision maker and included in each reported measure of a segment's profit or loss. The update also requires all annual disclosures about a reportable segment's profit or loss and assets to be provided in interim periods and for entities with a single reportable segment to provide all the disclosures required by ASC 280, including the significant segment expense disclosures. This standard became effective for the Company on January 1, 2024. The adoption of this standard did not have a material impact on its results of operations, financial position or cash flows. Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company's present or future financial statements. X - References No definition available. + Details Name: us-gaap DisclosureTextBlockAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for all significant accounting policies of the reporting entity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 - SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent + Details Name: us-gaap SignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 21 R10.htm IDEA: XBRL DOCUMENT v3.24.3 Note 4 - Inventories 9 Months Ended Sep. 30, 2024 Notes to Financial Statements A Inventory Disclosure [Text Block] NOTE 4 INVENTORIES The Company's inventory is carried at the lower of cost or net realizable value using the first-in, first-out (FIFO) method. The Company evaluates the need to record adjustments for inventory on a regular basis. Company policy is to evaluate all inventories including components and finished goods for all of its product offerings across all of the Company's operating subsidiaries. The Company recognizes an allowance for obsolescence for expiring, excess, and slow-moving inventory. To calculate the allowance, the Company analyzes sales projections for each stock-keeping unit (SKU) relative to the remaining shelf life of the product. The value of any finished goods inventory projected to expire prior to sale is included in the allowance. The total allowance for expiring, excess and slow-moving inventory items as of September 30, 2024 and December 31, 2023 amounted to \$86 and \$162, respectively. The Company's inventories as of September 30, 2024 and December 31, 2023 were as follows: A September 30, 2024 A December 31, 2023 A (Unaudited) A Finished goods \$ 9,403 A \$ 8,292 A Components A 1,054 A A 961 A Allowance for obsolescence A (86) A (162) Total A 10,371 A A 9,091 A X - References No definition available. + Details Name: us-gaap DisclosureTextBlockAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/330/tableOfContent + Details Name: us-gaap InventoryDisclosureTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 22 R11.htm IDEA: XBRL DOCUMENT v3.24.3 Note 5 - Property and Equipment 9 Months Ended Sep. 30, 2024 Notes to Financial Statements A Property, Plant and Equipment Disclosure [Text Block] NOTE 5 - PROPERTY AND EQUIPMENT The Company had property and equipment as of September 30, 2024 and December 31, 2023 as follows: A September 30, 2024 A December 31, 2023 A (Unaudited) A Equipment A 965 A A 954 A Accumulated depreciation A (874) A (817) Total A 91 A A 137 A Depreciation expense for the three months ended September 30, 2024 and 2023 was \$15 and \$11, respectively. Depreciation expense for the nine months ended September 30, 2024 and 2023 was \$57 and \$33, respectively. A X - References No definition available. + Details Name: us-gaap DisclosureTextBlockAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/360/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 6 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/214777798/958-360-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/214777798/958-360-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 7 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/214777798/958-360-50-7 + Details Name: us-gaap PropertyPlantAndEquipmentDisclosureTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 23 R12.htm IDEA: XBRL DOCUMENT v3.24.3 Note 6 - Notes Payable 9 Months Ended Sep. 30, 2024 Notes to Financial Statements A Debt Disclosure [Text Block] NOTE 6 NOTES PAYABLE A Notes payable consisted of the following: A September 30, 2024 A December 31, 2023 A (Unaudited) A Term Loan A 6,250 A A 10,625 A Term Loan B A 8,000 A A 9,500 A Line of Credit A A A Unamortized debt issuance costs A (86) A (116) Total A 14,164 A A 20,009 A Current A (4,500) A (4,500) Long term A \$ 9,664 A \$ 15,509 A Credit Agreements A First Citizens Bank A On February 23, 2023, the Company entered into an Amended and Restated Credit Agreement (the Credit Agreement) with First Citizens Bank (the Bank), amending and restating that certain Credit Agreement, dated September 24, 2019, between the Company and the Bank. Pursuant to the Previous Credit Agreement, the Bank provided the Company with a term loan for the principal amount of \$12,500 (the Term Loan A), and a revolving line of credit of \$3,500 (the Line of Credit), and collectively with the Term Loans, the Loan. The Company used the proceeds from the Loan to fund the acquisition of MRC (discussed in further detail in Note 8) and for general working capital purposes. A Second Amended and Restated Credit Agreement A On October 10, 2023, the Company entered into a Second Amended and Restated Credit Agreement (the Amended Credit Agreement) with the Bank, amending and restating the Credit Agreement between the Company and the Bank. Pursuant to the Amended Credit Agreement, the Bank provided the Company with an additional Term Loan (the Term Loan B), and together with Term Loan A, the Term Loans for the principal amount of \$10,000 and extended the Line of Credit of \$3.5 million to December 15, 2024. The Company used the proceeds from Term Loan B to fund the acquisition of the MusclePharm assets (discussed in further detail in Note 9) and for general working capital purposes. A Term Loans - Pursuant to the Amended Credit Agreement, the Term Loans accrue interest at a per annum rate equal to 2.75% above the one-month secured overnight financing rate ("SOFR") published for such day by the Federal Reserve Bank of New York. The Company shall make quarterly payments of principal plus accrued interest on the Term Loans until the principal balances are fully amortized. Quarterly principal payments for Term Loan A and Term Loan B are \$625 and \$500, respectively. During the first quarter of 2024, the Company made a voluntary prepayment on Term Loan A of \$2,500, and as such, Term Loan A will fully amortize in February 2027. Term Loan B will fully amortize in October 2028. A Line of Credit - Also pursuant to the Amended Credit Agreement, outstanding advances under the Line of Credit (the Advances) will accrue interest at a per annum rate equal to 2.75% above the one-month SOFR, and the Company will pay the interest on the Advances monthly, with all principal and any accrued interest on outstanding Advances being due and payable in full on the Line of Credit maturity date. The Company may prepay amounts borrowed under the Loan, in whole or in part with accrued interest to the date of such prepayment on the amount prepaid, by written notice to Bank at least one business day prior to the proposed prepayment. A The Company may prepay amounts borrowed under the Loan, in whole or in part with accrued interest to the date of such prepayment on the amount prepaid, by written notice to Bank at least one business day prior to the proposed prepayment. A The Amended Credit Agreement contains customary events of default (each an Event of Default), which upon the occurrence of an Event of Default, among other things, interest will accrue at the Applicable Rate plus 2% per annum, and the Bank may declare all obligations, with interest thereon, immediately due and payable. The Amended Credit Agreement further contains customary representations and warranties of the Company; customary indemnification provisions whereby the Company will indemnify Bank for certain losses arising out of inaccuracies in, or breaches of, the representations, warranties and covenants of the Company, and certain other matters; and customary affirmative and negative covenants, including covenants to maintain a Fixed Charge Coverage Ratio (as defined in the Amended Credit Agreement) of not less than 1.25 to 1.00 as tested quarterly on a trailing twelve-month basis, starting with the fiscal quarter ending December 31, 2023, a Funded Debt to EBITDA Ratio (as defined in the Amended Credit Agreement) of not more than 2.50 to 1.00 as tested quarterly on a trailing twelve-month basis, starting with the fiscal quarter ending March 31, 2024, and to the extent the Term Loans still have a balance as of June 30, 2025 and a Cash Flow Leverage threshold (as defined in the Amended Credit Agreement) of at least 1.15 is not met, the Company will be required to make a prepayment on the Term Loans equal to 50% of the Excess Cash Flow (as defined in the Amended Credit Agreement). The Company was in compliance with all covenants as of September 30, 2024 and December 31, 2023. A The borrowings outstanding on the Term Loans were

14.250A and \$20.125 on September 30, 2024, December 31, 2023, respectively. X There was no outstanding balance on the Line of Credit as of September 30, 2024 and December 31, 2023. A X - Definition The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants. + ReferencesReference 1:

CONTINGENCIES 9 Months Ended Sep. 30, 2024 Notes to Financial Statements 4 Commitments and Contingencies Disclosure [Text Block] NOTE 10 10 COMMITMENTS AND CONTINGENCIES 4 We currently are not involved in any litigation that we believe could have a material adverse effect on our financial condition or results of operations. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of the Company or any of its subsidiaries, threatened against or affecting the Company, our Common Stock, any of our subsidiaries or of the Company's officers or our subsidiaries' officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect. 4 X - Definition The entire disclosure for commitments and contingencies. + ReferencesReference 1:

[illegible]

SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8 + Details Name: us-gaap_UseOfEstimates Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 31 R20.htm IDEA: XBRL DOCUMENT v3.24.3 Note 3 - Summary of Significant Accounting Policies (Tables) 9 Months Ended Sep. 30, 2024 Notes Tables A Disaggregation of Revenue [Table Text Block] A A Three months ended September 30, A A Nine months ended September 30, A A 2024 A A 2023 A A 2024 A A 2023 A A 2023 A A 2023 A A Legacy FitLife A \$ 6,302 A A \$ 6,700 A A \$ 20,065 A A \$ 21,933 A MRC A A 7,210 A A 7,202 A A A 22,164 A A 17,468 A MusclePharm A A 2,465 A A A æ” A A A 7,227 A A A æ” A A Revenue A \$ 15,977 A A \$ 13,902 A A \$ 49,456 A A \$ 39,401 A Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] A A Three months ended September 30, A A Nine months ended September 30, A A 2024 A A 2023 A A 2024 A A 2023 A A A A A A A A A A A A Net income available to common shareholders A \$ 2,126 A A \$ 1,696 A A \$ 6,914 A A \$ 3,816 A Weighted average common shares - basic A A 4,598 A A 4,446 A A 4,598 A A 4,458 A Dilutive effect of outstanding warrants and stock options A A 367 A A 445 A A 345 A A 443 A Weighted average common shares - diluted A A 4,965 A A 4,891 A A 4,943 A A 4,901 A A A A A A A A A A A A Net income per common share: A A A A A A A A A A A A Basic A \$ 0.46 A A \$ 0.38 A A \$ 1.50 A A \$ 0.86 A Diluted A \$ 0.43 A A \$ 0.35 A A \$ 1.40 A A \$ 0.78 A X - DefinitionTabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 + Details Name: us-gaap_DisaggregationOfRevenueTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-50-1 + Details Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration XML 32 R21.htm IDEA: XBRL DOCUMENT v3.24.3 Note 4 - Inventories (Tables) 9 Months Ended Sep. 30, 2024 Notes Tables A Schedule of Inventory, Current [Table Text Block] A A September 30, 2024 A A December 31, 2023 A A (Unaudited) A A A Finished goods A \$ 9,403 A A \$ 8,292 A Components A A 1,054 A A 961 A Allowance for obsolescence A A (86) A A (162) Total A \$ 10,371 A A \$ 9,091 A X - DefinitionTabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-50-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-50-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1 + Details Name: us-gaap_ScheduleOfInventoryCurrentTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration XML 33 R22.htm IDEA: XBRL DOCUMENT v3.24.3 Note 5 - Property and Equipment (Tables) 9 Months Ended Sep. 30, 2024 Notes Tables A Property, Plant and Equipment [Table Text Block] A A September 30, 2024 A A December 31, 2023 A A (Unaudited) A A A Equipment A \$ 965 A A \$ 954 A Accumulated depreciation A A (874) A A (817) Total A \$ 91 A A \$ 137 A X - DefinitionTabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated depreciation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration XML 34 R23.htm IDEA: XBRL DOCUMENT v3.24.3 Note 6 - Notes Payable (Tables) 9 Months Ended Sep. 30, 2024 Notes Tables A Schedule of Debt [Table Text Block] A A September 30, 2024 A A December 31, 2023 A A (Unaudited) A A A Term Loan A \$ 6,250 A A \$ 10,625 A Term Loan B A A 8,000 A A 9,500 A Line of Credit A A æ” A A A æ” A Unamortized debt issuance costs A A (86) A A (116) Total A \$ 14,164 A A \$ 20,009 A Current A A (4,500) A A (4,500) Long term A \$ 9,664 A A \$ 15,509 A X - DefinitionTabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfDebtTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration XML 35 R24.htm IDEA: XBRL DOCUMENT v3.24.3 Note 7 - Equity (Tables) 9 Months Ended Sep. 30, 2024 Notes Tables A Share-Based Payment Arrangement, Option, Activity [Table Text Block] A A Number of options A A Weighted average exercise price A A Weighted average remaining life (years) A A Outstanding, December 31, 2023 A A 484 A A 6.82 A A 4.5 A Issued A A 10 A A 33.20 A A 5.0 A Exercised A A - A A - A - A A - A A - A A - A Forfeited A A - A A - A A - A Outstanding, September 30, 2024 A A 494 A A 7.36 A A 3.8 A Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block] Outstanding A A Exercisable A A Exercise price per share A A Total number of options A A Weighted average remaining life (years) A A Weighted average exercise price A A Number of vested options A A Weighted average exercise price A \$ 0.70 - 5.24 A A 349 A A 3.7 A A 2.29 A A 349 A A 2.29 A 11.55 - 33.20 A A 145 A A 3.9 A A 19.57 A A 58 A A 18.49 A A A A 494 A A 3.8 A A 7.36 A A 4.07 A A 4.57 A X - DefinitionTabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration XML 36 R25.htm IDEA: XBRL DOCUMENT v3.24.3 Note 8 - Acquisition of Mimi's Rock Corp (Tables) 9 Months Ended Sep. 30, 2024 Notes Tables A Business Acquisition, Pro Forma Information [Table Text Block] A A Nine months ended A A September 30, 2023 A A A A Revenue A \$ 44,455 A A A A A A Net income A \$ 5,419 A A A A Diluted net income per share A \$ 1.09 A X - DefinitionTabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -SubTopic 10 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(3) -SubTopic 10 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2 + Details Name: us-gaap_BusinessAcquisitionProFormaInformationTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration XML 37 R26.htm IDEA: XBRL DOCUMENT v3.24.3 Note 1 - Description of Business (Details Textual) - \$ / shares Sep. 30, 2024 Dec. 31, 2023 Preferred Stock, Par or Stated Value Per Share \$ 0.01 \$ 0.01 Series A Preferred Stock [Member] A A Preferred Stock, Par or Stated Value Per Share \$ 0.01 A X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PREFERREDStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - Details Name: us-gaap_StatementClassOfStockAxis-us-gaap_SeriesAPREFERREDStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 38 R27.htm IDEA: XBRL DOCUMENT v3.24.3 Note 3 - Summary of Significant Accounting Policies (Details Textual) - \$ in Thousands 3 Months Ended 9 Months Ended 12 Months Ended Sep. 30, 2024 USD (\$) Sep. 30, 2023 Sep. 30, 2024 USD (\$) Sep. 30, 2023 Dec. 31, 2023 USD (\$) Restricted Cash \$ 56 A \$ 56 A \$ 759 Effective Income Tax Rate Reconciliation, Percent A A 25.00% 28.00% A Minimum [Member] A A A Lessee, Operating Lease, Term of Contract 36 months A 36 months A A Maximum [Member] A A A Lessee, Operating Lease, Term of Contract 84 months A 84 months A A Asset Pledged as Collateral [Member] | Financing Arrangements [Member] A A A Restricted Cash \$ 56 A \$ 56 A A Geographic Concentration Risk [Member] | Revenue Benchmark [Member] | UNITED STATES A A A Concentration Risk, Percentage 95.00% 93.00% 96.00% 94.00% A Customer Concentration Risk [Member] | Revenue Benchmark [Member] | GNC [Member] A A A Concentration Risk, Percentage 23.00% 30.00% 24.00% 34.00% A Customer Concentration Risk [Member] | Accounts Receivable [Member] | GNC [Member] A A A Concentration Risk, Percentage A A 28.00% A 30.00% Customer Concentration Risk [Member] | Accounts Payable [Member] | One Vendor [Member] A A A A Number of Vendors A 1 A 1 Supplier Concentration Risk [Member] | Accounts Payable [Member] | Vendor Two [Member] A A A A Concentration Risk, Percentage A A A 10.00% Supplier Concentration Risk [Member] | Accounts Payable [Member] | Vendor One [Member] A A A A Concentration Risk, Percentage A A 10.00% A Supplier Concentration Risk [Member] | Inventory-related Purchases [Member] | Vendor Two [Member] A A A A Concentration Risk, Percentage A A A 10.00% A Supplier Concentration Risk [Member] | Inventory-related Purchases [Member] | Vendor One [Member] A A A A Concentration Risk, Percentage A A A 10.00% Supplier Concentration Risk [Member] | Inventory-related Purchases [Member] | Two Vendors [Member] A A A A Number of Vendors A 2 A 2 Online Sales [Member] | Product Concentration Risk [Member] | Revenue Benchmark [Member] A A A A Concentration Risk, Percentage 68.00% 68.00% 66.00% 62.00% A Wholesale Sales [Member] | Product Concentration Risk [Member] | Revenue Benchmark [Member] A A A A Concentration Risk, Percentage 32.00% 32.00% 34.00% 38.00% A X - DefinitionThe number of vendors. + ReferencesNo definition available. + Details Name: fltf_NumberOfVendors Namespace Prefix: fltf_ Data Type: xbrli:integerItem Type Balance Type: na Period Type: duration X - DefinitionFor an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20 + Details Name: us-gaap_ConcentrationRiskPercentage1 Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItem Type Balance Type: na Period Type: duration X - DefinitionPercentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231 + Details Name: us-gaap_EffectiveIncomeTaxRateContinuingOperations Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItem Type Balance Type: na Period Type: duration X - DefinitionTerm of lessee's operating lease, in 'PnYmMnDtnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseTermOfContract Namespace Prefix: us-gaap_ Data Type: xbrli:durationItem Type Balance Type: na Period Type: instant X - DefinitionAmount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-50-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-50-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (SX 210.9-03(1)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-50-1 + Details Name: us-gaap_RestrictedCash Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PledgedStatusAxis=us-gaap_AssetPledgedAsCollateralMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-

`us-gaap_PledgingPurposeAxis=rfll FinancingArrangementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=country US Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=ftfl GNCMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByVendorAxis=us-gaap_AccountsPayableMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=ftfl VendorTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=ftfl VendorTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=ftfl VendorOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByBenchmarkAxis=ftfl InventoryrelatedPurchasesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=ftfl TwoVendorsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=ftfl OnlineSalesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=ftfl WholesaleSalesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 39 R28.htm IDEA: XBRL DOCUMENT v3.24.3 Note 2 - Summary of Significant Accounting Policies - Disaggregation of Revenue (Details) - USD ($) in Thousands 3 Months Ended 9 Months Ended Sep 30, 2024 Sep 30, 2023 Revenue $ 15,977 $ 13,902 $ 49,456 $ 39,401 Legacy FitLife [Member] A A A Revenue 6,302 6,700 20,065 21,933 MRC [Member] A A A A Revenue 7,210 $ 7,202 22,164 $ 17,468 Muscle Pharm [Member] A A A A Revenue $ 2,465 A $ 7,227 A X - DefinitionAmount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - Details Name: us-gaap_StatementBusinessSegmentsAxis=ftfl LegacyFitLifeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=ftfl MRCMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=ftfl MusclePharmMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 40 R29.htm IDEA: XBRL DOCUMENT v3.24.3 Note 3 - Summary of Significant Accounting Policies - Basic and Diluted Income (Loss) Per Share (Details) - USD ($) / shares in Units, shares in Thousands, $ in Thousands 3 Months Ended 9 Months Ended Sep 30, 2024 Sep 30, 2023 Sep 30, 2024 Sep 30, 2023 Net INCOME $ 1,126 $ 1,696 $ 6,914 $ 3,816 Weighted average common shares - basic (in shares) 4,598 4,446 4,598 4,458 Dilutive effect of outstanding warrants and stock options (in shares) 367 445 345 443 Weighted average common shares - diluted (in shares) 4,965 4,891 4,943 4,901 Basic (in dollars per share) $ 0.46 $ 0.38 $ 1.5 $ 0.86 Diluted (in dollars per share) $ 0.43 $ 0.35 $ 1.4 $ 0.78 X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/20`

Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-599-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-599-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-599-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-599-1 + Details Name: us-gaap NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 41 R30.htm IDEA: XBRL DOCUMENT v3.24.3 Note 4 - Inventories (Details Textual) - USD (\$) \$ in Thousands Sep. 30, 2024 Dec. 31, 2023 Inventory Valuation Reserves \$ 86 \$ 162 X - DefinitionAmount of valuation reserve for inventory. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.BB) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480581/330-10-599-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1 + Details Name: us-gaap InventoryValuationReserves Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 42 R31.htm IDEA: XBRL DOCUMENT v3.24.3 Note 4 - Inventories - Summary of Inventory (Details) - USD (\$) \$ in Thousands Sep. 30, 2024 Dec. 31, 2023 Finished goods \$ 9,403 \$ 8,292 Components 1,054 961 Allowance for obsolescence (86) (162) Total \$ 10,371 \$ 9,091 X - DefinitionAmount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1 + Details Name: us-gaap InventoryFinishedGoods Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1 + Details Name: us-gaap InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1 + Details Name: us-gaap InventoryRawMaterials Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of valuation reserve for inventory. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.BB) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480581/330-10-599-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1 + Details Name: us-gaap InventoryValuationReserves Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 43 R32.htm IDEA: XBRL DOCUMENT v3.24.3 Note 5 - Property and Equipment (Details Textual) - USD (\$) \$ in Thousands 3 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2023 Depreciation \$ 15 \$ 11 \$ 57 \$ 33 X - DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_Depreciation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 44 R33.htm IDEA: XBRL DOCUMENT v3.24.3 Note 5 - Property and Equipment - Property and Equipment (Details) - USD (\$) \$ in Thousands Sep. 30, 2024 Dec. 31, 2023 Equipment \$ 965 \$ 954 Accumulated depreciation (874) (817) Total \$ 91 \$ 137 X - DefinitionAmount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-599-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-599-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap PropertyPlantAndEquipmentGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-599-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 45 R34.htm IDEA: XBRL DOCUMENT v3.24.3 Note 6 - Notes Payable (Details Textual) - USD (\$) \$ in Thousands 3 Months Ended Oct. 10, 2023 Feb. 23, 2023 Mar. 31, 2024 Sep. 30, 2024 Dec. 31, 2023 Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration] us-gaap:SecuredOvernightFinancingRateSoftMember A A A Revolving Credit Facility [Member] A A A A Line of Credit Facility, Maximum Borrowing Capacity \$ 3,500 \$ 3,500,000 A A A Debt Instrument, Basis Spread on Variable Rate A 2.75% A A A Long-Term Line of Credit A A A \$ 0 A Term Loan [Member] A A A A Debt Instrument, Face Amount \$ 12,500,000 A A A Debt Instrument, Additional Interest Rate, Default 2.00% A A A A Fixed Charge Coverage Ratio 1.25 A A A A Funded Debt to EBITDA Ratio 2.5 A A A A Long-Term Debt A A A 14,250 20,125 Term Loan B [Member] A A A A Debt Instrument, Face Amount \$ 10,000 A A A A Debt Instrument, Periodic Payment, Principal \$ 500 A A A A Long-Term Debt A A A 8,000 9,500 Term Loans [Member] A A A A Debt Instrument, Basis Spread on Variable Rate 2.75% A A A A Debt Instrument, Covenant, Cash Flow Leverage Threshold 0.000115 A A A A Debt Instrument, Covenant, Cash Flow Leverage Threshold, Percentage of Excess Cash Flow 50.00% A A A A Long-Term Debt A A A 14,164 20,009 Term Loan A [Member] A A A A Debt Instrument, Periodic Payment, Principal \$ 625 A A A A Repayments of Debt A A A 2,500 A A A Long-Term Debt A A A 6,250 10,625 X - DefinitionThe percent additional interest rate of debt instrument in the event of default. + ReferencesNo definition available. + Details Name: fltf DebtInstrumentAdditionalInterestRateDefault Namespace Prefix: fltf_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionRate of cash flow leverage threshold under covenant of the debt instrument. + ReferencesNo definition available. + Details Name: fltf DebtInstrumentCovenantCashFlowLeverageThreshold Namespace Prefix: fltf_ Data Type: xbrli:pureItemType Balance Type: na Period Type: instant X - DefinitionPercentage of excess cash flow for rate of cash flow leverage threshold under the covenant of the debt instrument. + ReferencesNo definition available. + Details Name: fltf DebtInstrumentCovenantCashFlowLeverageThresholdPercentageOfExcessCashFlow Namespace Prefix: fltf_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionThe fixed charge coverage ratio. + ReferencesNo definition available. + Details Name: fltf FixedChargeCoverageRatio Namespace Prefix: fltf_ Data Type: xbrli:pureItemType Balance Type: na Period Type: instant X - DefinitionThe Funded Debt to EBITDA Ratio. + ReferencesNo definition available. + Details Name: fltf FundedDebtToEBITDARatio Namespace Prefix: fltf_ Data Type: xbrli:pureItemType Balance Type: na Period Type: instant X - DefinitionPercentage points added to the reference rate to compute the variable rate on the debt instrument. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentBasisSpreadOnVariableRate1 Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na

Document Type: duration X - DefinitionAmount of debt instrument at time of issuance. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55-Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55-Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B>Reference 4: <http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55-Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2> + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of the required periodic payments applied to principal. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(22\)\) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) + Details Name: us-gaap_DebtInstrumentPeriodicPaymentPrincipal Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionIndicates type of variable interest rate on debt instrument. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 470 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/214747734/942-470-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 470 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/214747734/942-470-50-3) + Details Name: us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration Namespace Prefix: us-gaap_Data Type: enum2:enumerationSetItem Type Balance Type: na Period Type: duration X - DefinitionThe carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(22\)\) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-03\(16\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1)Reference 3: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(b\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1) + Details Name: us-gaap_LineOfCredit Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionMaximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(22\)\)\(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22))(b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(19\)\(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) + Details Name: us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(22\)\) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: <http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C>Reference 7: <http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C>Reference 8:

gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem
Balance Type: na Period Type: duration X - Definition Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem
Balance Type: debit Period Type: duration X - Definition The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Namespace Prefix: us-gaap_Data Type: dtr-types:percentItem
Balance Type: na Period Type: duration X - Definition The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Namespace Prefix: us-gaap_Data Type: dtr-types:percentItem
Balance Type: na Period Type: duration X - Definition The risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Namespace Prefix: us-gaap_Data Type: dtr-types:percentItem
Balance Type: na Period Type: duration X - Definition Gross number of share options (or share units) granted during the period. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem
Balance Type: na Period Type: duration X - Definition Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem
Balance Type: debit Period Type: instant X - Definition Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItem
Balance Type: na Period Type: duration X - Definition Price of a single share of a number of saleable stocks of a company. + ReferencesNo definition available. + Details Name: us-gaap_SharePrice Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItem
Balance Type: na Period Type: instant X - Definition Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriod Namespace Prefix: us-gaap_Data Type: xbrli:durationItem
Balance Type: na Period Type: duration X - Definition Number of shares that have been repurchased during the period and are being held in treasury. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480008/505-10-S99-1> + Details Name: us-gaap_TreasuryStockSharesAcquired Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem
Balance Type: na Period Type: duration X - Details Name: srt_ShareRepurchaseProgramAxis=fltf_ShareRepurchaseProgramMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember
Namespace Prefix: Data Type: na Balance Type: Period Type: XML 48 R37.htm IDEA: XBRL DOCUMENT v3.24.3 Note 7 - Equity - Stock Option Activity (Details) - \$ / shares shares in Thousands 1 Months Ended 9 Months Ended 12 Months Ended Aug. 31, 2024 Sep. 30, 2024 Dec. 31, 2023 Outstanding, number of options (in shares) 484 4 Outstanding, weighted average exercise price (in dollars per share) 6.82 4 Outstanding, weighted average remaining life (Year) 3 years 9 months 18 days 4 years 6 months Issued, number of options (in shares) 10 10 4 Issued, weighted average exercise price (in dollars per share) 33.2 33.2 4 Exercised, number of options (in shares) 0 4 Exercised, weighted average exercise price (in dollars per share) 0 4 0 Forfeited, number of options (in shares) 0 4 0 Forfeited, weighted average exercise price (in dollars per share) 0 4 0 Outstanding, number of options (in shares) 494 484 Outstanding, weighted average exercise price (in dollars per share) 7.36 6.82 X - Definition The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem
Balance Type: na Period Type: duration X - Definition Gross number of share options (or share units) granted during the period. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem
Balance Type: na Period Type: duration X - Definition Number of options outstanding, including both vested and non-vested options. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem
Balance Type: na Period Type: instant X - Definition Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItem
Balance Type: na Period Type: instant X - Definition Weighted average price at which option holders acquired shares when converting their stock options into shares. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItem
Balance Type: na Period Type: duration X - Definition Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItem
Balance Type: na Period Type: duration X - Definition Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItem
Balance Type: na Period Type: duration X - Definition Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap_Data Type: xbrli:durationItem
Balance Type: na Period Type: duration X - Definition Number of share options (or share units) exercised during the current period. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480008/505-10-S99-1> + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem
Balance Type: na Period Type: duration XML 49 R38.htm IDEA: XBRL DOCUMENT v3.24.3 Note 7 - Equity - Exercise Price Range (Details) shares in Thousands 9 Months Ended Sep. 30, 2024 \$ / shares shares Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding | shares 494 Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term 3 years 9 months 18 days Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price \$ 7.36 Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable | shares 407 Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price \$ 4.57 Range One [Member] 4 Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit 0.7 Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit \$ 5.24 Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding | shares 349 Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term 3 years 8 months 12 days Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price \$ 2.29 Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable | shares 349 Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price \$ 2.29 Range Two [Member] 4 Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit 11.55 Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit \$ 33.2 Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding | shares 145 Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term 3 years 10 months 24 days Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price \$ 19.57 Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable | shares 58 Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price \$ 18.49 X - Definition The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (g) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItem
Balance Type: na Period Type: duration X - Definition The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(iii) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem
Balance Type: na Period Type: instant X - Definition The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem
Balance Type: na Period Type: instant X - Definition The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (g) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItem
Balance Type: na Period Type: duration X - Definition Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding. +

ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) - Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> -Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining contractual term of outstanding stock options, in "PnYnMnDnThnMnS" format, for example, "P1Y5M13D" represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap_Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceAxis=ftlf_RangeOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X -Details Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ftlf_RangeTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 50 R39.htm IDEA: XBRL DOCUMENT v3.24.3 Note 8 - Acquisition of Mimi's Rock Corp (Details Textual) - USD (\$) \$ in Thousands 3 Months Ended 9 Months Ended Feb. 28, 2023 Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Goodwill \$ 13,130 \$ 13,130 \$ 13,294 Mimiæ™'s Rock Corp [Member] \$ \$ \$ \$ \$ Business Combination, Consideration Transferred \$ 17,099 \$ \$ \$ \$ Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill 7,630 \$ \$ \$ \$ Goodwill \$ 12,764 \$ \$ \$ \$ Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual \$ 7,210 \$ 7,202 \$ 22,164 \$ 17,468 \$ X - DefinitionAmount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 30 -Paragraph 8 -SubTopic 30 -Topic 805 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479637/805-30-30-8>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 30 -Topic 805 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479581/805-30-50-1> -Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 30 -Paragraph 7 -SubTopic 30 -Topic 805 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479637/805-30-30-7> + Details Name: us-gaap_BusinessCombinationConsiderationTransferred1 Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThis element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479328/805-10-50-2> + Details Name: us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of intangible assets, excluding goodwill, acquired at the acquisition date. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479907/805-20-50-1> + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482785/280-10-55-49>Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482548/350-20-55-24>Reference 3: <http://www.xbrl.org/2003/role/exampleRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482078/820-10-55-100>Reference 4: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-599-1>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482598/350-20-45-1> -Reference 7: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482573/350-20-50-1>Reference 8: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482573/350-20-50-1> -Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478546/942-210-599-1> + Details Name: us-gaap_Goodwill Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_BusinessAcquisitionAxis=ftlf_MimisRockCorpMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 51 R40.htm IDEA: XBRL DOCUMENT v3.24.3 Note 8 - Acquisition of Mimi's Rock Corp - Pro Forma Information (Details) - Mimiæ™'s Rock Corp [Member] \$ / shares in Units, \$ in Thousands 9 Months Ended Sep. 30, 2023 USD (\$) \$ / shares Revenue \$ 44,455 Net income \$ 5,419 Diluted net income per share (in dollars per share) | \$ / shares \$ 1,090.00 X - DefinitionThe pro forma diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -SubTopic 10 -Topic 805 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479328/805-10-50-2>Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(3) -SubTopic 10 -Topic 805 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479328/805-10-50-2> + Details Name: us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe pro forma net income or loss for the period as if the business combination or combinations had been completed at the beginning of a period. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479328/805-10-50-2>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(3) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479328/805-10-50-2> + Details Name: us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479328/805-10-50-2>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(3) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479328/805-10-50-2> + Details Name: us-gaap_BusinessAcquisitionProFormaRevenue Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_BusinessAcquisitionAxis=ftlf_MimisRockCorpMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 52 R41.htm IDEA: XBRL DOCUMENT v3.24.3 Note 9 - Acquisition of Muscelparm Assets (Details Textual) - USD (\$) \$ in Thousands Oct. 10, 2023 Sep. 30, 2024 Dec. 31, 2023 Inventory, Net \$ 10,371 \$ 9,091 Assets of MusclePharm Corporation [Member] \$ \$ Asset Acquisition, Consideration Transferred \$ 18,788 \$ A Inventory, Net 195 \$ A Assets of MusclePharm Corporation [Member] | Brands [Member] \$ \$ \$ Indefinite-Lived Intangible Assets Acquired 18,593 \$ A Assets of MusclePharm Corporation [Member] | Inventory Intangible Assets [Member] \$ \$ A Inventory, Net \$ 195 \$ X - DefinitionAmount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479908/805-50-55-1>Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480060/805-50-25-1>Reference 3: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480027/805-50-30-1>Reference 4: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480027/805-50-30-2> + Details Name: us-gaap_AssetAcquisitionConsiderationTransferred Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase in assets, excluding financial assets and goodwill, lacking physical substance with an indefinite life, from an acquisition. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482665/350-30-50-1>Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482665/350-30-50-2> + Details Name: us-gaap_IndefinitelivedIntangibleAssetsAcquired Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483467/210-10-45-1>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-599-1> + Details Name: us-gaap_InventoriesNet Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_AssetAcquisitionAxis=ftlf_AssetsOfMusclepharmCorporationMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ftlf_BrandsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ftlf_InventoriesIntangibleAssetsMember Namespace Prefix: Data Type: na Balance Type: Period Type: EXCEL 53 Financial Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial Report.xlsx M4\$!L!!0 (, [D,]E[4]0AUB[0] = 0 9%[C4']O< ,O8?!!+P+GAM M, \$V, /0L, 11\$!IQ; =<[P4]B0-!ZL+ (/>QLOD8!#LD) ^OCGI<VX>;QA&WPIG M*N*1#BV&5(C(!! 147BK9.7=>N) =HI6-Y #OGDK7A.YNJQ<4&GPZAA!W J=0U[R;UEA 6(M)I7E+ P04 M #).VY9,B)PPNX K=10&108U1R;WIS+V<O&ULS9+! M.L.P.(9297B>R[S]*8;.U;.G#&K;.QF.;+4UBQ<C.R1J^SE9FS'J[C1TN] MGT'."=-+7\$9J[C]2PW0W^K9+THOU.Q\$%9#,";U.94YTN7GHH]~4G \$(09L)M 42H, +^C2ZM)@T3L @.D+G&FDB;NKC16- @@~^!79UAU@~VZ+&C!^4P-OT M_9NSH8;(11!~^V@7XES]SMW@v28W)+.AB&M&W= M(MT9\$+2DW0.M&:7R; UYG& 9.KBU:HOHA'KO:AD\$5>)J621A~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~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d8R "P>KRJ;[17RQX%FH]^7F5[%ZAD]X39I M DDVQ;[LUB]>EFH9;8.A!%\$0%] \5L1+PZ3DT VP:P-P6T&Q[0]/<@/C+<+0H M68YU347BBY(2R^*K&@RBUGR& M^M/Y+0U4(VMDU)JX\$N&E1! ,F9B.MW0+119C?Y(2^2ACO4!U1?^Z @.E+L(M^ML5]8JA@G.1G1+7.2.85U+> <9X<@R\$N3PEU>+&OBN.6->?F>NZ^FGM977 = MPEMDJ964 FVKLD&R.Y<2U%Q,K8E\$POH^@DK 5JH[2?J4]!9EGT?0-#=-P=?=8V] W .' MAC:\$S.RA&E+@INQ+<(-600SUF+>V45QG.GVGX4YNR.7/;8JR/3V?C4QHJ.M+2-E3C37Y.H?03F^>FBA~!1QR0N8.NB61BHQO%FOU#<-^M0KJV,^~V(CQH%;(M+ P&S/O3Y@3^1J0 -=@%\$7C%WUK?E/9+~;~;O=? M=Y=1>F&8KBQ1U2ZQ@.59.MO-5D.G;P194W@JW&ND77T>[TOZM]<[>0BI^ MJBT85M)V#];~>ORHA 65V[V520T4BF3R]J4O>=?Y*Y6^GF5WE<44 M=VGC-PMZEC%NL8B'N?B+E-F'R'O..JYX]<@76D^Y\$Y=<#)NA&[Q]I8? ME=6J]N[&]1(NAG 851)2(EH&EX&K+3, 32W0RY4VU+16B;32=,5Y MS+1;3R/7X>+R8GYO/GOGE31=MYO..KEO^C M\$;06FJM/[C]^1..@/?>LNX'S;K=&SLZ/RZIE]9L<<^S&\$78F\$PZ9+.8T5) MW)=.6M;A8=B!0%5Q^<QRP6Y%+>@S4'U[5'M1%SEIRC7! ^I922SLC+N+;14% MMQN1#T76Q[O8R=.NU;1W-[X]P R+JM2 ^G75^KTA] E6101QTIGJ>@QDO9S1M9ASTK<4-@+ M.C.(MF8M-15S)]U4J[C^394R1E]@QNR1E^4WDDK=7TJZ]SL0:MK&A.KHYH@ M+1-];O97E6&B&K=W=E/GZ=>YUP>TJA+=[(1JU+)=j6T^2X0Y1] HM^NLUNFT: MH42SY4,<4J=30P&D6&K>N+>QJ%;KX(F(G,V,H,9M2W)>[J6LR16G^Q,9M .W.MWTY+L /K69WQ(N) 1^1(W%.._034[&83F ZU! M1LN[ZWM^3#M(1<=K..M!)UWV7%[P, ^13H7N65W?PX6 ~>DEPNSUCAEE&=9C0J;1M8C9J\$UK9J^BNC^Q8E]^A][W9L,WN^T6 08=>9)DS=M B^D[N- E^AE^P&TK[=OT<E#&(E4&5&? 2UVTJS^IUJ<>JP,;XAZDTA; =IC]7BZXJ]<M&511\$;Q4NJKIUF U_3Y+J\$YU=>2K318 _M!^D5ZJ+;0B>@QV/&9D\$M&LMW2G+>EWM[B^3CZ2O5QZ+PPWJW^/C/-SS>

M^DABOU*]SM2=**74^0L8%[R=^/=] %G6+&DJOYN&PO M=VJR-W-H965T&ULI9=O;^HV%; B15=3:W4-7(3I N@5- MNR\FH/M/MNHYS6PAC,I&T5TD654 ^T,7)X6CN^V?C*]*JFQ*]JSE*^<VO(Y)R3C*>=VX3 Mj6\$9j,VD(KV^~>S [3v2T5XYP&C]Ww6Mj,3^L17V F2+I5\$@0<8F~#4/PY MP@HXYM&PCK JH\$Z3TPKVV 1V.RG-HYD=U;"2 \$6^F'3A3I2V)JX6W\$5U^A M-C2V(6+)=?F G,JYGD/BOAN9U6^L&B.^j7^?A1G Cj1Q@4#N^CGE\$M&^U4 M\$~.L "1362D9Y*FAR1F2)Z+L;(QF&R7,4HWVF;KOC4*1QGSJ('E18*K' G! MEI: <1>=1^YIER*F@Q6M8DI^M10(05:@F\$S(BZ1^PGB+J;G;N2D^F\$QYJ> M \$1~>MFMRL^F>Z12^<F)~*]0E.12 ^?Rj=6?7PN9-V%+?*>=20^ M9.0JD, +P@^YjE ^&U4Hj]~^5K OE6X;^@<M-Y%Y@^SjH)=E10(=>)JY;KR2 M+3R18J(LH;H98%L)TjGB164NZZE7ZWV^X G.'13VjVH;D2;^N3J0^C^I^DR=??&HCjS(H&8M(G?XUH&. 1T^1U=U9j\$GwYl MTPWUEP4;G M~@Fj86,jK~7^11@]^#FR~G1-G1-L1[6?12=WD@O=S^Zl4+ M1VUXZSYJ JC,[lCQ.^I[UN&C&.^J2 @>7 ^K^F1~?R1WNVD3R3ESFN2@ MJb/BO@M\$E6)R5I?WZ/D7^];Qj^5OY&QA2)j4\$3#4-1G(BU.^A7lC@.62?6T MDT-T 3YZ~^*H2!N16R1F#0D)O^j^]-Y%&Z/A(G#+123j[HN,?26,1# M7[H6@FF#8-J+8^6S*^Z V-33#^R7^j+& KAIL86AU@#83:P ~,JMEZAC M1 26,j3^K90M\$M+^WjUW+^PYBPj:HPY 7Y8YGTP2 L4 7j^3K9QO@5374X^Z] M-5WWBOMUj1>^Dj,^*]ASW*O,<ZIE7U85jUC,S+ MJ 1.&K\$XE(T4/^9 VODXOI? 20^7Lj; Y%\$@ U+^ P04 ^?j,YY9E156 M5<+& #M^0 ^'AL+W@=0=26,D9E-J,8VN8A@Q,GW;Y2HAl,]^@^W^~16 @U="6,V+PG+M M-1E]^@OY MjKZFU;9D<5(;Y=F46)8C>~.TF,S Z7jFWY>R,?T66%NRN1-4VS^/RYR7^4^/^Y Mj\$]^/MRGj[50^Z.SLTV8@L^F/FWN2ODVj,PD:0^?K;4P8U MXG^/GjN=9Z2T7,7FWjYJ2LXGENH1RjA2?~>Q /? \$YBS+E^9D<~^MTTG7I)S+& M27fQ_KXF+^lEC2LTVjF?2+6YQ @A+V&S<S<~^?6jD\$A^+7E6U7 1V8+&+&]\$M^*U M37W>^G^*]8BGIV5 ^F5jBVj8I4DjL,M^RjR[;@L=A^T52QYOI? <%60N1^1:1.C90GJO+&Tj,ETJURT^*% MKGDAUA6^9+3P\$X~.W^JOWSYWHL6506AM^MS94j73^#N^YjYU-GW,#!:H M8j)5\$BBj,^WU49^H965\$NX0^TQM^N&I&B^C~.^\$FA(K\$1^R0D^<+<QH-S MTJ0?>%K ^J^@('6IHH^\$^j^%j^%(L2W;~.4* M5L99331.9^5)*U^&Gj#S#USD+FV1FIN@K <^AIS\$~^2YOC9P(ADT&^ N=Q MJUOT XAF09 9j9~\$j] #28Z;C&XSRO6EB15-?I?MYM^X: 1>JjH1^HP MHOYHE\$T(U1=H\$T^PSM?\$8 L-4EX\$D) JDF<~.E6+&BZ^8^N M~.WUOQ(MEYA\$&LADUTO1^V-TNB82^VD)R@ YGC\$V^H;RRKj>%P(ON%)&I^X-ZHDNH >W MJ^Q;M#^Qj1=T=W ^l6iQ=7^L^W @DF37A.2 M<5&S\$V,^?76V^W+FKR)Q 2AL[F0!EI^M@+1+1@j)];""WI->9%P+AFFV5<=W M1Vf!\$IYE<2DWj)BUT<Q@YQH^7Hl^%;.V7 Z^HOLU14Y2N@S\$X,YI K^Mj MjKT>~.Z-#M^NTN5 4AL@WD;^?90N^L1KUB@^W^HXHjT;@G;WOY_H M7^8^EEO;618N^4ERN00j[CjV56]j,^4G+ZjU;2-18^jR8Bj! F^0% .T^#H M-1D9UOVQ (7P^V^*MPJ8,^ 4^6 ^Y8N^?A&C&CjJ)+UP(^l^j[5]6)>^Y M1~\$J08N^8B(6/1,1LNUCjHTW)Jb,JS&GM^R4^G6@<M>X^A^H^,FL17??1>Q^Q^4+2J4L49E^Q\$,CSE<?P80 B^7J /OG(A+X^K KEF^L ML%[(IY.^/G(N7%)j5 =[^P=02P,\$% @R3MN6^MPPM3j@ H^L" @ M lX;]JW;WjY^J2,1594\$5,M8NWDWTFUV9jKMj0^2GX^?YIF<~>,GY8D7VJDCAI M@OjL^AS^G^1Q6HP6j^lVW(Q1WN6106Y+U\$X_X?Y^,OIT-8^CjUj3]^V MKYBLIJCOPX=>R1jCGWjWjWSR9^EB3-25&EM ENj,?< W\$6K^L2^?7F3jHj? M7E2K2J4 S)UjL T^lOjL^S^7 MBS M7C65\$G2j^T8=KKT6P\$53jD3j1MH+&J^U^<F D^FjFWIOHj+^H-7@CG^PjCjWj\$GVS~.Xj MSi&=G6>^RjLi@^~2D R.2G T= LS337^9NK^8Xj(=QFHSYj),Q+&F7W\$^Z M,I-^jS^?OERQ,"Z+M^BH3\$RA98^*S3j9T7]^&W&P,PH^PWU9DF+S^*Z3?WDU M-^FY9jQ,UCWLK\$^,8 4Z+&6A!2MIQAD?P\$Wj^%j,^TD,L D\$ 6j\$B&37EC^ MZD+ZD^CWN&YUVO,P? V0@Y^M^N^ZL7L^KXV^Mj]=SIO/XVfVc4^J^ Mj;A=OR-6+^D5+1^j,^S3j)W7 M5E>4BR<<B\$R.^ R M(7 XF# <~^*Wj]~%6\$2%LH1\$9&^0!#j9D>4 MH(A)5,0U^M(LON-Z^TO AN9&Z B>E^1^j[5J2Q<~DB E=2PTH26A&+1<A! MjNH>W+&F72 2J^ORV=8? Q2/CRSj4@<DJY^P16jQjY^?7\$V TD#8^jT^DjWV7TF0@<OTZCj9H4T^Hj3&=>QZ3j (%DXD)DT\$F) MRjRjOjD/ GTM= Fj4BVG;Z:D6\$^L5(1:UjL1D0D42^<)<OjE^T^j.Y(SN^<9K- M+HAUB@<1jY^*ZTAVj,^jW^218.218-1^j,^D#Sj^17ZjBj(6K+5400,B;+3# M&B,LH@ITy&K6P,N^Mj^:UU D+^L^S^LX%L^T%N8QjLMDME:E^L^U3^<~^?<T ZjSj^:G2>19^21j]N'=H= MBQVRLD-^#62,X4\$6PH(2U>BL^S1^W/W@<~^G9HjRP;^j0#N7.W\$T4V(E&# MSKE LW7Y7B8jE9^MP,8j1^QjB2+1R4+1^j34QCY&@^V81-U-~>4^PjB3 MjC@<WZ,K<70P90=00:8>Ij,IT,QI>OSTj)=M1^N^%QDH8R^7USA0!^%(Oj) M0i&^>QL&S.GPjWjE E K7%F:5(^3Y I786LjO7j~3 4+G\$512:OC, M(HXZAX,^#N>2)>@i5D+&UC00+^*O\$M^,(-<=Ej\$%j3l@^RjVf^@<U0j,HVAA M-SALD% #&4/LRVj84^j^Xj)S^j W.8@U0H\$Jb]N~*!O\$&Z.HR6(DB\$Y&H M06<#4+ G^X8VQj6jHw;AFDW //C%3Z?&9 L^9N8&A3V/D79/8O9jHj< M^R^L Y\$>H>~BN;Hw^?IMCN<@U^0^9=VX?ZSP.LCQHjN3+4G=V5B7F8M4Q)=F\$H@V^&Sj3IO@<S>P+AJ&Y N7ZU,5>N7j).jOR3 MDC,GBFQ\$XOL9G0? 9YR7-KA8+&4#UW^L 5L^O77^90L^9N8&8A/3V6jD7W.^) M3^40?OZKjY.HAP.3+U^A-Z/E4CQjGO)GR MDBP/KX,3AC~>^jOKBEC-&A.MR1.2#D^#? ^O^67? 3^H^H(HOY2^l Uj+^ P04 M^ #).Yj9V,5DFQTL ("H)@<^'AL+W@OQ%62BUV6B;AX@5= M\$O&KjV@<WjQYOB02+O.GAECEE^1EHV7^P.UFNjD\$2^*OU+^lIT(Q_PON9LHQ_MU^4S7<~[.SU? E,&#j\$D\$<^/V+^?jQ6<~O64\$&GjY9E7^YOCB M~>K~&Hw@<?ERTQj@+&FV DJ^>XG8.Pj^l WPI@<N^N-HQ<~<M^@j)=^VLN,3^2^ R/D+Ri4U>~? RMR4K\$2;EjENG,DGXP>T^@R0+L^>?>Z>P^TV.^?^H Mj;MG-&K-19.50j,8/DYACZ\$N~>2EF&J@<5Z,HW^I7&@.XMTST^PG6&0;#558RjLOV^C^D^I^T M4-^LL>DZ..A^jKW@<Q+58HH^R~j;73-VjU7\$K\$H5N69-06HYU^M^AL+L53C^ MCS\$R=E9EV^@UL^+H3C3#<+&OY^KS@<9-B^6TOSTURLR2LOEIUBj/YI5A6 M1UFSR^08S#P+39NO&)-^PGV#MX MQ2.5^;BUF+AQCB6jLj]>Q^ \$5fj Q6H0i&5XN1&Zj8 MPOl^74<7K\$)P.O^%AL^Tj^F^%WYG9W4\$7K%)A.O^%B,7K\$&8/8j B8LOV MR<^KS+&ADN89j]i\$6^A^Q^%Y^\$T\$>7M^Y^KR&E^A M^U^A=200B 3KX0K-UY^C:H0>X^FMH^&F^JPZH^@A^5~.5^HjX^\$M MU&F>04V=5%8CB,W(=5\$S^FN^H^LBI^XV? [#!>~%\$W@Y3HT\$?>Q? Q-7^H [\$+&~&0^44V^?<~>IDP-[K0- EP^j]Tj YKXK30j4^P^V>;VKDC+5K/551^jRVUF2jE= M^*2jOV/3^F\$73YN+7j^l^7\$RjT2Q06LjA369 Y&? #<^l>^HVj X_#;SE M\$&S&ILj^~^LRH6<~XRGD-9SE4^ZjYjTSjR,Tj?35R,TGjR6~>6^H,78T^CR<3j2SSj@<9-M^?CNVKN\$1.LjB16j5jLOEA~.3NjU7^l).iJZA\$=ST^>S!&G5PM618K+IA MX^@j\$1AJZD? YY^OR8<=+R03QjUS-RGH^*A^BN2ARZjTQ@.ND^Q^U^YjA RG7D M4 7ATFE_V0-W81O5^U^W81O6^4.A5766j6/CR&9j1^9j9KC? M5,5DQZ\$W8;5^ATT\$YEXX.^K>P>Z+5=1Q36B^T.Ck^6T3GM7+>Oj(Wj2XjN Mj)@^j.^Y.Y^TjYK5T3Nj[R19KVC\$P^8&Q jYPOH6M7jCj3Z<~<Oj@RMZjYj M? (VA^KS68E2E86jOC9E59^5Z%<~^EIMjGjY9G=VjWjK\$H\$)j^+ ^*C@Ej^:MTfj6jE=DORj9+BFHj+YjV<~#+= 5K4^D+R5?EFT2^7DB +CPM^\$IHK A^@ MSKQ<7j@?V+V&P0 M=M^VJR-W-H965T&UL255<~jH\$Z/TK^2=3A2j; QM^j#1@j[76(LN9<~^~^KF1PZjWjVj^j,^GK-GM=ATFjJ.R6BA>=^# M2#~.2^FOKjS T6Bd5^P-5H22=ONF^69Kj;6AjC2SWh\$js<11j#^O&893^;+6U MGDU48P67N@<FjBj^F6.K0738j<~<Q^AMXk1N(9Q~<K^%K^%Ww>?jUjNI08Lj0 M&JXD.^RjBj>?AU7SLXGw/QQ;7,1X#+Z^>^>H0>XND5=YPRR;3;1j M0jMH8Q,7Zi^DS@N75^2jVf7\$) [.\$F41AO>?;MjDFM?^j%0!^90i#<3^T%6j Mj%QMF>^i9YQOQ @%?ON^%72E@9N98jYj_BOU42Xx\$>7R6,5Z ^7^H NHT1 A^M4 4ECSS? Z\$Sj)jR.RZ9\$@<30%jFDZ:j5E0I5<~>=S96168jCj2%Z6?0V\$ MP>SMF<^Zj^V^U@<GR.798PVB^I5G5jJEGKX\$?C AL82Y4AMOMY2Oj9RM.^)MDj7C;7jLTOQX?YA3jYj)@jEG-C=IT M0DFT AM-K3EUC&9^O^F5LV4A^49^4WF,7E11(^*Q&Q57Ei347&0^>?jMjMS^j7j^VjVX^A^M^78BSYVQ M0(9WjGSj)AL21^8\$#0^?H0@<ALKYMB87NjV2A+IN6jCQ1NPj+<Q2jW^ MjO^C=V; 51+P04 ^#).YjY9YOGU6G\$ Ii^0^&^'AL+W@<Q^F2RM?>27.SG.IDP:1^i\$R3>[<KUjJj MB;7^6;6A63^><6 6j/G79j)Hj75O^i9^C^V44&5E>B^T>?>CjA+I^WC%<8 M^>^? V^3;X3^#HO^15CM08^L Z>Y>T>P>X7@<^XY^N^j).@<2+^#R^*R07jCj@CN^D70+J^R^H& M6 :+<XLZ>7?P2jL@j5jJ@<GjSjU^%J^CjZj4^?H0jGjA;AWO^i4XRX^>^K#N^P7j OD@S^M^<M^?P2^D^X9&0<0^Y41Ei^P^*216jTJ EF^#<M^?Q\$S^Z6A0X\$F6H\$UCA M-GGjZ\$N^XjT1L^N<~V^Z.Cj^~.BL(TjRjSAjP=^#C#3MGCYQj0^?HXB^<~<M^LQ3STP7UPNk OAWj]J.^_9A^GjV^Pj)=+T%+^J^A=DRA<~<IjJ @<1+938^<M^?7FKE11OjTj9VV4(HGA^6B 8I<~T=VRD1@Dj)Dj^~6LTZ(366 Z~.j) ME^1KIPBWUEi^6DCDj^l^B>~^,FE1Q8DW.F\$&2D 9UP35T\$jY/GVj>^TMV@V M4=5\$5&N&^Qj;^=,3Q.^TKUX4WTD^KjG(0,!*^?UWF8 JE^<O^S^M4WYQ!!DOPLQ,6!=0ND03Z,6AGKQM.+U &2NK2Q^O^5@P142W3+H\$=HEK@<E MHD<Q9jTjH^& Q5NTV6^A^H\$^*XjI?B^?YXW,Xj3AAL43@<Q.P^@5\$P^*~B^475U M^&V\$+LGN7^#SHK?P5ZG^54KZ.^U08>2^4j;W^UjL5A\$5jLjYjDBj66:Zl-R MIAPj3jP=EQ0 MH^KF^j9PL=2D 34-ET>+>XjJTMUN79 O3~.^)jJGAI M74@WjM38ZAJ~.YjZT@ 4@jL\$RSCWD@N LN=54jBXS^>4+4IAUEjTDBj^&9j ~WBSP^O83& @D-+Mj;JW 57HU04L2jO^#G M^=V\$W6GjW^%Kl^7j OCY+&P^jJH4H^%K\$H>SV\$<EB3R^!UO\$R7^1 5Wj,M^4^B&D^P=VjR-W-H965T&UL05\$S9;MM(Ej[W4Q3<~^Q^5F1) MWCH^X^C+&R^+&2?>^& SF@Bj)&4GH4L7B0233\$Wj?jH669=jjN@<=SD5A+&?7 MjQ?75?W\$K\$1UN,VZ^WSW\$73j^YlLjF^U^jCjZj4^?H0jGjA;AWO^i4XRX^>^K#N^P7j OD@S^M^<M^?P2^D^X9&0<0^Y41Ei^P^*216jTJ EF^#<M^?Q\$S^Z6A0X\$F6H\$UCA M-GGjZ\$N^XjT1L^N<~V^Z.Cj^~.BL(TjRjSAjP=^#C#3MGCYQj0^?HXB^<~<M^LQ3STP7UPNk OAWj]J.^_9A^GjV^Pj)=+T%+^J^A=DRA<~<IjJ @<1+938^<M^?7FKE11OjTj9VV4(HGA^6B 8I<~T=VRD1@Dj)Dj^~6LTZ(366 Z~.j) ME^1KIPBWUEi^6DCDj^l^B>~^,FE1Q8DW.F\$&2D 9UP35T\$jY/GVj>^TMV@V M4=5\$5&N&^Qj;^=,3Q.^TKUX4WTD^KjG(0,!*^?UWF8 JE^<O^S^M4WYQ!!DOPLQ,6!=0ND03Z,6AGKQM.+U &2NK2Q^O^5@P142W3+H\$=HEK@<E MHD<Q9jTjH^& Q5NTV6^A^H\$^*XjI?B^?YXW,Xj3AAL43@<Q.P^@5\$P^*~B^475U M^&V\$+LGN7^#SHK?P5ZG^54KZ.^U08>2^4j;W^UjL5A\$5jLjYjDBj66:Zl-R MIAPj3jP=EQ0 MH^KF^j9PL=2D 34-ET>+>XjJTMUN79 O3~.^)jJGAI M74@WjM38ZAJ~.YjZT@ 4@jL\$RSCWD@N LN=54jBXS^>4+4IAUEjTDBj^&9j ~WBSP^O83& @D-+Mj;JW 57HU04L2jO^#G M^=V\$W6GjW^%Kl^7j OCY+&P^jJH4H^%K\$H>SV\$<EB3R^!UO\$R7^1 5Wj,M^4^B&D^P=VjR-W-H965T&UL05\$S9;MM(Ej[W4Q3<~^Q^5F1) MWCH^X^C+&R^+&2?>^& SF@Bj)&4GH4L7B0233\$Wj?jH669=jjN@<=SD5A+&?7 MjQ?75?W\$K\$1UN,VZ^WSW\$73j^YlLjF^U^jCjZj4^?H0jGjA;AWO^i4XRX^>^K#N^P7j OD@S^M^<M^?P2^D^X9&0<0^Y41Ei^P^*216jTJ EF^#<M^?Q\$S^Z6A0X\$F6H\$UCA M-GGjZ\$N^XjT1L^N<~V^Z.Cj^~.BL(TjRjSAjP=^#C#3MGCYQj0^?HXB^<~<M^LQ3STP7UPNk OAWj]J.^_9A^GjV^Pj)=+T%+^J^A=DRA<~<IjJ @<1+938^<M^?7FKE11OjTj9VV4(HGA^6B 8I<~T=VRD1@Dj)Dj^~6LTZ(366 Z~.j) ME^1KIPBWUEi^6DCDj^l^B>~^,FE1Q8DW.F\$&2D 9UP35T\$jY/GVj>^TMV@V M4=5\$5&N&^Qj;^=,3Q.^TKUX4WTD^KjG(0,!*^?UWF8 JE^<O^S^M4WYQ!!DOPLQ,6!=0ND03Z,6AGKQM.+U &2NK2Q^O^5@P142W3+H\$=HEK@<E MHD<Q9jTjH^& Q5NTV6^A^H\$^*XjI?B^?YXW,Xj3AAL43@<Q.P^@5\$P^*~B^475U M^&V\$+LGN7^#SHK?P5ZG^54KZ.^U08>2^4j;W^UjL5A\$5jLjYjDBj66:Zl-R MIAPj3jP=EQ0 MH^KF^j9PL=2D 34-ET>+>XjJTMUN79 O3~.^)jJGAI M74@WjM38ZAJ~.YjZT@ 4@jL\$RSCWD@N LN=54jBXS^>4+4IAUEjTDBj^&9j ~WBSP^O83& @D-+Mj;JW 57HU04L2jO^#G M^=V\$W6GjW^%Kl^7j OCY+&P^jJH4H^%K\$H>SV\$<EB3R^!UO\$R7^1 5Wj,M^4^B&D^P=VjR-W-H965T&UL05\$S9;MM(Ej[W4Q3<~^Q^5F1) MWCH^X^C+&R^+&2?>^& SF@Bj)&4GH4L7B0233\$Wj?jH669=jjN@<=SD5A+&?7 MjQ?75?W\$K\$1UN,VZ^WSW\$73j^YlLjF^U^jCjZj4^?H0jGjA;AWO^i4XRX^>^K#N^P7j OD@S^M^<M^?P2^D^X9&0<0^Y41Ei^P^*216jTJ EF^#<M^?Q\$S^Z6A0X\$F6H\$UCA M-GGjZ\$N^XjT1L^N<~V^Z.Cj^~.BL(TjRjSAjP=^#C#3MGCYQj0^?HXB^<~<M^LQ3STP7UPNk OAWj]J.^_9A^GjV^Pj)=+T%+^J^A=DRA<~<IjJ @<1+938^<M^?7FKE11OjTj9VV4(HGA^6B 8I<~T=VRD1@Dj)Dj^~6LTZ(366 Z~.j) ME^1KIPBWUEi^6DCDj^l^B>~^,FE1Q8DW.F\$&2D 9UP35T\$jY/GVj>^TMV@V M4=5\$5&N&^Qj;^=,3Q.^TKUX4WTD^KjG(0,!*^?UWF8 JE^<O^S^M4WYQ!!DOPLQ,6!=0ND03Z,6AGKQM.+U &2NK2Q^O^5@P142W3+H\$=HEK@<E MHD<Q9jTjH^& Q5NTV6^A^H\$^*XjI?B^?YXW,Xj3AAL43@<Q.P^@5\$P^*~B^475U M^&V\$+LGN7^#SHK?P5ZG^54KZ.^U08>2^4j;W^UjL5A\$5jLjYjDBj66:Zl-R MIAPj3jP=EQ0 MH^KF^j9PL=2D 34-ET>+>XjJTMUN79 O3~.^)jJGAI M74@WjM38ZAJ~.YjZT@ 4@jL\$RSCWD@N LN=54jBXS^>4+4IAUEjTDBj^&9j ~WBSP^O83& @D-+Mj;JW 57HU04L2jO^#G M^=V\$W6GjW^%Kl^7j OCY+&P^jJH4H^%K\$H>SV\$<EB3R^!UO\$R7^1 5Wj,M^4^B&D^P=VjR-W-H965T&UL05\$S9;MM(Ej[W4Q3<~^Q^5F1) MWCH^X^C+&R^+&2?>^& SF@Bj)&4GH4L7B0233\$Wj?jH669=jjN@<=SD5A+&?7 MjQ?75?W\$K\$1UN,VZ^WSW\$73j^YlLjF^U^jCjZj4^?H0jGjA;AWO^i4XRX^>^K#N^P7j OD@S^M^<M^?P2^D^X9&0<0^Y41Ei^P^*216jTJ EF^#<M^?Q\$S^Z6A0X\$F6H\$UCA M-GGjZ\$N^XjT1L^N<~V^Z.Cj^~.BL(TjRjSAjP=^#C#3MGCYQj0^?HXB^<~<M^LQ3STP7UPNk OAWj]J.^_9A^GjV^Pj)=+T%+^J^A=DRA<~<IjJ @<1+938^<M^?7FKE11OjTj9VV4(HGA^6B 8I<~T=VRD1@Dj)Dj^~6LTZ(366 Z~.j) ME^1KIPBWUEi^6DCDj^l^B>~^,FE1Q8DW.F\$&2D 9UP35T\$jY/GVj>^TMV@V M4=5\$5&N&^Qj;^=,3Q.^TKUX4WTD^KjG(0,!*^?UWF8 JE^<O^S^M4WYQ!!DOPLQ,6!=0ND03Z,6AGKQM.+U &2NK2Q^O^5@P142W3+H\$=HEK@<E MHD<Q9jTjH^& Q5NTV6^A^H\$^*XjI?B^?YXW,Xj3AAL43@<Q.P^@5\$P^*~B^475U M^&V\$+LGN7^#SHK?P5ZG^54KZ.^U08>2^4j;W^UjL5A\$5jLjYjDBj66:Zl-R MIAPj3jP=EQ0 MH^KF^j9PL=2D 34-ET>+>XjJTMUN79 O3~.^)jJGAI M74@WjM38ZAJ~.YjZT@ 4@jL\$RSCWD@N LN=54jBXS^>4+4IAUEjTDBj^&9j ~WBSP^O83& @D-+Mj;JW 57HU04L2jO^#G M^=V\$W6GjW^%Kl^7j OCY+&P^jJH4H^%K\$H>SV\$<EB3R^!UO\$R7^1 5Wj,M^4^B&D^P=VjR-W-H965T&UL05\$S9;MM(Ej[W4Q3<~^Q^5F1) MWCH^X^C+&R^+&2?>^& SF@Bj)&4GH4L7B0233\$Wj?jH669=jjN@<=SD5A+&?7 MjQ?75?W\$K\$1UN,VZ^WSW\$73j^YlLjF^U^jCjZj4^?H0jGjA;AWO^i4XRX^>^K#N^P7j OD@S^M^<M^?P2^D^X9&0<0^Y41Ei^P^*216jTJ EF^#<M^?Q\$S^Z6A0X\$F6H\$UCA M-GGjZ\$N^XjT1L^N<~V^Z.Cj^~.BL(TjRjSAjP=^#C#3MGCYQj0^?HXB^<~<M^LQ3STP7UPNk OAWj]J.^_9A^GjV^Pj)=+T%+^J^A=DRA<~<IjJ @<1+938^<M^?7FKE11OjTj9VV4(HGA^6B 8I<~T=VRD1@Dj)Dj^~6LTZ(366 Z~.j) ME^1KIPBWUEi^6DCDj^l^B>~^,FE1Q8DW.F\$&2D 9UP35T\$jY/GVj>^TMV@V M4=5\$5&N&^Qj;^=,3Q.^TKUX4WTD^KjG(0,!*^?UWF8 JE^<O^S^M4WYQ!!DOPLQ,6!=0ND03Z,6AGKQM.+U &2NK2Q^O^5@P142W3+H\$=HEK@<E MHD<Q9jTjH^& Q5NTV6^A^H\$^*XjI?B^?YXW,Xj3AAL43@<Q.P^@5\$P^*~B^475U M^&V\$+LGN7^#SHK?P5ZG^54KZ.^U08>2^4j;W^UjL5A\$5jLjYjDBj66:Zl-R MIAPj3jP=EQ0 MH^KF^j9PL=2D 34-ET>+>XjJTMUN79 O3~.^)jJGAI M74@WjM38ZAJ~.YjZT@ 4@jL\$RSCWD@N LN=54jBXS^>4+4IAUEjTDBj^&9j ~WBSP^O83& @D-+Mj;JW 57HU04L2jO^#G M^=V\$W6GjW^%Kl^7j OCY+&P^jJH4H^%K\$H>SV\$<EB3R^!UO\$R7^1 5Wj,M^4^B&D^P=VjR-W-H965T&UL05\$S9;MM(Ej[W4Q3<~^Q^5F1) MWCH^X^C+&R^+&2?>^& SF@Bj)&4GH4L7B0233\$Wj?jH669=jjN@<=SD5A+&?7 MjQ?75?W\$K\$1UN,VZ^WSW\$73j^YlLjF^U^jCjZj4^?H0jGjA;AWO^i4XRX^>^K#N^P7j OD@S^M^<M^?P2^D^X9&0<0^Y41Ei^P^*216jTJ EF^#<M^?Q\$S^Z6A0X\$F6H\$UCA M-GGjZ\$N^XjT1L^N<~V^Z.Cj^~.BL(TjRjSAjP=^#C#3MGCYQj0^?HXB^<~<M^LQ3STP7UPNk OAWj]J.^_9A^GjV^Pj)=+T%+^J^A=DRA<~<IjJ @<1+938^<M^?7FKE11OjTj9VV4(HGA^6B 8I<~T=VRD1@Dj)Dj^~6LTZ(366 Z~.j) ME^1KIPBWUEi^6DCDj^l^B>~^,FE1Q8DW.F\$&2D 9UP35T\$jY/GVj>^TMV@V M4=5\$5&N&^Qj;^=,3Q.^TKUX4WTD^KjG(0,!*^?UWF8 JE^<O^S^M4WYQ!!DOPLQ,6!=0ND03Z,6AGKQM.+U &2NK2Q^O^5@P142W3+H\$=HEK@<E MHD<Q9jTjH^& Q5NTV6^A^H\$^*XjI?B^?YXW,Xj3AAL43@<Q.P^@5\$P^*~B^475U M^&V\$+LGN7^#SHK?P5ZG^54KZ.^U08>2^4j;W^UjL5A\$5jLjYjDBj66:Zl-R MIAPj3jP=EQ0 MH^KF^j9PL=2D 34-ET>+>XjJTMUN79 O3~.^)jJGAI M74@WjM38ZAJ~.YjZT@ 4@jL\$RSCWD@N LN=54jBXS^>4+4IAUEjTDBj^&9j ~WBSP^O83& @D-+Mj;JW 57HU04L2jO^#G M^=V\$W6GjW^%Kl^7j OCY+&P^jJH4H^%K\$H>SV\$<EB3R^!UO\$R7^1 5Wj,M^4^B&D^P=VjR-W-H965T&UL05\$S9;MM(Ej[W4Q3<~^Q^5F1) MWCH^X^C+&R^+&2?>^& SF@Bj)&4GH4L7B0233\$Wj?jH669=jjN@<=SD5A+&?7 MjQ?75?W\$K\$1UN,VZ^WSW\$73j^YlLjF^U^jCjZj4^?H0jGjA;AWO^i4XRX^>^K#N^P7j OD@S^M^<M^?P2^D^X9&0<0^Y41Ei^P^*216jTJ EF^#<M^?Q\$S^Z6A0X\$F6H\$UCA M-GGjZ\$N^XjT1L^N<~V^Z.Cj^~.BL(TjRjSAjP=^#C#3MGCYQj0^?HXB^<~<M^LQ3STP7UPNk OAWj]J.^_9A^GjV^Pj)=+T%+^J^A=DRA<~<IjJ @<1+938^<M^?7FKE11OjTj9VV4(HGA^6B 8I<~T=VRD1@Dj)Dj^~6LTZ(366 Z~.j) ME^1KIPBWUEi^6DCDj^l^B>~^,FE1Q8DW.F\$&2D 9UP35T\$jY/GVj>^TMV@V M4=5\$5&N&^Qj;^=,3Q.^TKUX4WTD^KjG(0,!*^?UWF8 JE^<O^S^M4WYQ!!DOPLQ,6!=0ND03Z,6AGKQM.+U &2NK2Q^O^5@P142W3+H\$=HEK@<E MHD<Q9jTjH^& Q5

Yl9#B<KJ9|,16#|1GIHfE;7T11:~H0%|SHFJQ|46E+~ M6[V*3*VIEAXD>|3&|6DDP<|A/O&VND>,K%#=-^|.O6-SL2>=8JTO1'@6'R7:FFRX/M.X"X"-V
-V<B2K|NRJ|NfL;FZW61#MO9+;Z'F|HS@75NK'93ACB; U:6 MR(AU|7Y;A>~V5|95DIOGAM6&DN'NB'<|.Q6,SHN.4Q4>,RSECG|@/FWR\$*GNIZ5;#|+U(>_ "U1G&QR2-T^P W|/?
>C>YA@=-.Z2;UJX M+3K.CW-.T9;VVI||OJW&.9ESBF5X7Y2_ M7C1YU@|(TE.Z2^IW [||^8;J'3+5%L0#=-Y\$FXAJ\$X)-XR#
(X>|6U*9J\$=L|),IWL<^J|),1MGWE0|3R|8|RWWSM;~^6Z&63AG|8(C0<^8|)'HMNN M;3>V;Y3|P3BW LEEA1'=>_YTN3<P; N OKZS/ #U+ P04 ~#*.VY9 M0KR(OZX" P'P0 &O
|AL/W+<0>F.2|]8F+V4|KJ|3|],62 MY84Q<| [ICN'N'.%RR>U!1=3P6N1<3=RMUN6UYZBDDP5352>3\$C<=K(ONFZ2|W MGBHEML2"BMP+3' R'19Q-Q|:V%\$S&B|U'|,XEZ'JHF#R;8JYV\$W
<<3UO;XK<= DVX3O&K<[4<0>FDY40 M;P.V9XO&X&2.;~ R+SC#/#=-S;~P'FVJOWPT'~S2|;J4RKJK FA|J MJK<3<=^A'BFM6'F|X|+|Y@T|
'4B5 87=GSN+W|A9j0610,F147&|>MFWLO1K<=XVV,W'M2|;@ MQ^44A'~?T(TOSH+&T\$FAX|JZY|BCQ56,Q0MD<K7'.21.);*3G<=XJ|J|),8WK1+%6<~8AULXAZ@; M#GRR@=-.
P|Y12+7= W8=0<+Y\$3SU);A.1 79P;P|W7Z0DB=<K4 M|H&S92|5&|S|&J|&T@XLP@DOH| 999RD2W72C>|<N2\$E4.;~2NO;G3P MTN0WCQ.O; .TD79>B+(&@9T.8)CJWH[F*
('Y<~N'D52'J|@6|CJ|3KJ? M7S|J|RO28W61|<O8YK@O|7'PKYJ12H#.#P' &O'AL/W+O9B.W\$9SMQ5<K2>Z>AB|Q<4.;~2QIY4K<R'P5 MQR5|7\$Z6Z MJ|P ++>3|32|N 96.8)CJWH|F76|
1Z39WJH|<88.94AD=>ZQO.8KMOW8 H.#M' L F|J;7=R'ME19+T&P5+<QLONR^W827|1M0K6C|A+9'C&S;9C38<C3>A M&<=V3.1X04JZUI5%<7|Z33| (A|\$. -J0.)OV&+<6'L<|<W?AX:8LT
M.X#Y9Y|<+>'Y059P5F/8/WJW7JNN1'.VBP'~B-EON1'P2A'H8'~#NUV'T.QXFJG(H3A|J24.WWWNC|P'4%G>UQ87Q|<M KJO)M1X0+8.X>2/4.3J5DYQJ-2027E1'Q\$9P.%1NB7ME&X.O-
|JHBP5\$*s\$0-L>J?J_321LK844ZJ8#W*%N\$K)4 QW7:Y#GBY@IPO M\$<X (J|OJO^~RUDJ\$J.%(<B_#-I\$46 9CB>QO 6<0'NXPA-A'>M^4|@DS|&'K# MW'~'Q/5I9VWBC 1+OQX=>S5RW8V?
P'WJZ9#~R+|J|P(WZ\$+E&#\$.I\$Z?MQ?8EC3R|Z>Z5|7NMN-Z|P'Y8C=QB< H'A%\$ R(Q;~.1'38F^061F3RDV,0E MB|/R..O|R\$T&D R-73C4<@~H.COM|J| @&9L7|P|PAOYW(M4*|L\$Z@|761
9MNNVZ~F+J|=F&U|L51.;JL|P+WG\$50~L|@BQW'RM=HN,=;~T&9B&RM|ML.P@V\$|S|N|>+<=J|'DNRX&9P8FBD4L.C**Z4 K| ME|@6G@679MD9;ZN+&#YB8'<=I0N1.
TH|)M7|;R9%:10| @D=|S'B09DD MV338<CJ|JMR|G&=1'4|UWCE\$SM9F1|JH8EYV;6Z&Z|6M\$MKM#<J|;:~M' 16%"@L-C|P%<+>|P|VQ|QNS,~\$'9K1|JY-8D=>+0HZY|0\$4 9|P
M'CGW1\$|&8|M|N1 >>+<C+LW+N;M# 6&+<3&J3CD4.'<U'<U'<X|MOF, M/5~N E7V6<QD\$<O96B1L|0% |FFS|N' A' 60P(6D 2#>=|@LIK:FDV MU6H'VGL|K|J0|>D+K'<G?
*YF=HBU&SGN,P?V98N|JU@L5FV'L' M2Y4 P72?7R3XIV,N,TLBZL|T=Y&V+>ASA>~7\$MPTK|L766Q|YQRZ@TZ/HW77)B9CQ@G MKBT,ZB-NZGP />-
>UQ0+DRG.E.Q|QM7<#N\$N'.9|T<~S'ZBWBH8T- MY*|6MGGK6J;~M'<=Q|RXV/FENHMDP8X;ATK'GP>3|J1;Z\$8;JZQD+FMET7?~M'Y>FF6K0X.WXRCV7=N,=#,S'P=02P,@%
RCMN69;56P1% @ " 8 M !D !X;|JW-W)K&ULM511;|P\$|XK|X.O2*. MTFQ@<XVTM4+P,2M|,IX0#VYZ;PY<~==OQ|SDX6=<@K.%|+<O?>| G|/|BR
MG39WMD1T<@<~VDY8Z\$PSQ;DM2JRS>D&:U|9;U|JZ9<~L8%L JAJ|HNB, M5T4+6=J|;F|R3+4=,R1KG|QZ;5<+<VNS?E<Q,6LX?S<C=RS4B>XGC5B<PMTGYNY
MH8@+~|M986VEKL>|Z|L(NXXM|ZNM#P.M\$P;V>W>R|UQ|J6\$9QY0B-PP<|Y| MT+&#%2KEB4C&JY23=5MZX|I@/?U=Y\$E+L+B5\$LO^<X'<@|<Q#4X'D!R| 'ACW@<\$P
MVBD+M'<B3P5>@<?&5Q; <X2S'6AR|VW BPMG.%42SN4?M4.(X37,179&-N#M|)JN6DN5U|L+&3XAE85|J|;H5Y|I7/@&\$MAT;+!<Q?X?|8%P>; '<S'<@<|(<^<S\$& TG_ZY@|F?>|
@<A9.W'M4B5>2WNANQW>~>W>V;I2.LHSOAVW|1OBAY|P_2QT>E M+|J|N|OJB K<8+=&+<M'.23V**50&1>V\$05./&4\$BV;+<Q'<OZ+<WAZZJ|G|
M|LA_KA_|P|7|R<4=>*U%OO=>~8?<F8C:PL*UT0?C&UO9M-3<X;Y%G| MBM4+K6B8AD9.6SX6D2M'9Y\$J+J+5,S+J+QZVD|3Q'MVZ|J|J|.d|&(F&+4.M|L%M^G|XQ?>OW'R%I@|JDC70
HMA'27K-62BU|YVTV L4 WQ12 L|OS.F3'Q041'Q4%8PEB1=Q3&7R| M\$@<G'>S;=FC|J4|J|<K+D><1A|&4GG4|J|01 M9H&KY:~H+<W+Y|J3Y|W/(61B+Z4|4X|1QVR|1F?|6I&_P)QOG-
AX@8C2=2Y M*~KV.B18I4K\$1.;N (Z3|5 <6 S\$1@<E+P30H V IS^<P#N\$>=INVT..@ M MV@.~|ALV.P|'CF8|>K'R'D|<XVB842|T1FK34M+Y~7X 6
QPQVFIH1,2Y<Z>|XLS|@<B2+G0216B0J3.1F+<Q'2,E|H0Q/ MHY3<0=>4?>A-PNQ'KER30J|Z>=<@;O|D46%~LLZ M9N.1'&J|S<9 PMPM0|GCCU+9 9XAU 73DVY;C2IW&|H%|B|);
[Q.WMS=JCT?>U|W|S|X8 M\$AMMCV%XX3A?>V+>|JW<= ASOK<~6M3V|R|GKYM\$>|J|2;4, P53,N+I MPC3MUH!A|L&NLO=<G%|JWZS -8'L@O|<KJ 9QV|>|4|7D|G|<?W+&O3|,
MY7B|Q/S'<_AOX|4+U=53Y|Y|CVK;JSV-07|J9I&|<.&M?R0W79%F;B M 021I&|<6A3TRIAE HDSC,NVBV4F;~>S&G-T:6'J3IHU.C8Z+>M&B+E520 MH'52P9Q|DJS |XU5_ K|>|<DWBZ8;E:EM:X
)S|A|B|<~<V>16-U=;H9 MTA1@<CQW9|03|N3BOL9|W3GEYF9RMRM.R|J\$E|VHJMAW|M'DF&O\$Z<= M?<BWB>~VK:TN?>A8<|>D&?UOA25A3RRG96KX|,XPBPF
M1Z\$<R>@<AUGM7|S|VZ\$=2F0.;FE:FE59|6 M#M+VE,F|@|<J\$&A# E6FFPE.KWKV M|WU;_@<6|@|+<V+T+&M6?|JH|3|L6K|T&PZ8ZW'Q|J|SR9+>~|<N|HMD3AGM~: 4K;+56V EF5L|DZ.9=53|
M.3P|VD|<|UW&MK|I|JY.E.2Q?>7747H|C=|TJ\$|FF|S|'I7D\$SG6Z8'JAJ M.F;KMG|<BKKQK|<V-U%>~8 F&XKJD@<Y1LE4Z+MP42T@5|J|20-1.0R+5N@<|
ME0 DVN?VY2U56T0J'J'HW8\$

[illegible]

`<page>`: normal; <report-id>: report-tr.pl.a -> cursor-point; display: block; width: 200px; overflow: hidden; } <report-tl-pl-div> { width: 200px; } <report-tl-pl-a>:hover { background-color: #ffe; } <# Header rows...> /</report-tr> { background-color: #afcf; color: black; font-weight: bold; } <# Calendars...> /</report-rc> { background-color: #f0f0f0; } <# Even rows...> /</report-re> { background-color: #def; } <# report-reu td { border-bottom: 1px solid black; }> /</Odd rows...> /</report-ro> { background-color: white; } <# report-rou td { border-bottom: 1px solid black; }> /</report-rou table td { border-bottom: 0px solid black; }> /</styles for footnote marker> /</report-fn { white-space: nowrap; }> /</styles for numeric types> /</report-num, report-nump { text-align: right; white-space: nowrap; }> /</report-nump { padding-left: 2em; }> /</report-nump { padding: 0.4em 0px 2em; }> /</styles for text types> /</report-text { text-align: left; white-space: normal; }> /</report-text-big { margin-bottom: 1em; width: 17em; }> /</report-text-more { display: none; }> /</report-text-note { font-style: italic; font-weight: bold; }> /</report-text-small { width: 10em; }> /</report-sup { font-style: italic; }> /</report-outFootnotes { font-size: 1em; }> /</XML 57 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3.html 144 226 1 false 42 0 false 7 false false R1.htm 00 Document Document And Entity Information Sheet http://fitlifebrands.com/20240930/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 Statement Statement Condensed Consolidated Balance Sheets (Current Period Unaudited) Sheet http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited Condensed Consolidated Balance Sheets (Current Period Unaudited) Statements 2 false false R3.htm 002 Statement Statement Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Sheet http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Statements 3 false false R4.htm 003 Statement Statement Condensed Consolidated Statements of Income and Comprehensive Income (Unaudited) Sheet http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-income-and-comprehensive-income-unaudited Condensed Consolidated Statements of Income and Comprehensive Income (Unaudited) Statements 4 false false R5.htm 004 Statement Statement Condensed Consolidated Statement of Stockholders' Equity (Unaudited) Sheet http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statement-of-stockholders-equity-unaudited Condensed Consolidated Statement of Stockholders' Equity (Unaudited) Statements 5 false false R6.htm 005 Statement Statement Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 006 Disclosure Note 1 Description of Business Sheet http://fitlifebrands.com/20240930/role/statement-note-1-description-of-business Note 1 Description of Business Notes 7 false false R8.htm 007 Disclosure Note 2 Basis of Presentation Sheet http://fitlifebrands.com/20240930/role/statement-note-2-basis-of-presentation Note 2 Basis of Presentation Notes 8 false false R9.htm 008 Disclosure Note 3 Summary of Significant Accounting Policies Notes 9 false false R10.htm 009 Disclosure Note 4 Inventories Sheet http://fitlifebrands.com/20240930/role/statement-note-4-inventories Note 4 Inventories Notes 10 false false R11.htm 010 Disclosure Note 5 Property and Equipment Sheet http://fitlifebrands.com/20240930/role/statement-note-5-property-and-equipment Note 5 Property and Equipment Notes 11 false false R12.htm 011 Disclosure Note 6 Notes Payable Notes http://fitlifebrands.com/20240930/role/statement-note-6-notes-payable Note 6 Notes Payable Notes 12 false false R13.htm 012 Disclosure Note 7 Equity Sheet http://fitlifebrands.com/20240930/role/statement-note-7-equity Note 7 Equity Notes 13 false false R14.htm 013 Disclosure Note 8 Acquisition of Mimi's Rock Corp Sheet http://fitlifebrands.com/20240930/role/statement-note-8-acquisition-of-mimis-rock Note 8 Acquisition of Mimi's Rock Corp Notes 14 false false R15.htm 014 Disclosure Note 9 Acquisition of Muscelparm Assets Sheet http://fitlifebrands.com/20240930/role/statement-note-9-acquisition-of-muscelparm-assets Note 9 Acquisition of Muscelparm Assets Notes 15 false false R16.htm 015 Disclosure Note 10 Commitments and Contingencies Sheet http://fitlifebrands.com/20240930/role/statement-note-10-commitments-and-contingencies Note 10 Commitments and Contingencies Notes 16 false false R17.htm 016 Disclosure Note 11 Subsequent Events Sheet http://fitlifebrands.com/20240930/role/statement-note-11-subsequent-events Note 11 Subsequent Events Notes 17 false false R18.htm 995445 Disclosure Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 18 false false R19.htm 995462 Disclosure Significant Accounting Policies (Policies) Sheet http://fitlifebrands.com/20240930/role/statement-significant-accounting-policies-policies Significant Accounting Policies (Policies) Policies http://fitlifebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies 19 false false R20.htm 995463 Disclosure Note 3 Summary of Significant Accounting Policies (Tables) Sheet http://fitlifebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-tables Note 3 Summary of Significant Accounting Policies (Tables) Tables http://fitlifebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-tables 20 false false R21.htm 995464 Disclosure Note 4 Inventories (Tables) Sheet http://fitlifebrands.com/20240930/role/statement-note-4-inventories-tables Note 4 Inventories (Tables) Tables http://fitlifebrands.com/20240930/role/statement-note-4-inventories-tables 21 false false R22.htm 995465 Disclosure Note 5 Property and Equipment (Tables) Sheet http://fitlifebrands.com/20240930/role/statement-note-5-property-and-equipment-tables Note 5 Property and Equipment (Tables) Tables http://fitlifebrands.com/20240930/role/statement-note-5-property-and-equipment-tables 22 false false R23.htm 995466 Disclosure Note 6 Notes Payable (Tables) Notes http://fitlifebrands.com/20240930/role/statement-note-6-notes-payable-tables Note 6 Notes Payable (Tables) Tables http://fitlifebrands.com/20240930/role/statement-note-6-notes-payable-tables 23 false false R24.htm 995467 Disclosure Note 7 Equity (Tables) Sheet http://fitlifebrands.com/20240930/role/statement-note-7-equity-tables Note 7 Equity (Tables) Tables http://fitlifebrands.com/20240930/role/statement-note-7-equity-tables 24 false false R25.htm 995468 Disclosure Note 8 Acquisition of Mimi's Rock Corp (Tables) Sheet http://fitlifebrands.com/20240930/role/statement-note-8-acquisition-of-mimis-rock Note 8 Acquisition of Mimi's Rock Corp (Tables) Tables http://fitlifebrands.com/20240930/role/statement-note-8-acquisition-of-mimis-rock Note 8 Acquisition of Mimi's Rock Corp Notes 25 false false R26.htm 995469 Disclosure Note 1 Description of Business (Details Textual) Sheet http://fitlifebrands.com/20240930/role/statement-note-1-description-of-business-details textual Note 1 Description of Business (Details Textual) Details http://fitlifebrands.com/20240930/role/statement-note-1-description-of-business-details textual Note 2 Summary of Significant Accounting Policies (Details Textual) Sheet http://fitlifebrands.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details textual Note 3 Summary of Significant Accounting Policies (Details Textual) Details http://fitlifebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details textual Note 4 Inventories (Details Textual) Details http://fitlifebrands.com/20240930/role/statement-note-4-inventories-details textual Note 5 Property and Equipment (Details Textual) Sheet http://fitlifebrands.com/20240930/role/statement-note-5-property-and-equipment-details textual Note 6 Notes Payable (Details Textual) Notes http://fitlifebrands.com/20240930/role/statement-note-6-notes-payable-details textual Note 7 Equity (Details Textual) Sheet http://fitlifebrands.com/20240930/role/statement-note-7-equity-details textual Note 8 Acquisition of Mimi's Rock Corp Pro Forma Information (Details) Sheet http://fitlifebrands.com/20240930/role/statement-note-8-acquisition-of-mimis-rock Note 8 Acquisition of Mimi's Rock Corp Pro Forma Information (Details) Details 40 false false R41.htm 995484 Disclosure Note 9 Acquisition of Muscelparm Assets (Details Textual) Sheet http://fitlifebrands.com/20240930/role/statement-note-9-acquisition-of-muscelparm-assets Details 41 false false All Reports Book All Reports flif-20240930.xsd flif-20240930-cal.xml flif-20240930-def.xml flif-20240930-lab.xml flif-20240930-pre.xml flif-20240930-10q.htm http://fasb.org/srt/2024 http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true json 60 MetaLinks jrn IDEA: XBRL DOCUMENT "version": "2.2", "instance": "http://fitlifebrands.com/20240930-10q.htm", "nsPrefix": "flif", "nsUri": "http://fitlifebrands.com/20240930", "dts": { "schema": { "local": { "flif-20240930-def.xml", "remote": { "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xld-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/rft-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org-us-gaap/2024-elts/us-gaap-2024.xsd", "https://xbrl.fasb.org-us-gaap/2024-elts/us-roles-2024.xsd", "https://xbrl.fasb.org-us-gaap/2024-elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/currency/2024/currency-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/exch/2024/exch-2024.xsd", "https://xbrl.sec.gov/naics/2024/naics-2024.xsd", "https://xbrl.sec.gov/sic/2024/sic-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd", "calculationLink": { "local": { "flif-20240930-cal.xml", "definitionLink": { "local": { "flif-20240930-def.xml", "labelLink": { "local": { "flif-20240930-lab.xml", "presentationLink": { "local": { "flif-20240930-pre.xml", "inline": { "local": { "flif-20240930-10q.htm", "keyStandard": 213, "keyCustom": 13, "axisStandard": 20, "axisCustom": 0, "memberStandard": 19, "memberCustom": 23, "hidden": { "total": 21, "http://xbrl.sec.gov/dei/2024", 5, "http://xbrl.sec.gov/ecd/2024", 4, "http://fasb.org/us-gaap/2024", 8, "http://fitlifebrands.com/20240930", 4 }, "contextCount": 144, "entityCount": 1, "segmentCount": 42, "elementCount": 349, "unitCount": 7, "baseTaxonomies": { "http://fasb.org/us-gaap/20

"firstAnchor": "contextRef": "d-2024-01-01-2024-09-30", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{ "body": "html", "reportCount": 1, "baseRef": "f1f20240930-10q.htm", "first": true, "unique": true }, { "body": "html", "reportCount": 1, "baseRef": "f1f20240930-10q.htm", "first": true, "unique": true }], "R9": { "role": "http://fitlifebrands.com/20240930/role/statement-note-2-basis-of-presentation", "longName": "Note 2 - Basis of Presentation", "shortName": "Basis of Presentation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "d-2024-01-01-2024-09-30", "name": "us-gaap:BasisOfAccounting", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{ "body": "html", "reportCount": 1, "baseRef": "f1f20240930-10q.htm", "first": true, "unique": true }, { "body": "html", "reportCount": 1, "baseRef": "f1f20240930-10q.htm", "first": true, "unique": true }], "R10": { "role": "http://fitlifebrands.com/20240930/role/statement-note-4-inventories", "longName": "Note 4 - Inventories", "shortName": "Inventories", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "d-2024-01-01-2024-09-30", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{ "body": "html", "reportCount": 1, "baseRef": "f1f20240930-10q.htm", "first": true, "unique": true }, { "body": "html", "reportCount": 1, "baseRef": "f1f20240930-10q.htm", "first": true, "unique": true }], "R11": { "role": "http://fitlifebrands.com/20240930/role/statement-note-5-property-and-equipment", "longName": "Note 5 - Property and Equipment", "shortName": "Property and Equipment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "d-2024-01-01-2024-09-30", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{ "body": "html", "reportCount": 1, "baseRef": "f1f20240930-10q.htm", "first": true, "unique": true }, { "body": "html", "reportCount": 1, "baseRef": "f1f20240930-10q.htm", "first": true, "unique": true }], "R12": { "role": "http://fitlifebrands.com/20240930/role/statement-note-6-notes-payable", "longName": "Note 6 - Notes Payable", "shortName": "Notes Payable", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "d-2024-01-01-2024-09-30", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{ "body": "html", "reportCount": 1, "baseRef": "f1f20240930-10q.htm", "first": true, "unique": true }, { "body": "html", "reportCount": 1, "baseRef": "f1f20240930-10q.htm", "first": true, "unique": true }], "R13": { "role": "http://fitlifebrands.com/20240930/role/statement-note-7-equity", "longName": "Note 7 - Equity", "shortName": "Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "d-2024-01-01-2024-09-30", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{ "body": "html", "reportCount": 1, "baseRef": "f1f20240930-10q.htm", "first": true, "unique": true }, { "body": "html", "reportCount": 1, "baseRef": "f1f20240930-10q.htm", "first": true, "unique": true }], "R14": { "role": "http://fitlifebrands.com/20240930/role/statement-note-8-acquisition-of-mimis-rock-corp", "longName": "Note 8 - Acquisition of Mimi's Rock Corp", "shortName": "Acquisition of Mimi's Rock Corp", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "d-2024-01-01-2024-09-30", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{ "body": "html", "reportCount": 1, "baseRef": "f1f20240930-10q.htm", "first": true, "unique": true }, { "body": "html", "reportCount": 1, "baseRef": "f1f20240930-10q.htm", "first": true, "unique": true }], "R15": { "role": "http://fitlifebrands.com/20240930/role/statement-note-9-acquisition-of-musclepharm-assets", "longName": "Note 9 - Acquisition of Musclepharm Assets", "shortName": "Acquisition of Musclepharm Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "d-2024-01-01-2024-09-30", "name": "us-gaap:AssetAcquisitionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{ "body": "html", "reportCount": 1, "baseRef": "f1f20240930-10q.htm", "first": true, "unique": true }, { "body": "html", "reportCount": 1, "baseRef": "f1f20240930-10q.htm", "first": true, "unique": true }], "R16": { "role": "http://fitlifebrands.com/20240930/role/statement-note-10-commitments-and-contingencies", "longName": "Note 10 - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "d-2024-01-01-2024-09-30", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{ "body": "html", "reportCount": 1, "baseRef": "f1f20240930-10q.htm", "first": true, "unique": true }, { "body": "html", "reportCount": 1, "baseRef": "f1f20240930-10q.htm", "first": true, "unique": true }], "R17": { "role": "http://fitlifebrands.com/20240930/role/statement-note-11-subsequent-events", "longName": "Note 11 - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "d-2024-01-01-2024-09-30", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{ "body": "html", "reportCount": 1, "baseRef": "f1f20240930-10q.htm", "first": true, "unique": true }, { "body": "html", "reportCount": 1, "baseRef": "f1f20240930-10q.htm", "first": true, "unique": true }], "R18": { "role": "http://xbrl.sec.gov/edc/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "d-2024-01-01-2024-09-30", "name": "ecd:MtrTermsOffTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{ "body": "html", "reportCount": 1, "baseRef": "f1f20240930-10q.htm", "first": true, "unique": true }, { "body": "html", "reportCount": 1, "baseRef": "f1f20240930-10q.htm", "first": true, "unique": true }], "R19": { "role": "http://fitlifebrands.com/20240930/role/statement-significant-accounting-policies-tables", "longName": "995462 - Disclosure - Significant Accounting Policies (Policies)", "shortName": "Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "19", "firstAnchor": { "contextRef": "d-2024-01-01-2024-09-30", "name": "us-gaap:ConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{ "body": "html", "reportCount": 1, "baseRef": "f1f20240930-10q.htm", "first": true, "unique": true }, { "body": "html", "reportCount": 1, "baseRef": "f1f20240930-10q.htm", "first": true, "unique": true }], "R20": { "role": "http://fitlifebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-tables", "longName": "995463 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Tables)", "shortName": "Note 3 - Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "20", "firstAnchor": { "contextRef": "d-2024-01-01-2024-09-30", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{ "body": "html", "reportCount": 1, "baseRef": "f1f20240930-10q.htm", "first": true, "unique": true }, { "body": "html", "reportCount": 1, "baseRef": "f1f20240930-10q.htm", "first": true, "unique": true }], "R21": { "role": "http://fitlifebrands.com/20240930/role/statement-note-4-inventories-tables", "longName": "995464 - Disclosure - Note 4 - Inventories (Tables)", "shortName": "Note 4 - Inventories (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "21", "firstAnchor": { "contextRef": "d-2024-01-01-2024-09-30", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{ "body": "html", "reportCount": 1, "baseRef": "f1f20240930-10q.htm", "first": true, "unique": true }, { "body": "html", "reportCount": 1, "baseRef": "f1f20240930-10q.htm", "first": true, "unique": true }], "R22": { "role": "http://fitlifebrands.com/20240930/role/statement-note-5-property-and-equipment-tables", "longName": "995465 - Disclosure - Note 5 - Property and Equipment (Tables)", "shortName": "Note 5 - Property and Equipment (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "d-2024-01-01-2024-09-30", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{ "body": "html", "reportCount": 1, "baseRef": "f1f20240930-10q.htm", "first": true, "unique": true }, { "body": "html", "reportCount": 1, "baseRef": "f1f20240930-10q.htm", "first": true, "unique": true }], "R

"Details", "order": "29", "firstAnchor": { "contextRef": "d-2024-07-01-2024-09-30", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "td": "tr", "tbody", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "f1f22040930-10q.htm", "first": true, "uniqueAnchor": { "contextRef": "d-2024-07-01-2024-09-30", "name": "us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "td": "tr", "tbody", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "f1f22040930-10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d-2024-07-01-2024-09-30", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": "us-gaap:EarningsPerSharePolicyTextBlock", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "td": "tr", "tbody", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "f1f22040930-10q.htm", "first": true, "unique": true }, "R30": { "role": "http://fitlifebrands.com/20240930/role/statement-note-4-inventories-details-textual", "longName": "995473 - Disclosure - Note 4 - Inventories (Details Textual)", "shortName": "Note 4 - Inventories (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "i-2024-09-30", "name": "us-gaap:InventoryValuationReserves", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "p", "td", "tr", "tbody", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "f1f22040930-10q.htm", "first": true, "uniqueAnchor": null }, "R31": { "role": "http://fitlifebrands.com/20240930/role/statement-note-4-inventories-summary-of-inventory-details", "longName": "995474 - Disclosure - Note 4 - Inventories - Summary of Inventory (Details)", "shortName": "Note 4 - Inventories - Summary of Inventory (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "i-2024-09-30", "name": "us-gaap:InventoryFinishedGoods", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "td": "tr", "tbody", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "f1f22040930-10q.htm", "first": true, "unique": true }, "unique": true }, "uniqueAnchor": { "contextRef": "i-2024-09-30", "name": "us-gaap:InventoryFinishedGoods", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "td": "tr", "tbody", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "f1f22040930-10q.htm", "first": true, "unique": true }, "R32": { "role": "http://fitlifebrands.com/20240930/role/statement-note-5-property-and-equipment-details-textual", "longName": "995475 - Disclosure - Note 5 - Property and Equipment (Details Textual)", "shortName": "Note 5 - Property and Equipment (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "d-2024-07-01-2024-09-30", "name": "us-gaap:Depreciation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "p", "td", "tr", "tbody", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "f1f22040930-10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d-2024-07-01-2024-09-30", "name": "us-gaap:Depreciation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "p", "td", "tr", "tbody", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "f1f22040930-10q.htm", "first": true, "unique": true }, "R33": { "role": "http://fitlifebrands.com/20240930/role/statement-note-5-property-and-equipment-property-and-equipment-details", "longName": "995476 - Disclosure - Note 5 - Property and Equipment - Property and Equipment (Details)", "shortName": "Note 5 - Property and Equipment - Property and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "i-2024-09-30", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "td", "tr", "tbody", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "f1f22040930-10q.htm", "first": true, "unique": true }, "unique": true }, "uniqueAnchor": { "contextRef": "i-2024-09-30", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "td", "tr", "tbody", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "f1f22040930-10q.htm", "first": true, "unique": true }, "R34": { "role": "http://fitlifebrands.com/20240930/role/statement-note-6-notes-payable-details-textual", "longName": "995477 - Disclosure - Note 6 - Notes Payable (Details Textual)", "shortName": "Note 6 - Notes Payable (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "i-2023-10-10-CreditFacilityAxis-RevolvingCreditFacilityMember", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "5", "ancestors": { "p", "td", "tr", "tbody", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "f1f22040930-10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i-2023-10-10-CreditFacilityAxis-RevolvingCreditFacilityMember", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "5", "ancestors": { "p", "td", "tr", "tbody", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "f1f22040930-10q.htm", "first": true, "unique": true }, "R35": { "role": "http://fitlifebrands.com/20240930/role/statement-note-6-notes-payable-debt-obligations-details", "longName": "995478 - Disclosure - Note 6 - Notes Payable - Debt Obligations (Details)", "shortName": "Note 6 - Notes Payable - Debt Obligations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "i-2024-09-30", "name": "us-gaap:LongTermDebtNoncurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "td", "tr", "tbody", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "f1f22040930-10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i-2024-09-30", "name": "us-gaap:LongTermDebtNoncurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "td", "tr", "tbody", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "f1f22040930-10q.htm", "first": true, "unique": true }, "R36": { "role": "http://fitlifebrands.com/20240930/role/statement-note-7-equity-details-textual", "longName": "995479 - Disclosure - Note 7 - Equity (Details Textual)", "shortName": "Note 7 - Equity (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "i-2024-09-30", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "7", "ancestors": { "p", "td", "tr", "tbody", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "f1f22040930-10q.htm", "first": true, "uniqueAnchor": { "contextRef": "d-2021-02-01-2021-02-28", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": { "p", "td", "tr", "tbody", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "f1f22040930-10q.htm", "unique": true }, "R37": { "role": "http://fitlifebrands.com/20240930/role/statement-note-7-equity-stock-option-activity-details", "longName": "995480 - Disclosure - Note 7 - Equity - Stock Option Activity (Details)", "shortName": "Note 7 - Equity - Stock Option Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "i-2023-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "td", "tr", "tbody", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "f1f22040930-10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d-2024-01-01-2024-09-30", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "td", "tr", "tbody", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "f1f22040930-10q.htm", "first": true, "unique": true }, "R38": { "role": "http://fitlifebrands.com/20240930/role/statement-note-7-equity-exercise-price-range-details", "longName": "995481 - Disclosure - Note 7 - Equity - Exercise Price Range (Details)", "shortName": "Note 7 - Equity - Exercise Price Range (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "i-2024-09-30", "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "td", "tr", "tbody", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "f1f22040930-10q.htm", "first": true, "unique": true }, "R39": { "role": "http://fitlifebrands.com/20240930/role/statement-note-8-acquisition-of-mimis-rock-corp-details-textual", "longName": "995482 - Disclosure - Note 8 - Acquisition of Mimi's Rock Corp (Details Textual)", "shortName": "Note 8 - Acquisition of Mimi's Rock Corp (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "i-2024-09-30", "name": "us-gaap:Goodwill", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": { "td", "tr", "tbody", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "f1f22040930-10q.htm", "first": true, "uniqueAnchor": { "contextRef": "d-2023-02-28-2023-02-28-BusinessAcquisitionAxis-MimisRockCorpMember", "name": "us-gaap:BusinessCombinationConsiderationTransferred1", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "p", "td", "tr", "tbody", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "f1f22040930-10q.htm", "unique": true }, "R40": { "role": "http://fitlifebrands.com/20240930/role/statement-note-8-acquisition-of-mimis-rock-corp-pro-forma-information-details", "longName": "995483 - Disclosure - Note 8 - Acquisition of Mimi's Rock Corp - Pro Forma Information (Details)", "shortName": "Note 8 - Acquisition of Mimi's Rock Corp - Pro Forma Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "d-2023-01-01-2023-09-30-BusinessAcquisitionAxis-MimisRockCorpMember", "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "td", "tr", "tbody", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "f1f22040930-10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d-2023-01-01-2023-09-30-BusinessAcquisitionAxis-MimisRockCorpMember", "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "td", "tr", "tbody", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "f1f22040930-10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d-2023-01-01-2023-09-30-BusinessAcquisitionAxis-MimisRockCorpMember", "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "td", "tr", "tbody", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "f1f22040930-10q.htm", "first": true, "unique": true }, "R41": { "role": "http://fitlifebrands.com/20240930/role/statement-note-9-acquisition-of-musclepharm-assets-details-textual", "longName": "995484 - Disclosure - Note 9 - Acquisition of Musclepharm Assets (Details Textual)", "shortName": "Note 9 - Acquisition of Musclepharm Assets (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "i-2024-09-30", "name": "us-gaap:InventoryNet", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "td", "tr", "tbody", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "f1f22040930-10q.htm", "first": true, "uniqueAnchor": { "contextRef": "d-2023-10-10-2023-10-10-AssetAcquisitionAxis-AssetsOfMusclepharmCorporationMember", "name": "us-gaap:AssetAcquisitionConsiderationTransferred", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "p", "td", "tr", "tbody", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "f1f22040930-10q.htm", "unique": true }, "tag": { "us-gaap:AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "presentation": "http://fitlifebrands.com/20240930/role/statement-significant-accounting-policies-policies" }, "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } }, "auth ref": { "us-gaap:AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "credit": "calculation" }, "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap:LiabilitiesCurrent", "weight": 1.0, "order": 0.0 }, "presentation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap:LiabilitiesCurrent", "weight": 1.0, "order": 1.0 }, "auth ref": { "r47": "r691" }, "us-gaap:AccountsPayableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableMember", "presentation": "http://fitlifebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual" }, "lang": { "en-us": { "role": { "label": "Accounts Payable [Member]", "documentation": "Obligations incurred and payable to vendors for goods and services received." } }, "auth ref": { "r49" }, "us-gaap:AccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableMember", "presentation": "http://fitlifebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies" }, "http://fitlifebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual" }, "lang": { "en-us": { "role": { "label": "Accounts Receivable [Member]", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } }, "auth ref": { "r640" }, "us-gaap:AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "credit": "debit", "calculation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap:AssetsCurrent", "weight": 1.0, "order": 1.0 }, "presentation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap:LiabilitiesCurrent", "weight": 1.0, "order": 2.0 }, "auth ref": { "r32": "r163", "r510" }, "us-gaap:AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember", "presentation": "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statement-of-stockholders-equity-unaudited" }, "lang": { "en-us": { "role": { "label": "Accumulated Foreign Currency Adjustment Attributable to Noncontrolling Interest [Member]", "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term investment nature, attributable to the noncontrolling interest." } }, "auth ref": { "r3": "r9", "r16", "r67", "r68", "r441", "r447", "r744", "r745", "r746" }, "us-gaap:AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "credit": "calculation" }, "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag":

"us-gaap-StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "en-us": { "role": { "label": "Additional paid in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid in capital (APIC) for common and preferred stock." } }, "auth-ref": { "r59", "r601", "r43" } }, "us-gaap-AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statement-of-stockholders-equity-unaudited": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } }, "auth-ref": { "r553", "r755", "r756", "r757", "r758", "r793", "r844" } }, "us-gaap-AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "en-us": { "role": { "label": "Adjustments to reconcile net income to net cash provided by operating activities." } }, "auth-ref": { } }, "us-gaap-AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "credit": "debit", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-7-equity-details-textual": { "en-us": { "role": { "label": "us-gaap-AllocatedShareBasedCompensationExpense", "terseLabel": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } }, "auth-ref": { "r390", "r391" } }, "us-gaap-AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "credit": "debit", "presentation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parenteticals": { "en-us": { "role": { "label": "Allowance of doubtful accounts", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } }, "auth-ref": { "r172", "r259", "r263" } }, "dei-AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": { "http://fitlifebrands.com/20240930/role/statement-document-and-entity-information": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously filed or accepted submission." } }, "auth-ref": { }, "fil-AmortizationOfDeferredFinanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fitlifebrands.com/20240930", "localname": "AmortizationOfDeferredFinanceCosts", "debit": "calculation", "presentation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap-NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "en-us": { "role": { "label": "Amortization of deferred financing costs", "documentation": "In reference to the amortization of deferred finance costs." } }, "auth-ref": { }, "us-gaap-AssetAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionAxis", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-9-acquisition-of-musclepharm-assets": { "http://fitlifebrands.com/20240930/role/statement-note-9-acquisition-of-musclepharm-assets-details-textual": { "en-us": { "role": { "label": "Asset Acquisition [Axis]", "documentation": "Information by asset acquisition." } }, "auth-ref": { "r282", "r293", "r294", "r295", "r296", "r790" } }, "us-gaap-AssetAcquisitionConsiderationTransferred": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionConsiderationTransferred", "credit": "debit", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-9-acquisition-of-musclepharm-assets-details-textual": { "en-us": { "role": { "label": "us-gaap-AssetAcquisitionConsiderationTransferred", "terseLabel": "Asset Acquisition, Consideration Transferred", "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer." } }, "auth-ref": { "r682", "r790", "r791", "r792" } }, "us-gaap-AssetAcquisitionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionDomain", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-9-acquisition-of-musclepharm-assets-details-textual": { "en-us": { "role": { "label": "Asset Acquisition [Domain]", "documentation": "Asset acquisition." } }, "auth-ref": { "r282", "r283", "r294", "r295", "r296", "r790" } }, "us-gaap-AssetAcquisitionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionTextBlock", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-9-acquisition-of-musclepharm-assets": { "en-us": { "role": { "label": "Asset Acquisition [Text Block]", "documentation": "The entire disclosure for asset acquisition." } }, "auth-ref": { "r789" } }, "us-gaap-AssetPledgedAsCollateralMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetPledgedAsCollateralMember", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies": "http://fitlifebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual": { "en-us": { "role": { "label": "Asset Pledged as Collateral [Member]", "documentation": "Asset pledged as collateral." } }, "auth-ref": { "r420", "r572", "r683", "r809" } }, "us-gaap-Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "credit": "debit", "calculation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "en-us": { "role": { "label": "us-gaap Assets", "totalLabel": "TOTAL ASSETS", "documentation": "Amount of asset recognized for present right to economic benefit." } }, "auth-ref": { "r104", "r144", "r166", "r197", "r226", "r231", "r248", "r251", "r260", "r300", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r420", "r422", "r435", "r503", "r502", "r663", "r664", "r691", "r719", "r782", "r783", "r801" } }, "us-gaap-AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "credit": "debit", "calculation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap-Assets", "weight": 1.0, "order": 5.0 } }, "presentation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "en-us": { "role": { "label": "us-gaap AssetsCurrent", "totalLabel": "Total current assets", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } }, "auth-ref": { "r160", "r174", "r197", "r260", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r420", "r422", "r435", "r691", "r782", "r783", "r801" } }, "fil-AssetsOfMusclepharmCorporationMember": { "xbrltype": "domainItemType", "nsuri": "http://fitlifebrands.com/20240930", "localname": "AssetsOfMusclepharmCorporationMember", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-9-acquisition-of-musclepharm-assets": "http://fitlifebrands.com/20240930/role/statement-note-9-acquisition-of-musclepharm-assets-details-textual": { "en-us": { "role": { "label": "Assets of MusclePharm Corporation [Member]", "documentation": "Represents the assets of MusclePharm Corporation." } }, "auth-ref": { }, "us-gaap-AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-7-equity": "http://fitlifebrands.com/20240930/role/statement-note-7-equity-details-textual": { "en-us": { "role": { "label": "Award Type [Axis]", "documentation": "Information by type of award under share based payment arrangement." } }, "auth-ref": { "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389" } }, "us-gaap-BasisOfAccounting": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccounting", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-2-basis-of-presentation": { "en-us": { "role": { "label": "Basis of Accounting [Text Block]", "documentation": "The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS." } }, "auth-ref": { "r83" } }, "fil-BrandsMember": { "xbrltype": "domainItemType", "nsuri": "http://fitlifebrands.com/20240930", "localname": "BrandsMember", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-9-acquisition-of-musclepharm-assets": "http://fitlifebrands.com/20240930/role/statement-note-9-acquisition-of-musclepharm-assets-details-textual": { "en-us": { "role": { "label": "Brands [Member]", "documentation": "In reference to brands associated with the company." } }, "auth-ref": { }, "us-gaap-BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-8-acquisition-of-mimis-rock-corp": "http://fitlifebrands.com/20240930/role/statement-note-8-acquisition-of-mimis-rock-corp-details-textual": { "en-us": { "role": { "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } }, "auth-ref": { "r282", "r283", "r284", "r285", "r286", "r415", "r677", "r678" } }, "us-gaap-BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAxis", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-8-acquisition-of-mimis-rock-corp": "http://fitlifebrands.com/20240930/role/statement-note-8-acquisition-of-mimis-rock-corp-details-textual": { "en-us": { "role": { "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } }, "auth-ref": { "r39", "r41", "r282", "r283", "r284", "r285", "r286", "r415", "r677", "r678" } }, "us-gaap-BusinessAcquisitionProFormaEarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionProFormaEarningsPerShareDiluted", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-8-acquisition-of-mimis-rock-corp-pro-forma-information-details": { "en-us": { "role": { "label": "Diluted net income per share (in dollars per share)", "documentation": "The pro forma diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period." } }, "auth-ref": { "r732", "r733" } }, "us-gaap-BusinessAcquisitionProFormaInformationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionProFormaInformationTextBlock", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-8-acquisition-of-mimis-rock-corp-tables": { "en-us": { "role": { "label": "Business Acquisition, Pro Forma Information [Table Text Block]", "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate." } }, "auth-ref": { "r732", "r733" } }, "us-gaap-BusinessAcquisitionsProFormaNetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionsProFormaNetIncomeLoss", "credit": "debit", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-8-acquisition-of-mimis-rock-corp-pro-forma-information-details": { "en-us": { "role": { "label": "Net income", "documentation": "The pro forma net income or loss for the period as if the business combination or combinations had been completed at the beginning of a period." } }, "auth-ref": { "r413", "r414" } }, "us-gaap-BusinessAcquisitionsProFormaRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionsProFormaRevenue", "credit": "debit", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-8-acquisition-of-mimis-rock-corp-pro-forma-information-details": { "en-us": { "role": { "label": "Revenue", "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period." } }, "auth-ref": { "r413", "r414" } }, "us-gaap-BusinessCombinationConsiderationTransferred1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationConsiderationTransferred1", "credit": "debit", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-8-acquisition-of-mimis-rock-corp-details-textual": { "en-us": { "role": { "label": "us-gaap-BusinessCombinationConsiderationTransferred1", "terseLabel": "Business Combination, Consideration Transferred", "documentation": "Amount of consideration transferred, consisting of acquisition date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer." } }, "auth-ref": { "r0", "r1", "r8" } }, "us-gaap-BusinessCombinationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationDisclosureTextBlock", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-8-acquisition-of-mimis-rock-corp": { "en-us": { "role": { "label": "Business Combination Disclosure [Text Block]", "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)." } }, "auth-ref": { "r98", "r416" } }, "us-gaap-BusinessCombinationIntegrationRelatedCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationIntegrationRelatedCosts", "credit": "debit", "calculation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-income-and-comprehensive-income-unaudited": { "parentTag": "us-gaap-OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-income-and-comprehensive-income-unaudited": { "en-us": { "role": { "label": "Merger and acquisition related", "documentation": "Costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs." } }, "auth-ref": { }, "us-gaap-BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual", "credit": "debit", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-8-acquisition-of-mimis-rock-corp-details-textual": { "en-us": { "role": { "label": "us-gaap-BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual", "terseLabel": "Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual", "documentation": "This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period." } }, "auth-ref": { "r40" } }, "us-gaap-BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "credit": "debit", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-8-acquisition-of-mimis-rock-corp-details-textual": { "en-us": { "role": { "label": "us-gaap-BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill", "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date." } }, "auth-ref": { "r42" } }, "us-gaap-BusinessCombinationsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationsPolicy", "presentation": { "http://fitlifebrands.com/20240930/role/statement-significant-accounting-policies-policies": { "en-us": { "role": { "label": "Business Combinations Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy." } }, "auth-ref": { "r99", "r100", "r101", "r102" } }, "us-gaap-Cash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Cash", "credit": "debit", "calculation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap-AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "en-us": { "role": { "label": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation." } }, "auth-ref": { "r116", "r505", "r564", "r587", "r691", "r719", "r737" } }, "us-gaap-CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-

gaap/2024", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": { "http://fitlifebrands.com/20240930/role/statement-significant-accounting-policies-policies" }, "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth-ref": { "r21" } }, "us-gaap-CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" }, "lang": { "en-us": { "role": { "label": "us-gaap-CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "periodStartLabel": "CASH, BEGINNING OF PERIOD", "periodEndLabel": "CASH AND RESTRICTED CASH, END OF PERIOD", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage, including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth-ref": { "r20", "r80", "r193" } }, "us-gaap-CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" }, { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" }, "lang": { "en-us": { "role": { "label": "us-gaap-CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "totalLabel": "CHANGE IN CASH AND RESTRICTED CASH", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage, including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth-ref": { "r2", "r80" } }, "dei-CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": { "http://fitlifebrands.com/20240930/role/statement-document-and-entity-information" }, "lang": { "en-us": { "role": { "label": "dei-CityAreaCode", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth-ref": { } }, "us-gaap-ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-1-description-of-business", "http://fitlifebrands.com/20240930/role/statement-note-1-description-of-business-details-textual" }, "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth-ref": { "r128", "r160", "r170", "r171", "r197", "r215", "r219", "r221", "r223", "r228", "r229", "r260", "r300", "r311", "r312", "r313", "r316", "r317", "r346", "r347", "r349", "r352", "r358", "r435", "r548", "r549", "r550", "r551", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r565", "r579", "r601", "r619", "r633", "r634", "r635", "r636", "r637", "r728", "r752", "r759" } }, "us-gaap-CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-10-commitments-and-contingencies" }, "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth-ref": { "r90", "r301", "r302", "r641", "r772", "r777" } }, "us-gaap-CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statement-of-stockholders-equity-unaudited" }, "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth-ref": { "r710", "r711", "r712", "r714", "r715", "r716", "r717", "r755", "r756", "r758", "r793", "r842", "r844" } }, "us-gaap-CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parententhicals", "http://fitlifebrands.com/20240930/role/statement-note-7-equity-details-textual" }, "lang": { "en-us": { "role": { "label": "Common stock, par value (in dollars per share)", "terseLabel": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock" } } }, "auth-ref": { "r58" } }, "us-gaap-CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parententhicals", "http://fitlifebrands.com/20240930/role/statement-note-7-equity-details-textual" }, "lang": { "en-us": { "role": { "label": "Common stock, shares authorized (in shares)", "terseLabel": "Common Stock, Shares Authorized (in shares)", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth-ref": { "r58", "r579" } }, "us-gaap-CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parententhicals", "http://fitlifebrands.com/20240930/role/statement-note-7-equity-details-textual" }, "lang": { "en-us": { "role": { "label": "Common stock, shares issued (in shares)", "terseLabel": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth-ref": { "r58" } }, "us-gaap-CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parententhicals" }, "lang": { "en-us": { "role": { "label": "Common stock, shares outstanding (in shares)", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth-ref": { "r10", "r58", "r579", "r598", "r644", "r645" } }, "us-gaap-CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" }, { "parentTag": "us-gaap-StockholdersEquity", "weight": 1.0, "order": 0.0 }, "presentation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" }, "lang": { "en-us": { "role": { "label": "Common stock, \$0.01 par value, 60,000 shares authorized, 4,598 issued and outstanding as of June 30, 2024 and December 31, 2023", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth-ref": { "r58", "r507", "r691" } }, "us-gaap-ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-income-and-comprehensive-income-unaudited" }, { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-income-and-comprehensive-income-unaudited" }, "lang": { "en-us": { "role": { "label": "us-gaap-ComprehensiveIncomeNetOfTax", "totalLabel": "Comprehensive income", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth-ref": { "r17", "r177", "r179", "r185", "r498", "r515", "r516" } }, "us-gaap-ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "http://fitlifebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual" }, "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth-ref": { "r25", "r27", "r44", "r45", "r257", "r640" } }, "us-gaap-ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "http://fitlifebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual" }, "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth-ref": { "r25", "r27", "r44", "r45", "r257", "r545", "r640" } }, "us-gaap-ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByTypeAxis", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "http://fitlifebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual" }, "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employee, supplier, lender." } } }, "auth-ref": { "r25", "r27", "r44", "r45", "r257", "r640", "r731" } }, "us-gaap-ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskCreditRisk", "presentation": { "http://fitlifebrands.com/20240930/role/statement-significant-accounting-policies-policies" }, "lang": { "en-us": { "role": { "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth-ref": { "r46", "r120" } }, "us-gaap-ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskPercentage1", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual" }, "lang": { "en-us": { "role": { "label": "us-gaap-ConcentrationRiskPercentage1", "terseLabel": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the benchmark (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth-ref": { "r25", "r27", "r44", "r45", "r257" } }, "us-gaap-ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTypeDomain", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "http://fitlifebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual" }, "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employee, supplier, lender) of the concentration." } } }, "auth-ref": { "r25", "r27", "r44", "r45", "r257", "r640" } }, "us-gaap-ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationPolicyTextBlock", "presentation": { "http://fitlifebrands.com/20240930/role/statement-significant-accounting-policies-policies" }, "lang": { "en-us": { "role": { "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth-ref": { "r43", "r657" } }, "us-gaap-CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-income-and-comprehensive-income-unaudited" }, { "parentTag": "us-gaap-GrossProfit", "weight": 1.0, "order": 1.0 }, "presentation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-income-and-comprehensive-income-unaudited" }, "lang": { "en-us": { "role": { "label": "Cost of goods sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth-ref": { "r72", "r73", "r465" } }, "us-gaap-CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityAxis", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-6-notes-payable", "http://fitlifebrands.com/20240930/role/statement-note-6-notes-payable-details-textual" }, "lang": { "en-us": { "role": { "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth-ref": { "r308", "r780" } }, "us-gaap-CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityDomain", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-6-notes-payable", "http://fitlifebrands.com/20240930/role/statement-note-6-notes-payable-details-textual" }, "lang": { "en-us": { "role": { "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth-ref": { "r308", "r780", "r781" } }, "dei-CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": { "http://fitlifebrands.com/20240930/role/statement-document-and-entity-information" }, "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format MM-DD." } } }, "auth-ref": { } }, "us-gaap-CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerConcentrationRiskMember", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "http://fitlifebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual" }, "lang": { "en-us": { "role": { "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth-ref": { "r84", "r257" } }, "us-gaap-CustomerRefundLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerRefundLiabilityCurrent", "crdr": "credit", "calculation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" }, { "parentTag": "us-gaap-LiabilitiesCurrent", "weight": 1.0, "order": 3.0 }, "presentation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" }, "lang": { "en-us": { "role": { "label": "Product returns", "documentation": "Current regulatory liabilities generally represent obligations to make refunds to customers for various reasons including overpayment." } } }, "auth-ref": { } }, "us-gaap-DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-6-notes-payable" }, "lang": { "en-us": { "role": { "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth-ref": { "r91", "r195", "r294", "r295", "r296", "r297", "r298", "r307", "r308", "r318", "r324", "r325", "r326", "r327", "r328", "r329", "r334", "r341", "r342", "r343", "r448" } }, "rfi-DebtInstrumentAdditionalInterestRateDefault": { "xbrltype": "percentItemType", "nsuri": "http://fitlifebrands.com/20240930", "localname": "DebtInstrumentAdditionalInterestRateDefault", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-6-notes" } }

```

"documentation": "The percent additional interest rate of debt instrument in the event of default." } } }, "auth-ref": [ ] }, "us-gaap-DebtInstrumentAxis": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": { "http://fitfilebrands.com/20240930/role/statement-note-6-notes-payable", "http://fitfilebrands.com/20240930/role/statement-note-6-notes-payable-debt-obligations-details", "http://fitfilebrands.com/20240930/role/statement-note-6-notes-payable-details-textual" } }, "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth-ref": { "r14", "r49", "r50", "r105", "r107", "r198", "r319", "r320", "r321", "r322", "r323", "r325", "r330", "r331", "r332", "r333", "r335", "r336", "r337", "r338", "r339", "r340", "r668", "r669", "r670", "r671", "r672", "r680", "r753", "r774", "r775", "r798", "r799" } }, "us-gaap-DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": { "http://fitfilebrands.com/20240930/role/statement-note-6-notes-payable-details-textual" } }, "lang": { "en-us": { "role": { "label": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth-ref": [ ] }, "rf-DebtInstrumentCovenantCashFlowLeverageThreshold": { "xbrltype": "percentItem", "nsuri": "http://fitfilebrands.com/20240930", "localname": "DebtInstrumentCovenantCashFlowLeverageThreshold", "presentation": { "http://fitfilebrands.com/20240930/role/statement-note-6-notes-payable-details-textual" } }, "lang": { "en-us": { "role": { "label": "rf-DebtInstrumentCovenantCashFlowLeverageThreshold", "documentation": "Debt Instrument, Covenant, Cash Flow Leverage Threshold", "documentation": "Rate of cash flow leverage threshold under covenant of the debt instrument." } } }, "auth-ref": [ ] }, "rf-DebtInstrumentCovenantCashFlowLeverageThresholdPercentageOfExcessCashFlow": { "xbrltype": "percentItem", "nsuri": "http://fitfilebrands.com/20240930", "localname": "DebtInstrumentCovenantCashFlowLeverageThresholdPercentageOfExcessCashFlow", "presentation": { "http://fitfilebrands.com/20240930/role/statement-note-6-notes-payable-details-textual" } }, "lang": { "en-us": { "role": { "label": "rf-DebtInstrumentCovenantCashFlowLeverageThresholdPercentageOfExcessCashFlow", "documentation": "Debt Instrument, Covenant, Cash Flow Leverage Threshold, Percentage of Excess Cash Flow", "documentation": "Percentage of excess cash flow for rate of cash flow leverage threshold under the covenant of the debt instrument." } } }, "auth-ref": [ ] }, "us-gaap-DebtInstrumentFaceAmount": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "documentation": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } }, "auth-ref": { "r319", "r448", "r449", "r669", "r670", "r689" } }, "us-gaap-DebtInstrumentNameDomain": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": { "http://fitfilebrands.com/20240930/role/statement-note-6-notes-payable", "http://fitfilebrands.com/20240930/role/statement-note-6-notes-payable-debt-obligations-details", "http://fitfilebrands.com/20240930/role/statement-note-6-notes-payable-details-textual" } }, "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth-ref": { "r14", "r198", "r319", "r320", "r321", "r322", "r323", "r325", "r330", "r331", "r332", "r333", "r335", "r336", "r337", "r338", "r339", "r340", "r668", "r669", "r670", "r671", "r672", "r689", "r753", "r773", "r774", "r775", "r798", "r799" } }, "us-gaap-DebtInstrumentPeriodicPaymentPrincipal": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentPeriodicPaymentPrincipal", "documentation": "Debt Instrument, Periodic Payment, Principal", "documentation": "Amount of the required periodic payments applied to principal." } }, "auth-ref": { "r14" } }, "us-gaap-DebtInstrumentVariableInterestRateTypeExtensibleEnumeration": { "xbrltype": "enumerationSetItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentVariableInterestRateTypeExtensibleEnumeration", "presentation": { "http://fitfilebrands.com/20240930/role/statement-note-6-notes-payable-details-textual" } }, "lang": { "en-us": { "role": { "label": "us-gaap-DebtInstrumentVariableInterestRateTypeExtensibleEnumeration", "documentation": "Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]", "documentation": "Indicates type of variable interest rate on debt instrument." } } }, "auth-ref": { "r502" } }, "us-gaap-DeferredFinanceCostsGross": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredFinanceCostsGross", "documentation": "Deferred Finance Costs Gross", "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } }, "auth-ref": { "r798", "r799" } }, "us-gaap-DeferredIncomeTaxAssetsNet": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxAssetsNet", "documentation": "Deferred Income Tax Assets Net", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting." } }, "auth-ref": { "r395", "r396" } }, "us-gaap-DeferredIncomeTaxLiabilitiesNet": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxLiabilitiesNet", "documentation": "Deferred Income Tax Liabilities Net", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting." } }, "auth-ref": { "r395", "r396", "r504" } }, "us-gaap-Depreciation": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "documentation": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } }, "auth-ref": { "r6", "r31" } }, "us-gaap-DepreciationAndAmortization": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationAndAmortization", "documentation": "Depreciation And Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } }, "auth-ref": { "r6", "r226", "r236", "r251", "r663", "r664" } }, "us-gaap-DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": { "http://fitfilebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-tables", "http://fitfilebrands.com/20240930/role/statement-note-4-inventories", "http://fitfilebrands.com/20240930/role/statement-note-5-property-and-equipment", "http://fitfilebrands.com/20240930/role/statement-note-6-notes-payable", "http://fitfilebrands.com/20240930/role/statement-note-7-equity", "http://fitfilebrands.com/20240930/role/statement-note-8-acquisition-of-mimic-rock-corp", "http://fitfilebrands.com/20240930/role/statement-note-9-acquisition-of-musclepharm-assets", "http://fitfilebrands.com/20240930/role/statement-note-10-commitments-and-contingencies", "http://fitfilebrands.com/20240930/role/statement-note-11-subsequent-events", "http://fitfilebrands.com/20240930/role/statement-note-2-basis-of-presentation", "http://fitfilebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "http://fitfilebrands.com/20240930/role/statement-note-4-inventories", "http://fitfilebrands.com/20240930/role/statement-note-5-property-and-equipment", "http://fitfilebrands.com/20240930/role/statement-note-6-notes-payable", "http://fitfilebrands.com/20240930/role/statement-note-7-equity", "http://fitfilebrands.com/20240930/role/statement-note-8-acquisition-of-mimic-rock-corp", "http://fitfilebrands.com/20240930/role/statement-note-9-acquisition-of-musclepharm-assets", "http://fitfilebrands.com/20240930/role/statement-note-10-commitments-and-contingencies", "http://fitfilebrands.com/20240930/role/statement-note-11-subsequent-events", "http://fitfilebrands.com/20240930/role/statement-note-2-basis-of-presentation", "http://fitfilebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "http://fitfilebrands.com/20240930/role/statement-note-4-inventories", "http://fitfilebrands.com/20240930/role/statement-note-5-property-and-equipment", "http://fitfilebrands.com/20240930/role/statement-note-6-notes-payable", "http://fitfilebrands.com/20240930/role/statement-note-7-equity", "http://fitfilebrands.com/20240930/role/statement-note-8-acquisition-of-mimic-rock-corp", "http://fitfilebrands.com/20240930/role/statement-note-9-acquisition-of-musclepharm-assets", "http://fitfilebrands.com/20240930/role/statement-note-10-commitments-and-contingencies", "http://fitfilebrands.com/20240930/role/statement-note-11-subsequent-events", "http://fitfilebrands.com/20240930/role/statement-note-2-basis-of-presentation", "http://fitfilebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "http://fitfilebrands.com/20240930/role/statement-note-4-inventories", "http://fitfilebrands.com/20240930/role/statement-note-5-property-and-equipment", "http://fitfilebrands.com/20240930/role/statement-note-6-notes-payable", "http://fitfilebrands.com/20240930/role/statement-note-7-equity", "http://fitfilebrands.com/20240930/role/statement-note-8-acquisition-of-mimic-rock-corp", "http://fitfilebrands.com/20240930/role/statement-note-9-acquisition-of-musclepharm-assets", "http://fitfilebrands.com/20240930/role/statement-note-10-commitments-and-contingencies", "http://fitfilebrands.com/20240930/role/statement-note-11-subsequent-events", "http://fitfilebrands.com/20240930/role/statement-note-2-basis-of-presentation", "http://fitfilebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "http://fitfilebrands.com/20240930/role/statement-note-4-inventories", "http://fitfilebrands.com/20240930/role/statement-note-5-property-and-equipment", "http://fitfilebrands.com/20240930/role/statement-note-6-notes-payable", "http://fitfilebrands.com/20240930/role/statement-note-7-equity", "http://fitfilebrands.com/20240930/role/statement-note-8-acquisition-of-mimic-rock-corp", "http://fitfilebrands.com/20240930/role/statement-note-9-acquisition-of-musclepharm-assets", "http://fitfilebrands.com/20240930/role/statement-note-10-commitments-and-contingencies", "http://fitfilebrands.com/20240930/role/statement-note-11-subsequent-events", "http://fitfilebrands.com/20240930/role/statement-note-2-basis-of-presentation", "http://fitfilebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "http://fitfilebrands.com/20240930/role/statement-note-4-inventories", "http://fitfilebrands.com/20240930/role/statement-note-5-property-and-equipment", "http://fitfilebrands.com/20240930/role/statement-note-6-notes-payable", "http://fitfilebrands.com/20240930/role/statement-note-7-equity", "http://fitfilebrands.com/2
```

[illegible]

continent, or region such as EMEA (Europe, Middle East, Africa)." } } } }, "auth-ref": { "r26", "r640" } }, "us-gaap-Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap-Assets", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "http://fitlifebrands.com/20240930/role/statement-note-8-acquisition-of-mimis-rock-corp-details-textual": { "lang": { "en-us": { "role": { "label": "Goodwill", "terseLabel": "Goodwill", "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth-ref": { "r164", "r269", "r496", "r664", "r666", "r684", "r691", "r768", "r769" } } }, "us-gaap-GoodwillAndIntangibleAssetsGoodwillPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy", "presentation": { "http://fitlifebrands.com/20240930/role/statement-significant-accounting-policies-policies": { "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined." } } } }, "auth-ref": { "r268", "r279", "r666" } } }, "us-gaap-GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy", "presentation": { "http://fitlifebrands.com/20240930/role/statement-significant-accounting-policies-policies": { "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined." } } } }, "auth-ref": { "r280", "r289", "r291" } } }, "us-gaap-GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-income-and-comprehensive-income-unaudited": { "parentTag": "us-gaap-OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-income-and-comprehensive-income-unaudited": { "lang": { "en-us": { "role": { "label": "us-gaap-GrossProfit", "negatedTotalLabel": "Gross profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } } }, "auth-ref": { "r70", "r74", "r113", "r197", "r260", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r435", "r661", "r663", "r761", "r762", "r763", "r764", "r765", "r782" } } }, "us-gaap-IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-income-and-comprehensive-income-unaudited": { "parentTag": "us-gaap-NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-income-and-comprehensive-income-unaudited": { "lang": { "en-us": { "role": { "label": "us-gaap-IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "totalLabel": "INCOME BEFORE INCOME TAX PROVISION", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } } }, "auth-ref": { "r71", "r109", "r113", "r500", "r512", "r661", "r663", "r761", "r762", "r763", "r764", "r765" } } }, "us-gaap-IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } } }, "auth-ref": { "us-gaap-IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-income-and-comprehensive-income-unaudited": { "parentTag": "us-gaap-NetIncomeLoss", "weight": 1.0, "order": 0.0 } }, "presentation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-income-and-comprehensive-income-unaudited": { "lang": { "en-us": { "role": { "label": "PROVISION FOR INCOME TAXES", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } } }, "auth-ref": { "r115", "r126", "r211", "r212", "r226", "r239", "r251", "r397", "r398", "r407", "r518", "r681" } } } }, "us-gaap-IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxPolicyTextBlock", "presentation": { "http://fitlifebrands.com/20240930/role/statement-significant-accounting-policies-policies": { "lang": { "en-us": { "role": { "label": "Income Tax, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } } }, "auth-ref": { "r180", "r393", "r394", "r399", "r400", "r401", "r404", "r547" } } }, "us-gaap-IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "lang": { "en-us": { "role": { "label": "Cash paid for income taxes", "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } } }, "auth-ref": { "r22", "r192", "r402", "r403" } } }, "us-gaap-IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap-NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "lang": { "en-us": { "role": { "label": "us-gaap-IncreaseDecreaseInAccountsPayable", "terseLabel": "Accounts payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } } }, "auth-ref": { "r5" } } }, "us-gaap-IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap-NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "lang": { "en-us": { "role": { "label": "us-gaap-IncreaseDecreaseInAccountsReceivable", "negatedLabel": "Accounts receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } } }, "auth-ref": { "r5" } } }, "us-gaap-IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "crdr": "debit", "calculation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap-NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "lang": { "en-us": { "role": { "label": "us-gaap-IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other." } } } }, "auth-ref": { "r750" } } }, "us-gaap-IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crdr": "debit", "calculation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap-NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "lang": { "en-us": { "role": { "label": "us-gaap-IncreaseDecreaseInContractWithCustomerLiability", "terseLabel": "Product returns", "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable." } } } }, "auth-ref": { "r464", "r750" } } }, "us-gaap-IncreaseDecreaseInDeferredIncomeTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInDeferredIncomeTaxes", "crdr": "credit", "calculation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap-NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "lang": { "en-us": { "role": { "label": "us-gaap-IncreaseDecreaseInDeferredIncomeTaxes", "negatedLabel": "Deferred tax asset", "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from income or loss that is recognized for accounting purposes but not for tax purposes and vice versa." } } } }, "auth-ref": { "r5" } } }, "us-gaap-IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap-NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "lang": { "en-us": { "role": { "label": "us-gaap-IncreaseDecreaseInInventories", "negatedLabel": "Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } } }, "auth-ref": { "r5" } } }, "us-gaap-IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap-NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "lang": { "en-us": { "role": { "label": "Lease liability", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } } }, "auth-ref": { "r734", "r750" } } }, "us-gaap-IncreaseDecreaseInPrepaidExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidExpense", "crdr": "credit", "calculation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap-NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "lang": { "en-us": { "role": { "label": "us-gaap-IncreaseDecreaseInPrepaidExpense", "negatedLabel": "Prepaid expense, other current assets and sales tax receivable", "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods." } } } }, "auth-ref": { "r5" } } }, "us-gaap-IncrementalCommonSharesAttributableToCallOptionsAndWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncrementalCommonSharesAttributableToCallOptionsAndWarrants", "calculation": { "http://fitlifebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-basic-and-diluted-income-loss-per-share-details": { "parentTag": "us-gaap-WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-basic-and-diluted-income-loss-per-share-details": { "lang": { "en-us": { "role": { "label": "Dilutive effect of outstanding warrants and stock options (in shares)", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method." } } } }, "auth-ref": { "r216", "r217", "r218", "r223" } } }, "us-gaap-IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-9-acquisition-of-musclepharm-assets": { "http://fitlifebrands.com/20240930/role/statement-note-9-acquisition-of-musclepharm-assets-details-textual": { "lang": { "en-us": { "role": { "label": "Indefinite Lived Intangible Assets [Axis]", "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } } }, "auth-ref": { "r281", "r285", "r288", "r667" } } }, "us-gaap-IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-9-acquisition-of-musclepharm-assets": { "http://fitlifebrands.com/20240930/role/statement-note-9-acquisition-of-musclepharm-assets-details-textual": { "lang": { "en-us": { "role": { "label": "Indefinite Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company." } } } }, "auth-ref": { "r281", "r285", "r288", "r667" } } }, "us-gaap-IndefinitelivedIntangibleAssetsAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefinitelivedIntangibleAssetsAcquired", "crdr": "debit", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-9-acquisition-of-musclepharm-assets-details-textual": { "lang": { "en-us": { "role": { "label": "us-gaap-IndefinitelivedIntangibleAssetsAcquired", "terseLabel": "Indefinite Lived Intangible Assets Acquired", "documentation": "Amount of increase in assets, excluding financial assets and goodwill, lacking physical substance with an indefinite life, from an acquisition." } } } }, "auth-ref": { "r285", "r771" } } }, "us-gaap-InsiderTradingARLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingARLineItems", "auth-ref": { "r725" } }, "us-gaap-IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap-Assets", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "lang": { "en-us": { "role": { "label": "Intangibles, net of amortization of \$93 and \$72, respectively (provisional)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } } }, "auth-ref": { "r281", "r770", "r771" } } }, "us-gaap-InterestAndOtherIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestAndOtherIncome", "crdr": "credit", "calculation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-income-and-comprehensive-income-unaudited": { "parentTag": "us-gaap-NonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-income-and-comprehensive-income-unaudited": { "lang": { "en-us": { "role": { "label": "us-gaap-InterestAndOtherIncome", "negatedLabel": "Interest income", "documentation": "The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business)."} } } }, "auth-ref": { "us-gaap-InterestExpenseNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseNonoperating", "crdr": "debit", "calculation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-income-and-comprehensive-income-unaudited": { "parentTag": "us-gaap-NonoperatingIncomeExpense", "weight": 1.0, "order": 0.0 } }, "presentation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-income-and-comprehensive-income-unaudited": { "lang": { "en-us": { "role": { "label": "Interest expense", "documentation": "Amount of interest expense classified as nonoperating." } } } }, "auth-ref": { "r235", "r747" } } }, "us-gaap-InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "lang": { "en-us": { "role": { "label": "Cash paid for interest, net of amounts capitalized", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt

```

    "parentTag": "us-gaap-Inventories", "weight": 1.0, "order": 0.0 } }, "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-4-inventories-summary-of-inventory-details", "lang": { "en-us": { "role": { "label": "Inventories, net of allowance for obsolescence of $69 and $162, respectively", "totalLabel": "Total", "terseLabel": "Inventory, Net", "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer." } } }, "auth_ref": { "r740" } }, "fIf_InventoriesIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fitlifebrands.com/20240930", "localname": "InventoryIntangibleAssetsMember", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-9-acquisition-of-musclepharm-assets", "lang": { "en-us": { "role": { "label": "Inventory Intangible Assets [Member]", "documentation": "Relating to inventory intangible assets." } } }, "auth_ref": { } }, "us-gaap-InventoriesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "order": "debit", "calculation": { "http://fitlifebrands.com/20240930/role/statement-note-4-inventories-summary-of-inventory-details", "lang": { "en-us": { "role": { "label": "Components", "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": { "r741" } }, "us-gaap-InventoriesValuationReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryValuationReserves", "order": "credit", "calculation": { "http://fitlifebrands.com/20240930/role/statement-note-4-inventories-summary-of-inventory-details", "parentTag": "us-gaap-InventoriesNet", "weight": -1.0, "order": 2.0 } }, "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-4-inventories-summary-of-inventory-details", "lang": { "en-us": { "role": { "label": "Allowance for obsolescence", "documentation": "Amount of valuation reserve for inventory." } } }, "auth_ref": { "r87", "r742" } }, "us-gaap-InventoriesWriteDown": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWriteDown", "order": "debit", "calculation": { "http://fitlifebrands.com/20240930/role/statement-note-4-inventories-summary-of-inventory-details", "parentTag": "us-gaap-InventoriesNet", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-4-inventories-summary-of-inventory-details", "lang": { "en-us": { "role": { "label": "Allowance for inventory obsolescence", "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels." } } }, "auth_ref": { "r266" } }, "fIf_InventoriesRelatedPurchasesMember": { "xbrltype": "domainItemType", "nsuri": "http://fitlifebrands.com/20240930", "localname": "InventoryRelatedPurchasesMember", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "lang": { "en-us": { "role": { "label": "Inventory-related Purchases [Member]", "documentation": "Related to inventory related purchases." } } }, "auth_ref": { } }, "us-gaap-IssuanceOfStockAndWarrantsForServicesOrClaims": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims", "order": "debit", "calculation": { "http://fitlifebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "parentTag": "us-gaap-NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "lang": { "en-us": { "role": { "label": "Stock-based compensation", "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims." } } }, "auth_ref": { "r6" } }, "fIf_LegacyFitLifeMember": { "xbrltype": "domainItemType", "nsuri": "http://fitlifebrands.com/20240930", "localname": "LegacyFitLifeMember", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-disaggregation-of-revenue-details", "lang": { "en-us": { "role": { "label": "Legacy FitLife [Member]", "documentation": "Relating to Legacy FitLife." } } }, "auth_ref": { } }, "dei-LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-1-description-of-business", "lang": { "en-us": { "role": { "label": "Legal Entity", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": { } }, "us-gaap-LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeasesPolicyTextBlock", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-8-acquisition-of-mimis-rock-corp", "lang": { "en-us": { "role": { "label": "Lessee, Leases [Policy Text Block]", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": { "r454" } }, "us-gaap-LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-8-acquisition-of-mimis-rock-corp", "lang": { "en-us": { "role": { "label": "Lessee Operating Lease Term of Contract", "documentation": "Term of lessee's operating lease, in PnYnMnDnHnMnS format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { "r800" } }, "us-gaap-Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "order": "credit", "calculation": { "http://fitlifebrands.com/20240930/role/statement-note-6-notes-payable", "lang": { "en-us": { "role": { "label": "Liabilities And Stockholders Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": { "r63", "r108", "r509", "r601", "r754", "r767", "r795" } }, "us-gaap-LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "order": "credit", "calculation": { "http://fitlifebrands.com/20240930/role/statement-note-6-notes-payable", "parentTag": "us-gaap-Liabilities", "weight": 1.0, "order": 0.0 } }, "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-6-notes-payable", "lang": { "en-us": { "role": { "label": "Liabilities Current", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": { "r14", "r49", "r50", "r51", "r53", "r54", "r55", "r56", "r197", "r260", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r421", "r422", "r423", "r435", "r578", "r660", "r719", "r782", "r801", "r802" } }, "us-gaap-LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "order": "credit", "calculation": { "http://fitlifebrands.com/20240930/role/statement-note-6-notes-payable", "parentTag": "us-gaap-Liabilities", "weight": 1.0, "order": 0.0 } }, "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-6-notes-payable", "lang": { "en-us": { "role": { "label": "Liabilities And Stockholders Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": { "r63", "r108", "r509", "r601", "r754", "r767", "r795" } }, "us-gaap-LineOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCredit", "order": "credit", "calculation": { "http://fitlifebrands.com/20240930/role/statement-note-6-notes-payable", "parentTag": "us-gaap-LineOfCredit", "weight": 1.0, "order": 0.0 } }, "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-6-notes-payable", "lang": { "en-us": { "role": { "label": "Line of Credit Facility Maximum Borrowing Capacity", "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long-term obligation to refinance the short-term obligation on a long-term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long-term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": { "r14", "r107", "r811" } }, "us-gaap-LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "order": "credit", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-6-notes-payable", "lang": { "en-us": { "role": { "label": "Line of Credit Facility Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": { "r48", "r52" } }, "us-gaap-LoansPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LoansPayableCurrent", "order": "credit", "calculation": { "http://fitlifebrands.com/20240930/role/statement-note-6-notes-payable", "parentTag": "us-gaap-LoansPayable", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-6-notes-payable", "lang": { "en-us": { "role": { "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": { "r14", "r107", "r331", "r344", "r669", "r670", "r689", "r811" } }, "us-gaap-LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtCurrent", "order": "credit", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-6-notes-payable", "lang": { "en-us": { "role": { "label": "Long-Term Debt Current", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": { "r167" } }, "us-gaap-LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtNoncurrent", "order": "credit", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-6-notes-payable", "lang": { "en-us": { "role": { "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": { "r168" } }, "us-gaap-LongTermLoansPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermLoansPayable", "order": "credit", "calculation": { "http://fitlifebrands.com/20240930/role/statement-note-6-notes-payable", "parentTag": "us-gaap-LoansPayable", "weight": 1.0, "order": 2.0 } },
```

```

{"en-us": {"role": "Term Loan, not of current portion and unamortized deferred finance costs", "documentation": "Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion." } }, "auth-ref": { "r14" } }, "flrf_MRCMember": { "xbrltype": "domainItemType", "nsuri": "http://fitlifebrands.com/20240930", "localname": "MRCMember", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-disaggregation-of-revenue-details", "http://fitlifebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "lang": { "en-us": { "role": { "label": "MRC [Member]", "documentation": "Relating to MRC." } } }, "auth-ref": { } }, "srt_MajorCustomersAxis": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/srt/2024", "localname": "MajorCustomersAxis", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "http://fitlifebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual", "lang": { "en-us": { "role": { "label": "Customer {Axis]", "documentation": "Information by name or description of a single external customer or a group of external customers." } } }, "auth-ref": { "r257", "r676", "r702", "r707", "r787", "r813", "r814", "r815", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841" } }, "us-gaap-MarketingAndAdvertisingExpense": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketingAndAdvertisingExpense", "crdr": "debit", "calculation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-income-and-comprehensive-income-unaudited": { "parentTag": "us-gaap-OperatingExpenses", "weight": 1.0, "order": 0.0 } }, "presentation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-income-and-comprehensive-income-unaudited", "lang": { "en-us": { "role": { "label": "Advertising and marketing", "documentation": "The total expense recognized in the period for promotion, public relations, and brand or product advertising." } } }, "auth-ref": { "r76" } }, "srt_MaximumMember": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "http://fitlifebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual", "lang": { "en-us": { "role": { "label": "Maximum [Member]", "documentation": "Upper limit of the provided range." } } }, "auth-ref": { "r129", "r131", "r133", "r134", "r136", "r155", "r156", "r303", "r304", "r305", "r306", "r363", "r392", "r434", "r463", "r537", "r538", "r544", "r569", "r570", "r624", "r626", "r628", "r629", "r631", "r651", "r652", "r665", "r673", "r679", "r685", "r686", "r687", "r688", "r703", "r784", "r803", "r804", "r805", "r806", "r807", "r808" } } }, "flrf_MimisRockCorpMember": { "xbrltype": "domainItem", "nsuri": "http://fitlifebrands.com/20240930", "localname": "MimisRockCorpMember", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-8-acquisition-of-mimis-rock-corp", "http://fitlifebrands.com/20240930/role/statement-note-8-acquisition-of-mimis-rock-corp-details-textual", "http://fitlifebrands.com/20240930/role/statement-note-8-acquisition-of-mimis-rock-corp-pro-forma-information-details", "lang": { "en-us": { "role": { "label": "Mimi%u2019s Rock Corp [Member]", "documentation": "Relating to Mimi%u2019s Rock Corp." } } }, "auth-ref": { } }, "srt_MinimumMember": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "http://fitlifebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual", "lang": { "en-us": { "role": { "label": "Minimum [Member]", "documentation": "Lower limit of the provided range." } } }, "auth-ref": { "r129", "r131", "r133", "r134", "r136", "r155", "r156", "r303", "r304", "r305", "r306", "r363", "r392", "r434", "r463", "r537", "r538", "r544", "r569", "r570", "r624", "r626", "r628", "r629", "r631", "r651", "r652", "r665", "r673", "r679", "r685", "r686", "r687", "r703", "r784", "r803", "r804", "r805", "r806", "r807", "r808" } } }, "ced_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://xbrl.sec.gov/ced/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": { "http://xbrl.sec.gov/ced/role/InsiderTradingArrangements", "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "documentation": "The terms of the arrangement." } } }, "auth-ref": { "r726" } }, "flrf_MusclePharmMember": { "xbrltype": "domainItem", "nsuri": "http://fitlifebrands.com/20240930", "localname": "MusclePharmMember", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-disaggregation-of-revenue-details", "http://fitlifebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "lang": { "en-us": { "role": { "label": "Muscle Pharm [Member]", "documentation": "Relating to Muscle Pharm." } } }, "auth-ref": { } }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/srt/2024", "localname": "NameOfMajorCustomerDomain", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "http://fitlifebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual", "lang": { "en-us": { "role": { "label": "Customer {Domain]", "documentation": "Single external customer or group of external customers." } } }, "auth-ref": { "r257", "r676", "r702", "r707", "r787", "r813", "r814", "r815", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841" } }, "us-gaap-NatureOfOperations": { "xbrltype": "textBlockItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NatureOfOperations", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-1-description-of-business", "lang": { "en-us": { "role": { "label": "Nature of Operations [Text Block]", "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward." } } }, "auth-ref": { "r117", "r127" } }, "us-gaap-NetCashProvidedByUsedInFinaneingActivities": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinaneingActivities", "crdr": "debit", "calculation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap-CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "lang": { "en-us": { "role": { "label": "us-gaap-NetCashProvidedByUsedInFinaneingActivities", "totalLabel": "Net cash provided by (used in) financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth-ref": { "r189" } }, "us-gaap-NetCashProvidedByUsedInFinaneingActivitiesAbstract": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinaneingActivitiesAbstract", "presentation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "lang": { "en-us": { "role": { "label": "us-gaap-NetCashProvidedByUsedInFinaneingActivitiesAbstract", "terseLabel": "Net Cash Provided by (Used in) Finaneing Activities [Abstract]" } } }, "auth-ref": { } }, "us-gaap-NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap-CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 0.0 } }, "presentation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "lang": { "en-us": { "role": { "label": "us-gaap-NetCashProvidedByUsedInInvestingActivities", "totalLabel": "Net cash provided by (used in) investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth-ref": { "r189" } }, "us-gaap-NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "lang": { "en-us": { "role": { "label": "us-gaap-NetCashProvidedByUsedInInvestingActivitiesAbstract", "terseLabel": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth-ref": { } }, "us-gaap-NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap-CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "lang": { "en-us": { "role": { "label": "us-gaap-NetCashProvidedByUsedInOperatingActivities", "totalLabel": "Net cash provided by operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth-ref": { "r80", "r81", "r82" } }, "us-gaap-NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItem
```

unaudited": { "parentTag": "us-gaap-Assets", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "lang": { "en-us": { "role": { "label": "Right of use asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth-ref": { "r452" } }, "fllf-OperatingLeaseRightofuseAssetNetOfAmortizationAndLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fitlifebrands.com/20240930", "localname": "OperatingLeaseRightofuseAssetNetOfAmortizationAndLeaseLiability", "crdr": "credit", "calculation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap-NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "lang": { "en-us": { "role": { "label": "fllf-OperatingLeaseRightofuseAssetNetOfAmortizationAndLeaseLiability", "negatedLabel": "Right-of-use asset", "documentation": "Amount of right-of-use asset net of amortization and lease liability from operating lease." } } }, "auth-ref": { } }, "us-gaap-OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-income-and-comprehensive-income-unaudited": { "parentTag": "us-gaap-ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-income-and-comprehensive-income-unaudited": { "lang": { "en-us": { "role": { "verboselabel": "Foreign currency translation adjustment", "label": "us-gaap-OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term investment nature, attributable to parent entity." } } }, "auth-ref": { "r4", "r9", "r103" } }, "us-gaap-OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited": { "lang": { "en-us": { "role": { "label": "Comprehensive income", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth-ref": { "r10", "r12", "r176", "r179", "r104", "r208", "r441", "r442", "r447", "r497", "r514", "r744", "r745" } }, "us-gaap-OtherNonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpenseAbstract", "presentation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-income-and-comprehensive-income-unaudited": { "lang": { "en-us": { "role": { "label": "OTHER EXPENSE (INCOME)", "auth-ref": { } }, "us-gaap-PaymentsForOtherDeposits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForOtherDeposits", "crdr": "credit", "calculation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap-NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "lang": { "en-us": { "role": { "label": "us-gaap-PaymentsForOtherDeposits", "negatedLabel": "Cash deposit paid for the acquisition of MusclePharm assets", "documentation": "Amount of cash outflow for deposits classified as other." } } }, "auth-ref": { "r748" } }, "us-gaap-PaymentsToAcquireBusinessesGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireBusinessesGross", "crdr": "credit", "calculation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap-NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "lang": { "en-us": { "role": { "label": "us-gaap-PaymentsToAcquireBusinessesGross", "negatedLabel": "Cash paid for acquisition of Mimihu2019s Rock Corp.", "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price." } } }, "auth-ref": { "r18", "r417" } }, "us-gaap-PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap-NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 0.0 } }, "presentation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "lang": { "en-us": { "role": { "label": "us-gaap-PaymentsToAcquirePropertyPlantAndEquipment", "negatedLabel": "Purchase of property and equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth-ref": { "r78" } }, "us-gaap-PledgedStatusAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PledgedStatusAxis", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies": { "http://fitlifebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual": { "lang": { "en-us": { "role": { "label": "Pledged Status [Axis]", "documentation": "Information by pledged or not pledged status of asset owned by entity." } } }, "auth-ref": { "r420", "r572", "r683" } }, "us-gaap-PledgedStatusDomain": { "xbrltype": "domainItemType", "nsuri": "http://fitlifebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies": { "lang": { "en-us": { "role": { "label": "Pledged Status [Domain]", "documentation": "Pledged or not pledged status of asset owned by entity." } } }, "auth-ref": { "r420", "r572", "r683" } }, "us-gaap-PledgingPurposeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PledgingPurposeAxis", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies": { "http://fitlifebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual": { "lang": { "en-us": { "role": { "label": "Pledging Purpose [Axis]", "documentation": "Information by pledging purpose of pledged asset owned." } } }, "auth-ref": { "r461", "r683", "r692", "r720" } }, "us-gaap-PledgingPurposeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fitlifebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual": { "lang": { "en-us": { "role": { "label": "Pledging Purpose [Domain]", "documentation": "Pledging purpose of pledged asset owned." } } }, "auth-ref": { "r461", "r683", "r692", "r720" } }, "us-gaap-PolicyTextBlockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PolicyTextBlockAbstract", "presentation": { "http://fitlifebrands.com/20240930/role/statement-significant-accounting-policies": { "lang": { "en-us": { "role": { "label": "us-gaap-PolicyTextBlockAbstract", "terseLabel": "Accounting Policies" } } }, "auth-ref": { } }, "us-gaap-PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parenteticals": { "http://fitlifebrands.com/20240930/role/statement-note-1-description-of-business-details-textual": { "lang": { "en-us": { "role": { "label": "Preferred stock, par value (in dollars per share)", "terseLabel": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth-ref": { "r57", "r346" } }, "us-gaap-PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parenteticals": { "lang": { "en-us": { "role": { "label": "Preferred stock, shares authorized (in shares)", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth-ref": { "r57", "r579" } }, "us-gaap-PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parenteticals": { "lang": { "en-us": { "role": { "label": "Preferred stock, shares outstanding (in shares)", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth-ref": { "r57", "r579", "r598", "r844", "r845" } }, "us-gaap-PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap-StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "lang": { "en-us": { "role": { "label": "Preferred stock, \$0.01-par value, 10,000 shares authorized, none outstanding as of June 30, 2024 and December 31, 2023", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth-ref": { "r57", "r506", "r691" } }, "us-gaap-PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap-AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "lang": { "en-us": { "role": { "label": "Prepaid expense and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth-ref": { "r743" } }, "us-gaap-PriorPeriodReclassificationAdjustmentDescription": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PriorPeriodReclassificationAdjustmentDescription", "presentation": { "http://fitlifebrands.com/20240930/role/statement-significant-accounting-policies": { "lang": { "en-us": { "role": { "label": "Reclassification, Comparability Adjustment [Policy Text Block]", "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error." } } }, "auth-ref": { "r736" } }, "us-gaap-ProceedsFromIssuanceOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfLongTermDebt", "crdr": "debit", "calculation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap-NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 0.0 } }, "presentation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "lang": { "en-us": { "role": { "label": "us-gaap-ProceedsFromIssuanceOfLongTermDebt", "terseLabel": "Borrowings on term loans", "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer." } } }, "auth-ref": { "r19", "r548" } }, "us-gaap-ProductConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductConcentrationRiskMember", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies": { "http://fitlifebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies": { "lang": { "en-us": { "role": { "label": "Product Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence." } } }, "auth-ref": { "r85" } }, "srt-ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies": "http://fitlifebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual": { "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "documentation": "Information by product and service, or group of similar products and similar services." } } }, "auth-ref": { "r138", "r139", "r140", "r141", "r142", "r143", "r154", "r254", "r465", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641" } } }, "srt-ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies": "http://fitlifebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual": { "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "documentation": "Product or service, or a group of similar products or similar services." } } }, "auth-ref": { "r138", "r139", "r140", "r141", "r142", "r143", "r154", "r254", "r465", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641" } } }, "srt-ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fitlifebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies": "http://fitlifebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual": { "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth-ref": { "r88", "r121", "r124", "r125" } }, "us-gaap-PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://fitlifebrands.com/20240930/role/statement-note-5-property-and-equipment-property-and-equipment-details": { "parentTag": "us-gaap-PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 0.0 } }, "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-5-property-and-equipment-property-and-equipment-details": { "lang": { "en-us": { "role": { "label": "Property and equipment, net", "totalLabel": "Total", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth-ref": { "r7", "r456", "r501", "r511", "r691" } }, "us-gaap-PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap-Assets", "weight": 1.0, "order": 0.0 } }, "http://fitlifebrands.com/20240930/role/statement-note-5-property-and-equipment-property-and-equipment-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-5-property-and-equipment-property-and-equipment-details": { "lang": { "en-us": { "role": { "label": "Property and equipment, net", "totalLabel": "Total", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth-ref": { "r7", "r456", "r501", "r511", "r691" } }, "us-gaap-PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-5-property-and-equipment-tables": { "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated depreciation." } } }, "auth-ref": { "r7" } }, "us-gaap-ProvisionForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProvisionForDoubtfulAccounts", "crdr": "debit", "calculation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap-NetCashProvidedByUsedInOperatingActivities",

"weight": 1.0, "order": 1.0 } }, "presentation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "lang": { "en-us": { "role": { "label": "Allowance for doubtful accounts", "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable." } }, "auth_ref": { "r187", "r264" } }, "sort_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "http://fitlifebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual", "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } }, "auth_ref": { "r129", "r131", "r133", "r134", "r136", "r155", "r156", "r303", "r304", "r305", "r306", "r362", "r363", "r386", "r387", "r388", "r392", "r434", "r460", "r462", "r463", "r537", "r538", "r544", "r569", "r570", "r624", "r626", "r628", "r629", "r631", "r651", "r652", "r665", "r673", "r679", "r685", "r686", "r687", "r688", "r703", "r712", "r776", "r784", "r794", "r804", "r805", "r806", "r807", "r808" } }, "sort_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "http://fitlifebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual", "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } }, "auth_ref": { "r129", "r131", "r133", "r134", "r136", "r155", "r156", "r303", "r304", "r305", "r306", "r362", "r363", "r386", "r387", "r388", "r392", "r434", "r460", "r462", "r463", "r537", "r538", "r544", "r569", "r570", "r624", "r626", "r628", "r629", "r631", "r651", "r652", "r665", "r673", "r679", "r685", "r686", "r687", "r688", "r703", "r712", "r776", "r784", "r794", "r804", "r805", "r806", "r807", "r808" } }, "filf_RangeOneMember": { "xbrltype": "domainItemType", "nsuri": "http://fitlifebrands.com/20240930", "localname": "RangeOneMember", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-7-equity", "http://fitlifebrands.com/20240930/role/statement-note-7-equity-exercise-price-range-details", "lang": { "en-us": { "role": { "label": "Range One [Member]", "documentation": "Information related to range one." } }, "auth_ref": { "r1", "filf_RangeTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://fitlifebrands.com/20240930", "localname": "RangeTwoMember", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-7-equity", "http://fitlifebrands.com/20240930/role/statement-note-7-equity-exercise-price-range-details", "lang": { "en-us": { "role": { "label": "Range Two [Member]", "documentation": "Information related to range two." } }, "auth_ref": { "us_gaap_RepaymentsOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfDebt", "order": "credit", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-6-notes-payable-details-textual", "lang": { "en-us": { "role": { "label": "us-gaap_RepaymentsOfDebt", "terseLabel": "Repayments of Debt", "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation." } }, "auth_ref": { "r740" } }, "us-gaap_RepaymentsOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfLongTermDebt", "order": "credit", "calculation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "lang": { "en-us": { "role": { "label": "us-gaap_RepaymentsOfLongTermDebt", "negatedLabel": "Payments on term loans", "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer." } }, "auth_ref": { "r79", "r551" } }, "us-gaap_RestrictedCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCash", "order": "debit", "calculation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://fitlifebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual", "lang": { "en-us": { "role": { "label": "Restricted cash", "terseLabel": "Restricted Cash", "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } }, "auth_ref": { "r737", "r751", "r810", "r812" } }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-7-equity", "http://fitlifebrands.com/20240930/role/statement-note-7-equity-details-textual", "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } }, "auth_ref": { "us_gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "order": "credit", "calculation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "lang": { "en-us": { "role": { "label": "Retained earnings (accumulated deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } }, "auth_ref": { "r60", "r93", "r508", "r542", "r543", "r552", "r580", "r691" } }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statement-of-stockholders-equity-unaudited", "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } }, "auth_ref": { "r157", "r199", "r200", "r201", "r203", "r208", "r210", "r212", "r261", "r262", "r292", "r405", "r406", "r409", "r409", "r410", "r412", "r418", "r419", "r424", "r426", "r427", "r429", "r431", "r450", "r451", "r539", "r541", "r553", "r844" } }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "order": "credit", "calculation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-income-and-comprehensive-income-unaudited": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 0.0 } }, "presentation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-income-and-comprehensive-income-unaudited", "http://fitlifebrands.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-disaggregation-of-revenue-details", "lang": { "en-us": { "role": { "label": "Revenue", "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } }, "auth_ref": { "r111", "r112", "r226", "r232", "r233", "r246", "r251", "r254", "r255", "r257", "r360", "r361", "r465" } }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRecognitionPolicyTextBlock", "presentation": { "http://fitlifebrands.com/20240930/role/statement-significant-accounting-policies", "lang": { "en-us": { "role": { "label": "Revenue [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources." } }, "auth_ref": { "r602", "r653", "r658" } }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevolvingCreditFacilityMember", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-6-notes-payable", "http://fitlifebrands.com/20240930/role/statement-note-6-notes-payable-details-textual", "lang": { "en-us": { "role": { "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } }, "auth_ref": { "us_gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "order": "debit", "presentation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "lang": { "en-us": { "role": { "label": "Addition to right-of-use assets from new operating lease liabilities", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } }, "auth_ref": { "r455", "r690" } }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": { "en-us": { "role": { "label": "ecd_Rule10b51ArrAdoptedFlag", "terseLabel": "Rule 10b5-1 Arrangement Adopted [Flag]" } }, "auth_ref": { "r726" } }, "ecd_Rule10b51ArrTrmtdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmtdFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": { "en-us": { "role": { "label": "ecd_Rule10b51ArrTrmtdFlag", "terseLabel": "Rule 10b5-1 Arrangement Terminated [Flag]" } }, "auth_ref": { "r726" } }, "us-gaap_SalesRevenueNetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalesRevenueNetMember", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "http://fitlifebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual", "lang": { "en-us": { "role": { "label": "Revenue Benchmark [Member]", "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation." } }, "auth_ref": { "r257", "r730" } }, "filf_SalesTaxesReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fitlifebrands.com/20240930", "localname": "SalesTaxesReceivable", "order": "debit", "calculation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "lang": { "en-us": { "role": { "label": "Sales tax receivable", "documentation": "The amount of sales taxes receivable." } }, "auth_ref": { "us_gaap_ScheduleOfDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDebtTableTextBlock", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-6-notes-payable-tables", "lang": { "en-us": { "role": { "label": "Schedule of Debt [Table Text Block]", "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation." } }, "auth_ref": { "us_gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-tables", "lang": { "en-us": { "role": { "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } }, "auth_ref": { "r760" } }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-4-inventories-tables", "lang": { "en-us": { "role": { "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } }, "auth_ref": { "r15", "r64", "r65", "r66" } }, "us_gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-7-equity-tables", "lang": { "en-us": { "role": { "label": "Share Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]", "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms." } }, "auth_ref": { "r33", "us_gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-7-equity-tables", "lang": { "en-us": { "role": { "label": "Share Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } }, "auth_ref": { "r11", "r12", "r94" } }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": { "http://fitlifebrands.com/20240930/role/statement-document-and-entity-information", "lang": { "en-us": { "role": { "label": "dei_Security12bTitle", "terseLabel": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } }, "auth_ref": { "r720" } }, "dei_SecurityExchangeName": { "xbrltype": "securityExchangeNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": { "http://fitlifebrands.com/20240930/role/statement-document-and-entity-information", "lang": { "en-us": { "role": { "label": "dei_SecurityExchangeName", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } }, "auth_ref": { "r722" } }, "us_gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentDomain", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-disaggregation-of-revenue-details", "http://fitlifebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "lang": { "en-us": { "role": { "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } }, "auth_ref": { "r111", "r112", "r113", "r114", "r226", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r257", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r290", "r299", "r300", "r510", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r662", "r663", "r664", "r666", "r706", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841" } }, "us_gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpense", "order": "debit", "calculation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-income-and-comprehensive-income-unaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-income-and-comprehensive-income-unaudited", "lang": { "en-us": { "role": { "label": "Selling, general and administrative", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } }, "auth_ref": { "r76" } }, "us_gaap_SeriesAPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeriesAPreferredStockMember", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-1-description-of-business", "http://fitlifebrands.com/20240930/role/statement-note-1-description-of-business-details-textual", "lang": { "en-us": { "role": { "label": "Series A Preferred Stock [Member]", "documentation": "Series A preferred stock." } }, "auth_ref": { "r738", "r739", "r785" } }, "us_gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fitlifebrands.com/20240930/role/statement-note-7-equity-exercise-price-range-details", "lang": { "en-us": { "role": { "label": "Share Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]", "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms." } }, "auth_ref": { "r33", "us_gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-7-equity-tables", "lang": { "en-us": { "role": { "label": "Share Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } }, "auth_ref": { "r11", "r12", "r94" } }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": { "http://fitlifebrands.com/20240930/role/statement-document-and-entity-information", "lang": { "en-us": { "role": { "label": "dei_Security12bTitle", "terseLabel": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } }, "auth_ref": { "r720" } }, "dei_SecurityExchangeName": { "xbrltype": "securityExchangeNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": { "http://fitlifebrands.com/20240930/role/statement-document-and-entity-information", "lang": { "en-us": { "role": { "label": "dei_SecurityExchangeName", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } }, "auth_ref": { "r722" } }, "us_gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentDomain", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-disaggregation-of-revenue-details", "http://fitlifebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "lang": { "en-us": { "role": { "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } }, "auth_ref": { "r111", "r112", "r113", "r114", "r226", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r257", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r290", "r299", "r300", "r510", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r662", "r663", "r664", "r666", "r706", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841" } }, "us_gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpense", "order": "debit", "calculation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-income-and-comprehensive-income-unaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-income-and-comprehensive-income-unaudited", "lang": { "en-us": { "role": { "label": "Selling, general and administrative", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } }, "auth_ref": { "r76" } }, "us_gaap_SeriesAPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeriesAPreferredStockMember", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-1-description-of-business", "http://fitlifebrands.com/20240930/role/statement-note-1-description-of-business-details-textual", "lang": { "en-us": { "role": { "label": "Series A Preferred Stock [Member]", "documentation": "Series A preferred stock." } }, "auth_ref": { "r738", "r739", "r785" } }, "us_gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fitlifebrands.com/20240930/role/statement-note-7-equity-exercise-price-range-details", "lang": { "en-us": { "role": { "label": "Share Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]", "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms." } }, "auth_ref": { "r33", "us_gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-7-equity-tables", "lang": { "en-us": { "role": { "label": "Share Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } }, "auth_ref": { "r11", "r12", "r94" } }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": { "http://fitlifebrands.com/20240930/role/statement-document-and-entity-information", "lang": { "en-us": { "role": { "label": "dei_Security12bTitle", "terseLabel": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } }, "auth_ref": { "r720" } }, "dei_SecurityExchangeName": { "xbrltype": "securityExchangeNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": { "http://fitlifebrands.com/20240930/role/statement-document-and-entity-information", "lang": { "en-us": { "role": { "label": "dei_SecurityExchangeName", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } }, "auth_ref": { "r722" } }, "us_gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentDomain", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-disaggregation-of-revenue-details", "http://fitlifebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "lang": { "en-us": { "role": { "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } }, "auth_ref": { "r111", "r112", "r113", "r114", "r226", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r257", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r290", "r299", "r300", "r510", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r662", "r663", "r664", "r666", "r706", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841" } }, "us_gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpense", "order": "debit", "calculation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-income-and-comprehensive-income-unaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-income-and-comprehensive-income-unaudited", "lang": { "en-us": { "role": { "label": "Selling, general and administrative", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } }, "auth_ref": { "r76" } }, "us_gaap_SeriesAPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeriesAPreferredStockMember", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-1-description-of-business", "http://fitlifebrands.com/20240930/role/statement-note-1-description-of-business-details-textual", "lang": { "en-us": { "role": { "label": "Series A Preferred Stock [Member]", "documentation": "Series A preferred stock." } }, "auth_ref": { "r738", "r739", "r785" } }, "us_gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fitlifebrands.com/20240930/role/statement-note-7-equity-exercise-price-range-details", "lang": { "en-us": { "role": { "label": "Share Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]", "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms." } }, "auth_ref": { "r33", "us_gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-7-equity-tables", "lang": { "en-us": { "role": { "label": "Share Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } }, "auth_ref": { "r11", "r12", "r94" } }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": { "http://fitlifebrands.com/20240930/role/statement-document-and-entity-information", "lang": { "en-us": { "role": { "label": "dei_Security12bTitle", "terseLabel": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } }, "auth_ref": { "r720" } }, "dei_SecurityExchangeName": { "xbrltype": "securityExchangeNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": { "http://fitlifebrands.com/20240930/role/statement-document-and-entity-information", "lang": { "en-us": { "role": { "label": "dei_SecurityExchangeName", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } }, "auth_ref": { "r722" } }, "us_gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentDomain", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-disaggregation-of-revenue-details", "http://fitlifebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "lang": { "en-us": { "role": { "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } }, "auth_ref": { "r111", "r112", "r113", "r114", "r226", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r257", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r290", "r299", "r300", "r510", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r662", "r663", "r664", "r666", "r706", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841" } }, "us_gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpense", "order": "debit", "calculation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-income-and-comprehensive-income-unaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statements-of-income-and-comprehensive-income-unaudited", "lang": { "en-us": { "role": { "label": "Selling, general and administrative", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect

"http://fasb.org/us-gaap/2024/", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": {
"http://fitlifebrands.com/20240930/role/statement-note-7-equity-details-textual", "lang": { "en-us": { "role": { "label": "us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan.)" } } }, "auth-ref": { "r378" } }, "us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "crdr": "debit", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-7-equity-details-textual", "lang": { "en-us": { "role": { "label": "us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash." } } }, "auth-ref": { "r382" } }, "us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": {
"http://fitlifebrands.com/20240930/role/statement-note-7-equity-details-textual", "lang": { "en-us": { "role": { "label": "us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth-ref": { "r387" } }, "us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": {
"http://fitlifebrands.com/20240930/role/statement-note-7-equity-details-textual", "lang": { "en-us": { "role": { "label": "us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth-ref": { "r386" } }, "us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": {
"http://fitlifebrands.com/20240930/role/statement-note-7-equity-details-textual", "lang": { "en-us": { "role": { "label": "us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth-ref": { "r388" } }, "us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-7-equity-stock-option-activity-details", "lang": { "en-us": { "role": { "label": "us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "negatedLabel": "Forfeited, number of options (in shares)", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth-ref": { "r373" } }, "us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodCross", { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodCross", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-7-equity-details-textual", "http://fitlifebrands.com/20240930/role/statement-note-7-equity-stock-option-activity-details", "lang": { "en-us": { "role": { "label": "us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodCross", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Cross", "documentation": "Cross number of share options (or share units) granted during the period." } } }, "auth-ref": { "r371" } }, "us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-7-equity-details-textual", "lang": { "en-us": { "role": { "label": "us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth-ref": { "r33" } }, "us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-7-equity-stock-option-activity-details", "lang": { "en-us": { "role": { "label": "us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "periodStartLabel": "Outstanding, number of options (in shares)", "periodEndLabel": "Outstanding, number of options (in shares)", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth-ref": { "r367", "r368" } }, "us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": {
"http://fitlifebrands.com/20240930/role/statement-note-7-equity-stock-option-activity-details", "lang": { "en-us": { "role": { "label": "us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "periodStartLabel": "Outstanding, weighted average exercise price (in dollars per share)", "periodEndLabel": "Outstanding, weighted average exercise price (in dollars per share)", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth-ref": { "r367", "r368" } }, "us-gaap-ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-7-equity", "http://fitlifebrands.com/20240930/role/statement-note-7-equity-details-textual", "lang": { "en-us": { "role": { "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth-ref": { "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389" } }, "us-gaap-ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": {
"http://fitlifebrands.com/20240930/role/statement-note-7-equity-stock-option-activity-details", "lang": { "en-us": { "role": { "label": "Exercised, weighted average exercise price (in dollars per share)", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth-ref": { "r372" } }, "us-gaap-ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": {
"http://fitlifebrands.com/20240930/role/statement-note-7-equity-stock-option-activity-details", "lang": { "en-us": { "role": { "label": "Forfeited, weighted average exercise price (in dollars per share)", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth-ref": { "r373" } }, "us-gaap-ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": {
"http://fitlifebrands.com/20240930/role/statement-note-7-equity-details-textual", "http://fitlifebrands.com/20240930/role/statement-note-7-equity-stock-option-activity-details", "lang": { "en-us": { "role": { "label": "Issued, weighted average exercise price (in dollars per share)", "terseLabel": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per-share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth-ref": { "r371" } }, "us-gaap-ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis", { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-7-equity", "http://fitlifebrands.com/20240930/role/statement-note-7-equity-exercise-price-range-details", "lang": { "en-us": { "role": { "label": "Exercise Price Range [Axis]", "documentation": "Information by range of option prices pertaining to options granted." } } }, "auth-ref": { "r37" } }, "us-gaap-ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain", { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-7-equity", "http://fitlifebrands.com/20240930/role/statement-note-7-equity-exercise-price-range-details", "lang": { "en-us": { "role": { "label": "Exercise Price Range [Domain]", "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices." } } }, "auth-ref": { "r38" } }, "us-gaap-ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit", { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit", "presentation": {
"http://fitlifebrands.com/20240930/role/statement-note-7-equity-exercise-price-range-details", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit", "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock-option awards on all stock option plans and other required information pertaining to awards in the customized range." } } }, "auth-ref": { "r38" } }, "us-gaap-ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions", { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions", "presentation": {
"http://fitlifebrands.com/20240930/role/statement-note-7-equity-exercise-price-range-details", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable", "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied." } } }, "auth-ref": { "r35" } }, "us-gaap-ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "presentation": {
"http://fitlifebrands.com/20240930/role/statement-note-7-equity-exercise-price-range-details", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding", "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices." } } }, "auth-ref": { "r95", "r96" } }, "us-gaap-ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit", { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit", "presentation": {
"http://fitlifebrands.com/20240930/role/statement-note-7-equity-exercise-price-range-details", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit", "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range." } } }, "auth-ref": { "r38" } }, "us-gaap-ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis", { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis", "presentation": {
"http://fitlifebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "http://fitlifebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual", "lang": { "en-us": { "role": { "label": "Supplier [Axis]", "documentation": "Information by supplier." } } }, "auth-ref": { "r3" } }, "us-gaap-ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain", { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "http://fitlifebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual", "lang": { "en-us": { "role": { "label": "Supplier [Domain]", "documentation": "Specific identification or general nature of (for example, a construction contractor, a consulting firm) the party from whom the goods or services were or are to be received." } } }, "auth-ref": { "r3" } }, "us-gaap-SharePrice", { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharePrice", "presentation": {
"http://fitlifebrands.com/20240930/role/statement-note-7-equity-details-textual", "lang": { "en-us": { "role": { "label": "us-gaap-SharePrice", "terseLabel": "Share Price", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth-ref": { "r3" }, "srt-ShareRepurchaseProgramAxis", { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ShareRepurchaseProgramAxis", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-7-equity", "http://fitlifebrands.com/20240930/role/statement-note-7-equity-details-textual", "lang": { "en-us": { "role": { "label": "Share Repurchase Program [Axis]", "documentation": "Information by share repurchase program." } } }, "auth-ref": { "r786" } }, "srt-ShareRepurchaseProgramDomain", { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ShareRepurchaseProgramDomain", "presentation": {
"http://fitlifebrands.com/20240930/role/statement-note-7-equity", "http://fitlifebrands.com/20240930/role/statement-note-7-equity-details-textual", "lang": { "en-us": { "role": { "label": "Share Repurchase Program [Domain]", "documentation": "Name of share repurchase program." } } }, "auth-ref": { "r786" } }, "rfF-ShareRepurchaseProgramMember", { "xbrltype": "domainItemType", "nsuri": "http://fitlifebrands.com/20240930", "localname": "ShareRepurchaseProgramMember", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-7-equity", "http://fitlifebrands.com/20240930/role/statement-note-7-equity-details-textual", "lang": { "en-us": { "role": { "label": "Share Repurchase Program [Member]", "documentation": "Information related to the Share Repurchase Program." } } }, "auth-ref": { "r3" }, "us-gaap-SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": {
"http://fitlifebrands.com/20240930/role/statement-note-7-equity-details-textual", "lang": { "en-us": { "role": { "label": "us-

gaap-SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth-ref": { "r680" } }, "us-gaap-SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-7-equity-stock-option-activity-details" }, "lang": { "en-us": { "role": { "label": "Outstanding, weighted average remaining life (Year)", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth-ref": { "r97" } }, "us-gaap-SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExerciseableOptionsWeightedAverageExercisePrice1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExerciseableOptionsWeightedAverageExercisePrice1", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-7-equity-exercise-price-range-details" }, "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Exerciseable, Weighted Average Exercise Price", "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding." } } }, "auth-ref": { "r34" } }, "us-gaap-SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-7-equity-exercise-price-range-details" }, "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price", "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices." } } }, "auth-ref": { "r95", "r96" } }, "us-gaap-SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-7-equity-exercise-price-range-details" }, "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth-ref": { "r97" } }, "flf-SharesForfeitedDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fitlifebrands.com/20240930", "localname": "SharesForfeitedDuringPeriodShares", "presentation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statement-of-stockholders-equity-unaudited" }, "lang": { "en-us": { "role": { "label": "Shares surrendered by former employee (in shares)", "documentation": "Represents the number of shares forfeited during period." } } }, "auth-ref": { } }, "us-gaap-SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statement-of-stockholders-equity-unaudited" }, "lang": { "en-us": { "role": { "label": "us-gaap-SharesOutstanding", "periodStartLabel": "Balance (in shares)", "periodEndLabel": "Balance (in shares)", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth-ref": { } }, "flf-SharesSurrenderedByFormerEmployee": { "xbrltype": "monetaryItemType", "nsuri": "http://fitlifebrands.com/20240930", "localname": "SharesSurrenderedByFormerEmployee", "presentation": { "http://fitlifebrands.com/20240930/role/statement-condensed-consolidated-statement-of-stockholders-equity-unaudited" }, "lang": { "en-us": { "role": { "label": "Shares surrendered by former employee", "documentation": "Amount of shares surrendered by former employee." } } }, "auth-ref": { } }, "us-gaap-SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies" }, "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth-ref": { "r83", "r194" } }, "us-gaap-StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementBusinessSegmentsAxis", "presentation": { "http://fitlifebrands.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-disaggregation-of-revenue-details" }, "lang": { "en-us": { "role": { "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth-ref": { "r111", "r112", "r113", "r114", "r158", "r226", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1027", "r1028", "r1029", "r1030", "r1031", "r1032", "r1033", "r1034", "r1035", "r1036", "r1037", "r1038", "r1039", "r1040", "r1041", "r1042", "r1043", "r1044", "r1045", "r1046", "r1047", "r1048", "r1049", "r1050", "r1051", "r1052", "r1053", "r1054", "r1055", "r1056", "r1057", "r1058", "r1059", "r1060", "r1061", "r1062", "r1063", "r1064", "r1065", "r1066", "r1067", "r1068", "r1069", "r1070", "r1071", "r1072", "r1073", "r1074", "r1075", "r1076", "r1077", "r1078", "r1079", "r1080", "r1081", "r1082", "r1083", "r1084", "r1085", "r1086", "r1087", "r1088", "r1089", "r1090", "r1091", "r1092", "r1093", "r1094", "r1095", "r1096", "r1097", "r1098", "r1099", "r1100", "r1101", "r1102", "r1103", "r1104", "r1105", "r1106", "r1107", "r1108", "r1109", "r1110", "r1111", "r1112", "r1113", "r1114", "r1115", "r1116", "r1117", "r1118", "r1119", "r1120", "r1121", "r1122", "r1123", "r1124", "r1125", "r1126", "r1127", "r1128", "r1129", "r1130", "r1131", "r1132", "r1133", "r1134", "r1135", "r1136", "r1137", "r1138", "r1139", "r1140", "r1141", "r1142", "r1143", "r1144", "r1145", "r1146", "r1147", "r1148", "r1149", "r1150", "r1151", "r1152", "r1153", "r1154", "r1155", "r1156", "r1157", "r1158", "r1159", "r1160", "r1161", "r1162", "r1163", "r1164", "r1165", "r1166", "r1167", "r1168", "r1169", "r1170", "r1171", "r1172", "r1173", "r1174", "r1175", "r1176", "r1177", "r1178", "r1179", "r1180", "r1181", "r1182", "r1183", "r1184", "r1185", "r1186", "r1187", "r1188", "r1189", "r1190", "r1191", "r1192", "r1193", "r1194", "r1195", "r1196", "r1197", "r1198", "r1199", "r1200", "r1201", "r1202", "r1203", "r1204", "r1205", "r1206", "r1207", "r1208", "r1209", "r1210", "r1211", "r1212", "r1213", "r1214", "r1215", "r1216", "r1217", "r1218", "r1219", "r1220", "r1221", "r1222", "r1223", "r1224", "r1225", "r1226", "r1227", "r1228", "r1229", "r1230", "r1231", "r1232", "r1233", "r1234", "r1235", "r1236", "r1237", "r1238", "r1239", "r1240", "r1241", "r1242", "r1243", "r1244", "r1245", "r1246", "r1247", "r1248", "r1249", "r1250", "r1251", "r1252", "r1253", "r1254", "r1255", "r1256", "r1257", "r1258", "r1259", "r1260", "r1261", "r1262", "r1263", "r1264", "r1265", "r1266", "r1267", "r1268", "r1269", "r1270", "r1271", "r1272", "r1273", "r1274", "r1275", "r1276", "r1277", "r1278", "r1279", "r1280", "r1281", "r1282", "r1283", "r1284", "r1285", "r1286", "r1287", "r1288", "r1289", "r1290", "r1291", "r1292", "r1293", "r1294", "r1295", "r1296", "r1297", "r1298", "r1299", "r1300", "r1301", "r1302", "r1303", "r1304", "r1305", "r1306", "r1307", "r1308", "r1309", "r1310", "r1311", "r1312", "r1313", "r1314", "r1315", "r1316", "r1317", "r1318", "r1319", "r1320", "r1321", "r1322", "r1323", "r1324", "r1325", "r1326", "r1327", "r1328", "r1329", "r1330", "r1331", "r1332", "r1333", "r1334", "r1335", "r1336", "r1337", "r1338", "r1339", "r1340", "r1341", "r1342", "r1343", "r1344", "r1345", "r1346", "r1347", "r1348", "r1349", "r1350", "r1351", "r1352", "r1353", "r1354", "r1355", "r1356", "r1357", "r1358", "r1359", "r1360", "r1361", "r1362", "r1363", "r1364", "r1365", "r1366", "r1367", "r1368", "r1369", "r1370", "r1371", "r1372", "r1373", "r1374", "r1375", "r1376", "r1377", "r1378", "r1379", "r1380", "r1381", "r1382", "r1383", "r1384", "r1385", "r1386", "r1387", "r1388", "r1389", "r1390", "r1391", "r1392", "r1393", "r1394", "r1395", "r1396", "r1397", "r1398", "r1399", "r1400", "r1401", "r1402", "r1403", "r1404", "r1405", "r1406", "r1407", "r1408", "r1409", "r1410", "r1411", "r1412", "r1413", "r1414", "r1415", "r1416", "r1417", "r1418", "r1419", "r1420", "r1421", "r1422", "r1423", "r1424", "r1425", "r1426", "r1427", "r1428", "r1429", "r1430", "r1431", "r1432", "r1433", "r1434", "r1435", "r1436", "r1437", "r1438", "r1439", "r1440", "r1441", "r1442", "r1443", "r1444", "r1445", "r1446", "r1447", "r1448", "r1449", "r1450", "r1451", "r1452", "r1453", "r1454", "r1455", "r1456", "r1457", "r1458", "r1459", "r1460", "r1461", "r1462", "r1463", "r1464", "r1465", "r1466", "r1467", "r1468", "r1469", "r1470", "r1471", "r1472", "r1473", "r1474", "r1475", "r1476", "r1477", "r1478", "r1479", "r1480", "r1481", "r1482", "r1483", "r1484", "r1485", "r1486", "r1487", "r1488", "r1489", "r1490", "r1491", "r1492", "r1493", "r1494", "r1495", "r1496", "r1497", "r1498", "r1499", "r1500", "r1501", "r1502", "r1503", "r1504", "r1505", "r1506", "r1507", "r1508", "r1509", "r1510", "r1511", "r1512", "r1513", "r1514", "r1515", "r1516", "r1517", "r1518", "r1519", "r1520", "r1521", "r1522", "r1523", "r1524", "r1525", "r1526", "r1527", "r1528", "r1529", "r1530", "r1531", "r1532", "r1533", "r1534", "r1535", "r1536", "r1537", "r1538", "r1539", "r1540", "r1541", "r1542", "r1543", "r1544", "r1545", "r1546", "r1547", "r1548", "r1549", "r1550", "r1551", "r1552", "r1553", "r1554", "r1555", "r1556", "r1557", "r1558", "r1559", "r1560", "r1561", "r1562", "r1563", "r1564", "r1565", "r1566", "r1567", "r1568", "r1569", "r1570", "r1571", "r1572", "r1573", "r1574", "r1575", "r1576", "r1577", "r1578", "r1579", "r1580", "r1581", "r1582", "r1583", "r1584", "r1585", "r1586", "r1587", "r1588", "r1589", "r1590", "r1591", "r1592", "r1593", "r1594", "r1595", "r1596", "r1597", "r1598", "r1599", "r1600", "r1601", "r1602", "r1603", "r1604", "r1605", "r1606", "r1607", "r1608", "r1609", "r1610", "r1611", "r1612", "r1613", "r1614", "r1615", "r1616", "r1617", "r1618", "r1619", "r1620", "r1621", "r1622", "r1623", "r1624", "r1625", "r1626", "r1627", "r1628", "r1629", "r1630", "r1631", "r1632", "r1633", "r1634", "r1635", "r1636", "r1637", "r1638", "r1639", "r1640", "r1641", "r1642", "r1643", "r1644", "r1645", "r1646", "r1647", "r1648", "r1649", "r1650", "r1651", "r1652", "r1653", "r1654", "r1655", "r1656", "r1657", "r1658", "r1659", "r1660", "r1661", "r1662", "r1663", "r1664", "r1665", "r1666", "r1667", "r1668", "r1669", "r1670", "r1671", "r1672", "r1673", "r1674", "r1675", "r1676", "r1677", "r1678", "r1679", "r1680", "r1681", "r1682", "r1683", "r1684", "r1685", "r1686", "r1687", "r1688", "r1689", "r1690", "r1691", "r1692", "r1693", "r1694", "r1695", "r1696", "r1697", "r1698", "r1699", "r1700", "r1701", "r1702", "r1703", "r1704", "r1705", "r1706", "r1707", "r1708", "r1709", "r1710", "r1711", "r1712", "r1713", "r1714", "r1715", "r1716", "r1717", "r1718", "r1719", "r1720", "r1721", "r1722", "r1723", "r1724", "r1725", "r1726", "r1727", "r1728", "r1729", "r1730", "r1731", "r1732", "r1733", "r1734", "r1735", "r1736", "r1737", "r1738", "r1739", "r1740", "r1741", "r1742", "r1743", "r1744", "r1745", "r1746", "r1747", "r1748", "r1749", "r1750", "r1751", "r1752", "r1753", "r1754", "r1755", "r1756", "r1757", "r1758", "r1759", "r1760", "r1761", "r1762", "r1763", "r1764", "r1765", "r1766", "r1767", "r1768", "r1769", "r1770", "r1771", "r1772", "r1773", "r1774", "r1775", "r1776", "r1777", "r1778", "r1779", "r1780", "r1781", "r1782", "r1783", "r1784", "r1785", "r1786", "r1787", "r1788", "r1789", "r1790", "r1791", "r1792", "r1793", "r1794", "r1795", "r1796", "r1797", "r1798", "r1799", "r1800", "r1801", "r1802", "r1803", "r1804", "r1805", "r1806", "r1807", "r1808", "r1809", "r1810", "r1811", "r1812", "r1813", "r1814", "r1815", "r1816", "r1817", "r1818", "r1819", "r1820", "r1821", "r1822", "r1823", "r1824", "r1825", "r1826", "r1827", "r1828", "r1829", "r1830", "r1831", "r1832", "r1833", "r1834", "r1835", "r1836", "r1837", "r1838", "r1839", "r1840", "r1841", "r1842", "r1843", "r1844", "r1845", "r1846", "r

```

"documentation": "Value, after forfeiture, of shares issued under share-based payment arrangements. Excludes employee stock ownership plan (ESOP).") } } }, "auth-ref": { "r36", "r57", "r58", "r93" } } }, "srt-StockRepurchaseProgramAuthorizedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StockRepurchaseProgramAuthorizedAmount", "credit": "presentation", { "http://fitfilebrands.com/20240930/role/statement-note-7-equity-details-textual", "lang": { "en-us": { "role": { "label": "srt-StockRepurchaseProgramAuthorizedAmount", "terseLabel": "Share Repurchase Program, Authorized, Amount", "documentation": "Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership." } } }, "auth-ref": { "r786" } } }, "flrf-StockRepurchaseProgramExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fitfilebrands.com/20240930", "localname": "StockRepurchaseProgramExpirationPeriod", "presentation": { "http://fitfilebrands.com/20240930/role/statement-note-7-equity-details-textual", "lang": { "en-us": { "role": { "label": "flrf-StockRepurchaseProgramExpirationPeriod", "terseLabel": "Stock Repurchase Program Expiration Period", "documentation": "Expiration period for the purchase of an entity's own shares under a stock repurchase plan." } } }, "auth-ref": { "us-gaap-StockholdersEquity" } } }, "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "credit": "calculation", { "http://fitfilebrands.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", { "parentTag": "us-gaap-LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://fitfilebrands.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://fitfilebrands.com/20240930/role/statement-condensed-consolidated-statement-of-stockholders-equity-unaudited", "lang": { "en-us": { "role": { "label": "us-gaap-StockholdersEquity", "totalLabel": "TOTAL STOCKHOLDERS' EQUITY", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth-ref": { "r58", "r61", "r62", "r86", "r58", "r62", "r61", "r719", "r754", "r767", "r795", "r844" } } }, "us-gaap-StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": { "http://fitfilebrands.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "lang": { "en-us": { "role": { "label": "STOCKHOLDERS'2019 EQUITY", "auth-ref": { "us-gaap-StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": { "http://fitfilebrands.com/20240930/role/statement-note-7-equity", "lang": { "en-us": { "role": { "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth-ref": { "r92", "r196", "r345", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r359", "r430", "r622", "r623", "r638" } } }, "us-gaap-SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": { "http://fitfilebrands.com/20240930/role/statement-note-11-subsequent-events", "lang": { "en-us": { "role": { "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth-ref": { "r458", "r459" } } }, "us-gaap-SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": { "http://fitfilebrands.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "lang": { "en-us": { "role": { "label": "Supplemental cash flow disclosure", "auth-ref": { "us-gaap-SupplierConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplierConcentrationRiskMember", "presentation": { "http://fitfilebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "http://fitfilebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual", "lang": { "en-us": { "role": { "label": "Supplier Concentration Risk [Member]", "documentation": "Reflects the percentage that purchases in the period from one or more significant suppliers is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services. Risk is the materially adverse effects of loss of a material supplier or a supplier of critically needed goods or services." } } }, "auth-ref": { "r84" } } }, "us-gaap-TableTextBlock": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TableTextBlock", "presentation": { "http://fitfilebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-tables", "http://fitfilebrands.com/20240930/role/statement-note-4-inventories-tables", "http://fitfilebrands.com/20240930/role/statement-note-5-property-and-equipment-tables", "http://fitfilebrands.com/20240930/role/statement-note-6-notes-payable-tables", "http://fitfilebrands.com/20240930/role/statement-note-7-equity-tables", "http://fitfilebrands.com/20240930/role/statement-note-8-acquisition-of-mimis-rock-corp-tables", "lang": { "en-us": { "role": { "label": "us-gaap-TableTextBlock", "terseLabel": "Notes Tables", "auth-ref": { "flrf-TermLoanAMember": { "xbrltype": "domainItemType", "nsuri": "http://fitfilebrands.com/20240930", "localname": "TermLoanAMember", "presentation": { "http://fitfilebrands.com/20240930/role/statement-note-6-notes-payable", "http://fitfilebrands.com/20240930/role/statement-note-6-notes-payable-debt-obligations-details", "http://fitfilebrands.com/20240930/role/statement-note-6-notes-payable-details-textual", "lang": { "en-us": { "role": { "label": "Term Loan A [Member]", "documentation": "In relation Term Loan A", "auth-ref": { "flrf-TermLoanBMember": { "xbrltype": "domainItemType", "nsuri": "http://fitfilebrands.com/20240930", "localname": "TermLoanBMember", "presentation": { "http://fitfilebrands.com/20240930/role/statement-note-6-notes-payable", "http://fitfilebrands.com/20240930/role/statement-note-6-notes-payable-debt-obligations-details", "http://fitfilebrands.com/20240930/role/statement-note-6-notes-payable-details-textual", "lang": { "en-us": { "role": { "label": "Term Loan B [Member]", "documentation": "Represents term loan B", "auth-ref": { "flrf-TermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://fitfilebrands.com/20240930", "localname": "TermLoanMember", "presentation": { "http://fitfilebrands.com/20240930/role/statement-note-6-notes-payable", "http://fitfilebrands.com/20240930/role/statement-note-6-notes-payable-details-textual", "lang": { "en-us": { "role": { "label": "Term Loan [Member]", "documentation": "Related to term loan", "auth-ref": { "flrf-TermLoansMember": { "xbrltype": "domainItemType", "nsuri": "http://fitfilebrands.com/20240930", "localname": "TermLoansMember", "presentation": { "http://fitfilebrands.com/20240930/role/statement-note-6-notes-payable", "http://fitfilebrands.com/20240930/role/statement-note-6-notes-payable-debt-obligations-details", "http://fitfilebrands.com/20240930/role/statement-note-6-notes-payable-details-textual", "lang": { "en-us": { "role": { "label": "Term Loans [Member]", "documentation": "In reference to the Term Loans", "auth-ref": { "dei-TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": { "http://fitfilebrands.com/20240930/role/statement-document-and-entity-information", "lang": { "en-us": { "role": { "label": "dei-TradingSymbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange.", "auth-ref": { "us-gaap-TranslationAdjustmentFunctionalToReportingCurrencyNetOffX": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TranslationAdjustmentFunctionalToReportingCurrencyNetOffX", "credit": "calculation", { "parentTag": "us-gaap-StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://fitfilebrands.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "lang": { "en-us": { "role": { "label": "Foreign currency translation adjustment", "documentation": "Amount of cumulative translation gain (loss), after tax, from translating foreign currency financial statements into the reporting currency." } } }, "auth-ref": { "r69", "r797" } } }, "us-gaap-TreasuryStockSharesAcquired": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockSharesAcquired", "presentation": { "http://fitfilebrands.com/20240930/role/statement-note-7-equity-details-textual", "lang": { "en-us": { "role": { "label": "us-gaap-TreasuryStockSharesAcquired", "terseLabel": "Treasury Stock, Shares, Acquired (in shares)", "documentation": "Number of shares that have been repurchased during the period and are being held in treasury." } } }, "auth-ref": { "r10", "r58", "r93" } } }, "flrf-TwoVendorsMember": { "xbrltype": "domainItemType", "nsuri": "http://fitfilebrands.com/20240930", "localname": "TwoVendorsMember", "presentation": { "http://fitfilebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "http://fitfilebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual", "lang": { "en-us": { "role": { "label": "Two Vendors [Member]", "documentation": "Related to two vendors", "auth-ref": { "country-US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "US", "presentation": { "http://fitfilebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "http://fitfilebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual", "lang": { "en-us": { "role": { "label": "UNITED STATES", "auth-ref": { "us-gaap-UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": { "http://fitfilebrands.com/20240930/role/statement-significant-accounting-policies", "lang": { "en-us": { "role": { "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth-ref": { "r28", "r29", "r30", "r118", "r119", "r122", "r123" } } }, "flrf-VendorOneMember": { "xbrltype": "domainItemType", "nsuri": "http://fitfilebrands.com/20240930", "localname": "VendorOneMember", "presentation": { "http://fitfilebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "http://fitfilebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual", "lang": { "en-us": { "role": { "label": "Vendor One [Member]", "documentation": "Related to vendor one", "auth-ref": { "flrf-VendorTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://fitfilebrands.com/20240930", "localname": "VendorTwoMember", "presentation": { "http://fitfilebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "http://fitfilebrands.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual", "lang": { "en-us": { "role": { "label": "Vendor Two [Member]", "documentation": "Related to vendor two", "auth-ref": { "us-gaap-WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation":
```

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

publisher: "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C", "r705": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "044", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C", "r706": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "044", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C", "r707": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "044", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C", "r708": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "044", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E", "r709": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "044", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18", "r710": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "046", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1", "r711": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "046", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6", "r712": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "046", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1", "r713": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "046", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1", "r714": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "046", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1", "r715": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "046", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2", "r716": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "046", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1(a)))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3", "r717": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "046", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6", "r718": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "046", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10", "r719": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "046", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12", "r720": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b", "r721": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2", "r722": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1", "r723": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a", "r724": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1", "r725": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "r726": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1", "r727": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405", "r728": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3", "r729": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25", "r730": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18", "r731": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B", "r732": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "SubTopic": "40", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2", "r733": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(3)", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2", "r734": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4", "r735": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "XV", "Paragraph": "Question 2", "Publisher": "SEC", "r736": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483504/205-10-50-1", "r737": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1", "r738": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1", "r739": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1", "r740": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section

"https://ase.fasb.org/1943274/2147480097/470-10-S99-1A", "r784": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147481139/470-20-50-1B" }, "r785": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147481112/505-10-50-2" }, "r786": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147481520/505-30-50-4" }, "r787": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147479806/606-10-50-5" }, "r788": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147480429/718-10-50-2" }, "r789": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "3", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147480123/805-50-15-3" }, "r790": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147480060/805-50-25-1" }, "r791": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147480027/805-50-30-1" }, "r792": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "2", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147480027/805-50-30-2" }, "r793": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147480175/815-40-65-1" }, "r794": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147482106/820-10-50-2" }, "r795": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147482907/825-10-50-28" }, "r796": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147477401/830-230-45-1" }, "r797": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147481694/830-30-45-20" }, "r798": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147482925/835-30-45-2" }, "r799": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147482900/835-30-50-1" }, "r800": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147478964/842-50-50-3" }, "r801": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147481404/852-10-50-7" }, "r802": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147481404/852-10-50-7" }, "r803": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147481326/860-20-50-3" }, "r804": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147481326/860-20-50-3" }, "r805": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147481326/860-20-50-3" }, "r806": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147481326/860-20-50-4" }, "r807": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147481326/860-20-50-4" }, "r808": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147481326/860-20-50-4" }, "r809": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147481420/860-30-50-1A" }, "r810": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03)(1)(a)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147478546/942-210-S99-1" }, "r811": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03)(a)(16)(a)(2)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147478777/944-210-S99-1" }, "r812": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03)(a)(2)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147478777/944-210-S99-1" }, "r813": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147479432/944-30-50-2B" }, "r814": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147480081/944-40-50-4B" }, "r815": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147480081/944-40-50-4B" }, "r816": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147480081/944-40-50-4C" }, "r817": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147480081/944-40-50-4D" }, "r818": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147480081/944-40-50-4C" }, "r819": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147480081/944-40-50-5" }, "r820": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147480081/944-40-50-5" }, "r821": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147480081/944-40-50-5" }, "r822": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147480081/944-40-50-5" }, "r823": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147480081/944-40-50-6" }, "r824": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147480081/944-40-50-6" }, "r825": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147480081/944-40-50-6" }, "r826": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147480081/944-40-50-6" }, "r827": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147480081/944-40-50-6" }, "r828": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147480081/944-40-50-6" }, "r829": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147480081/944-40-50-6" }, "r830": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147480081/944-40-50-6" }, "r831": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147480081/944-40-50-7A" }, "r832": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147480081/944-40-50-7A" }, "r833": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147480081/944-40-50-7A" }, "r834": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147480081/944-40-50-7A" }, "r835": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147480081/944-40-50-7A" }, "r836": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147480081/944-40-50-7A" }, "r837": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147480081/944-40-50-7B" }, "r838": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147480081/944-40-50-7B" }, "r839": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147480081/944-40-50-7B" }, "r840": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147480109/944-80-50-2" }, "r841": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147480109/944-80-50-2" }, "r842": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147478009/946-205-45-4" }, "r843": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04)(10)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/214747910/946-210-S99-1" }, "r844": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09)(4)(b)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147479134/946-220-S99-3" }, "r845": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09)(7)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147479134/946-220-S99-3" } } ZIP 61 0001437749-24-035027-XBR.LZIP IDEA XBRL DOCUMENT begin 644 0001437749-24-035027-XBR.LZIP M4&L#H10 (C- 97A2-S8Q 3DS-FAT>U, M?Ww, A-LN-D4> ^T<68H2<=>=4Y6, ^X3B,7JHZZ0< 25\$#!218)3,7OJ<M1.C?B)0HVN<N=>#J A SP2782> M83-4#F => GA4S+H&B<=>F2Y1?> %5.W@<RR896 %E%WI@I=>GOLP^A2<WZM<=>J.W@W(GIJI4V15<3ER{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v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{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

[illegible]

43HZED#CEJ'5&RHCRF-[Z]+(<2(S6_AXH5\IX7(L.)>24
M48+2EA1N&R]:8A#3",I%2H+67]!B#&7#8WD"-Q07>44,#?LS@G='M0F9P4/
M+C/R#B932A'5\$GJ'6+ M_HOM3T89:DE#(YX[|\$9S1^TQ=D/GNFC!YIJUB-
YJ:9C:~>6#0'V'"#H\$Y+T73(M5/D'"J+& M\$[|J5^1^&ZU_':AGGY9I04?7#?-\$YA?
UN&;5.&W08?7ZOLV"-;7E@_# +4?= M>->:|>[H1BI<2?&LRSC#*RJHRW-
2K\$@MF.+W"YWO() (F%K7K@.;?/+G4#E!. [J9NJ@IWWWR MFK@&TYS[|?
U_-'=^&1:P5QQX:| #86U_0;|RCXV"W@'Z';1 M%UP.U<@6#81GW1|
J%TIF^%"%2,@5(:|B*-\$G4V6U-ED6)U-|*FSB6=UAB;F M^@Q,LX\$^:W*.O,(H
<.E_ |0C_7RQU ZMV_, '7>9Y.!5& Z16@E8#_ \$K3?1 M%S=|P.O.<.,? ,|T
M,6#G9_NGN|OIS1Q=7TW.KJZOYE?3^S|%. =45>\$OT&6;IE#|;|N7|D)WR9|Y/
M^3/S4QY,L|EOE4TCX|,(>%LY7/| #4[Z7/WZKCD4EOL#U?Z_RV0HS?VW^>,U^ M;K>3J-
*L|O&QP;REITX2J! :3'J|.Z7/B?J|U;?12|?(|J'TR@; MC*ON&VL:5MV%Z?RP)3^?
CJ_#R*J|PM+Y%SP%WV7JVRMIQBX7OE'H: MN#YH?@V-'%/#XEK>NV1TWFZ2;
<^.;!%+FDM #/GJ33+;|JGWN'A.8|PCH|X. M@Z=N",| #P
F/DRIYM>_NW|J)6=V0ZA^XNL,Q>1+X.D';6;0AF35U|)&_K.A?*[3!%=K-X 35 M?
9N#J#V_.Y0\$%0A_F7Z8/ZK?%N0Y35C'ZD|EJUBRO6=-MGEK0RE_8\$#0W#|M
MA,YO1H|OZ'+ZJF/|^CR;081S6ZG=Y/YU2- 3ONN\$MX<6#P98;| %L> L4/|.K *X&+ZG
M>M^C.;YY2)7A' @U.MP!-"Y@Z'%B#XSG(@C M#2-#\$FX2=1;Y6OJBL|.AMJ4-
20\$|99"EH+8H7!WH1V/ZKYAZA(&4U7.;W;T|LC2|Z?4U*F M7RIZ:V0%(Z
MT|>T|USC04W?_';L?H'G=:FK@X|E24B\$+|[\$|PD2>L"-BQ"-2H_CU9I%64B
MF92/AHIC/U3GDKA%RQ,+3M,TVJ'>&A@Z|99V,%|CADI5)!E+GET?
U%X|I83BLU| %GY|6HS M%)\$S^ '8'28"[-PM-I^= -|??9M<7T|O|?_O5'|^ ^|. ?T?0_/UW-

_Q'F_4R! MQ42?;U8K2NR.J.XUAFKH;)T=2@[T<_J\$(T
>H^2.DQK%%@>:XV+OP=B_7@ MRC_*<_.G_D39DWN63T
%.TFG+83;JLN')1/H/_D+XOL5:1JGA09V<'+'*JAM MS?
["'1H+8IRM^04GYT]1\8A9M096G>&.K5N?ZAD:"\O3[(?I1:F(D-2-&W-M J
N.)48TA1Z(G EL.#SB>OYQ.U\N\L02)KI@-3+=:9;E=65B9ARF). MIF=7\XN)>+?
AX(V:SJ/(\WNU'I>^A-N: V2G%:WCL&^M55J9MZ%NW\$F.DD)CEZ(X%\$J)?=?DK/47!\$UR
MT@:QUK[,Z1<6N(T%FV=P/#2D6037U_81\$@/#9/S9FL[^!YH D0/8)(DS(\$*[1
M])?"4%U8:IN2&:++/4G&(X=H0JDI#^*X,85P7(ICW?%L6(F!1B(&:.\$&%}Y;VI M.-
W:/\$UJ];/#^NK\?UB0QR1/6+//P9;.+E&9M%>P3)+S-W.&N0DP"MGJV>ER M'C8
<+I&WC8;M]2\$I]+ (Y7>Q\ -H8;\$M8C/YG^;WJ'IWV^G_ =3]/75S?GL MX_2;
(%*NR75BQDJ?28LU.:R[ILA&[QL#3S7=29*!/\$7)+?5Y<>MOZ1CH %Q75@^CW3_K;_DI"-
//\$F!ZRW:X6O MTV<6,U51)K+@XCIH:A+3N:6_[-=?\$"!L,-!
25*Z%KL=N14>YE@X;I(0U? M#V*/R1X+G^U31W7LJ\$N<(;[N'F^XHT([ZNHJ#1?LB;W?
SM!9],/5S_5!Y<[VW/E8Y9G)S@>ZF]_.[J_/Y]+57)O27RKRRJ%)\$ \$1GD3\$L
MN+^Z=XL%/?IYYZ(GYA=D,7JS? 3GU7@(@U;,"SX!YTTB2('3QQS%/ LPWJ!T
MN8IB:F_FO&!EF\$IMP;G>ITC"4_4:#=^Z_?!Q)>YFXEUFU@QV8?J"B0AA_&H3
M^RK,7^U9>3?N// =X!X_ JODYL,47=T@D9'W^JPZ^':T9=<9KK7'"FKM!'A2 MV*
<[I;_J0;::/U#;ARF@2V^ZII+7+\$L2..GU-"2B_48S2<59-387G!;1(
M;+6Z2\$4!!ZD#R=7QU4\$+.%B.*P>T'.BVI0G>DZA-C(5-"%R#>-5K; M%I45/_1K K!;
<+@'D;=P766*@\$ \$SN8+B3/_5=V"8=40A!XVZ.LUJVV>YM]T MVPDJSMIOK669/
[76!YDNK\HL/V (\$D\$CF0D-+[K&**OK=:.#&K*GK,P L'EV MI<@#ANK(!
)H\CTV=13\%SO;)(L'LV]2_*?#;U4&3Q;+
(R7UMGTS9TA8Z!D!W&,=2+XV40];DRP1O>D/?@!J?Q<="BWCO/\$A6:!'
MAAN5%&.8YJEASA)] =H6KZ-QY9] HZ]S_E:W:SO00019XSMK&]>,H\BS@LZS2
MLXQY'M-0FA;O/Q9IA2_ (BRA=2CP0G&)R"-!YEMVVM0\$K Y2V^!%YH\$H*ES%K
MCAZC!'0P(^##40>;^ M@-Q2P^_Y>_2@'4'H<^BF>,!(G8X[R^W>)<9>
(%7!8Y3'FQ*_YUA7FLBW\L8 MI!;F"A?5AI64J.C?6%#5:BGM(F,5/#2CV1(9ONY(MNB%7+
"JDT%V'7%;O M;DMOJ(X\=L6=N%X7;XKF;%VF.2Y+JA4?TKPF7?G\$U/L8J"34D+A6
2T5J\$/& MJ Y&S;4@9@SV^\$@CV"_B&Z?*)^!G&3%H]^!Q-6YNH.\$6L4+=0Q]3@812DE-]
MM90\$A\$!8Y<[9+;_'8*GF@J^Z"BT>D.,93".@1+<:H:YJT)X M'YM*!.=-
(8))\E_KDCM/)U55I_KB04KGI;R@M"=S'),A[C74]&&K'I:HFY M)]
(^,K=ECRTHP];BD,HRH, M1!<4:1BX(O8=KJ(TQ\DT*G)*5W^3;+7!X,H"?4#=#EQ2HL:
(6;>@R E+.\$CUV M>0_7JK-,0LG*V7NF,'QAB%:1W!=B}&GO*G-RI@6508LESS8)N8T1
T2DO, MY)[XK '.^;L6;/O.WD8IU9CGT2JMHQNY:M\ S7:9;"=V^")L0,^VE*3? : M?
V!S6HGA!,1%K_%<).>)8E+I\$HXS B,K:@^6JZH-VB\$-V?
1#COIH\$B[T\$G'00/6^V#Z%J.PW>#D;"5:O%*5&T%#SAJPGI!BEF-Q1T!]
M\$,WE[P/E>M5K=(CB@S?E-";9N"OG&)E5-@_D*3H&C(?!38-O*TRE \9F>
@8DVSH%JA<2[!0X M7GRBPAZ?=?^#^#LR3."9K5K\YVK#G4_\$M7.T]^'U<#M]?_,P
(;!0&NNS VCO M%B=:J/5FL'.(EG62=C;A. ||==?XDSO" %WCI/<#G]4A41 M*9(TCXK-
%;WYEOWA"E)OF%,1AXU)Y1YW/NNI@#4&N/A*!"!T%OGDT09W?3 MCK,3;;V@ 9V>;K?
0D>/4PRKZKS?-CP?+-Z+UJMKC#SSA?TSL52PL9J(:B]2TTF%8%A_.JAWM\$L\$.H(0-]
MYH0\$3T'56PEBQ%Y_T;<9EQ:<[,X O#\$ "UF@&X<3V^PA@6SJ?0R-QU5"XJU8
MEQ(UH%)T!\$S#GN\UZ]J3I>SA4)(Q-!P\%V_'ZRO
M]27"#W;#&_%). \V3@E:Z]>L;M51J(\C'T]*"Q\$EVM>KUJLH.9!3U]>E&*P
M]*K.MP:7M4\$J]\J:0_M_/.BB0;YSW54T'V=;>B.
(<6AGE88J2EQ\$HC.3?,&+=KB135BKS*DPE*BP2=' M\G'-
J]3:L%>S@N+DE@4/)3]G<0'%YIPDA^:TYE< N5& \CR*FY. JF@X09P*M1
K44((8*=ZE2H?Y!,A11](VH6*>,%&_S*)#SY3P[P)VH/C/NR1888-N_B
MT,\S,L@ (GY5TF)BE^2,_ (>K" MF#8\75T7D1TB_!RET/W4=%0@POI(4AO-]
(=XM!74B%7B0ZK'\$G).;VL3-H< M"6Z??7\&2\$,7C&L).,2G#M5/)9XMIF65
M+NDE6A2XVS\(>\$CN W->-JKD<55;?*/SS IX2]08YMB71K<;;T.,+Z(JZN^B
MKCKC[D\H,T66>84[OS9JE M8LX6=6[FH3J4#8'D]!Z [53&#+=CKT?
W<3"B"_4MD@RGP+FU1?K"2:4JF7AJ@V\O%U4U*N\UVYC+ X"\(H16\M@:
'!'"2<8D&Q=*(G06]?4D@'4G6GRBPAZ/!]?@?JJN\ MK
K.Z7HOI7\$3;\$SW5QZGJR@3:%V]C\&E^560^+(WU*B!6%RNY@GP3#!2T(Z6
M\$]12TZ9OT-^H3=55[H2>X!\$S+GO;C'-FN:V+#+:J=SK-*RDG\KW5:X\$2P_Q6^M &X["61?
>TU" F2#69T18%>U^M"^B>H)N\$M42@K],O2^BHI*;T^<11EO
M=J,L^HZG,,TUT[*T)^J^\$@HTD2930\$=B:Q>&'L\$^S&MGL\IQ8TL<=\$Z)S;*M?D,E*-

;-^4Q;:/M#J1J,*I_4Q.\$H)TG^M:-OW:I3X MWM_Z:RRVSFW1-
\$C4\$CC%K|#/%U+HKL5NBW[\$DJ>Z 3(5<>]H[OW#_.T.@I)
MD0TQ.+1;4#X/[!8G]+&TPQQ_3!;+;/DW?NO[Y!+0W!3NJCM2>'=MU|.71=
(0*+G9""7X;:H3,O[58&C9);_ \$!4I"RR[HUO_G=+;V/#G5EZ"Q6C" M0
^+Z3%_(:8Y5QMOQ)P>5!/\$=F+\$KKS?:*!15#X3JS*:.0HJO\F2(CQ::H M8UAN*>^?
HA*7XA CQ4\@(<4<#H-W7"F[0GS;XT98 >\$R2]3D9QRBE+46HG>:J MI2E
T)*J.!\$/(PUWQ_R%-)D=25L\$,(%W)QH8XFN7DC MI""A!!
E#GDSK_B1,EOLZCT(!"CA.*#!= 3/M5C7=@%9=(MV!*_5(>8J46:5 MXP<|26{CE" |H+|
{3})1&FM0@^,(IK8<_9&(3DF*>)(B)@5,#@FXOFW: +3FD\YY\$;RK;5 FQX<
MX<)K>HBQ\$U1C-DN3TN(M9H[B&Y4E#M.I24^XI%\$T@[ST&&R0ER1+\$VY-*]89
M5_@\$'&P@!NT^V*"#>W3U:I283B"<='SRW[9QJX(G,^DX@U_#YZ/A]H>Q+JO
MOY:HA_A+6[.E,6N#O?7):!8(H\|F;"KU+'Y^JV>)3B2?L;)H]5%&;JW>QI)= MDDY&,SL
AB*!+4 \$*F #S,XK("=)7?BP(JA@9)Z2Q>FZQ+5%4"(F02C'+YTN MNQDCL%N"
(\$P[\$@NK21PL44"+_K;JRA-Y.VV5#^S9L?O@P]GPN_38<=Z|_--MJ"=0C?
2P)DC5!2FU2_AX_(%0B>U[V7<=EH|\#+-<%U6JL?4\$@T!
MUPC<@?)7%W""\$U8+T(1F>/T_AA6ID.VLY%_/LA,5OC@5U^D2%X_TF/I0D)?J-MB=
<\$R0^-(L718""NA>I:GANQ:'&C&CEJL <2\$3E_B2;3 @4"748QGO!::DJ! MA?
#K03Z|,"&">S9X3_Q\$KG){P}|LHR|[6);VB MEGW/?D)1X!-J#YJGDYSC1"W20=X/QN)
(F_P!=HK \$2-. XBHYK=0ZEX2/'^P,)JI#_6;1&;0+-S4E:B M5VI]-!8*F5\$KC?(1WI=P
5W]42L!D_3PZ:)R@P38J6_"L2RF@QQ]9N@1Q^_WV5:9R427<_X\$:-Y3,UYE MJ!W!F?NH-
+O-!SU*.1E?EAR79U9SMW,Q3E5<8^D\$)MSO:.,G,U;:)ZL>HX3 MM4@#>FZ/V7CDO!7P)H
;;O(E%9D_XH%67&|,H'.JL>^C0H9TC"!01)N"OU2 MQRQRJBV:K.RZ_U^:/|+.X;TQP"K#P?
JC'ZR_FV\$ _?M@=T=9V/I@Z'.? SZM(?# M0JTJ8IN\K)4D#%!/VXNI_?XD?
U82@YCI6^@96=EL%V+5HLKY-FLQEP"XI@_ MJ:D)D*JEW C%0J>G" |B_&_7Q8J4|F-
*.A9:IJ8/MIO-2<_U2U&-*R=RMA(M7OG3'ZS0W&V1QJ(XS^,!4,VQ!>2UOCG""*X*#J07
M4HV5H4,*U+K2<9%)C;YIP7;.:FOU4MC F\$ M I1X36S.S?D: +WHIR\$)131>*FT*N=1U-
PV+ZSB==D2K*|];6C_(9GZ*D84WH MNJ%0^226^!|PZ:"IDR!NB OYU%KRP3&*<
D(Q[18:]\$)GZ-)(D*+>'S9!1+) M&FJ>*66ESP3B&+> /S=.RU_NL4%^P75#*+2>RJ?P!:
(A:|H|2<9#9|J9'=. M,-QCP#\$. =UQH:0J5##XL0@?#0Z4O(/IRE5"TVS:@ {DZ
^/!;R\$ "N)Y> M52EVM(!^;&K,\$)>)-NM".64DCE|)2#L.&1].W6-W3#CGKHRA8E>,
[Z=7K02R MJSS!7_X#BT,U!./@CZW| \#PIE@8KXF@1Q1OJ-5+ 3:+, (H_OCRMJ\$Z=U3^H|
MF2S9F^C/>[45C]X*!| \OT(*;M_B-RAKJ-4.|@#04,.LYD>.=4W=SAQ[2D M4ET_A@JU3?
|PL++9!^=)U^R0AFEJ)>4D466//T.E;HAW9(?WELK5^PAJODB! M.
|=DF@:;!QW%TG1G|*QL^[8Z-D@KPV"EE&AOC@_MS^G4=)|44R>*7T%=3W+HSL07-
>A'IU%4N4Z_K%05.D'5=OY><8?;HO94FST6-MT5)YL8"7?NSD=1:?!^Q-&H@D'J>O
M)\$|FZV.3MIK_!AE]0'0XVN2C "07&| "C@ZU!Z|_OY*,>42!(Z9ZD#6% M/!*MZ9=56JO?
NM)BKT;4^A*D&Y4PN!80#5+T];6C&4+"A!@I?8?!CAHTLEG" MSH??.?%9US5-
Z70#C83MULD!1CC#?<;|I\$7G91G2L\X3E,|<=8NGQLOUD17&\$ M.\$;T-
B\$Q6!'_|>Q]F:CR0:81ZUZR3[?8@J2<#C"P+RK==YKI)\$DH^|KF|=I M?A12H#06?-?
O@>DO7ZP'.2Q9S,HLX)EB#>Z3JA^(48!F>2B7J4Q0B!;?_"O" MV>(RS:;|3J/LEM0U-"8/S+
<;BZK=Z7QJJC0E*/RI4GID;ZE+1G4GF(\":QC M55:A3_JL|;3\$ZC(F>.:F%P&^E3?BG0
P'1@,E3P#55Y@SB^5-2)9%1

NRQKTH_/DJG*= %D9.M7C M*2=-=B+!2((@F\$WS:;?EVOQY\$C" I'C8FC#
F!U,|C@;:EI>L> 5_XG=ZAP MWN@JB..DV;EQLMNP)(=_WE"%L<[PN|M44E?
*Q<625="C">^LS(AOV:8F M-42+B3Y\ (N?TG|_B3E|\$
0_D:;^D!U\$[|Z0'6HC7XC)#"QX0AAZ1 HT/_ 7 M7I >X>CS@8CXY ^H]UOP'G:CB[#A
M/"S|>5LY5H\2K8T|WLF4LZUM*SO<=GJQ\$ _V0N?9!38Y4UTVKJTDUT3 M'TG-
B8'10/\$10'4N0 U:U,\$;LO[\$\$'-[FA5).>;#<./Q3+/BMB#/:7Y4\$%1U MN*GQ=@#6N_EV@-
_(@#. >BP43CM/ WC/49N3:B!)39|9)V5?N!HJ9YLYQ2W1 MK I?V*J@MH/L/(7U^
&#H0ZI9%7X+"LS)F)>T.:;/_|@K>RM]9/3WX(V/'MJI2%|_1V5RJ(-M37-
CEVGI963GAT/4D6L\ (6MDWX'.=A)'U+KJG!:=M: +V.= (TWZLBHP];9>S
MQ;Q(V)LQ_E*=4:_J6C:X<\$ 32L&ZEI^/E*KO6)/AP]R_F9%Q\$+2]U34Y\9
M/8@3Y%|)*7"50^76;DI51/,Q-^8IY>=@3::UH9PXXX^A&EDXFY MW9J]&-L!"M5(>
<@|3SD?:J>A|Q&|3*D\$N#^WD(P*8')(J_,RZ!)9)TEP0D]J MJCLEZM_2+%|"4[X(C+DA-
#:GZXED"5VT*;W^51MUU3W\K;D.%^/PJLR[9/P& MU82,2*TKK\$2_?E=EKS?
1K\$.FMA0."./.*#X". "Z%K@F(*Y3YB.L? TQEVAR MS)L,?
8R*GS!KU2DJ#*/V\$5"BY,"=QT#L,/)BUOS,TRG!YAY]QOL8WN)+GG\O&0L_ (/IBN):G!A|YP!

M82[E*] %BEOXK%VB,<1DB7D;TJ4EIQIWB3I#J^B M#>J'/%NPWN("1(- TK.
(3A?:1*'>")\$.:T0Z*XMTC936*8=\$>"+A0#HLH? MGY> @_YU5SG5W51,4RP*
<5#Z!GXA\$,/V)?J2(NPT7(3-RJ33HO(4W-UQ%*1&
MVEI1R#1'SM'FZ>)^LWP@V<%F\$/X=X/+<@^/#N[F'4->1:4@M0*VW3T@JJ#IP
M1-8O,QGD1L@HM>VU02J4K?-?J>^ #/&5W+E.CBESK9[L|? \$W"RX""UQ*E
M%SDA^,R:X.V##RMXHPJD\$#%>*GHR;GH309NH6A=XMAA,=Q: '1(HXU5&=AX;
(3%;ZHBJN@E|?'=1EG^/8I*B2-C(2#-"6S'YCS"#".'\$&;
M| #9%%LB&J9ZX8-V(V&6C(J@|E0"=(1R0-2XY#'*@9Y"5V6YQLG%NF |E7EW
MBCH(@_JQMN*Z?_H%%W%:"JM1PP&|XQ|T\$?IR0NE3!O%,.9V_B;MJB^| \$Y5P/
M,_. 'U+0\$+^9J(*;\$'N^|;6_>7404Q"P?|-R6^|!|;E|K)#M9\$HW*!VDPB7B
MB,,X=@4+3J2X8FI0W9U+ #*G#/X(J!:(<|HMS-7H)3:<%.NCL/81X=K2Z1-M,|-0U#
|<2\$3MZ(|04=L"<5Z;|,9-U RHM-HNE-(10.J.%YK(^6(H=;,<:^FM4:(&)UQ^K9!N?I;O3R>
X,HD@JCRRMO5Z)IN MH=GB0,!)6EU&K*9JM?D8?4F7Z^49*0KR0MEZ'JWH7ZJ-X.(\$
0&|5NF@|G7I-MTJ\$)(#YP="RQKD9.\$6H.4\$,5VI*%U.;MZ%X'DDMB@_-' ^H3+\$E=J-M%=-
D0Z&!P3T@G0<%,YQC*90FY2G18929Q)1%U9\$6^M-.4N@/|@E,,DW7U1(KT
M9YQ,EBQ4^, !+N!+33G2P.!:K#1(T='A3F<(Z<#.7+,J'=A/T(X>^F|.D=<= M!1\$V8L#?
8!KZG.1EFC2A!/,BRL%+@KA>Y+NY8TN0B-+YM*E1Z(/>5NKH-M>72I#R9#T=
<8,"*#GVU#CMJ|BAD"O!(6?0&^ZD.AQQZ\$K#. <J4%1T"8 MP#YE)A-
=SAFZ?J|I0_OW!#M41(FRDAO"8@97[V])2_I7=(SYI(4%V3J4"W669ON+1!&E4^ (B@#
M|=P9EV7D):)R@!:D0\$F# '44-^B!'|I|J N%?Z&C4'Z)LC=L^'3@Y)TNV" :L MG4/U! 9D-
QI5@M!J:2X6L?7 T**X@W=,89VM\$7NC*: @>@2>^OA|^CJU3^=TLEGF|V0V|J
MR.0E*I(F4OP# '5B55WFMTCX4I!295 XQ00|^Q0Y=^SP4|0H0V'\$O(^D)UR
MJE"7|KWJWU3I=,D,_NDAU!_9APT25MK,(T;M\$3)=1H|L*A'=JW(D^/ZWP(Y M4OT,'
,L!^|O|E=.:!RS6U_;<*E)%F=X1,)_-)|?H^FIR=G5|,;^:WJ|)S06Z MG|_ _^
OL^N+Z=W|;| #T/S|=S?|1**Q74;P(E*!U/-0BO+@>\$M*VEOB M#ET5;)C'\$G5ML|J26R.
(/T44FUJ>FA|VHM3|XI^4F_MK>_P'3>'8-7 M!9|N MKN93IF\$F|^F|UT7081(1S|RO7KC-
YH_E)(|7RS7!/ +W BS1. MQ?7"53|5Q?0N"^CT%-<(-">CK:\$<\$2FHJPMR'-
=A/X#SU&_ #*B-/;BDT M'A?,|31YMXSA+|"1/4+(|L-Y&&HT05OD=4^IP TT%%A-
/SS)EVL2/U%6L89-M*=?%8#6@ @= %J1) =2U1#"W:X0U09
JQEVBR\$%_L5WURL_95ZU+J39,,A\$9Z M'4-T+3BMR57C#.M\$DS&4:'
IC*Q(G.%XVS(B8^0YT,I'9>0*V:E2\$)"AC>K
M.E2MNU##.4WMN\$F#.D;U:.'N)K&J"RY645'I3>4LREC<;EBZH|GFXZ02U2YC-M-P<=S:-
Q+?>83-!E@I?0*U>,61?>D=" F0/6)T1N&9F1=J0QRC;J8(- \$V"D M(CT\$P\$!O&Z:I|Y|_7K-
>3>V#T>:&3GU-+|"Y:-LH?P?8=KQM" T(H4P4+KU9>!@'GK31:WF9SJ_@J53X 2*/M+_-X
M3.X+)683" <|7CZ:X^(|B|JRZ>XNN:0.C@=?101P74L6Q|>T5^-,;#7=I'68M
MT>97@#C9#X0D++J":D^|7&5D@_ \$|+H3&)>|U@<|VNGA<+:Y7ZJ668H+ F;!9-M
6H<_0H!|OQQH,\$55&#M+\$|OQ*4YS_V)?OR\$DW6&9XNM?C^OS0:E?@.ZGT/% M61&-
<| %MZ&J=TO)"6IHH6C|R/T=Z"&%U-(" &1SI,J|BW@G^>,<
M%TOVZ#SH^9\$/AD:W|P+UX>-!S,<3)J);SDBBQYT |E|;276+BU;LTYA*_ \$6: MK2N<:.)J#
(&C&UJ\$65I_&8DL8RZ*M|VY/\$">.ESEJR!N?_0A;Q5YSTF!I_ 4|
MU&EPY9SP<'A*Y+L,6HK:H\$2B/0|J5G4,>
MJLY=OE*=>S)?|A^FT.F8GZ0.&3|'|M7+1>|V|36AMCK=\$.RT&;" (^X8:VL-=MD*
|?%:,1D/_Y<9P'4@=H+_AZ/44S*0_QTC7H,:7%C#6L MH%RW@=W6\$SCN\$'L@1'H?
0:HH#P+W4ANV1"67I@07=0\$KUGV-FK;MW1A:>L?5-M%*%EE5?TK^SL1-43|M22J&?
&)EV3B!).(ZI#P@*46587.0)CLE_7W<-AW8J: MI%T_C\$|,|CK=F6_INFT|_-
+6:8S06)V+V;HJ*ZKGZ-2:LA8_XO3QB|J|D9?DQS=DEI000.F|F,F403M^)(IN)%
<1V6N|K50VF+7IV@EDS\$Z41|M;O2ON|F=H'9B|)G9P3?
AW)|C64NA,W4D|)%DU\$M@%L6070W80E#3"%@^#&-(J MX%SOH/Z;L\$&_;!M3L-
Y>P07_\$\$)(:H|^X6>U">8:/FP;H4DYR&VZRACIO_| M41S2@J2|BO-9.(M7?
3109X4ZTT+S4_|%(UG2|^>THK0%KI8)G/T-ORO.%LU? MF&.BX<)&=
(\$7|%:K:EJG425)=R(S6%W2L1SXTP3KAQ+_ :TTE M8?K,7TZ&GKV'QD-
WFPBN^WB>%C&J,8=/5QCF,=%FW.LTE8^WB>SJZ|6)!21I
M#\$:Q)NDC/YDZL_EOX*2"BITKD|=(E@(|O-|Q-F>+3V7=9U'IW5WPC95G|P/8
MSBNC,73L26== -ETR1_#,+N*O)5=RK37>8'ZM*(SY/^Z3I?"VGT^4(|AJG1
MVLA/(4YM_0/B|+|^ZY%(-ES=B:0+_CIW='O-.W8,^72)B+&/89^+J1SYEF|<
M(AVZ7-^>5Q-9URZ1(3EX#9K@;,'|VZ6|:>N8_.|P\$46N=W/?)AU'MK7|1;6S
M!J56ZC7LM^ -Y**8U6LJ)&?8PDRNR80OVZL MY1CVX %I(S=E;6_K-
NK2#9<;63I@A_NZ"Y|K^F_Z"-;7|'_8;Y9^IO_#U!+ M P04 " #*.VY9PVE\$0JDX

!58ZW4DGZ5T[YY1\ZW*-V];8[N2<>4G1)"0A-MH0@%(-U6?OT I&3)\$@\$L4"1
PJC:.VV;"13"1US6'?^SZ=%^N81489)JNO; MHH_8-RF*2X&SVZJNO=Z/QW>GEY=LW+
(^R)\$D)AGYJFY&W_D?_/_/M_MC4:~489HE*/DS
M'FCZ':&S=Q^_^Z'=QOJMVMR{33}GQOL\$G\5SU\}CUXJ;E<^M?
29EN(Z00_3)N_Z\$7B*"IAU{AC91" #;: MD(W\$GT;O/XQ^>/_=\$TO>^7\9'U/9Q9RB
MZ:}OIWDZ'6W>(<CXWP:OR%=+/F\$87BQ3J;/=#OM+BA@G+/&ZXGJ8TPL6NQA*
MQ0=ZRA&?H6L<-ZRD)'XQ8-\$[VPGAN+O9N3Q78)PV;OXH42C1(+_L=YEN-
MQ2=JA+--=VGT@-)?W\H>5JRD8KH0NH:E)6ZNT"Q*JSI'3YC5,"2A,"I<\$J(
MO_QQS;"NR<7.,K T?IW>;[L/\$#RVD4YWOL&+9J#-LT8@_E"BO8:~9%RPH{
ME.9L\YTGM-O_?10XITO+X@LLOG\T9Y7NZ3SJJ;QK*.7L7J[EX_IO\$;0KF4\;M; M+FGP)U-
\$*4JNJNZDIV*YWY<||0|+D-U?8J:BY->W.2V>,8QH-(\$.7S1FN+=
M,J+BE(CG.\$TVK:>4+,PW)0+[L+SCCF#)N?"&KJQ@ UAMI-%VTATZ=B:-ZF E
M.D%@Z(/73\^D#O \$+P?*@30@J7R0"1AHCQ ;-%Y]_O:O6(#C2D[T><9H'S
MSEPQ7UQK^"(*VZ%);'); \$/2MH&|%?2OH6T'?LJE0'2-3.5#"/HP>(H;9
MB\$Q'NYT9ZEZ:MJA4N4"L!\$TK:%I06?)\$3*>;Z3B.25\$N9HDX*:4;KK8Q-!\$\$ M?
2GH2T%?"OI2T)>"OA3TI3JJ2QJQR:Y*E)"X*"0GAI43MD1SJ:\$+@RU(N"+
M+"E&1MQTHAN->?>)8.\$BC?8%:.GS#K6C4[\$9412=DF1?W-E_W((((">"GH&)=
M7?"U\$Z7_C2)ZGB5G_//5\;8A[9#+L_4JOJ>((!)?TJ4M6A*Z
MKJ)@"*"WP>,V/%H;|J],R*2.UP27O0L49?VSERZX%W"3A)S=;_R-6Z'NI*;"&
MUCZGXJ2[H?DF]QD>4;IG\L)X<),^O_P4G)>RXGM\UK*^3=T0LDCKO)8E-SN
MD5ODJY00#QJEEUS8>_H_:"5E5\$+7/7JDL2#97V+UZ+J[GRIZ(S#\)F2;_F;O,8D+Y5"^%P
M/UTIMW=0*PN\7>'XH)R&-Y_>+C'>:UVO4JBE:_SIW@>93,DV4GJ
MR*SPQJ5/(-=K18/)*UA[,5S&\$?#LKVKEI'W7BB0T>DU^*),@(#;\$[WP7X.'
M3/3F(T^GB18+I242#,H'#V>)THX,1N8'OZ:~VB8,1N5'C^:~SAP !N6C'U-%MKWJ"\$?
G))T0,+!U@@['V"2'0.@N&YA?OMAB :PF,SB=?T9\$[M. 2GD\RKXE; M"HZ0L1+|%
(24;D8X/C)PZJP*3@BQG)PCQ'1F1'AJ/@D!^N,F'!4C-7A'J.B MM%+"(3&6A'L,"<2B#?&6
3N,3(F<0-PA/R3A&'^5SA"QM)PGJ4HA?"=C(;C/*TL95PG' MQ!-
;,"RM!0Z+)P9A4((?!5/K,# Y"(X+L:";SJQ4:31V4VDC-G?U3*.B?B)
MD10GXBZ+T4.4BKL=1FR.4,Y&|5H:7Y8?<%1D49%@3K?A7)JGV4X_EM(PVV0V
M5+!D)W)04L%F',=|*2?G3TOQP<99#=#@J>KO<)TD95,*/_0ASIDZC)' MG&EFP2Z-
(SY/(S:7L+?[R'HAYK6B^UN4%OO;KH[,+J|R_D:IERV*
J)DULANB;"UI/Z\}563D^~KDC'H&[CE?T">S3
_<)^_JOE3G!;"!*7AVZ2IY3&)2QP(7X17>SR(V593FJ5YYNEN.5J[HE7*&((**_&O5A'-
W8EB.YFT-+RB B? M%_EJDD9\|2<8@NA:E4+MU FE@=PRWBQQ".T8RO-M0S:~XV)1H,
("S14+'&,9XO"&H<0RA-^;Z7-QX0FI\$J0TLHJ)4Q_*1G?)U"^M[XU\$?
|B(=H[H&ECEOTS^2RLW:_)GP3.^C M)\GXCG^A/JG^C?8%YJ7*0R4\$^Q/C]=5 T\$;
E0N\FPR'XJRJMNA +O5N)BC' MKY+0X6%\$/B !JU>#<>EI90,S7.1V=3 ./0U?A>\$ #"
!@J'3N%6S26%L60'# M8Y|&1?(HM1,2;KBAJ"(P'CT-' +5=+I K5=@7'H:N6J&BX%Y&
Q,3S.U3|=M4T L<%O-\$K7Z?/HV/'?J!'V<(%#ON2\Z+V"-1J/ MRDOOBS8,0^:(.'9?
E&7C*02)D?9%8S8#QR2"U!==V@PA;9"0+UJU&2PFH3Q> M*=:
<<,>U>>+EFVZJG1Q;+YHV.TL*UE8F2\;MQE(1M'V'2K=0JHFFM9/3_-M85H6-;#%RT+,-
Z7IG)U&*40*I89+.K\$,%^T*3,-0%F;ONA29M"81F/ZHD^9
MH=16M%AW:I<3>ZD)A/I02*\T+C-P3// ME#UO_C*J)KCG(<1^FSH--U+19)
MMX,HS:+D/51JZ>".MT95#M*4?!.?X+0,U(Y-,B/0QVTE1!:/(.5-4)A&J
MH:7JDI2BY031LA:~9&P&+5V-J"HE."[R:~XGVU-)/E(9"WEA94S^/<&L)R_&KJ>6A;
M0USJ#,N|<%4^\$[1F8YP&8(WXB_C5-O.SYPWX8+)YD%[JT8/4?
O9BI24,LP\$*XSXABQ.Y+*77NZ!;KD'-8UP==AG\$!09H874\$FS"X
MC31X\$C\$<2WA7TCKE^@RG12YU-6FHJ?I2"45XEFVBYLHXNZB,JOO,-^|KPM@)
MFG(:^2HV>,,H^|7)(#J3SL6\$DJFT)N8.Q4B\$J#OQ\HH-4.!UP47!4\)/JZS@
MTV2=W,\$%@PK'G93\$|Z><1ER@Y:-"TU-[X)QCO,
[./4\$9DDJ7#;7M6QG*3{J})ZYXDS)>1^QJ7JAP-MLT:13V6RR:32|*JH874\$7R+Z%Q*JBJ,
|>43\|.9"XFS-GF00L\$96Q|EONUN M)&&[EJ;?7#K:~G>G9<6,>D)(Z4>9HVP:~QS8@;
I0,Z1XC?O(1,3JJ*%WQ-M+#+@&AU,+M#Q_:(V\$6.CM4V\$|L?
Y#G%#T4NW)'W9!*I+D2PRG@N<8?\$.~0-N=!F?K?D2A\AY(QE|&B&;HN%@^^(WDS7
M^CXTT++A6_HPT@/F5:~<1N_P+V10IY6&*, \$0)1BB!\$.4H+3N^9&RE'<31PD7
MU('30:S@IPJ5C*J?NK=J|7>ILHT_KIB-DWL9J|K%K");N/-MFPVJ|G4J|W-MY<9H-
0U-|";*NS%R8!J_-=JNYBP(@C?'2&I6[V]R'B9/, #=
M(#VK7SFF(EN2[93P':&JAF|::7@KGJ226K(+RQYJ)!# ZFKAWOB=NM[N=25JY1?

D#B>|;=;2=V<:_B\$ |;,\$@;5T5PF-M1Y9;C#A-2,9G2&W6.(BVW[D>3KB4"4:"
(4WVM4E3RW'E+V_\$4\$YQ-;'=J&1@-M/!W>C'@?'|T0V_&R%F;Y-@-44?C-
J\$6'M8B5KJE1JR(4#:A@R"6CXY,%55-MGUU1N"R8M3')B:B7A3#WJNH|-'^1_?
&^F";J;R\HL71+GH\$QZ!|=)A69K.E-M_TIR&AK\$M.O/+>|40ZY0OI9G=3GBV?"&!<#?
=47?X0Q1A"UP1?G@-_D\$ZM#.MXUU=/_3-M^V-#7(S+MO<;%ZWJ|U!)&6|
{3AB|}\$T)=|89_7(55WT)&\$R&>H,MY.E7%)MI,INRN;-|&R|,50WRJ&ZFN&&K5I@|3D9|
IQP?-6!'V2:<&J&X9*\$6N7G3'?MJ_3=YM|U?;-Y&Z|T555T:R1A|^06|745XQ2|D+ #NR2E?
4A-*G\$BSM*03%S*_MJ#S><9SCQ^HR>K6#K^/E3/(&R&;KEQ_/Y=(JD.X=)AQ5,-
TM;,-!3E&S>P|T3>U&MRY6-WDQW0;|>K|R^|.8F|+LB-EW&C|;)?C("6WSN|=J-
W>\$3J*5(MA%VV|T-MH6?CV=YY:CRD;5-WI>=K>.-
*>K(17X5\$MJZ\$L)6#M|,AFSP6D:AI|WAT\$XJ6-M_,12EZ_6-7-JAX?
N<*ZELLSI^EKJWRG.T1GY)I--Y81V^66L\$):B=00?/S9^MCRB-^/%Y0>BF4N8-/4TC+
UB-GJ'H|.'SX!@!G4-MV)N:OZ@/XQ7KBN5'?-&:%_3KB|8PV.R+ E|4A_'6F#'-
QEGS@GY|47;#(.:!O(2-W-:E*Q_-#-|.O-;7SS4(7V7V8;2|78KXP4^!;,>
M&')*83FE0E2Y\$)\$E|!%12:9.005K'9|!%4U"N:;!Q<@|=-\$XK502|I-M0"#K)
(^LNXSX"%%;HEHGQX,D5'SHB?*M8@5R"670&|5'VA|DAT1R=Y=ZOU0
M%ZU1<#P80D|JO@3C"/B:QX^|ND(R1|43>J)|M0#KIVM>6"/)UI9QWCJ(L-
MT=6Z05\$;#MB=K.FT,0RE?QQEB-M"";X"K(|UTY_=C|#
|)HG3/GBMF@'Q|Z59.A.U1GL5'=;AZ4|8<%9M>>?)8C-MBSUU9PUU5
1R@)^D:5W.GAJHS83J1D'=OL0ZF0|^I0E56>"ER"GHR!2U%GH
MSJG1QU76;/73EW5F/OQ=Y.JM!*PMFC;J"F8ZE"L-DSH0QPIV6
K_FG8/=D08ZB|'DCDF7/&;:R6R8SC1A;!WHJ-M|P26\$JHM-
LDE2;YG%A3=|VE^DHKX5'7R'!*#%<\$?@*_Z.LHY-S=3;;E*.: '=
M|\$LD@O_&D|U)K;^T&|#"3: +K|CJ\$7+DKHP^IT?;3BH6|S;QTX@X-Y-M3?-
?.B*1|A.!!FV^!"Y8>0>*/E|9?69Y8^QF25@><0|= #K;|!|*PNRKS_""MZ'
\$KG4XL\$?|;,&+%8A'1E3#;,#S+|!3'\$7|.54'|XIJR)4EQ0%,|6BB:O|J
MFU:KYOP=8<@JWTQ7E;,"_F4KYZ_||?7NSW9_O!!AT:L8%+;F-2V3DJ19SRK-M%
(Q:-1Q*W@)3GZ|/Y2P56|4D.'K;18<\$/'C291W2AZ%A&Y)FQ67;G7(9^X|LTH7*\$
M)"2M=,YIT%V4JE;|)E*%#!NZ_D6IHBOYE-"UT7|V7XR0074+26N=|+=+K.#TA:
MZ/SW.9J,AHOF-0Y+|M#U7^RQ|?HC|)W:1UL9IS54UD@;|G-MO"CJ|S;|I^ZYPIF;J|KGG7-
U'2VX3O'B8|7*;B#:SKF=4)(4<7ZS*=@BF7LJ
M,EL|B@S235D9*.):VLZY016BI@3&@V=VN)&ND)JGG7-TAV9"Q/B,R(Q&RSG7
M|5+IU|32=L_M1B3:Y4'R=;6T=F^V?9GFKW1C*FF=<+VM70-B7\$9NEW<1_C1)
M43)#R9B=DE3H6C1*U2,-;(|\$&R&(ETR-M>F9+X1>|'-
G,|EGO>O|DP|ENX'8'@QFQ2';:P.X*UF';EW*1-UL-|!H^"-P-M%""*U%17,9A2XG=T+-JIS3
A"19T;JZ5SQZUR%U)0VN<89|-)09>\$J79^!;5+MCO4HRVAM7Q0CM\$BS)0EK9#=
3=BR;M\$CR@I1:UH=RJBBM1R&66I|RKE22V.7
MRWE\$T4G\$4/*9D\$08'*Y)AA;+E*P0VM@>[FF4,7ZZ*EPLBI3=3"BJGC,5E|:
M:QPV#*L;RLOM8O#UF4|?O983|8.ZV=Q0S9>H|9N@EPW=7?62T|UOH/:A-!B
M7VXLPJ;Z\$+!5")(.0=+|<(0@Z0TB?@=)U|M+B,9OX<.HE;XV8N3F|@\$.05>%
M&#F+?;,\$\$0I-C#S+0P?#3.D(/W1%TP@QG_2P-+N,3|U/AX52\$H?ER|(M625-M(-WH|
|Z@+#+>*\$P-+M%=H2-S8^WBH;<: ^("+/AX%: T|Y0LB&T/B>(>-.SSO
M"^S^|P420Y"Q&/S>K(%S6)?)XZ6FD0X#(<^K0!;|KZ^'DP%#TO!ZP^AX%!MH\$-?
F#+C"Q5JY+PO#U+IM\$H'MRT|:1*>|M9=0,'2'@&E(F|N|DL"S1)\$PYHOH:KC1&
(4V@3\$:RE4&B|GB"IS:LY(@|H,*M9!P;%^(|WOLP/1<&4H<|(97"SHFS1
MT*4X|;CE1:3@WWNP,3SME2M^W|)W|7=|7J%>_"TB!)<N5M1K&X|P6G|P
M+U)450JX):%=2JH%8%M2JH54&M-MZH|:U?
PL=Z|F_53^PT;+*C#94+N2M+:I5"E9"+K4J|&E9?(<JX(E\$V5EPC
M5T_28N_1@X\$:K*&VSOEEQC>D0NQ-BMDA)W3(KZAGJ)PA.O+A6H&&/P)'=JQ;|S\$C2
M1YS-7NX>RLK4H#;|4A4L5<%2%2Q5P5+5@7%" +GT0T|/>%TP4|CHQD9%|P4-O
MRM/)L+X8-=6K16|&'I"20,<:BT3OB2Q&N!P7%99SU.>#7!XY25B-:8@7Y"
M':\$&V|O.Z<-SV#/-|W@&6SH&029-QTX-7|N8Q'SE:'W;|^93;=?=?=_!W_?:M_7UEMO1!?
9I==NHIVNKZH)S00=>2@D-'=5W68KE%RW7=F0D517,7W9F6MIANM(-M&?
X('+F"SC=UG'+.R|U2'-Q*-Y"6WK(CBX.'XUS4%^+|?;UPSFI0OFH<68-V
M=AU#SP6V3LEBB3*V%HZW=6Y.5EN;2;0J57>Q@+>K.\$M\$%)K6&=QE5SW-K/PK
M&Q?YG%#|TJ^P#-)<343#%T7.#N"X45Q!?-GG;?;|""?<%\$MA*=E_-#|
UV|#0YY@ED4'K|_%F2MK"T?;K2G(M#.|7^D-M1WO!+CV/C
O!+@V#71J:XQR\$O-PRBF+.(.BBQ&9CA9X@=F(?DC16J7-M%+B=|J('9\$::B><+@A'<.,?

@:..@E.!X':#T&%R3P349 M7)--9H7N8">-Y1A?\$_+KYB#AR!=K*F#"P!0+7P"Q8;
fJN44SF*!fJ^:.. M;%>?#@P!6<2+>
<178PB<7J&QG:KTQ>:=.&90K?/MVM<fF60S3#??JN!RSD!-@G60fW\$
M)H\$1S%BF(G7*LJ),J29VRK?.J*>E'ZX5;/@C<';-8(*F.,YNL*/-G?[\$Y6 M7Z(_"3U-
^9FN6,H-W]*GD6XYU&9H'?&F8*,-MI@HPTVVF"C;7j6-#V\$2(LfMNRj8*f5S8B8-^X()
(%=:!JfX8LW5S8^&M@5?X-%/E.;D9Ej@.F+'UEB+'?.\$9 M'(N0D17+%j)!6<#@:FKJ: @+:R-
KP+KWP*J XJ="YS!CFN-[3*;'9;#>W^:7K MJ-
8W(=Y2*=IQLM60j:|RG74=!Q'^X7J1|M_>.@DVRVR)%
fHj_ ^/B>=SU.R#)'R44:S6HxE1.W8.+K(M(@/?1+L36WL+#FRGZ2fSL;?
@,|SNQ%2#;|R/,5QQ'^.XI@47 /+9J,E27&, MQ9VQZQj>2KFJ "G3-UJ*CVK&5@B/ZC0\;N?
S-/Y0N|\$W;;S;/JS(.T.3-1N.M4 5j|j?9;*QD;"7A7j_ *O^G\$9N/LT3\ (O*P'Z-4j,
(50fjX':.V=D=%LICS M4AGT;S'fjH1/PD&XN^A>T1, YD4O(#_!R)G8+1\$&R!./fj=B9
M^/(N?TUV-RKM:(fjGj71?R8D^8;3E+.VfXS8/%)NZ;;M^S*Z_ =^;CE+|fLNQ M=%P"1O?
1\$VRBZLBM|Gf%A0*\$KO@&@8#K#-#"Z@CV>- (ZCZ#!'8%@.'YZ!4YEX?;%
_ ^004V#P'AN=GG^!I:.#<'@_ 7+*P\$+ M8GX'@_))f"@KG:X:.F5f WS?L#;!4KP-
O)"PS'R2KYNZ-6&H^65f'V<@|5N
M4&192^V'\$2L6BxBN1!TUG=4X%R8A@R#)8WNP653N: #9#*\$7U(.IC/YPNj+*=
MB6&O(%0TFU'^ <2jN)fNS0"E&5?G.C5j:|<=&<f14j3"QK-W6)f\$#;=<5#f# M:9&C!#3.
(fj6',<.>.(Y!\$Z4'Wf|!GSZFNG6W.0>7MfSEK9Y50W=B!4jWf'0'
M3_QLjJZA4VM7<|T\$|=Z.>JfX, M2/_6?UKKJNAS8:Lj9",WU#UAS8.R&93-/O/Y^H-
Y4X4M,F@309M,FB309LT M49A,1"\$&M+'T9*2):+Y:L0;C-
#?!5Z63QLI2|"WV=2;C%@**I0;%0KXD4#: ME-\$'MY;<6G\$T2;L'V?)^88IG4
*,QB4j:.,j9G/UZ=,03>BH%<%02KH54&O M"Gj57jJRE8<<:%0_E?^PT3):B>\$T4Z34+
f&I/T\$X"6j3&f5)_6U VA+DfUKW M/TVA!U./DfQ)4(R"8M1G/E^?8j39>6K9Bj0I+5-
W4?)0E!ZW"@fDH|"TG:4'j2ZFK,)H\$7)*5DL4<;*N5O^E8V+ M?.\$XH_@UO<&6IZXfA>=V
M!&P;Sj:F@LH, @Z)Y!fPRZ9j|j@^YHGNV(Q_Y M,H=:0*YE2=R!fO_+*
K>fBU2UQ=X@=F(BK,C)G39S"9@^%;;MH)&K 4;@AL; M@N" MD6&DT
2SK!IH3@>,OAA)(+0A?19385_X@_Z92&Af)Vf_0?0O,Y^03 M?DVWfj
5!ZTX:;5!*PY:L5ZW.TH(>U MB%)#5W*!LRB+<90^fREGU3>Y?_E)=I4RLY96
M!)=342+Y9EI;;VH_LHf00Q-V2?)&&"-'=TP>H=\$
M58OQ2QZ_H,4#HC*|2j_ "C;*X.U=JEBF8/fCFjE7S80D^3;97Y^IBT(fLjP;2 M+8; CSC00-
'K2^J=V3L%\$C)+P*>N=^AT:&'H^8TM?;8Pj|;XV\$S:=F!C,*IA M?IS9H8VN>GLI2U?&B;
(GNjJ\$XO4O6WEX_8<_OMfMR<"#SHT3_0SR<9;LI;#
MLfF84A'T(283j)5CH>0M;/7Y^E3.PL'f#%CfKjM&42KVO\$E!XfFXHU+.!K")
MIY8L&:N%&/O-j#>^>1!:&_*P1j|+;?'fI_B9#U60EGTU"TDKGG;=1.EJUDB)
M6F#@_AM9@RK07T;300?5>SF^fMXE)*UUSD>GZ_R I(7.?Y_SLYCQ;ZKY^"JZ
MXXU1C.8fABC^V_:0X;_||27ZDj#3@N5DP470FG-&362!OR>|*!:UZ\$F?|=f5
MSM1V#;^5P'CPs_XWTA52f|1SCNf03(@YGO&9T6@YYSI0*OV:6MKN
MN=V(9;L|2+ZNEM;J4V-JV2N;5+4WE.XO):T3KFj1C/ CF'\$9N5W>Q77FDQ0E
M,Y2,V2E)A>Y!HU0j_E CNXYLDL5f|M/2^G&+V5fG*(OGBXAJW-K 9Hf'LGIF
M2^%/A39S/99fWK_9;/9;N!W!!%'QAVB&WD.'L-/ \$47C! 4L"4f.E<=C"f@C6
MPN8!7fJM"MC*ZDC.IU,D,Lf0919SWNZCIUN^?W(.&HV_HZ/NLSVXA
M_!5UJKN6SAVWRCU+06F?8_f)P5=\$J8Zf124+CG6HRRCM7US@="QIEC_)?
#J6D(f00@_M#W/S:'JX"2>DA_6IEC09THU.X_O*86& MQ/'UCX?:UN0+(O(L_U@TRj
33B!R("3F<>@XP+-P*Y27R_Q%'E,++VO)U?)_M+\${
XZFCE08!!NRA3QOPfjN/-09#f4,_H8"=P|" N:\$O&f50I9F-?2%T?#(M,8Q@_*/T8f114j)971:
#XM%;9Y2)9KYLF^:Vj-(K;fWdVT4@fL7GCH"_'7
MD#+=SN.5!)XEBG!X7PX;PXW&R+T,QNACOS\$"E*QH,7QEZ =X^X9P?8;HT#?L
M3C&3H/1ZO(-)-WCSX@-"^f(MSRQUJCH8M)fZ#HfVXj<\$=?NREX/<;2;9;&!@_M?NXW;;
9H@I*|Vj.R)V09A5JP*#fTFf0U+8<23KXT&>\$,01.491AZ%*<>MSR
M\$AG@<7_fjYfCUDfW%^Q,&&W@_#8/O+@2CM^4-
37)fNjL<>P@M0fSWL+EK4RJA^;H5B%LUFEL^OFSM.:f5FL:DB MNAD.L+!j-
YW;+++7.Y0C"S3"=ECP5;XY7%Y@OYJfB6*&"K 4FOMPj2IP>/&RC MPX+%*9K,(UI?S4Y-
U (#T@L\$NUE*Nf.RW+7E7/22APM^7FV.XMjQ/M^X9?E1 ME!;),(?P
YS_+^>AY\$+;S);M9JE42E3G*NHW&3 fRYPVW-DjI^!ZA-R+P.
MU^RHI58G>UY(>/8_X=ELGR*@[=@f3/16.?WN/G3SO/%\$@4G<0f?>-X-%H@UX
M\$S9@!H9:0_%NX81;G/KHYG"\$A,9F?:3ZYL (-:71AT4/\$<#SB+^92:5KD*!GA
MTLXZXO"ST1+1\$2NOj&fFDK3!BDT#I;WQ!-'EI^9*j2)GXPn#K&CVHjMBKf1

MS3C3;'/KW8G@66),4-(ZY?JLPA?(JQZU5<[YV43+^12EIV2Q(%G)\$10G.<4/
M12[-_WMR&J7IS;)TGXVSY/=(A'?E,G-4"V^TBL_URBNGX15?!9(QU=(.\$:Z'
M=1A_1W@VYXMO_(AH-\$.;>(SUDJRF[DV1\VTW\$Q*<9""&;QG|T*>Q'K"GVG.-
MW@&KO#LLS: 'YW&P|Y">V^749=#A2!8(^K04 @KKRB\LI4#RSN#GA*JUB3W
M#J,T"6=N0_.,*%V%|+9QXD&4-S!@PEN|P(D%J|+@,C\8|<(JW2:177U@.M
MO*!WV333&C 4[*R=VEG|>,UZ"Y:U=2+Z;U%:5+DO? K31R0WG,D:N+K!)MB<
MAJVP8;:5"=@NH45*=>J\$Y|.Q#Q!GOY@8,\$;D, MTH'7|5,%2":R*=>T?
<5%+^"100>J2M!V8&_X.%I2LD0T7Y7A6^CO B_+I>YMR\$Q?:J/6T(RW8&D(CC-
31>4,|>G+F1*35Z*F|)(\$YUA0_X)S+&AX0R(76R@2Q),F-X|A8%.7E
M)KO|#O|Y1>4.FR7C!:\$Y_J?| ^V0|@DD:93E_=KX9A\$0&+.OUKOPR4H8^4WF"
M)ZQ1\8A=T>JFCAR3P8U:8#B<+=[95"H@D(5%*I>*>1|=! "9',4=S)' ^>XHZ
M\$|"ZRW;LK5_)1&)RH,C_5/| #1LOJMMHCW40 MJE4S(U8"@IXIPKX&7K(+S/&
M%Z3X/N,DP>) #1^EEEE/ ^Y7-QH\89FD9%NJ|_F#9OYK(!L7U*'E'&U|*X|.8B
M)=^N4)60>| ?P>9DNUO(6=>^PB7|V|N3;J;G3S%B;\$/:PL#D+V|UR! ?X"26G
M|XC.D&!)L' K-I6Z\$G)|X%/"*7D&|YFI|&2/AE7@%'H7N%JE"2;">E"S"+9*9('"%YBY;5\F4W
M4P6G^V3.N'TDZ:/XMB^_?)UX9|0FN/J"JR|\$1-8'7G,SND)O(*:RH""^8*/15
M8J(C^H*WL.ITSY|)6J5X06*N0+ #/H)H3/Y^((,\$;*LPD.6Z|J'V=J74VFZ|
MRX'L+0ZUMEPP#CTO'&N 0ZTCP9=U82-@JN=+HL|!4SW.0('9DKL|6'L+S3%&
MM0Y#HOH*5U,?2X=5"88!U5&6|.|.8&@!W6|@(\$R+@S?6Z!T5FHP)#|-'D)C M(W
4/WL!U30|"DP+K|X@ @LLC-L,RR<-8#DR\$!(N7 Y?|.XVOA*.I\$=RNL)M M#;,?
#'T'|2A'2T(M@S-5EX(NO4PL+,ZRJO@%*|\$L)RI"CE(Z4?9|TX&8!HO|)XYEZ<% M%0(-@-
DUI:M*|NL7),L!O-J2!P"Y4*@W#\$U,8S/JQ!#%V+H7G,,78@9"Y\$/
M(2+H2!R.BPCJ^,JP\$0G3|R71YTB81T0?2\$|-IPI|RK05H40"K@UWL&3Z7TD)
MHLOZ8|.W.,E^!)>W?T9\$E,OYGR)WZ)E M0>-YQ-"\$DAF-%G)/
(2^#;9R\$O|UT,WYTQ)7<6Y56%! DK?;O&= MM4>*&KBL@YX&BME-D;,\RA*U#!L%B@.
M1FGX%0T;&*S;Z_R_L*>|P678?T1|.TYY.'@^J,A6(@3@APN'.3AZRS. DGA(-J?Y7&:
>0RM9|)OD:D M9&P4Q3E?=-OL^ V,IHG^H)BT"("TJ)_9MP+5M6WR^?L2GJL1 MKB|
(G2*<%|+4WU'VE|PG5R5(!YU|,\$C\$=@P/UX4BY|+U?D8_!KR,\HX=+RZ-MR#!HI_?
AS|4>8|O3>:LS;FT&X31!IA\$3P|*Y10IP@71#-H:%|9 ROMPAW,1&
MJJT3;Y%0_<35J"3+*==0BB@5E0\$ _J)!VPTG(S_(@/ZLT2U4Q8F<%Y5^|6G&5
M&WO79K59=%+MTOA%0.5Q6#D5K=HA0H|7Z|GSLA\$TWM,\$BR\$C2^KW2R/-Y'
MMT7G9I?NYMCK0=;\$M.!+=HP>9)=2K'=Y-YW.:U1N|N8|T""V96VVT&\$>_JO
M#VA!T>@NX-W+Z7F\$=;&#H/D!S% +CM;NXNR|G,)F6V|B|JO9_-SS,MIK'5- M=I@-|J-
?&HN8PR0VO&1LN2LW*DQP:90={I),8,SE@(->LTQ.Q6(' ^3(?EU M+?
44;75|_XUHNZ@L!)8!YF@9G%U| "GOU>Z7U;A*U| |=\$=G\$%6PN"CQ8ALM
MOY/B%HX.>QH*8H>C:%!:.M96>AHO8%?F&:/437F#9=>HVNAPNAI68>3-=/Q%>
M!/5|Y9|'SZR.Z*G V3EO0|7V:_+I>UU+^FR!Q\$T#0=TN.)4>M'^-6=|8FFX MW^!P;;H&?
()F.-NF9,H%5?D6ODF+;'H3=J)_K,&71-UU.|6U9E90(HULX2BQ&7LS'RT\$
MPO9|*O4X\$'8XX0%=6\$6|6V3V<%5;G;Q;N?9PA1H'7V&(-J|L\$Z|P++:7MKL. MXF;|_AUL.
|E>88AM+UP'#H*|?AE%HMPQPZ*+\$9F.%OQ|9R,J,AQC0I<;P|DH M?WF-
'3#>J^GK;89^'<=CB+K- KLB_@6M_Q3G/(O(8_'4I"UP(39#8^|?|G>
M#6G3I7!2,+XKLJK<>37YUY7/U0% X';.1R,/ ^J)0.^&<'SX/?)X(7K@@RC _M;LI?
|ODVQJHC5N9H-7F%HRMZ:UB<4)!Z"*ZS*;B'_ &G6_2(L@+=3#
(J%E#%F#.7/=Q;:L^2*_UG4-|9< M>A\$E8|6-*USXGN%GXN={63X3DGS#J0&6W?'@"&<-!
(ZY"V|J 9H_PZ70P1VM
MTDIUP@=I+&OY@I#>A0(2X'RQ|P,F#\$P)|@60X&7LM9>QM_<#*;G=;=VA@27 M/?
F_NX7:6|R/AL*?>Y0Z5^/|.&I?4C(JOS;"VS\$V3+1NI|->F>\$-. Y&?>^ -MM)
|'8F\$BB%NLTY&|S^K|+LOV/+YH0|CZ@(?V 31\$LO|!E.BUQ:N|?|12,W MV5 UC+(-I|Y@-
OW<'QK2:7!R-8M'8TI&*':.\$S+=;:8!XMUL% @/WF+|B.@#Z;G|GD+W5YF_-3BK5?|/D\$Y)|
F(=2|WBI28@4SD:I(G?(L M<|0#QR%K|BBPE=36R5|TM^:DQQAG-TA1V0?
HGJR_1GX2>IOP04DRR MAF_ITTBW"%Y""|7GY(@W.1HQ6L?G)KQ#.TIE:T?K|?D X;J =
!;DA#N':SM M(=P|&_ ;4,B;'G:DQ1/\$%RR5TBDQDYA|P4105|7+|+Z8V77SHZ&6|0L|^JER
ME&3N" TQ'| -@:NXD00IQC\$3*RY_@ "F@T?X%#*/_70!|C;6/BFIJQ7F+ '2T CQ M"G--5-
8.B&MO_43|1Y1.XG_Y_U!+ P04 " #*.VY9I33|XL<3-0#|A\$ M% &9T;&8R,#
(T,#DS,%|Q,'\$N:'1M|+WK=N)(TC;Z>_HJ P>->Q?CR:.,SO_|.GIZ>GXJ79L6@^?
I&:S^>D9GSGR'CJWZ'CEP>>1 MI;-JY7*R2?X-
G@00U"UQ;.KSWE?!H|:LJ;8JT_:5#E^,|_L:_@;ZKU|'NU MV""4/FF&|!A|=DI
^F5/PB&HAFZ9M#_ M7/90/SF6;-ACTYK*#JPNO\$MJE"MGY9JT(J/_HA?4/PV1#)Z-

J_1JU;*E6I9 MJ@80<>VR,Y_1Y2*.970\$WA)|@WJ4"QZW+2?N^<57*W_@.A9]B%WTYB?
X?CF? MN.>D6FA.H9%;IAXS#!WEDC4WD9B>1V_SL0U5&JYI2N_7_ ^NN_!L_
ML(5HZ4]S?&HE(M>MGABY55IX8[K48M2K7RB3X[U+"UD4[+^!BU
M&*CMKPS!=P['B1N%JN?IN18UYM:*N M/ AB]2#+LTAYPR]6'E8=:TU1K(
*00Z\$7_L:22I7I.:++Q,JJQ<=>V+XRC M%(C+@&'E2I_'H,U^?
+)^^ZGO^'_^+_E,OD*S40"50EHSD9>IB_!LR3>]-R M9)V4B21] @V"KR+2>:-
Y7JF2^SM2+H,1FU)CC ,OW3U1Y_/_;HR#0"94Q[" MX(Z(XOWVZY\$#V/O\$K-FGBR^?
O'^^&9GJG-C.7 ?Y&L.395O[BYX3J3)S/A/V
MP5B>:OK\G/SS3]=T/@^U*;5)ESZ1OCF5#>_#SV0FJVA;STE%,TCE6-*,SP3@
M8IO6.9%=Q_P,*Z-JCP\$E5;-GN@PO-4R#XG?:\SD.B%K>CYJJ4@-&!S_#\$UV4
M\$TWQ9O+L]-\$(_%M.ZW7JF<)4@?%#UP1&_IWK@X:PM4\$LU9Z#C5H8DI;A"
M4>_I[&_!9\OQH)_\W];3;*FHG5O/FEUN3V>Z.:TX)C*C]X_8\$[.AU1*QBW
M;YO.!Q/9HNBOJ5?F= 9N!/,=8"*R\4!1["[GRT?NY3E^Q\$BUGV>:YVAX6M"?
M\4GS;&6VZ/R?JZXU![UQ=-&(F^F-)2OX+O^E(&)O,>&D7*GJEPVM3V>NI4Q@
M@/>6^6#)4[8"T5\%B^:FO=F]MCZH@PM*MLP9K9Z[F\I8 =M"A,\$[4@/+O& M5/"
[RJKE%6J:%,9@CO_!|#S95#+E6#BP41C9]Z(F'EM.?:!|[|%/+|VKM=G>0LA4V_L_=UB
M6K4]3>LD8EJ^\$LG2M&)U\$;_"H O_]/ZN*[IR.E X&,Q!^9WV=)DB%4Z;!Z
ME],5P+U5GL1Q;2704R@523P+UYSK_ ^H.:4K7W2"U#>YB MV) G 7+B*]? MF&/+6|#-
J\$ _J1T3_WC\,R&60T0;V%.=A"2ALOY-N.S&9 +OA"JOQSL%/_LV]1<<40E@U MY-3T7
<3<9A?V+,#T)3B]3\O(VE]C#NO7(UL#;4A9:FC]H>QWVP1US'YE>Q#G_CJQA8N+
MNR[!9RD+TX/?-!5_'X-N)6RD_+ #X:KSVVKHOO['%|\%]JV^?L0@G^V6WW(P M
7*Q'&'P=|00%L-40X_B#)8DO&^"WP,BGU;68K\$VB!2V,&!D6FA&%-0#B^68
M,K^=7H22V^>:0Z?!\ZX+O@]_Q=2_?C4[E^AO]]/PY?+?1R\),U,(-8LNVJ<.B
M"5MC02;3_ BAW1O?N;:BTQE ?'IE6C/34U>^'MHSSWW6T0=T3[U?52#VC(NL
M.=X8B*I-T3TUC:5X1DWHB*5GSS>9UI=/D906J[H8T
:8]/85G(OEB.!+JWYW1OX7TVEC#=#!";[5JD(((L/Z/)]?WTY]XR2+MN>0;ID6Q3% M1,'&
JAR4?VQA9W5(I)J]TML;J(M18?U+ =P_P?6.U MBZ=;BX:03*JFN#S&I6MK!K7M=<;?:5/-
[H/OC^O"-Y]CIN"S.F(B>^3LQBYM[5TN^0;ABN!LDIP]6+ 5);.G0F;W*K.GJFS'-
YK]UUYQ?:5 MT6^8;JE4R]4S@>(DW7ZVL,FY_1Z'!+/V9DS"['K#F(0??6_6@9\D=0B].VHU
M?2NAR^;UAYQBMR5X1]=!!_'SJ,8D8M@: @Z#%L'4',8K@JE9#558645TI#"# M'!?
>;WUO<;! R)L(.=L<(6?L_,3[\$/(JYM>0XCK6.=_) 4.#IS5=-8XRGOG M9\$%6O??P'+?
TWA#/B"15#AL]1^!7DKC,Q+>TOJG['VI20N-[K MLF%?SMO/U%(T+%77%-K'DP=>*33^-
'PR^59.>YBY'S.OSG]/N8V\$H\.(0\$) M(TO02#]V.8Q>Z1FTT.!9S%_H%0&-T C?;T2 MA-
L'VWI:9"3NX(M)9&KK;K?4%HP+C,5I^\$OX/\$V_W!=SZ9]L;^Q*MSR;XFWWZ_63-W
>:FM.\L M8:64QUS)*YKB(\$Y<61M_A)NLC91LV=?76HXA?S+>81Q_]\\$]F:\$]H(#\$.SB M/?
A?D:[5-D)>#Q5J36]-F?/RA9<#]_VYU>%G2W@\$-SB1#79L]!5N<'[^^\$UV
M9.5\$[Z;\R#@[L*_T\$&+6OA'8?/W&)K@'F\8FH0?3;9XO?:&K]#BF[%O"F"+
M]J]Q_+9G]Q[AV'"*_P\3+C?+S,<8.#;?@HY#\$[?0MY_-7PE_(*#\D.\$5?00/%!+FETB/<\$'-
JY; O'X0UE=N#4MN#':_PX_:/ M;/9\R8?
@!U_R(9(K?,F'X,=AY".FV)"_!4_M7H;K46_UZGZ@%6^LN/:RW;L M_L2[Z8]S(3]OH"Q+)W
M.]*K*^C[(:^L(_>HRN,E@M[U7]PWXGAKB=Z/<#^Q5.+7K#9:]?Q30
MX[F_5FN;>K0EB%L IA3=2R[KLQ_)O"NOU=U<+UW4Q"%PF8J!46HIF"S\N)&=TP/.54
M,G.0/Q*2R5OB*+UH]#"2>>7:CCF-ETSOVES_(6_C M2AM_I"VMXO;6^L_ ^ZC
M\#8IUYGG2\:"W,H/8?Q.(7T".D17N&J]/2I0K7'_0G0U^Y5WD1G?\$)K(J1(24Z",NI-8(3%I
M2PQ7]]@*B1\$2P[W\$|2"14B,D!C^)^2:5*MHK.)IL36_<<63XJZ^QOOP]X15\$V\KIOKOWI
M,KNQC#NZ8&4YUOS|^Z 8KHx0'"\$X61\$'1
MY42,#NW1H9=E.\$!>6TB2D*2#91E22G3S*TG"K\N#&!TT-LKU9I&0(2%#N?3H
MM,BRQRM=MNW>>."8BB\Q|\$9JM^XM.J:6A1=;P3=|HSIV,B\$XQ\|J22[O\Q);
M7FY87+WH/97S-L9KLY;0ZV!UL:'9!60(MR]1:B3UT@*I%;2)*BL!E,^M21P62I;=DR8**
<.Q\LCMZ4GEB6TM5-?1I M9/U>UM2.<27/-">X% C+CW'MU;GEB(OPZ-8TL>4>O,^[%?
+AGUIN',(5IS:YI MY60_=FMX"9-<*8+4UY@Y@L7(%-,#N<8A).0!R=A?VF:S6
BC'TFV2;.=@Z8 M*(QOVLQZLW&*,*W9-
:V<[/EO#2]AD@O%;F'*)"Q\X0)DBLG!YLH)CW4,) \EN
M()T(1R@GCE#;.!\$.32;9)AR3'#!1.!A<.,M%T;JPH[FPIPF7R&X&\$V%/, \DV M84]SP\$1A3]-
FUILM[85IS:YIY:._PG;P\$B:Y4.P6IKS S!8U5,*T9M>TKKMKZ=W10AV\
MA\$DN%+N%*2\P\X4+D"DF!YLK_-7,U1/?XQ"%637N>NGY@TINC)4EFF\ S9\$-:LLY?
OFD/9^#,39=2Z\$V3!E_GU!990-0 MM4?
X"/_O/_\NG50^ ^Y]X'_WT949L9Z[#_;;PMO)8GFKZ_/R7(4#>)EWZ1/KF

M5#9^KX^RI<'PS@W3FLKZYZEL/6C&.7Y]M*U0TJ1--9(M;\$(!9UN6=7!6SK&Y*
[56:7X977SO=H;M:S(8MH;MP9=/HXN#CV#00OK>[PP{
M[0%I=:.)^S]7WUK=KVURU;N[ZPP&G5XWE6']NS7XUNE^'?Z)7)]?'5JH5&MO?
G64#*+@YM>_XY\3\$P3*/K3D%N%.*+2Y^8_>?CX@AHZRK5#N_-L%#AK=C
MB^\$CIC>4ZM&%5"G_B\G7\L47!UY%YH^3D6F!/?/Z!&-6j*[/9/_1C(?%[_9,M5H+?
MU_T)TUU)O!CY6=_&6=CIUSV77,X-+>YCXGQQ=_/2WG_[VMR_.R%1!
MQSD6_(Z_J@'E1VHY>+>FSS/'G/D4:L>UGJF?P^-{6KID0/_O%P)V:NGS/IV9
MEN/CH79\$QDC2_9L"B_2S<#XR37TDZ(H)B_&,C&N>UD\^OT3,S)OT)T?=>+\$6
M:QVW6.^3)(SZM/'A2C]ZWNK/VSW;_|\@_?9]KS\DJ]_[@^MHI,>P2TW1!4M&I%JI-
)LZ\$DC\#3!/'KA-JJ%0EL.3)8/;>O;7MY8]Q-97\$'NNPC=E\%"=M"?
YY697GY3F5K3(UCBX&=.9X_F^M4B)(2NB]PNF]H25#Y,-ZZ(<57V,SQ5?/MM.
(;JEO=08>IMT0TG]/XS@)-@%D23RI/6#!;E1K)TVAJ]4U=Y8RR/3<X7]
[_.: =HJJJK38!#'IZ^K\W\$. \$E@J\$!/?!O%TNG"-SZ.3D%B.V; MSDV;7((.O!Z42*=[1P+J9?
Z[&]O&\.T%_!#^UE6'+8@Q!P3:[\$01+;)/;,*
M)G!4HAE\$.3,|M|Q/>A0]ZEC[(J;R*%FXI=Y;CZN+84E6+VK;_SRV\6?)%4:H<732J4IT,CB\$({
M4EEZ9QYX91Q7\&//&H/1C *Z>BB-Y4G+_1RHF29=/:L>[&((F!T9"J8!3:
MZX23I'MO@A72_S]M%C)5N&=V-JHV&9NYE!G;Z6C#_B_M@_ET9.H?T
CG>+9=/Y/\$F\$N?/8U'0,2?)IHR67&.^)S_4E/%\&GS6#9UMKTM^M%
K\+E4'3&I#1R1\$R^C#UQE17TE,I,M\BCK+B7_J!Q7)-S7(/9\$MN@[S29_M7T%?
^#W9#Y8/,|O#VYOLK\T0K'4R"&O\FB*4?Y6\C9"YB)GAQ^C84N
M1(5OP0KBHS.+*I391'E*6-V%33[^X#;Q';!;M@3\$ _<9@NU19R([Z^JDD,C_M
T]2Q^W]L3_NC\PI_U#UIC4"R,#7H_!!/Q]B3\#0["?PUN]-ML#&R,Z)PW
M*T25Y_9Y(LD\$[V2)XU40H\$YP9,>U_|WCR[\^H/8+-/N54QZ_PO^7=\$VRJ"](-M"U-
!BX5KYP_VJ/RL"J3LC%<A0]QO@6Z4%8@I89D1_M;L@|JP0**_)3_LM%(S//\$#_M![1<#2Q-
V+R/&/MW%2\$FYC8;73K5PE?U7#H95UO;#._SRMC*^
ML+MM\$1]^G9.J6;.N@%4/IC4/[*H4\$>ZPIQDW%?H%OF8!LNV2Y\CF)Y-I>FA
M0""2'>D:3)T:Y1ERP92_LAE?>1,.H+?A;.:WJ^V+DO\98T_1XV"7P+6.#%RT
M<51TS6)JL#&&R4)BUZ;L*1B!=UHGHJ0=8A"DI<^1^),&I#\$R,6"&)H8&CYK-
M;)8A&XHFZ^@78CD@/HRG?5794FV"=7^:&K=G6/L@?XR*"8Y%N!D.-^T)A"6+MT/-#
<).%?UY5;Q!:=^?Y\$9(SU\9A_P)](9F&_8UF3Z_JNV@[_CCBV_*'
M62"%Q;UX2.XXAZO:8I/NFH_>*3^I5O*&@3#&Y(MCXFX"/.+C_X:M"2R:A)](&
MT8HDK#15(*ZA>1\DS<1*>%E8PSVA-U;O&(8.T(98F\$|&%%8'Q9-=D&I@;S
M.R+^#_.O1YWNS=%O=1HGI6J=2D0EV#_%PNDC->2Z0MD;+BI5R)/U/AI;)L
M3@A\A\2(JCUZ:/FUZ/[KY6^+C(OG]!"61R'A1_K!EY"53_I^='2Q]J[N]O%_MRT(-OX^&
D16-I);R@QL8*_O&];9R_B3/[<|^\$ND<M;WMTY6V?
R81ZPZK.GC\#M'03'@L*S#=#A/@=QT;CO=KZF;!@;!
MSFSZ]H)Q)&T9W30;M^V'[A]^7YY]/FA9UG;M6O:SQ=VZO&WCD=:K7G?8[[@/?
M;*J'SK8?1AVH%O)-JH0S^M3Z/Q,1@YK_4|@V5+OQY5CV(6=:5PI+?'
(R5QI\K00<^0#BF#TNNVNE>=UBVH_M8E2%K6&X-J!.IVOJ+U&R^;
(V&FQ%7RQKZN#>XYSCH+0!/?PY'Q0^8=.B72|M:ZF4O]("?+-(L^Q;)EGYQ_@Z2X["?
Z3:C.O!X&A4@.S3O_3,PYL^12UF6L_MQA],*5L\L\$U9%?5X)MWG.\[N"F1DKZ
M^915NU,7BF1K9'1-]HOF"0&(E&^8D;ATSCZ3EB'K\$(9NXELY8IR?P7EG=H8/
PN\$(1@P_TX'>44=VT7=R];(U,U_%/M=Y&^9O_(D-
A5A=CE7NSJF1(L&MXEY'7M>+>,A6JHI1E2:9.TMA#61.14^Y\$M)\$O;0+@/U!M^:_T"W]
'B"*9CV4'03"G94^&XY%Z:6ID2-M)W3]R8VL.*8E)\$E(\$D^2E*VA; "_817JZH\$1PG>;-7?
RC9B0_M.R%W/,E=MC)>UW0LLR3R]QG6W%-#,ZV0O_G9\$K+%D6PU,B5;/78:KF-X!VPS*
<4(C3EY_7SV:_M^B,E/PSSR1N9:W@_6YK]PR[!KPKH;UDS%I&^=P'.V,NO>=T(I_-*
<*>+V?C!=MB\WKHPM<=@42R"LCU1G4V6=
S5G7L(3P\|P#P_Iz\$_JDHL%3WIB\EHO@G5%_M_S9J5+7QF&*C0>|Z1&Q6,'8=UZ(-TRB]
(\$*?9]B3GZKXC3:=Z9K7Q_25U4/V_MY%.*.@:QL69=D6T*BSDW7?
@1S[&S.WU>6Q1<,N#35#_DS_,O8Z3LKTF.H"/M56R7UAZP)Z:KJZ_ QRCBF._M!,E]?
E:/T1K";!6U<^L:.(ZHC7MYXBL*2_M3M]^&:-KXMZZRG0Z#
|67_K9>;,M.D;"P8RRWJPK#\%@@%]]\$-L4:(9+U_2/MW^_6
/C7Q6#OV.#%V"XO;P+BS40L=AIU!_4CLD?"/L2"GLAI&#=#;:2!84
MB_2)Q/[NBBR1<.MFHE;-EQLUH:777M((:Q-#JO!."7%*A0)IB@L;\$!![P6
M)V4OLD*>V/KK#>3E)SF@A_1-)Z5&%\9*U_O68/_C#!!VO,*4F=F2;=-WF/##-2UB(4'6"!8
M6\$I?6#>_0Q,"9'M|>DS^|>&-768_J".JZ\Q9LZ89UI6'P?#;N,>.WT:(_5&<M(X+O!>
[B8'R>A<7>7;.#FU31:RUQU@KHB=#)\$_)/_JT3>?S&F>]#S^3)7)

M8S!9X3#Q6>RSQ.=/Q(J'BHC2Z9OQZNGU;'F0+SJ4#-MWK,1F=\$%6ICH8MN"K MH!?
&VV/A=+X9:A9SU>M>M|N#|C5V(1GT;C07P(%K!;N_UV8Y*] MC.Q#!TVAZ=I@>
<%HT6>%SIQEIRBT(O)' +KK&!"K0 +|3%?O6C57|OP?W9HA_ M&FU5H07:|BJQ1-
C')?!M+&WL*SL-#X@Q6_3|^47?E=" OE'9;QD6F8PE?@9Y
MY|&LS^I%DCVY%| =O(>R51D2Y;)2|3VH,\$=[':O,:UK?&ZV"#FQR5\$L'_W%A
MH1%K/EB7|(A+K|]KI-&&.6IQPL;:O_]OYGA=|5[TCXK914ALU/|:A)=3@"M7
MX+JFBH|MB6&KQA6VPMN70D_G2)1X%(4/WT.'PP|C!|*D!(';\$:7Y8A#"| =2U+|MQ-
<&Y/=,*J+ .8M|. *2)=L4GQ2F+D?2MW6GF|*%\$/TKPJN:W! ,*VI:>L%O|U/<6%
MS=5P0UC!' _# :U\$=9?ZOQ:I#,_3DY?KP&NSV0BPI9_\$.|>K/JV\$FV_<|W@B
MK]*H29%7:??@WR2RNT0@^N XNTG#M|H,LS|Z1TXOK,FH;7Y=1KN%M&2C;^#;0
MOZV XHUI7?L\$@Q'V%P.|8A7+SJX.W4M!8/%IS%Q.=A7;@|SE|,5<6\$TXEDMK
MCU1_9IBH?|JO|/=Q.*%Z#I4N=|N*F6*I4S?NT!!|I*DK/=E9W>T%IG6-?
MFB.OI6BA=|? LTFQ8YBO?!6|
)S=6H_4WA'L9R^1_HI;4J_L*J>)#UPZJ0HG)"|JO;YS\$+>-&.6R=MY1|
|^OB<,74H/|_OI+)KHE^\$T!R1XP:76R?ZD\;E5*I\$)#FY@29'%JUHRIK*&&H9-
0RVFO"X@#I%MF^: ^-FNSF?&1T_ :TS)4 MUMNUQ=#ROBQ?L_XR?W H(\$2=
(2R;:2VP-.R|M|<_ :3A)L=AL-VG@R)P7)T"5 MSM@XAJ:##;X*9+NY5\$-Q^F7W+=|\$.
(ET5JHT.0X# .! *47&Y^R90\$KBLETZ: M-
7YQR9\$|.UAXFL|37X*&H"%.\$V;;XV5)*VQMZ|Q9M@H/\$,ZPP2FK^Q"^+C<^MQ-
Q;_S=IBR&W06OG|@%2JX9KA>,|4HZ|E2(\$X@&:A)'C1F0L7\$+Q'LU0Q_Q<2:I5^4,'&"DJ|
<MN7KBC<8*(%EME/B:R#QV\$=0I^LBSU?_Z-
V\$P&.C//!XN9| %H8+&H)&S@|_Q|7TN)>JER M*GIQ"K"^=:H@NFM|K9(!*RU405\$') 1?
GJDT;-<&M6=4|?DD:9KCD9%>R|^M|\$E41?O;#:A|+J_U#KQ=M1
#XTA9ZQ5I8VTH+\$@1F2IM\$UA0EG4XKU?@YSQ|\$US@)FB0C2J:'K3 M:"|1B)ZE6"Z:)|1-
7M'#OWC)55W&(11W7,D1@QXWJ.(TJ=- (NEVY-H@*M>|! M0'?@)L_?H3_J1Q>-4W\$.D2-
RW* T|LIX(P.7/\$JQ|)+G|OTYLG)%"^2&U)H2 MW90-|L^_GU4EZ?/BNH(9MJLQ#6'WN-
\$H447;&|F|6^!O_KLC#=\$*:U2\$N>.(M'#?
@C.H'MI&Y*PPX.;)R18OE6/O\$Q3;=G)2+9>6*>RSY=.*F-76FPEYX6=9
MNSU,R\$%.Y&#GXIK|JR \$ _YV#%"7UN;7?D+7JBUH9|W_K6IN%|Y|8K4*U5&DT
M^/7^4!+4<&Y=6U_|N"LE&KB1A&^0M-|HH1-0-<=@J)P|PVA;-XHJ&M>05 MJT1W#?
_B|JJ"|?%|3XXU0S84"N;/%C=|<^21| %R? =VL: #XB'<-)|UTKTTL D)
MQ^UJ.8!+4=&Y@NB4&J6&:/W/E|?,B3U\$E)4=9A17MW7B|*,P?+RHEK.=
M2_=BTM!=TU#>=|RSP7'U+P?(*2I0=Z|>VQ=0&Z)^3P2'+XWARC4#"TN8;XM7
MW&WJE0%#|EU=(!UNRL|.EIY^%JWY!0U!(|.: MZT"^39#-6(V;JZ?X%?/\$-4.EJ'O*0:N6(
MN.Z;RHT3^\$>U;WQ;^3VU|A/9 MHNN.|(+0.GS*QCYVIWL3Y_5O?)|U.H.N'%>B
M=J;6/@" .6N01Z95(|#0WNT1W@PFR1^R6ZTQ,"ZOA=HEX3F.8T=SLEM/#C5*J
ME"J19Y|7U|]F|)(B| (A|L&>R\$8ANV:9*67LN3S051.M<:4JP!*\|^4#VZ KT
MRR=|ZL+_AYBN8SNR@=)+9!N+,09TYM#IB%JD5@%'5QE|8K75/\$_E=BG-8XB
M_H(F&)I1&?6-TEZKV&9Z)0|08^V9JN6_J&6N9|[*_*87.!)43\$9E8K=*.F5
M=TQRY!;F/J# =P>|,J=3TWC=6U&97"W|.QT?H|AP&85YYM-K|?T0?
<@HL:C2C2I>V_H!H;|C>=2#OB'|\$YC|?'J=4 MV3D,"B'T57_S+6AR?.<!"T
I+ "YW#H4*@\$N.HJ'BE*#[E6PM5=40#;(.OK:F M0F1\$%'FF;
(NK!H_VF/CV//%A0L+|MX# =SO&EK(FH&W0,J6-6&>33|(BN).71W36MAY
M0U,TYZ,P?/QHE8UW_=>U2L#KML_JUI+1UQZ?=[YCM|DN!L8!^C)/U@_Q*!U
MXW*/0Z&5V+ D|!.#K<05;#JR:|!\$+%_W=F!:%%?;;,BASXEBR80/N6&3;(A;B&&:KT
MQD/Y^;VJK%Y-|JCR2P9\$'=X;:3+GWZ*MH:_K(WQE|_+|;#A
MK%@|W^#Y|FYU&+-8&FLD-J\$0 K!" 1K6*LWAA!)94%H"4SWV|603
M27C)@#M\$T64;P'?_J?*WHW5H52H_1PF=_PF3;081^#RK|^I^OXM^65@|^*L;
MX^D\$<%(GX-%%62HO@#59N)7WK: M|F6_W?JMW+H9MOOG1-:Y+D=Z ATF0SZ
MF:P,9T*|.501Y|ZS^/<^*^U^4'^E_=?1I?;|?KON+^8:GB(NV0G+) #:|/K(
ME|'%36=XV|EID|L^N)^#\$NETKP#6H|2&<|7K7K>|@_8U@9|&O=O.=6081K<8
M_KEK=X<#TKL)#6|T>|MW;69|PP_W/?;W^#/.|^WB?<%/GOX->WUR?!;&_|K
MM|VA=3O=-KGK=8??|J0_X09M>|A1I?M_O(0 C|HG3M(8|BE>AE!M9G\$;"N+6%=XPS6
MM5*SPM'!-P%K3F'=C;-6\$I_:NMXLU1L(EVKDR;%5P_F*9J8X)>S7G@D|QAS(-
KHW<>QJQ*"41.B)?> M^"NB!0|P4.M14Z@|_SLJ)O.(#{BY^2&.)|
<+)&H)A!U|4\$DJA4A\$D(DTA&) M6@(16^(B43TM-0-'2@|W|=K|U|'2_D09_|K'O
MU_E!#CT*RYG\$|OW^32GQY'#DFA2E,7_S5GWAWJ;-5M|!PL
M&RH^8/B=4YB(Y;)&MH0F.6"#^83;)")LK2&V1\$5"

MJ/7X8T!U'!6(@_4H'A1"08ALCK5#,UV+-G1'G/>,"1;VB:)DDJ?Y5\JAC.5
M\$V;W^[1.%2RE|.XX(L1R1XP>[211B[A6\IZ63,U'E MSA\$Y?K";1(GF7K';*-6:
(E(1.R6O1RIWU'J@EA>?*'^Z\$"\$SD%M4Q\I319#" MC|*):8VU59!RZ=J:06W\IRIR.-
\$/&UW>\NS3QQ\['=#QY:N^J=#C6.!R@J:C@ MK<%,|2W RS%X8S:JMPI3]@{>JB2";
(\{8/>F"WKK0*50.-7 M*C4DCET'CH*5(F^K7-.9!;!AH/-"EJD)7/B+?9#06*7
[73J,04,6T4^8>A@ MHB4\$G%T;M9ZZ0B!R(M Q%1';!5-"8\$0 I\$;@8C9P-VJ0DM>C,[2V\I(7
E%L M@8BI"M@JZ\$M>(\$J&1,(CN*^8FY226>,*T/3D75BSB@F'(P'0KV=41'RY55-
M)7%K5R^B\^/00.V0.DLQ=R4L.3%EH0D+OI*3A*J5=%I7DA".I*0Q-U@B4A"
M_>A"DDHGM8H0!2\$*.8A"(XG\Q)(R"E*E5*NG5R2;^< NE0V_/8 *5S+\$4%.
M,*^(Y'(^O7R32W\Z"D A4KM?@ZWCNQTkwTW\7RG<;D,0&(CBR2;BTBBXZA MF%-
Z;JH)YRD,U&4S1\$Y?H":1">FA(!:QP/Z]=/TTD\$"J!P#-8GV2\EI5*E2
MJM;\$K3,,J4DT74H.J8W2:95CH'(4/X@,8I;)Y7QZ^2:7\^GEFUS.IY=O M(9||*(\4%-
#F2+D%.,*^(Y'(^O7R32W\Z'#DE M1>Y4@-TQ+&H\1&-I,+ '#F4*6\T,FC.)LR4!?
UN&VG,FU/*RG;OFY+GJ?!(O M06LD/B_?QEYZ(B.^B/@2XKWY50==B,&!Q2")@R7)BH&0
R\$'AY>#)(Z5)"H' M*1;31RS;1XY04UB0GB1QX"-1D%9/N%+6'SF,?PJ5E(V+?
PIQ4I\391*C2Y(H M\0SXZY|=ZYK&HCG#SLUWTSM9+*J2.(9K\$H6>R<.U6N?
*_G&'G\+ "-8ERS^3A M*I4J*78C\$X#E&+!)5'TF#\A&4\1^BDV6UX.,&|.BL-
@08R@3V7B@Y,.#K!D? MB6\:=KX#CD+TOHC+A21Q6Z6;-@>E:|(:Q:OZ2@K>A0?M\Y
M/@9^J%=DDXSY>-I1UIUC)F1CB*(NY3;7:6\JW0X.MJA(QJ"/"
MQ\QJMB2N40WGM\Q=J'==U1SRA\J\$>UTA&*D(QFD25\0F*ACA0+%6%X&B\$(QT
M!").ZU_W9C&D4D5*;Z=\$B\$:Q12.)NV7W)AKUS%U(QU%4*K*9)E7;W(Y
MGUZ^R>5\>ODFE_[T/("I47QB,+K(D,N6S?)/IMOS,U&;^0^H\O=|\@TZ0
MF^>D,)6.;V"UVF&"UZ\W\2-/P-*N^YH?Q,[?:S8\D0 M,VF&;T\#IW:\$+|\@0"Q3UUD-XQ5"
[KK96SIKEQY \$4+>6ZR*R2FUX_E')M#_*=:BURR4@R
MW3?JZ,60%+FD!AUKNX;DIRG>W"8*J(HM#6;7,ZGEVJR M.9]>OLFE/SV./("BI7B\[:&?
V,UY20=-Y\|&SKJJNB.=KGO_ ^ Z:(D?=TS4 MDD1_12YUWGV!?
+4DI=@\:3U6J14Q=A="\$0A%\$EW,DQ *J7228H6Y\$ HA%"&A M2*)7>A)"
<5)J2OSL>@BA*+10)-&/0FAJ)7.I*Q9"HX"/9JS3*YG\$|OW^1R M/KU\D\OY\))-
+OWI<>0!%#?52^|;?3+XUNJWSU_+^F8=[843+D%.,*^(Y'(^
MO7R32W\Z/DD1;XN\|E*V-47L0A&M7>A\:@TFLD77TZEMV3(TX\\$. MOF=
(6J15*QNG530=FZ.+RG\$|:VE5(20Y%9*HPWAO\4H?2\$A_'0U%T)2:"&)
M.J/WUB\U081\$.F\|P%| M3*(*_I.*&M\I)M(Q1\2)H011 ME= MCJC5&\-
G\9\KV(YLH(Y838\|MV>VMU&AF3)3Z>%#9%2\$HA)26FJ"4^I\$S3IC2R)BD5BI9LRL5|>OL
M;W+I3X\C#Z!0Z68@?=6\N^>WO\6\|@|O;;^SD^CGE"?A\$N0\$|XI(+N?3RS>Y
M\]*?D4\2J"KKST6^3HBWDQ^Q.=&82QT*=OU/T;8!LHO7F/L6"G8SC\!K50: M53)?
O\$MS!%ZS@M>HPO7BW6>3I:W.HB4Z;TR+P@(3Q;4L:BASXEBR8>LR0\&L
M_L^UG2DUG)Q"&NU\$-+LF=BFKJD9K..('7N,BHHZ;;!MR-)S)M2Z,J\9:A#I=:RUP!LJN-
Q*S_>FQ;YP'\$L;N8X\TNG0 MO)?A-/#3 F:5:/(K1>"5A1!DZ(*Y;<-;#;E:/5F=N2,HW"Z
M:'MT*W F&L-SSF-GT<|M4(H1)R*V#:4C\]&&@W7;?"SS)VMD'(2(Y%9&HSJ#;
M1L+)BXA4JF6NW:\$0D9R*2\$P-R58Q;/(B1&JE
MTY/3C(F('RK^!/\^3'6.H\6H^0(^4+7'BY\^BHZC?ED;XR^?E^-APUF)E?Q0
MR8^45HR,8>U@AC. 1*R!1\#MN / M'BQ9AY6T'&*.B3.A-O84,E0
"57Q)Y8CD;'ET%@S9\$/1X";@0\|P"V\$?OS:= MA)<,N\$,47;8!>_=?+W\|6H=6I?)SE.3YGS
19Q\|M+SZKN\WN^B7A56\$O\|HQ M,7(-YW4.'EV4J^4%L":+Y,1\ZVN\?-EOMWXKMVZ&
|?XYD?4G>6X'B@*#;8,N MJY+9<";4FT,5<>ZG'/Y>8?
^+RD;X7QUJ\6I_ OM^O^8K\A*>*BK9!<,H!-(\ M\|F5T<=,9WG9NVN2RW^I>#TI8<
RP\J4UG*M>|H\K=';20"?PTZ-UVKEM#^&4P-MA'_NVMTAZ=W+
|VKW\|U;J;_<\$OI/VO\YWA'SCDPZ|=KT^&W\|KP7_=)K!\^ MI-OIMLE=KSO\B!MF
F,O'T/(H\J\TD-C\|SZ<^Q!M%JIC/E#QP!%9\JV;*CV MQW2&|-V0754#K?HF_->25Z*I0>Q_H
(4905_-|L-{Y"M5UW\|N?K=GLK+XW5,G M8!6&^*?
1&O1U;;F%|6=KJJ%=8DK\|F>4\6<+7;^*.%1K0-RK\G3;.DPK>>Y*W MQDE\|'+L'CUZ.32
.R8B/3W,59S*-Z|.1XU\JL)LQ1QWM=&P>.J?Q8*(!B M';-=0*F:%I3" P2>M\$#58?
@BZU\&UB=OG"8B9K*J@>CT_-!X)/J?")/U'N M4T?6# B/EH:9%,X1I*?K\$S\$ADG!GN9Y=
MOLD)WF67G.!==LD)WF67G.!==LFES\OB'LNNI7TL&T,M5I3\1BUN\$6HM#KY5
MS=L&N6"H8*A@J&"H8&@NYBH8FK.Y"H:F7#68:WO#LIURK_'02=EMI_NIHSQPY>IH&
EUK/FEWVV@BP+@)W=#JB5JC_%SM(-MM-X\|S#M=U',=VY\$_-W#
<+GV_ZJ5&DZ/K#OA#5YJ7@?&#|+J(#NBLQU\<&+J M*K5L\WV\ INCNP4\$JOE\$=7-
G5"J;C-S+FMHQKKR#3=%>*U2:E:J N4"Y: ^B

MO%K9&>5!1Y2VWW7DH/#&OM;IM7X7Z.8-W3&WN52EW97XLD-VK4MRJ M95JJC
MZ9H&TK),70=YZ.#!&&H[AQ2+T*4N)S6>I".O%R7Q+Q@QRUIH.J&'+7HID?
W3'G(J'=MVJ7KM6N!0W<,T3/5W67HGZX"JF'\$.TUIZI6OZ+ M6N:Z#2KS:W[2AU]AT=Y(
NWOS0\$E@ORW@NBZ"*Y(<>/)PD(0 [HX>\$SA>0 M/SCD3Q/1^8=.&0E1\$:)R<=%\$Y2^
N6.'B<)>9B*EJ-5/%NL^93QXCT4I&X'6U1 M:I44TDLJ9T*MB)LR;TW;?
NNV3.\$Q"7QO@V\IY822P+K ^J&P7DTK=R1 +D!^ M*)# '7&3;/;H/<+Q5AU'0X@(-
^3X\$9'-MHP%:OE."Q6M\@A058ADT(8)YGG4 M.:L/_6"HBH2G,4E0C9*70LI+,-OONF3 A
M-T)NLB@WF^VY[R&KMI' O!%K54M2-,V# 'D)R"BTYS:REZH2)\$H*604&K;{;} M+ZP-
YQF_HA6"1=V44:3,7PW\$7#5=,%K94U'Q8X_143'=-Z9G\EQ"ZYU=58K
MHDU_!PZY:@;P;O&):1JPH. ?&>_S)41'B,Y2=&H[BPX7S<2D4J6>7D,9(4I" ME):B5-
J9E%+M6%8KU9NG0H2\$"!URV#%MT>J-W<>1UUVT M%@! ?1A? =3K=-
[GK=X;OV]^W[\$GJ0YC3A) M4RM+U7)-\$OT-
EQ:WM"U[_ER=98L%MEG>T%V3EMM"%1G!-7-G5'-11>,2NFD MV10H%RCWAQ-
SNKY1V1GF:7:H6)Z2KY7J4GJM*B(6NC!'XC,#\A.>AMJDPW MD*@VJT(PA&#\$>3B-
J!9YOEP!V"M8BYD)\$:9J71[\$'.I;M407:M<"ANH=IF.KOLNY2EN2|
M1/UP%5(/6;J\$0""=7[0WDD#[]>Q-!B2#_S?9:=2\$ W)#C1P!B;@K<3@!V3A\$) MG2|@?W#
(QUSXMZ7./W3*2(B*\$)6#BTK,'7_2-A'LQ13T6JE\$%H6G0"Z
MM\$=:B*O4^=0Q(KU4)&Y'6Y23F"OYJH>ZCD3:JUH@>6-?EWJJ,9#^5EX3 +?
M2>!,2CFA)+ NL'XHK%?3RAT)D N0'ZJLZ*26M731>Z1CTYHCB:JRCIS6'&5+
M4#;,;1;8C<,N1RFBHE4A ;0*D1A:OR=*FCT3VJ0U-7L7;<<._6!HO4KHZ0B MWEJ8
\$#%F+M\$=LZWS&2!GEK:PRQ%.\$)6"BTKR6RY[YX5\$W(CY":+ M,FP;".\<9?
0G2\$Z"Q%I:SZ'#174PJ5>HU(4I"E#@0I?K.HI1F!S-L7-9,KW&9
M\$%*"BE!,B=9I8W=SE.D6: ?4J1_V-(X4RMS6,!92^&.\$[B1>^0]FB>DEJ9"VK MP%&25-
SME6%RZ=^7(<@)WA6/G.!=LD)WF67G.!=LFESSN.O.Y42A-R"ZW"
M(5F0\$[PK'CG!N^R2\$[S++CG!N^R22Y]W"G=16L!\&5T,?S6;[?]7:|_#8@
M]>YU^YJ!*!.N? ?DTNGBM5#CC,L#(P5H\$%\$>1NT-[D;R#4TUGKH*A.9NK8&C.
MYBH8FK.Y"H;F;*Z"H2G,E:/@1&P)9)A<^F&V("=X5SQR@G?9)2=XEUUR@G?9
M)9<^[SCRNHNV)?!_WV_ (%*0]L]S=Q >NW[\$GJ,YC3A'4RM73KCNYE%/L25! MX<J
[8H]F?8GE&_J34.*;7ZZ4XE_ID-(Q"(JH]>A(L]@]XB+ZDF3)W\$0 M:I'F8CJC>?
+Q(\$HW2Z_MK:EJQ[9=JEZ[%CA3]S -4_U=UEW*\IN7J!^N M0NHA2[2_%2E(
O_"B\$G6WWTM1\$1Y.EA),1:N00F19= +@TAYI(6Y0 MYU/%B.12D;@=;5":43?
Q[3NYU',FU%K1_LN+_+K4Z8V\K-PF 2^D]"WE'(Z M26!=8/U06*^FE3H2(!
<@/U3)7+.6M6S1>Z1CTSJ\FL31736YK<++EJ!LMF\L
ML!N'78Y21\$6K00)H%2(QM'XJE#1I)K:I:VKV[M>.'?K!TDSK-T5)1;RVL "
MBC%WB6R<;YG) CVUM(=9BG"\$K!1:5I+9<=|*R;D1LA-%N5FL^WW/638-A*8 M-
[;CI=)),[U^D)R"BTYS:QE[82)\$H*6/4&K53;;T! ?61A2%<97QB[HSHTB9 MO_B+X?
E745M>:E^KQ/0\$>&=^L?-N;56:V(-OT=..2J+<"[Q2>F?<">3H%F
MO..7\$!TA.DO1J>TL.JFW%:MY;<4:Z1VJ\$*)42%&*KB^I5>H[RQ(?O-D[5,-1JF:
MHB3LYM-QE"@5MWIEF%SZ-V4(==)=MU MA)|&I-
V];E^3J\$KAT<5KU<(9%P%&#I8BH#B*W!S:B^
=G&HZ<>1UUVT'8'_:W6_M_I_\$*D(/4)X]/T1>Y+F-(D3;4L5'HT* M1P= ^4/7ON?
+U5FR6&2?{079>VWWT1"H%JA^'=7-G5'-22>,2B.]?DP"Y;RA M/.9PO539&>9|-
*DX*YU*-9YP7I@C|=Q!/:A4&COZV,JM@3D>4PWL\K5K@:&JAZF8JO?5>QW*
MD_3Z!Q;'F\ P6S&NBDP.YB%[&P+Y8*D'+^!=|S5A5MJ|@-DOH18
M"+\$XG%C\$W\$PH;7+M4P&1RE\$6K&@E7"Q\$+(JDFZH V>F;&K;X!")K\KDX/=
MS2Y;!P?2_EG9;NG8MKN:XOQ=UEW*+-\$EZH>KD'K(E?E)'WZ%
M1;N44B8H>>2_D1UJIG?GEL_O_BO'CH))%0^)Q@L+.03V<8]>+&4\$!4A*@<7
MEN.A_"P<)>H'O)/"=S';T[ND D@76!J4-A?;,JYCVDC@3(M!<@/50U=;68M6_0>ZCJ9V-
AWZP)-/Z1>G21A>E"TI'E#5_QUBZ1;?M\UB@IY;F M,\$OQC9"50LM*,OOMN^? \$A-
P(N0S8A.866 MG&2.=Q\ P9R=,E!"T+ K.9MOYPMJ(DC"N,GY1=|86*?-7
S%731>,5O945/S8 M8W145"?ZA%MU)=^OE[G1YW5BFC3WX%#KEICOEM\HMK=
[^\;"+M[M.K Q>B M(T1G*3I1/?4/NFLR='E M0I'BE=M**B%'"SF*NAZ
OWSH'N2/H[(O(7PY%[X8V8NZC6#S([2)W\$;0*%53 ME(3=?#H_4?
H3_#LRU3F.%O7+!7R@:H\7/_T4G47\96V,OWQ>CH<-9R53Z"<* M_3SAZC!FL3362&Q"
(019A:)*7*4YG% B*]@ (33;FL%;\$;!T@ (5OP,0)_N#! MDG5829019S["?
>_5]C_HG+Q_E='G];G^ ^VZOYAO>(JX:"LDEPQ@\$|BC@'P97=QT
MAK>=FS:Y[+>ZUX,2Z720 -:CM(9SU>M>M[N#JC6!GP:JV\YU:PB_#(PSUVI
M.QR0W@VY:@V^X1@)CO^V]^!_G+XE>OUR?;FW0[W3:YZW6'WP:D#:. 'T:YO

MB=0)+*Z_-Y+"2#|T%#!NIFO+AFI_3< (WPW95?!.C3?I)Z\X5P79^ ^BG+|SP
M^1KGUR.,B:FN^U9U\,LJDY7%[YX* 4LPQ#^ ^UIJO:|@M##Y;4PUM\$5/H;;L4(#^D9E?
XOD,)N?>|O6/,3UXY\$TP&P KR&^.8FT#BL&,-WR@8/N M]4:MP>K^+PAW5S,HF<+?
3VR""8Y5,J SAX6FJ \$7 A^S)[S7VH'7* @6\$_.Q! M?JI"?K:5'_00N!
(2@9ILH*;&%6J*6X1U6DF|+Q=\$1(2%0N2FW|LCO?MVOS7L
M=+^2UM6P\WMGV&D/S@|!E-0TB: A:"1,@R-]=J!CY.GIL,5_S5FACI%O>1NT
M5.6E8U\$|JER|OBQ7KQ^J7\VDU)0X;E8J\,H)7C?K)I?WXQ7B) 6_1F|9^F\$3
MQR06!;PJFDZ)L;"&^#G^ILCVA,PL\U%3090.S1FU9 ?W.!%0CYJC45LX_(*&
MH"\$G_DL7]=5SY48VH;CW;^OUA9L// M.L4?6H;:"O%\1_?
JK,&O;|4!C@H+V|T:YZ0&VQ..0UB.S&)Q0@+?++9TW7R2 M#84BF%B%K#-V=5;5Z\$*<(
PC/QHFJL70MH;Q'D,Z&UYZ8UK7/K-;/J|W+5/F M5|P_) _|HS7F| \$ICL|X^AX;K|I")O-
\$)KT+W%N;5&&K&(S4X6)"=7"R/9.JLVO**3V'R^%\$D4?J_ M9A4ZQL8^("SD&|&97-
*4/8%!L8@1(V/\$ M4"X>#W6K=\$PM:WF VW@ ?-LB<|J1SCF)NNYJ4Z,Y=O3Q>9CIO?
&US_(:QG%Z MA>S>U4RFU|+6\$F.\$2N|PTKN%|G_ *6(|-8G-C1*RV|FLC&
J#1C'"EH&U3 MQV,%-KHFCs1=5
T*H*&J!K,@%H+O'U_LQ&+I:GVB&TYA&//CYL4572U_?Z/ M8E'9IM?
4^|=C!\$SO+WC^|KUFCkTF#@"5?_S&:&">,'9M6%H OJ@WN0(NCT42 MQ?'T?
9,8;\$. "R|,(4>J)*K>ZOVV,,3M'76(5*IB'Q\$.M0@'^,D_7&/0FL1E M9'M Z|)EJY8:-;,\$%)(+""
L89%.) (S|J22YA"/G1+%&E5N^W@P'/O>/Y0_EY M-
PU3#VN8TPJ_ ^H4#2!46P5\$U/N^WC0DA>*70M<+110T<6\C"Q8CW%IW)FDKH
M,Q81TA(QG0FUB,+N(""&T,VX,JFAE1D6'G415'E6N^WICX^VAX|WJV&FES% MEJRA*?
_@CE/SRF5@L76/914LKFN.S:U#>2PA9R M8PM/HXJRMbHC|
6E,; >H2!BWS3'PNH6L|E*G-PZ7; ,4,E3UWZ]? .O/M:M5-Q
M5)LC\$XC|*1.2U<%+HHWIG)O-1);7_+X48@(1R*RGWJA!\$6\$WX#T@"+"D8\$O
M8K1KN?3%GFOHY!W;< WZ_./^OPB,^0N,JU.^Y(/C=@F&EJ'V\$"!+%;C\;C?)
M=W%RQI7>XPYDA<7T?@J:|H_IVM\$%7|NTW:.6"Q=.WUNFZBH.L:CC6D;MVDW
MOL260Z6T|=CC(H_J5\$!=P2N1T+|U9W+EVC T:B46HG,4H<=<|)O3,SA%%I2S M_11;
|550.*H;?\$M0.#+VQ0FMJZ=L'-U-;|3+MQO I=J*"SK.WE.M%;JAPKX M?N^S_7+^W<8#%
(OXHK7@_*Y;S:63!D=*B\$-%1:_JZG*.AA^JZ53GJL*.3*:. M!XN0|D\$2|0-
'!>7"WW;C60OFH-OI&;VJZ_!^2FW|LCG>|O|<&PT_U*6E?# MSN^=8:<|J\$ TB!0U!
(YLZK'C|_*ZE3+"RSAQC=@ <:V?:JMGIGZXVFU)#|;A
MJ(SH+) \$|-.4Y|M4>FBT%F&S1>Y_O|SJ@IF6H|8#U.^ZC2UQMhXL*Nv*(1B+W M=>Y;-
/BJK!/) >0XL|!5+S&.W\$;RT4T;SjG3ZV89A*#_ (ME6G-
CH7BX2?/F<0=GB_TSJ5K:P:U;6I_M4P|-KLYUIZI6OZ+6F;L%F&9)X7#
M'8SRCJHX5P:3&="7QA- MUU9T>C^1K6DANI
4HFHG1HTE<9|HH,9N3(N5WUY|&,NFU8TJPRF:*2Z\$0,09 MJBON*.
U6(MYLH7Y6Y>C.;E&JQJ&17R|5<_ \$6;PU0;3Q26Y2H:V68O5-|SV7
MD[Y1Y|,) >/^ ^ .I_PT5:1FQ8R<|UJ(>1D=7;ODK-,Z|NCN#1-(N".%# MT."!D<:
(O?>T1!W\$VGV^I>B8(X04/0R(.*)JPNPZ5I6>83^-,V ?_ =H=:4 MZ*:
<|Q/RG,93,>%4\$LU7(8Y2%07M&|N<=FS;E0V%JL:WIO\$P!)Y?TU%LB4JL M^E_LM?-
\$CA^X)M%U=7>XOA;U-R#8KY8:%:Z28MS:PMS|IR^*P_UMH")9PB+O M'3:3:.3:IS;?-
N_73V!3&Z6STPSM'0IAR(TP)-&R-4EAJ+.[R|LH;;:07 M)XY|K>?+!W|7_2,9:P:XD&);/?
68(4|)-%'-6;+|";@?7);AIQ9Z=P:9\$Y! M'(A)/JF|A?#:%,Y,ZHB ,YK6E_0\$#3\$=E&VW6P@?
6-:%;!;5OPU>F1-M.@.C M@4DR=+B%%|V/ Y)\$|^/V>\$P5IS=N/RL3V7B@?=?FA/0-
J\$OP/#X0_@M OX'<2:'2<5:G@LGT+&H(&=S0XTA!%|V:O
MOK6Z7|NDTR6LU+75O2;|JF#8[UP-V]?L,^'P|^+PURM)-\$U_EQ-S#U,PU9?7
M0/BN3=A=|ERHG1M7GU4Y;ES-2CS+P-Q_GT2G=>S(-1+7|Y>:H|PN?W\$D;7. M??E:M?
Y-MR%J-V)T8!K!>*:I_-D:KDF
M|5'M'2:M)Y7.FF>BO8R0K%0DJQXA6=6|2%:M5#TJ|S9AH<>1@% "(=\$.M@M.'#
MHK@6;ZJ5&J@5U71'.EW7*_ _@6AW&CSM&'S8B|. '^LPP'T(=UC*I.J^D51JVK
MPUH1/0TA:(&@G42Z|)#D0-' ;+8DU*+YFWFZ!%^!UIYQV*I0FX#"|RL2H"!45# M0?
&").*O|VGEYW0#IB^CBX\$|F^D43|)NG(I_O@?E=NFMEAU22*ESM91?-HF_MV|9&R94V(
8=.KLP%- MJ- Y(J)K|DC3"|"Z,,/Q6!*M^OLX^M|XNTU;B(C>R)\$U YO !0?)|)K2 !NW M"
(U;'QGS'6.WVMD)O|&;P#8GV\$ZBK_|>L)W)^RE|F_L3_#LRU3D.3!|H| (-
M4+7'BY|^BC9.OZP-YY>M+|H,AC&+I;%&8A,*(7PJ%+_)JS2'L,YZQ9S.9&.. M|LPP'2
A6-"QP3+F#Y:LDYELL8RY,Z%@[0J*C6P?R_ |Q(|LR Y=A ?PN.W M!ZS7|/%KTTEXR8 [1-
!5/|Z=/_U|K>C=115*C|'E0|GS#A91^!"|+ZKN|W MN^B7A87?7|T8QR-
|CH'01+JY06P)@LO[[HUM5V^|+=;OY5;-|V_YS(^I,|MMX/J9?1@#+JHK?*&,Z'>'*I8-

NO{G^OL/!%N77^5T>?UN?{J_F&]XBKAH M*R27#& 3R*. @%M^TQG>=F{Y++?
ZEX/2J3303I>A+V"\$BW-VP/R+!KGK= MZW9W@ =^>MU!{9SW<+3/ Z-=ZU,,AC"!W?
M{G"0RD!O>GTR_-:&_KM-CNC MU.UTV^2NUQU^&^#Q)!CLH'T/0{QLJTFM
D\$%.&#L0;16J8SY0P?<_HGIVK*A M@OF@SPJ=.03L';\$GJ Y!Q\D?TQG9=T-
V(3"AZIoT#R%CR6OM52WRD^_C=-TI MF!E,Z=JK5.S\+@6{8W#QR%{3ZEQ1"@X*S-
4;99+4=?O@9/_Y?N3W/@3N&C>49G\SH?V;:<.:D#.
M>>V\$C>)&S:A4&J%U<>2X6N+T7{/\$/T>B M@:,57(I@H7NE&8;Y"(!H"S?"E_-+
(TZL)3\$JZP:U M;?P#U54P46%:X
W(NC,IHXNF:.*#7F+.&F6CR_.#HLL&W@!0QI&.35UGEPV2 M\$P8{7)BA)U@*=EMCC
MX&0\ S\$ML@'24@;DNW@%K8SY0H&J50BN\$9.{]"827Z3,, D:A#63'M+02N=3, MKJ2-
RH\$*)L6^Q@/J34-BAPZB\.)H'3.P(-_AM6B!QYKX?W7UO'9&B.-!G> MU-)UPG0(+9+?
=04ZL\#Q@E;.:?"EO4YF.9N\ M4+00B*#J KC1W+GVHI.{&N M3_I(*E8F& MX0;R'7FR1-
(5,YD+F5NN_J?NU8JLVKB-1;(O*9{ @T7K!8.8: INQ^ 90'AX1C'.A,&+/'N E2"]P:CI*!;IO
NA9*9 M+CL8^&/<{<) 81"MJ?P7+LWKHPA) K)*.OT{ %C?/U815!)E>-
%MHB;!CJGRY\$^M1B5_.0WE2>R*#,*9@\$ M^X=|3&{
K\$Q1SVN&E^9!\$30J>/M8*L\$;LY3X@XE+^_3T=#S6"!TH;;MB'P,O M5L"W8#LR"=X%?
%5^E# #C S474K^\$9/S.HT_-[_?09" N,*8MC<>X\$M;SYI= M'E T%JU{BXZI!?-
DWJ S1Z8A:J^FQ>VH-T/%_>?UE^"_09:MG,6KJ{SC:Y5_Y M&; '*QMG>30?
FZ*)R7)%>I,9"4SX=F7I@ MG6Z&MS?^PP'SNK*MRG^2*Z\0\$NT<^
? !XX% @GG{CO^ ^@H-+V=8 \$BU%P>I/ M\^6L<%9^K%!%6*#R}.@,V-//KM
<3P+8P2BN)+OTA(ND'PNTW:D4QD*% ME:I@32CH\$D^AX8LM%2^LJ:SZ@^=/H*57,-
R'I^0%+)G!"S.LGQ8FX;HA;4@ M\, #3T\$SP)ZZ3'AMU(*@-Z=\$JI3_Q1YKX08NV+
S="7Z\,'505<,RO\Y)BTV M1""OSYE+"<;9Q*3LPO;#+ "ZQ :1"=S MPG.CO
M:>&RPY+97E2Z\$ L\$-VJL1!#P!=A&, E+4V!O ;SM)&W@-[%5B\ M(C;SL\$N*2'X'1K%;2-
YHU,)J#[W=WK?X?:#8'G:_ =SDWGM4=DM;55>|H=XC- M-NJ
[MYVK3CNK.;8M+&G]1=#M&T%P\U%;1@EHA'6,MA(1YB0E8Y M/4U1,+2+^R4_P?
RL#!XYEF_Q6#J:VYC\$P/JR?>5G1Q;LJTLAP0?8YX"\R5/ M!KS-=D?
@Z6@RQIWH08\$U5H+G@_XVQ'RJO9:>6D4CJH-L^:E<;9'F.{=>\$*;F4+ M1DY"8RV2=(UJ)?
Q%;K01+L28PFKVT""K(##AT(0/R?7"]CIV>^LBHW0%3C8(MGK\$B@@"-
Q9UYJIA6!@5RQ7YC!MMB/C+&<J.%.HH?9N206#!C*K"2:'AE M/C!QY4EG=4A@%IRGE
S1;W07X (+@6>]SJ_P[\$=\$ANOWVGH+*4G%&NR9.0F M#R*_%^]GJ-N5;\$2,[AW).O;{
FE&"?W M(8(S7"JPO@1_F)50\B8ACF(_A2_L*BD_8H\ C.JR=D(O
M.R8AU4@>9,WPV6\ "%P. V^ ("M?7F\$F&>NNXKB>&B4P,S-D: ^20@&&TAJ_R
MEB1&!JD,T=\$"#?,7K U'T?"XN=B=1{H @_@J-3V3Y05/L#XXX(NLEI,UO,DW0
1H@BN!BCEYBT M;7LD6NUP0@^L^E3^00E=65QY MN;B^3F;WS;
*"TQ;FK,2UY!Q&I^D)ELD\73.(88-^" 3\$)#I ^:;#JDPJ MNX)FS,^M167OX/TS=Z1K8-
_4DE_H\$4/G.5J4-PFJ9>,8 654R(_^"1U_8 MMU!ZLQ"[K.);:&^D"#:7#Z!R4]<(NO1<^?
!(,#!0C2L/Q(I*\$1;:;(Q:L ML^R\^<3{ \$F_ GP2QP2{;(YLW\$<' \$X.%+?YV.Q8=N!;6&J@4>
\$0P/?JFD\ M:Y&HY5<<(.AG" V/AK*0G9EK@7=AH TQIBN]PC-"KQ>HD<*&FA%4-("Z'-;
M8R_':ZLU*B&YBF^J3I>@F3S{KVU^+MJK_SBCW,?(27%EL*;(XSTX&7('K# MJ%]?
W*FLHF/"H<1ALP']#=#M?'&T_VL/JXXS-6DCFKZ,AR%.JPGU/IE_)CC4D
M2:K43JMGC6JE(J5K'0/W/33J(AG\$J6#6I=#8S\LU@M%L9.LI) W*XX\$N(+189&(- M{?W-
U:(HZL,B?|\$2&O 2 G|=2FK AQ^/V8MQ<*Q21)^09/J1K_{?L92)N;3? MBW'#AV L-#
>:/<5P]"Q5\F*.AR@L52?C.O+HBW0+WR/8;&+BG5>F-JD=@VW M>H;!X+5J3+N"?-)
(R{9#9V1JJE3W7*F%*X;*GZE\YN)02\&P]W^N^L"T]M.\$ M&HN-Y\#_@"AK:@?
>\$R[F!_OC6KT=K*?T\$=04OGT\#_XPJ#Q.5'ZP*(,] N[M MGRPF#!Y;=?4%N-
)J3MWR//37"N'N3-JJ^!^?^7E*:.1UAT'+5F+.802@ P MRPN/U3\N;/'<4T'MF^WYOS1N1+
f'U_BX@("W^>[G.&PO\(_^8\2.#3_98PT9 M^IW5)/EL+84U2\@J9'R*6YUE5=."<_)
<_)RK5C)8\$ N8"/+;RVK!)1=&=8;C;Q M/!E<9< 3H,N: ^_ [.0ELALY;8!2..ZL\@3Z#SP-
WPU2;S3+S S.:4AD]?9B^JQ =#1? MW8>Q6&@\$R%<<5LGQJ*GH<2TK2_UJ3PR"MK5?
7CIXI4C51-Q/!7J:JPA M99NM+&KR-&(I2('B1B>K.HG%^.*\$9V;:L((!3%F1S@*+3
%;B!=6PQKH4:JP MTG%JS*,KB2%&,#VT@,Q%U@1KP14K?O&R5_#J>?CA{&UI!6Q!+*
NJJ<)<M:!'!;!
(L%E^1=HJGGOZ&0\$1W'IZ7E{5F\0\B>1&&FXM40^J5J'E\$F=I:+00W1F*_0{FSJG.
MTNRS17YJLS*47&#G7EAK:DJP<&D8 !L3POB%|?D^O41! 5U-841Q\|
(KP%MLVP31HV\$MJ%O_:RS#JY=*_\$U_7@JJC<3#F
MBY,\$WLD!M(UK*M/S*R: ^IO)7:H:@J4[W+Q):2[W#"O%#9X8\ M+ #\@1==PJN7
M3X=K{5};+ \$KM(2=PS8Q\#-,,Y?X.NA3OZGV\YP4=4-8=J M33YHQ_2X%'RDR):*^UG6

17WH7^'S@S\$U[*7T{(!?C#HK/4&_#;KH*UH/AP35"C8G, #. M>Z_?'\$L#1X^B:7@0>R.
(X?TB^KRLG?[%QJ)B:6>/#LM"W|+;26BKK*L1V
M'U=4BS)E("%;&&P\$GK>.X&"|>)L{)}7,DE*?|&L%ZI,^0\$<_@?9*^4-8D0T M'&\$}B-
ZA077@^,U'RQY-L&C3)AL6CKM08Z0I:+&WMD^4#2W|')E3H(S(/@D
M.IZ&P|JZ@MIA|O#M:-"@2#X6>S08,-!1NM#T^8QH/L;8-KDZC:50!{4(B9-M&[.(?"?
F\$WO,8&=Y2{[W7\$(18,6M.&87G"8+E84S#^MX-
O'@'Q0=N:5/D*>+&#H7TJRZY)ZXJY/UV MUBSND->75MZ1'YJOSYRKD5
MO@EZ1YP/S;5T&^C:7[X&M#3X-2I=E@58H#N\$O+BPTP/L&RY<4>*?F%01%?ZW"?&4!
M?1D8W")P#=#T{CD'/%BK.EQ|P-\$!+Q-66F"L)1_6Z^94EH,O"5/K/|^YUVL^
M5)JQXHR7-:1GRHE=WWT{B-3,?IV:N;|&]*V(L6CV/%|;X|4TEE#W>GD=#+:M@:;
|.703Y?&LL&|&YYA'B=|J=KM|-G6RW+9FE2CHY'3I,\$U0747D7")6
MR!"-0A7;\$C^+P8%I|.7NXU, _5J6J| M5.*I#IC&37.NZIC:\$7YVYZH6?
A9:.9PO39)MB*PV.IY1&#^!T\$VP(|#S"K6: M\$57O/2>VH-
|%29EP2:-=A.;P>N|!=0&LK;|?}3,-KH1-^2IM#B0F'@M0P6/S
M'XPB|M3>|!0(_G_8V"M,*YB";GVJZH@8[SE62X!7H+OV;NAN72I#%:API*NA0'TO:B@4#H
A>)I MH7JM-X-X3Z-J!B9)^AX.L^/?ZOY^)Z,;WB|G%:K7S(IH9P2(0B?F!WG!_E:Z M8,B1*
<GH9=5WSSGH08GQYX%UTK, +QI<?*T(K@;@|T!X? U_-7'ABTM^TJG MF96Y5)+^?
S6*OSJ*M|)BH:F1NOU\$|1ZB^*#9K%&|RBB>%8S.B"SN)XIW4\$E3 MFOWE 'V-
XQ7"|:SH>4;=W|QO*6<=)93)4J#XR6R47H|,D|>VT8YPL9JATKB
M3TY7%)UGY7(IVR(!P)6(NKM'IP.EW:J5M/),5Q1VKWF+:Y^PNT/87509)9JN
M*.S.N5CW/#ND=-C=;BNM_G+>7(W>54/OK,N#SS9!2H?>K8'2S;S&7!+T+I'A
ML:O@R+K!JUB697FHY)%,TSUEYH#FO)NC;|?*LG0H=RL9@V<)<CBW"=9 M\$=BJ2=7#
(R1*6V_M|/QJ)#I\$),KAQCE1|6?;,67EQF"MMP5D4)PXJ!CG+R?&YL364U&)TF!L
M1SFIPPW5QMB<*/2/=MR8&SW1.GVEFL:U!A;,(8S-B?RVRLEC.X"QS59Y;5;J
M|C_!O^(*^2|T!3ZST6H5RT40>MAFHKO,(Z=B|V%_@511FV2+&FKH@!5.N?
4_T#5#PA!^--M6-N(!OO=@(\$=-%'-9-|9|)^=2^P"KYC8'M%G@ W,Q5H0:NK" M%3-
(59X-974%*)220V;JHB6\$,>>?1RT@A-P278OH:60:LTT5T"Z|D8%NLT
MF8|'%^LYV6!7@/RQZH41&6#Q\$2Q"|OGR3 %8!|TJPE?U1#>E1(HZC8EJ|PS MS7-T?
^9Z2#=#NJDD8 IW*YB.*V;:0>QOSX^#;<)JQ2'*.!R@!2"
<((^A7CSTD&NP/3FUCL<|2RDD(Z)X8B\$FJZYMx>1!,R;Y%"X:X3M7/_T M5-
_E|:%6^5,_LC&0?_A5T9NUWFZ V|-M=^&O8[13:F350JPED M_ ^*6#OPKL86JJ|&F|)#%ML
P&C(\$E7;SRFFB9A-;>GZ|5'K"F|HE^ON,*E=3S MZOE|5?|K.V'W4U\$|\$|(YI6M'|?
S:6<4U|RLEJHHK6|I'Y|H"^W**BN[7N686T5^'5#X| MMNM&3:I%-UK2QE1/6""-1-T%-
(!SX58EHMM\$TH8R27=A"LZ.*"ULZKRKR"&
MK,S^!#&TVL>=5GVTJT1'AF|,T\$@6"00E=%4R#7(\$Q\$=X7GS;4C(J|E;#-'F M-8F&R-
@PZ#13V.T4S&I|?H9-MO9XC2|^\$G<_FIKW@7/8<<>^BML4?%L&(-+PPGNX>|:)<H,N?
U|SSV|<#O|*6 M|{COZ, S+|L^P17_YB8|MX9L<2Z.M<\$^;ERH7%(J_L|JHNXWGR+
|/FS/>[0S MR5XZ;-F*/N \$|=L/L+!L-.P_6=I@3;J_-"/H6.|S\$S|{R6+F>W1L@<#M!?!+X_@ M
(Z^0:{"2|8;B|^+\$|V#*3L,("5|K=NP16JNE,)YS_J37(_?,-I\$@'!=4,FM#A+R"?@:W;;5?
PMD^B,X5U/XIZP"^WHLM,=<%()+;1 M1DS;,(LE(^<*PS3NU':|8PPC8>|PT
E<|YBKCB5R# *E0^P3#3 MW"F)|DFP MIWAC>Q\$F0#V9+J|V/>(**9O?P"F8O(
M!|)I">))|1Y84HRI\$7,"U)X'22^DYJK208U,; 5F);C-#1*2N#=#E6,,#^|, M9:'95=
*AL!X!X1|-0D2XHX"W M9+L I4XW_5?8=6?3:Z:?!+ -9.|3F+57JL
M9:'|58L==I<6*Z0"19G#@#@S)BAE8DP)0|QJ #H/LT> 00\$7;#!:BTX1:D|F
M4X7>570YA;UVQ,N48W!L3XXI%"Y?"@/90B|S#74<9(HM#2B&B3|"6"@#WH"I
MN):\$|1>XO|PIA|GV6=-#G1US"4#;NP UVKHWP)0E2>H&/PE^*7&AW6|UNKU>
MM|T?@MXW+)1+!|NL"|"I,*U!7!.0U*1,,9#>|R8E#H(F@62"J@PI!W.A_(AL
M,9%K@|{CZ15-X<_F#PQ|C3.&KL#9NRJE3+|D\$=H9P0
MRAJ<<@MS4AB&6CSZ"COJW@M"2^22P1>Z@7EA(GL'V,4"5XB9-YP2UC#I98R;
MTY";"|+?(43PW\$|F=P"P_T)"S% 2<1^;A/@:;9(+ (W8\$JR-TB=%R@UZ08|- MXSNHI
3R858' |#544NJPO5);REH7,A%A+?I|@V?-(!;S/7V'1E=!PU_ |,FT M)=G!VUUOE| BQ)@D<
04UCFA&-ZBHBD|9NBKX)XP#%1MFH1I^(98H#Q+F!D
MN>UAQA9@6Q8"CX.M!=,|N3Y2'!*\$|!|@D0^)- E'?XR=M)Z4L/Q'QKGNDLC
M1G,K|3J>_TZ|3T-4|DE|(-F1>)W(\$;3V)\$Z1>PZBHQ9+Y
M'K'\$&&L!.2MR/X/DGDJ\$7|J2VTUYRR"F+87A%LL.% Y4#! |HB/+)=)F@|K(4
MMVV(W<9%@\$RD-N(*&TZ<9TF|&:-D7JD M_->D;KB'8)ZF+V\$S\$7%>X'N@>2GD6V|
<57-9,N:9 YC_QR:LR!9R)U27XL;X(| M|C%, -KHQ=)HI-
J)&5&T3'R3X<3R'L\$,N>K_ \$CHIWN(@UX))X5Q0S|)%K|\$!W

MK7"CH'^3"UN/AIMPR0MRIL?SEDN@N4/^>U4MALF!X:CZAR%'VY.=A*.%HJ7-M(O!;M
-D'#!?7] &,Q>|_97/Y_@/ PV)3X%UA*"=18PSBB/0'0(4EY%J\$5SY MF:F:8P,F6/9,,
[=D\$"!0'WP(!!#4E!GKB4 <^0)8?&9&:GZ+=C&TY.>JJ# MZSYX)8?K[Y2X(1E,-
#Y%EW#X_4(@1NPY<2|I+Q 1?%S4MT7C:6Y)X\$GA;WA MYME9@=7JAJ:X-"9;")(A28-4
4?^28E4LV1,*H-+Q0T4B:'XJXCH&W5Y97-M1VJ4%=U)S!!8L"Q
HE7RD!!L":WS4L"4!|2G099N024M.+QH"IA;U*,-4_: MK5ZS/3SIM)I#)L6*,9&\$;
<5["18/HNOOXJR#2^-=2;)K\|PQKETL^E=T+(-,@3V&"W>\$ \$MO""3]&&XFP9-M3G&F?
N<)>6RC8GYB)CFXNY0)EBQHDQ4AZR011B#NY&"4/@1>)|\$B"\$Q>|!<25#H\$;NN%2
M0!/?O<"-0(WLEY/+13@!/*<=4*[PL2IM#5^-BY!=<(<=1F.C^|RB?T)C8-N(EIH
M"5'XU|>"T|%U^=8<0|^:R'&';Q3AN00 ^"88G2K:K:;Z))?5C'%84&
(,BYG<:Z+Q=^+F^VH&AB6B\$ A#B=|HX1/|'-M|,*XEC1.UT?)B6M+9QQ0%F<+KCI1?D-
+,Z5Y8!;6>='=VG|,?^W8#P;AK%-4Z00\('NB\$6%M?CP1;B#G%-J0?Q5@N+%YS))V)?
M!APBY+X_FTR|E9(2OZ*/0<4;JTZ> E8K2,6ZHF2P|(>@,>["#9/I)K M*%%Y =:) _AND-
\$,W5'L,1*!%2H*HG>&E%Y",8(2).TMG\$YF;Q%(2C&0AC4Y% MK&N\2)Y8+#X>Q0MD7
EOG9.\$ {4+QO^2@H
M39M"@I1'0H)%'A/*3#2F#+91J71&VQDQ2THR8;%C7P!&G&'(@,BPO<7Q2A%-M+0\$JK
*B"0_39B*JM?3FF",RQ((-F7L4|(&EH|((VXV4+E\$.@:QFM/F5-'M
MN6%):1)I8TJ.F+:\$JV*+XK!+\$|B2Q\$#(L2"*7#Q!TH8=4-J4(%J"D.
M\$:8/-8|>)*21*43TCPB58)I8%V(6WK_-"I8"?+U*H""#+=SH#*Z6Q4R.D4J M!0%7
&W3@? \$|GR&KAG,R%DH4:D3#W0I4H_M@&\$%".1PDS^HH?+18.<8AY'E
M'T2\$9>U5\$=#GE\$DCM&!CDAASW|NF_0RZ'YPN>/HY0YPE(C-BN0W-\$<1#<M_(-
|Q#2R05FS*+|=*/3Y0|BGU*XQ!1I'Y-D70CS8P?\$6_@QSB0A&Z0@/1?M4(!=5*6)S80%2
SIRPQ-N7 Q,>R@-=%EL.P\$V9R^#/EU!K-RZL^#F4,%ZP:F MQ1PPPT*S26:(P>HWO+3!
M/M#7|"=):>)*(>A%VE#ZH-JF\$%)!4TD:%JQ=0V?*H\$Q&#H0N/%UQZ).G\$8 ME-
7W/'QG2HELMNJA1B')|(-K!|K+QVAMP'HGIJC^A0^\$&@,MGWQ'D7WF.;3R
MAH9%E*86Q\$17900>EZ_HF8="T53^@SL: M%7"TZ0WL
""|Q7;R:2H\$B!9.9,7BF*)RVB3Y;!!HDH<3O2!./GFW#<\$B%#*,M
6/U2F|(%5B)#5F,.^&0)1U;L;-THKYH4_W!)PJL&XJ)5%8S.2HS#(6*XHN2?MM'2IR0A;'+
|V/(IQA F/:OPTH_J?H'"'+C#S|G:Q"S)@)7(>)8Y-;#?!+QBZ% M=S%6-R?JJNL5:
Y.E514Y4HJ1"H>O+F0OYV;0O=WE-I*V>N(H);0F^Q9Z1WJM9H\9"TG9E[3K-(<=R|7*
M15R%G!7R1[3/HY_>21 2:J\$C9VTL!PO7^V6+MG4^3+%M.SLM7O+XE)XZX5&|_Q?
G)Q"9H/MBUIGG4>|T#4HC./3N_C|UPP;|H=?QD)Y_#^J!_YZ\|L-O0\$M0XMYFVC|I)-
KF5D|H0=RN,I#HEYN(U7KT4KSHU
M7M5X5?.K&J_V!|*|*RZ|*.)I:&3WR0*9K'O;V#GNZ&GA|/%T-O#V>KGC@E:@A
M>K.KL'9G^~H-T9;.P\$XUP;36A|D0J^+R&*;2>UEL.Z=%;\$ZRX;,:QP->B22;+
|;K;E@VLZVTVL5U*|ZT3RK6PK@FBI-H MM,MW.&E,MHLIJH
MKK33*.DTS6H"N(|\$V""|J3#*ZFM"S|E64?\$W)JANRHJ|2.UF^1568:"HA5E46
MB7.:3N7;504B<;=;G#RMD;C\$2+Q>^ZYR('B4LU77F0.*MM\4J|I4A.W"LQ M\$I?
(B*E:...MCZH*:/4G<'XSN#%+54+I>.9?%\$0_9KEGS5D0I^=7::|JA:UDM
MPY|O)5W@O48L/Z*:XA*F8&BC6(?X_M,-4UY.71DZ7|)(9-O4?=?,?E,9YTZJB M1|/"/-/?
BE&V>YKI=I70"L)#33-M|7;VC&9*9)/6@;548\$T6-JF6"9H?5MA#/O?LG("'
<1)GMA.ID^9@E%|O&WK63 M?GE4@DHFTU295KHY^3;/B0ANG5:&)ZV:5FI:*8A684|7
V^/IZN!M|?3%0~|JDF5(N5M5\$4A-)C\$AR+NZL+"ZT\$R)I-7K-FDAJ(BD#D>3<
MU%E9;&A'DF2X;^I6B6S\$JKFO/U8B!;IF6P';VJ3\$|+IL2^+2"^SS.DNM)I-2
MD,DF16=W1B:=^I) 32:E()--RM#NB\$Q:C6YM*|9D4@8RZ6U2F'9GTF2P;WY'
M:2W^!/^*KN: T\$WCTY^"?].5MZS^IAO,OU?3Y5ZZZOKA@?6V;MAK80_YMN5-
|J|D_ZW9-^J|OJMP;M_G+7^LQ32!W".F<0H|K_^JYG3!;))8_G-M.,7%,UH|BRW?A5,2S>UV
9)=;9A^-2P=-OAKIT^KN)MR=F;YJJU8+X+T^&
MMN\RPYK|'OX#!.AQ9V8@\$3,/I_@B3W0B=D39M!##|SUZ-RH7M9,*2+C|N<M|J:
|+X1=@+RISN.8|#@Z%18+=!OMD6*JE&:H9/9/(/?2F>K%IX*%X.1CU83'M.7.G'!|&?
L(TU>/WM@/GHK/Q@IXR^0,WJ:37^+|<6,2#X2UP?!LFPOO5CX8W MI0?
E+F'G.O:RD00'GV#B:'98YNCV P-T&=V>L3M|CF%JXQ2_&+:QR;;X|(E M_\$8!M\$9"-
V"ML%(8U."16"P-1U6)XTX-|JB.-ET@%Z0UP6)PZ;&|SV*(B><&
MB_7GMC@0SU\$M=P|G8&D+@H?8\$6P&?XWF@9|42YPQ@XE,0QT;IC@6_T?CDW#
M=#BG7W=(,01H=PBF:|QTY3L-OP,^|2"SVD9&PI9B=_B7^0IXK<=(+OYGOK
M/'N^|N38|<':^HBP|FWVC>V=&8I@9.6-VL8ZGOVZR_N*7|H-MA9"_Q?|ZEV&
|U7HOCO2;I>KX-&U2F'X9PZ"B!/O0?G^P%'\$?D=R|Z; %)#F M50T><W\$&?@F"WF)G
Q\$!82S JH*,"0/|J;Z"|(C171@<+>1/L8UO+Q;Q)LG

MGWL:A"]7(M,*3)\$'4A/24X343A+2A6#]-I #2A)@JVEZTDQ?E^(/B"N@QI"JM[#&L
(\$X<2",E@4&B#6#9M-\$-6>NG*3XJ!:(R)|">=S#L+6<-W#_H"!KV\$.L"WW7M2
MB0*Q'(P(8@Z60#.!JC-733C'B6//<\$30?QP,1"&I*J#1Q&87VT\$&I^(O^"0W MI8!WY\$:
\$UHU,ZN9V9XQLTXF,PL)!DSN*9#{O65, \$0@Y*6&FZTF\$|WY5D0Y
M#79'MHBD0Z":!1HDL"/UGMZ@R0?O@1L|DIKLST0),*,:=|+2#|EM8EJ1&T M;T;
(&)4SQJMWJ1)AP?N@WPD,)N6&0:M*,*'8'F'0"IV'-D :3Q2WU_C)S% ML(3+!..D^:L8I323-
<#1_AM?*D8>1/:8N N9/3TB#+|/%E9"EY3&/9!P%-GMH^019LL::SBZ<8D#E"%KTW1I-
)4=TJ_TA_13|-'\$7|36\$Q/11_M5%"9%3.-!6&0 1|_?Q^KB[P2WAR/G?
L\8,|=NTC0J6(==4:3PBE-VH2". M>KZ#TDE|2W@)|_MD3 H,#'<:&O6V|Z"@Y.'4*V=.
(J@DBJ04C&:G81L|M"R-
M'|_R'X3|H_IQ@/33(#=WX^N/W_X1|85N>Q.E=^0WY:~0A|58JS+;U|7F*12
MG&@8#GCS^?&'F_/1/XY'G^|,;X"; MFX_JP@V\OYA 8?'8S0I_W|X|WX7|C M6|1#2TP9
8,V(/XA%V0 E#WC)6G_X2V_1U*JHK|0A),@;A |@&J@\$=!1*"#V M|>#+
#+!U:'8@I8INO/YR:/O(2/W#0ML.+Q<=W7A--JRE73FP+^6:Y&?DC|
M"UW3DE>E19QB+1#3Z*@.3 M>T6)|S"IGC@|CW^UXYA.|?PMJW?<(&(*I)4AH\$?
DRT\$H?^2NYABD+P6._TYG M<-(>=#N#5J_3'/1>S_&?
IM+T*B0CWS|#DT8%^G32|!"FZ@_JDQQ)10^5QS1|M11H/*)2>H-Z&V-
I(QWN)T%UHF2CX|1/_,>>6&R\$^>;|H&U(UT9EP@7F 5,I)Y;
M0+:F(#|=PQ2@W:BBLX=81H,J05+@\$Y;|B|S,X?=D=^~SX<0NAWGA:W,1G!/J
M9G12.\$IX-,(!3W?K2?>#1QP^A1EP.?(('I<<@L|;LN'QVDS U:|!4LLQF6@E?
PBV+%D:IN@!|@2EJ2\$>I+M%!)YW&E< M#R@>#A(-M+M.<)P)+1IA->U8UOPMU:>4-
|J|=&B;()Q3,XHV2 1*("XM= MV@^"!)"|%,)OBG<98/#"R5'8ZQN3&64BM!5I/NR&J
3/|2U%QEA|V'SW*[N8 MH1H@Y3U@NGB,C(G@S8^&JYDV1=S>
(I:V@:GC>L@ULO0&2HF8,\$X<.#(DFS_'BPS:XHR6H^)\$TCY MN+,A&#G@%T',,>XD!;
|AFZH#@PO|1RR3+|/+52HKP#TK?K(&\$#+L->4|0D|0 M7K".D#W#3!-
#>!5L5ZI(-ISB'ZKIVL'V75198!|+!TZY0%,UXQ!SI@C5-'4
M,8|V"RLGH|^826XF'D8A@)H/>60| K;@%,P,T\$'8|H!:O'UROV06U2B
M2MSA3&;O"K#%AL*S_HRBZGNJHY/Q/ NZ02&| #H17J.U:|/^-I<(#.@K5(4'7% M<:NZ:
PE3-SXD+JAD|N9)*V*EC@<"P_@8MD&&?U"V;1##_NKL0\$|JQVC<##
M2|Z\$B6D_[M2\$+DQ|N2*'MD.L/'"'D':=8. !GY+! ?V1=<:3_0SX',7>/'R|P M49?
=J>YW|LD&Q5VPNQ&)0=5B%Q:LR_,JHC=4G@"58.AK?VP"9Y,R1"5F@LB- M|JYB2H-
-S_J-(<&+.6>\$&<&*T/(!9@ \$ QB\$&-N&OQ!K#KR0I()E(LN60J: MU!APZ(GO(-/(5-
D*,S9VA*+H5DAX&GYZN95S83W V=G.(I)3Z52F7J|58/;2
M^/3RZN|MU_&P=;'IUTF/I(G'3ZSB|M_G5_>7=UD*|99 AP\$)
|DUM/>&-8%QDYH@<*9A0* LB|XFIH0TM0Y|AXF4.%2D: M0095,.2/ MH5O('KNV"?
R#!U^ IF(X9-CR'YCB(L2,"^\.|\$|?_N-; J5% MU/F!!QHN:-BJR! %\$#(GS#0F81Q"HH|
_S#\$@.M*H5R\$YG*%@BCH2' 8 S4R MFS8AC(%(94YLOC(8YMD>>CX2&)5&H'S|;KF,U?
F_RVY8;KTXD=0O<2W+>F< M\$=\$P_9F?<|+'4Y5=C-RK%;D2|U|!WN(-
Q|@HW|3|4L;-8MI7WLJ|&200'+?: MQYW6CE?
>ZK>7EDZQP|FP3|Q%MD,|SNN?"5KRNZG(\$Q"CW%VF?|Y85|O5@(_X M)K^:A)
X\$ZZU.^KJE=,^~IUEO>W9.:@R' 9LC";)C@"NC08|(|MEC>S6:\$&-MQL|Z@V2Z
M%5@=RRPGM#U>N|HL5M.|&H?V\$(>6Y%.I4"B">/5ASW0.BF#*2PMMOE@HV.VC=
M|W9%!(4AP-;G^"WTCM'1+4_UFOBUQO2O/%6)2A7MN)SMH%EPJ:)/"?=&U2H6
M/7\$IOKWK2_%YE|W|O1=|*P)?T8X;VCOGRC=9G'5A'I?ZF%OL+7_8@_5-K!U
MJ+1/EOU3I<'6\$@F|'=7G*U30G861I,6KB*M|E^|#SB?.E=W3>U21VJ"0V:.)8ZJ6)_:&SI:O!
MU\$JD9E3!6K| #K*T#9W>O54JU<.;WW%*J@|:|+J8M+|FW*|H*9U"K 9M3PHG2/-
DW0BA7V>""|@Z|QKV>:P=O)GB+:Q/6-++T|S|J8TX5 M"+O^0PR|D6+O.?38|?
L^N;J^OSF|M|L=/F1G?_SV|7UU_/+NPK>|J&|(') M54INY@%
(GYW>OI_IS|DHO83(PXRJ&W7B-Q7#E8PQ5X&^34_UD2Q_-L)|F_-C|7-
ZU:9+9H\$1LJS09,#5A
M'@IAGFR<;%8T8;8&-6&6.36M"AGP=6I:A1)R3C9.3Q_KE0^DM|QP5L*QFPW"UH|AV%DA
<5+|T.CTZ/6|VZY>!^ M)#-_Y.-5>WQYFC=?9QC4-U|G'-=?>08LI(M"G7V<9U|7&L1VW-Z
M/@9/1C|JQA|BA =?27=9+4|8MMW>,+,XF|L3NT6E?;?>:Y4G'J%KL<6_0
M."N"+F.%A.:QJ/_2;Y| M\$N'\X9-8\$"XL"W:6 HUT\$O_DNH|=:_GQ?D&(H|N6|)"=NK'"#-?
UJ3B|9KN' MWFBDPC=X^IVL#D=KZ/SN.IK31S|A#@CP3X:%N'2&J/226|!
|4+|/74TB|T4;UC N"B&15FN:.*1\$0KZ^;W88?&I_O=M9|3>V)8BW X=WN*JU^B6ZSE|!L
MJ_\$8|3BK5L.VI.46|+C=5)K-D_+B<8ED8A4,WS,?M*^#+YU68>V|NV'RP|/Y
MD<2D#2,\$W7)%"&KKMC+TL6%614T?M65;&BF.> 9DY|P.7(|7=2,"KK4B565|

MEG1H6J|KF7(D:'?4+M(GK4BHU2<1(8D4.S Y)HM4#25V2YL^93)= &#WPR'
=C9P8&ARV7?5"M|_A(%2Z.7UGL\$Q|ONHL
M0(42%_04NC,>M,*BFS1<9X;EV0SO0,Q\$71(LXG'#78^*U*:/F+W%(?"(V|'#
M91#@|= *OK??OV*/A35D&#-*#!')7E28BFL!6J#%.+08_.1-58JH(RJAK6T M-
(7IM.3H;FL;U<=FZT1A8^X|S!CP&AX'?7C0|P;|! M-V.:X"5L)/9@X)'%AZ5-
JZ31,1/3@X,*,'/L#1CKIJP.|!T/4P1RRZ6TF|F M.R*;|>-V9Y5ALU[4+O|Z)U7C(UI.R#/[Z_/
(?#,,=J9UP|Y&X\$U*|Q\$ @XT9IN\$MZ'QN@BF2OZUE!L*:KB:I M|J0?QLR??;
=AXHOG*E8<|!;,'B\$G9P33!*)S"HD%A<27NP|Q7&"|60&E6P\$ M*N(H(01<@;VQ4>' +. %
:+-XMSW.;O=4-5_- =EY@;/.G /I'++>X MD3S:SG=\$"DV=&QY|GOO.W':YN|OZ/#N49;
<<\$%I?CPE72(9=:9Z-K+S5?%J\$ ML>><89J|@I>>%F@!^U|AI?CR=, ^70'DK6D|
60RU2:1&H)V(-V>RY0|+;,2S M|SD1*PT68^!I A%QEL1!;2#S6CG.O";|_XOSX)|4>L|P%
9T72KK.H=H*/K# M\$W C+IE(!5^U^YQBDK3|_9)H/9!HC8PB?| V3-
PPH'=8.J+5\$J5'UA(|,81=
M)7GPJZ^ ^JYG|>JK"&RH(,|=3QB=O&/5E4,9"B)PK&9|+/X5/0ZP\$ES?(|
MFB.S9*#+JVP.0% MP"?F)_&=KQPQC!R#IED%3|,R&0]?K'L_(<|=4,XX/J M&N|MW.&J?
F7|'|4+.P;6&|K))#C|MH4TCTZ;3<&RQ3RAJEC^X'3L=D6/Z9J MD>PW++
<1P/_8Y=JQ|>-X:N@_IE_A0& P^,Y'*0CO.A:Z>MB\$,O(0:_%0?_L% MAP"%|NCVZM/-T3M
X;,%IN%,N\$-WUM2F83@LV7M#4G|A.B ^BDSL/4M(-72&F
M_1N(H2%0,TZP|E0U3393OW,&|, OJ|JSM4%&>7X;B0'YJ8?8((>H8)MI9\$%
MF#/095*&C%43\$PWA?8<#!9LP29CZW6#_C&.:9@06@!N-B3&B|C@_P1'S6'/O
MQ3BWUC7>Y/O7W#%LW="NQ0ZN@RUMZ-K*NMV|HEQGO|5_|.8W\$,S;W#2(H2RS
M:JEHJ^|\$.MN\$/!42@1%K43(E%(8XG IS;,:!G(;_IX#3Y9;2B|>8CE.
MA|L@;2;)E<%5C1Q1D=PX?^#"'!_11/),,!SQ.#7C!
MGTMOVIJ(YFH\$;Q@G_38ZX#!YQB9+WIL" LW*5"&'B|@B C4,F;"G:M.> L8%<M_%<3|
/15)?#YD?29)K/34,CIK?NFS?R3<12,G5R9%Q.IOE3.O5*23;QS\$E* MC(U'"^"%/!;48?+|
I%D;9!D&6(LE/!PJE)K!>-M&|0F%D@^%Y3^7|72FB M(OH&
(('6<)L!N@&RP1M,"5|A#S)1&BQ:*4^73 MT>,AX3+./US%MMX\$:3:C8RR?CN"U%?5 M
3DHP=0- C+T @470+20#.0Y<)VIBE0;.,EPC0"4_ ^>#=#B-K?/=DP/U,=:?L
M\$T@M|H5+XL0V0R|H8?JSH1ZJ43D-7Q77V-A+FR'ISB0SPLWAWH*MW04|BZ1=
M=VU4Z"/)9C4L,ER!|MQ3EMG_&'GUG|Z|/EGBC-|1+LNZ:@R"3YC\$|9S|N-V?
MXC5H.BB"|OG5Y/P'&(EN|. @FVD0+?
709ZH048&*"&+X^!SF3MBR5\$|8-[KL|AE=TLKAB"-6&P84 M@#)G=?
2V#0K&\$T|,CDXM6SH5@D!NG/H"=2;,&UM6B;:CEF>WGJU|1|4%;%UL
MLNHM,,LCOPE:O|LM5Q.T 3MFY_ |=G'W|ZHT/(LK;,:!EJ|XWM1VJ|0;:,59V
MXSDZW9QMKB@@|VS872"2; 2W#MW5/1FN"S:AZ!!2BFS31\$"UI*QW>[2] M=!TG?
C0""N3|O.7.@R&CQ7NXS6>SL(MDKD,+CD:A 'W<4W"/KEM"&T"3"1R/
M0SF|JV"-WLL05PZMG&2\$QUL8\$Q>BD|/\$|HFKR8: ^_*"Z7,<5<X4>Y;NI:EW-R3'|&7?
F7E@BF6=3;/R?P3PQ M3@": !X;\$21MT8TG)MS'&6\$|1C<,ZW*34?9@;XB MD?
B&\$,Y)4L_|>TZS]=9>|KV3H9U@YL#&^\$8AL:<1|CFF
MO'BP/&>*OA&2JE1@;SR)BSF!UF&OGWL O6Z@?7
M78EU""^Q,>'C\$16!|XA(&HJ_-D.X3;H=8BE-)67+*NPH#HAN"W,+TGO-9#,2>Y
MF+Q!\$J<9'0I 4Q5"\$VDR=CC^'|_-(8V+9P9)FY|@U^ ^M(%J G)_86/9/J|B8 MZWC"Q;
|8+@)<<^HM8&-U3PZ|64;D4G, ^IN;-I(("%/2):@),3TRUX|2G,TV
MCBD66K,@,TXAL,,=|,"O-/;# |'MU?=QO"?V\$P0YMR MW3?YU23;6")ZD
@Q0MO#|!9WF#69CG(L'Q&.LI!18-DT)TH5>.F*2L2A9]= MO!4)?WM4N# MEJ|9/)
XZ%0)GM /!L9MN|3DU1VOLWCOL_H-RKT '+S%^JS*KE?_@ MCF: \$ECBM9+!6I-
A388'2X8E7J'#|=J**#TW*36;>+O@JN.^*Q6CJ%ZA|" G MN=-
[4VS1]*O(U%66DTD.NY)X*5L9Y%0V'N35|4I5-MYNBH9T L201-@DFV8) M#.O>677OK*
<0?>T2WGF9BEM\$|T |&@D-Y%S: =>H:V^|=AO#)=O/M=D4\$ \$6
MORJ0&F7*2,S/P/QTS@^?C:.WP2J|!FL"M'35TV|-(.G;|9-5;4*X'%1P4; M@P|K:5"
|1&IF%;K*B<3=6H4LCV3-JC^8%2YZ76TRF=:|<9|GS.TM43.L\$B)> M9?
\$J^3D2CQ_B3+I/@O=7T.A|'0:|9H22C1= 930:S1+_ 2Z5E5Z/L7)!:
MU2J1",HJ/J.JH69.\$*/%FF,0HB(ZXGQ-)T0!_-(TJ0D6H#K^'W?LE%..N7!2 M|?
1Z7\$M0LHS77DP.>N68&'*5(#G+|*GLFF!5*F:;!DHT70\$T<%P:<)=(B:J"
ML^J3|4RXX1VZ\$E6))N_9@BQ=,;(@[Y=\$--A3|YL+[7.EI77434A5F5JRKK@
M79A:F\$%4!Z,8UH16\$4+;F>ZY&4:52"&M@E4LMOLK3# MJ\$B0JJ5+U:%B|
<|K4|7<#XL\$/|U|K%JJ6->Y%4L*'F9@G4;92TED%X/1,3 ML|9M2ZUG70?WK;HG.
|JOM=:MO!AK*_1F'HN8W"YN|SXU78@Y_7)?| WW45+T

MDHP1^599T2ON7BH5T^H6S,;&I<:IH%)>B:|A^7CRXK[A;+6DM=,2.RC?+A%
MU,;91;ZR\$I-20KUU#1PB#10EQ"12XC4G*3F)#4G*<<*>4(SK|FT)M/7*4QIM3TI,!
^BK7:M]=9\$|+JRJL0T4(NJ|?LFRYWZ|BK1|)%4)(;VRW%-KKW=/{3};
M#C"*OE7XUY7%LJHH(9'&0U5FR MO5>^H96-
>9WU+I8<)N9|F|^W@7F|1KLN#5BBZ;IE8>N=K+*7A5#4Z|.2,*NN M)K%D-)GYM&G?
PNY)353EF:XXHGI&:M9.B&J=O,-B6B9>)Z;|*CIK,P5')2V
MOF\$)4+S("K;ED5DK+G"42PO<&=\$E7OG X1R1 C^H,)S&-^GK1EICN|&N!5R) MIBN-
,Z"SXM+'H6J-L1R_6FO<\$Z)ZMHPK#X7URT)ANY)QR_2U2L8=J\$PKD2?|MB:I\$U?
6\$=P8%^R/O'NUJ|X2W6HU>[|ED6*):905YPHN.P12)>5ORA!=;S+DN M-K/58C,
|=TF|L*I3MUF\$5I=%M7OH;6|UGRTQ:KJMZ78CNBV%0S|&MZ5VZ'==;
M*QWZ)V6Y_%)H MV<%,H5#'BIY"TD SKV)OKSG,8/62;WJ.7T8LR?8)?7>T7-AT?TB)?6.
(A^M8:/R&-=%'<[MXLR;A1M MFZ(C'W?!*RC|&;P:=736O|9V))OBP4>"
|=+GUL_M;M>_ =0|]-?6-8IKLMKC
MNJG%N5;/J|J@='4"Q!UQ>W@U%HR YJ4OGFAI|;Z300*3|EI-3G82H'Q/7>K
MUE7(BZ;|+4K3PETRSZ;|8R|0|X^83THE4'?D_>R6 M*2RYMVT(^_-'5^ ^IMN/ 1EI*|_?
A'=K7^-4KJ8W^ Q%B7W|YF#Y9;0RFW M'4":'1R='K?:Q| |O/A=J:A2_EZ|/G|^/^->@?
QZ-/=-^JT&X-E|YG"@;/ZIH<'8%A,A15;GF-8KJ&Q|!|7T.<-"Q)&%\$11GPZ_S-KMV M_Z97|
MT\$>SB7|B)3?-#VTJOMWQFC558NPO*6"4Y-E),\$JPPH)QD1Q-),!<6 M&_GW| 3AO!
(G\$G8/<,(?I)()*)X-IO[CC8%F+\$Q2G|Z?#9W+07G+L-ANPH M>7KP\$N.1/L-4+Y?
L&CH@^Z|PEL.CTXGQP'_|1|950^&9BCSK!()7MKO,9 M@%+"=
|PI,V8SKANJQ|T%B@8D"1T^(:R))!1Z|ZT!;QGXL|;|IG_ZJ@G?6_@/
M,"I/-4TZ5WS=X>H\$M!&Q X_JU4|4PXD8,CP#U!3BB"?F\$;.B&%+G<|?^:=%
M:|I#F!RM?1E+2L^GN|N>+(4|3@UM2L>A@+N=)PT&S69!DG2P6) MD&LH)Q
H>')KQ%M2I_4?VM/=8B|R;)/3KGWCDPCQZ|K?HNS|!'R)2'<4D<:Y M|/'_PFW>
",*\$>JX039&M<*'7KZB|T9A8*@8P*IU YDA&FW.(G;T_Q(|RIYL> M(?+'97H(V228|C?CR:
|SR0=L(G\$P^"G9|U,| M'T\$RHX=IXP\$.|:V|(H"75\$F_%+XGO|C).Q?,12TT^|/
YC|BH.(Q1RH9C M69(8.3@P/AH3U^--877+{|NA%2 TUV &FXUYPHZ|!|R&?
P"97,!OP5OQ,52P MR!J7#2:%VC4U0-HZF*3'YBIFZQES5'C"8L1C/E4?#-
M);2S&:/S|^0XN,E MF7&6T7|F%';"WM0\$(1|2 \$P#>0*X(4XJ;B>!*016F<|:;
(17*\$;PCFK@#*X M9|WFXCDQ&QE2ZF+YA8GO-584;I3NPEWST7<0-X@H4(T^!K@
Y@O4!|/4>'M:S M7#-XG/!')VFO.ERS|RUT+ M=[EC 3HOQFE6*72^;%0Y2E_F>SPHS-.X1:.*
:ML!\$|FR6BL+#6M_,L>|T3|;RS-SMO+V^<'&)(;V#^F0O|9*J2 M@R5LR0:+
(;,%MD6AN+AF 9'R0Z337?:WK<3%838NMO8.%_N=%^#BB#Q+&=A&
MW@242WGGMW;H+GT8X1ERYP'LQ>PCN;0MT=:#SM^EWGOQW|JLU[NT07|SF"8@
M@!A0-KYXU&T08Q\$|PE;4#0.HS^)^-6^H1_0(<+=UT M^MBPZ(
_&BZ&7\$|G6>KUW6LN|_K>EK*1V#>VQ+FZ.V=#ZEM%FE|K/7S)1F?_
M_'9Q>W%W<77)KCZQKQ=?+|(G|OC\$+;NY.OL'|.|NZN8ZZ=|RVUG5EL4|)|/|@J
M&"KMH9(A053M3|HP4.DW36&'P&=4NJ4)1-SIJS\$S0IWZ!@GKS';F#?;V-^/T MZ.O-
V1&@_>F|/06!@V>|K#ULCPEP/?;Q^UA_|%4>X6-<@4Q*% :|+Q?7@ M3/P,HX0/M/' +
M=_BQ(7X?X4I\$|/4P/!&XL<4N:XB.3M && K>H&B0ZW(@+LF_V!@03U|1FAWT
MLFXS|X(^ (NE^@7-S)@9<:T_)%D'B-+_P)?HREN<)<|_!XN%GQ|!4J-'=3 MU?
ILV_HC8/R&(;|TN|DN*E1T|R7(Z|ZQZQX_M;A25;%-'K03|C>DT>C""3 M,<,#^ KP6J
T(%NF>IYCC'W*#T)5",B3O"X4X%U8',@1R'KBV#/I@&#WCOWH
M3<7P2S@:A&/(W^,2Q@ML57!;|)\$FAG,RFAM8YA9-(5#4C: #@R'O%|V92K(-MZ!FH<
:HP,%IX7AP!O8V!JT*[PQE+4;+4&B3|8I0|^_I,;@?!5:(X|* F4ZR MN6/KOH: !SP&Z2\$+\$+!
.5>%-X1SG0FR>R5:1,=E/./1HR8Y!|;G'RUTJDCE =?:S2 MXV;YL'8<%1#%|>?!K#CD(S=-
DAF!C-E"\$JJRL;IM6.S3_@3G|B#H,@KG# M'Y^ Q5N:
4=Q80GNA'SR[3=+|74#P*L(Z7MNTCN) 'W|\$@V(JLH<)QPK:)=)
MQP^."HE(<'@V'4_5B)UJH-&@OXF1ORG7T00:NG2QRV""I+*X,H1*.:H<0/,3
M9GALJNK,UC3?(57>8_|M4C|XD1&P!A2@O40UJUN-|X*M'SK^IX3#*CP69O-M6^ ^
OF?V|? \$QV,@=9B\$O&>H*PO)=!P8WIJ-%D/,#;|>MR(-;8=#NU-8U\$7
M,0H)*'@X/&R=CST41E(S&Y|+;DW3XPX^5T0& MQN)Z3C
JWL=C7VP0,*,0BI%S)_0:2CP)E5<2R?*,=|E)MF;WQY0@X"+\$1&)|L
M8LD!T&|O.P"\$B+R9BD=00,>*__.?P|_N7-7"SR(1%DCH#E_-3OY=G>C|C-3L
M1)9<<_Z#KA%0@0F18NTYL07|)#G8;+#+- M>6F9T!--
DFIY6NKI:GE:87EZR3UF6)H|JT5J645J5LYN42(5T.6"L.7+AC=- M;=%-
Z;;JYH.U7*WE:BU7#U:N?C1,RA.P0OD:72>M)6U))6W.'9&M2=J|*|(K M
H_GJH.%\$JW@58E7FXC>UM%IJ|\$LO^0M3:6G8M.;PC2%>%J"+E+\$'#XQZ;)E M|"

<,OL<3WF0:D4BF@&^YI6%*T-+/-G%3CS(>5&UJ\RKOPQ!+BGV%%R%J9VZ[6+W
A?)&X/TDR.N#(J, O:86FN8\$"'6YK)'VS=U M)JH'FWA)\0&O57*+LD+HQEV4JA\$]J%J:+Q I?
Q-,81)J%3(L0Z19\XI"6LQ L M.!1+VW)B9P+[-<)\$&#QPF:4ETB?V,=7JV?B,"3N.
<,:%B22BI,CJ?*"#HXMf* M0E6#7M9UJHQ+C:~9*YR1)R*]CU<3F2O;;T\$/X+~)/P+:C0@G-
+X';F=5[5EQ M\ZR7U3HYXQ;D81U5AXZJN7R]*GE735Q42./I&FEKJ\JH#?
HYM532UQP/[LC; M,:65DK('='T>?5&BC=_G*)ANAND:AE0,F!2U>;V-MTOB\$*M7RVF
@QW? SQI+-W\^W9\JN7\^O?
1S5_9H9ES'RZ;H5U47@|*Y@2AVVF<=<=3L6BEG(+N%*B:O&WH
MNYK)K\|.FZ%~9/OW4[K>@2N+|CO\$=5IQ>R6BT^=?B=8+I5J^:!.WQU_[FD+M.
<=J|M17;9D_9*,&V>8_HY)T[AFD]_#*S)Q6,'+*>*B&NPECX-G*QFM)OQ_
M_,|T11'|EC>F)N(HYG@4R,AML=BU+KRGALV\YK@IFQXJ@~\$RFU|)4W=!:6N
MP+GZKF/"2',CC(^+,X'H(\$NXN4M%N6AXCV V@88N/.(A[S9.+H]DU<8W^%
M2&&R!B0>|)YL8M3A2!<,EAMAH>T/A%)\R9:V7BU"HQ!D+~>8OUKBX,LO6^; M5/"?
BW#!7T!_7;IU^&'Q5?VO[9QADBH-^H&6O X)12.;62,'EQ\WIZ#>R7+A
M".*|A@5JEF<[BU4GV\JR+CKX[P(EH^CR(SN\NKR\N/Q|?
GEV<5X9E\,3YF4H!/HJ@9AR)XBC!)>IOUOVH\GU^|]#7PW\PS:<[SC:&3N% TI48
M9"@/)37L'WU*AFX 0#'^C9\$M.\$X,%ZKW*M,)|I?I0(/BBW(#B*:Z#-
#6KWJ3|+@"/_~D#.I^C\':7N7*_<*,6BUDKBQ6>N[VVX?; M\W|^
T[,SO^%_+@JW#=#N&G!4LT61H1"*C#^\$61F"UN:VQ\GM3(J.X*TBMR H
M3X(:%%XMI:\$BENMZ|(7(1E;0+)|89.XK!|QW,'?|2N*DK%0\$EB6+7K81/70|=V/6Q?
OF3P M_F?7^G@^RQ)'0|"(YKJ>_~|!|1-TO%/-+9?:DD8,^>RQEZC>'JO-G7\$2X7 M=^=?
6;L1T_I79,CF+K[;;/2*6/W7T240%5HCZ:JK'R]NS[|=WF)T%LT4>.[+
MOV\O;C%4^~GB<@3FRN@+&B?1007G\DYO_WVY8X>N;H^OQGA#|=9E_5SDR4/
M2?!2):JD52H4?|Y+RBB%:BW57+B&&ZC,698*=0W)3-1SIZ3/CDF D=\$\$;_W7
MMX0'A_QIR4%3LEA41!(UG\#|XM3%BJM4)8J;+G|4EI E4BC_*8J?@HR\X93J M"-
@G@FP0.-8@8'/.4?NCH'1I4|\$O>QF?J@A1.C"J#MH\$UJX|V_XNVD.&
MRPU+/L7Z03%U;/N>V*)(2HQ5@!,A[6^6B97A*.+|B%TK:\$BPOS!RK@-45\$?& MA\$7?
MWC=-&R;I/&Y%V6^HY*B-@ZRG!JQ@JL'+ "S.'ZNB!7\RO"_HG0X@'7X7
MEM80J4A1@5FI)<>*RKZCKC!C/4PQ2F|<*&_MK%PH*SD*?70*5=.;'J.>J1F
BZ1QH@A'8G&^ZOU"_O M\N,MNPRF5]CUUX_L%FD2=GH+QK3U11W#GV?
HK1A1\$J%"CX,6=+|0==B^<@_V M&HX!9V/?!QP MIG,J^?
@_ 'T"MW<\$ \$|@1\$|,%A_(-8@<8>&RJ,-*JOE2!%
(&9CSXT4U/\$^T&DRC3\$XE>@@_OXADNE^)H" MXYZAPTT3.5 4RH#!+))FE+|Y3H@Y-
I@HB<4H92DE\5L*U:C)\$P1G,|QIQ M& M8>P@A8#6&E^GJL/%5VK
<;+ZHFNA|A5T24U%=8D3XKQA/NMK,1>!A MQ&Y+ 1.J!-XG!4-V]?
>9.E6!87)@N^YWM8&J\$)O9I\$-\$MTBDDR3TEP+|QQRX M>YN|?
C8F!@>1DA%R*FAV,,\$'H3 C#>P5; ?EXR_-MQL-%LQ!>5M0G"%;MDX
M12D8^=6Y&Y,A|F(VMLV "7ZZ^_))/ARL_U)U=25/=J;.#
|@XB"G.3&S.SD._:N;1!P6*Z|B!:9"CXG5CKS|BNO=FD7R<^ M72\1W7YEI\$P6
U9%NT,3:_%*M5G'Z-@GPW\$|=F9@7!W,J02Q* MCDQ#9060U
<0NN3%TE1WVF"W'#@6F+-L& BP3 N8+K3I>J"<1XYIF/H>S- @ MV)5Q>@='&9G\ (9;.+;
(Z*L04MI2.GSK&6"9,@BM\$CR1TW|=)HG^U:P7)O4:W M#,+F+.J0?@Q=M|]?/?
<2PZ?.@V MOPK=YGNJS:~QW\$&K#30ZP;\$I2X0'2W77BIJ&2U M]?Z>5%L?
E+|<^MT2\$RA!YX)#F^ZW%*E@G%G#Z%51-V2#:RVEF_.HH7RH4*Y(
M%Y+2R<6Z"|E+Q.*RUES6+B0UDAT.DI6VU4V-9'N+9&=3#&&QMS^_JY&K1JY7
M0JXWI46N6OVLF%NFY/Z6J"S[DBF7*RW-L%K1TL-Y==UM%2K@X(0?G6GOY(U
M2^CLOEE"JZ><#:.EZ1)0(\#.\$:"CG&#U|!H!RH Z?2;'2! 6VD.>C7"YNN M
)"WBH3WFQ*J7SONQ5:X^G5FBUIN|:MNW3|Z< UL?5\A^NL:NNVU#T&3
MZ^_J0#.=BA7C|A7!JG:SQJK|Q*J=JQ9KKWTP-.8X5>/45G'JI#"E-A/RJGI M5LW1^~
FQ1061B>\$=MHY;2C4#F|,UFZW:O5 ED/>4_LG.5;8:Y,6+Z*/3EM)I
MUD|\$2H\$<I4M:3NV|:PR&3) M=R4Z_2H NULDK,NH8U7*R053WW+3!
(VJP>YED7:J|:AC<4;7PY)I#U%9Z5OT M@OU5GM<^K#/K85^|<O:L1\,%_,2)
|8C/5C,4W\V+1/-EG7AG^#?L:TO0!_S5-C!Z4_96N(?TNMZV_OHS70
M\$A):H%0"IOZ81+!Y|ARI*=:9(0;X_JN9TP6\4GI5\2.;S0Z0M%U#B|X0_<M\GE#%#;\$1
GSQ93_"R:TS|KBDZ#W<&CP3SP!W,V M6FEL-?36W# '@_3G@DJTS WO*&7!J
*FP|CRH7A-(GN"7XF=?/5=S>374|69 MB2|4U^4>X.;CU-"F|)\$|EV<\$-Z|TCP;5|.2FU(-
<'H4DV8SIY,X%TV7C"5 MZ5PS#8MV^87?J|J"?
3*|+|:.\$!YMNK,*=0\|/*T_ \$|Z|/(\$_JY5.LZW P?;? MX-D*%%K&!/Y@V+

!+%EQU%*8!;!LQ"!#*T6J_B0/F<6J;W%7-:&'9L.R^26"M M;=\$
58+CUYNSEP!OH+217B1)P3?J?.[8/X!;/0YG/3%5;S4L*W'('WT'L[_7 M/EN%Q9B7+
(/KP9,!H(#-_=Q6NOV>@G^*PT\>_%0U)P2/Z.6)8\JBA*!RNT9 M=UPJ-T+/TQ.2!O 9MQ+
N4H0/9W&,OL(2.-/_@ (YIOE4@6)E00L^L,W-&H' M>!0**+KJ:@\$+DH,K\(<[YQH6-
C87"M"+Y1JN!TMDCX8WI7DE5+(7!P)2@Z?5 M>SBK8*&N.N.!Y(1)24H_?=Z' M-;Q%[D-
Q&6 WO'<_G6N&UD>FD)X!TT@%! M\$I&KA/<*H@O"74A"<40=&/55"V-B-9=7E:DTL
"SU1+U=5*4!WHMV>VZ^&I M?+9MW66WMJG'5-W@QWOZT84?-
J9Z4>,=@L+;3RF\^&VIV7^&J@N:Z\$E<<\$/=EJJ(MW'UP@XE,-J7&/FM) 1J6^LA-
M\$_^EN68H%|R,06(H5BU<^1IVRVRP>/_EZ)MH!\(X5&P2^"<<26\$,0C=NR M>
<@@5Y)@*#EH(1YUG|2(J@ WW9B+VJ\$:IU_EOT&;K@;JD-O%*[Q\#QD",Q6
MP1VH*]42SZ#&17GJ6>3L()N(T*/5C=G#@!+X#*@80DERT8,#X:C6\PF,Z9%6
MX5"U0#BX_W%Z^@SGMQ;8%*,U>|<)K9M4%4L/??H'Y<O3,+!/_?A?
OSAYGSTC^/1HOS MFU^9:CZJ"S?PWF* @VN)1YT=:SY2+3;31)2_#|7JITG^R(OGRIZ-?
TAO^>--M9BM//+7\$E!\$\$. /A/@KC*DL'O&ZX/H- /<2.0 LCGXL8C"WLLT;1DL^+0A
MPT@J&=0X)8-A#\$|&+U(RT/Y?TDRE_#>XJJ6Q4V8U 7V@1>G3%\GU@ &BV.@
M%W_,+0X:_R%7!),%NT[K1%V3*SFG? =R!%!NP!>0AR(33CHH.S"8NC=QT>5-M.\$?)?
H.;A20^JCA^(%F!C79(6-)+K]'*UAMRHR+%9H7XJMD?PW9B+(-V|D
MOZ((OQ!KJPOUAZB:1+|>28:JNYZ+_N=.>Z6_H2)@PX2A"TH8BED@?_"8Z|T*
M4XJDZZ[5?H|YT\$USA|2(K6T8)+\$Q7Q:VB>,"C(NSI7A16JF-VRIQ1|Q*NT7) M-
Y&R=6\$E;A|!>GV-ZPF%)U,7/#PTIC0W8(!4X)Y>G01|TC4-A,4P:9P|_N7-
7"ST(-FAC6';Z:K0&NUO:>\$1%/ M:!=
BG7_J'^4ZRG"VYX36|#07,5EATMZ[2S0'>5WYN=*;'N^)U09|S/UWX2.
M7V2:=97Q=Q8|M(:2RGF M &HH'RJ4XSLK)'L=9"L4R-9C61;M1K*SJ6K=
<_,VYWZCOP0A,9%X?+=='_Z+1[HG1|=?:ZB) M!Q"@V:H1H!P(4\$"UTU93:?:*NPM_V
A0RAH)1Z>[*PRT)PT\$JE;?=OFFV8&K
M8E6H0MH>*+WASIJOU44CJX)6':73V5F'H1JM*E*+M*NT=V=XUEA5\$.RJFY'6
M|L9E=3=^-?ZP%=U2JAJ@0[248;XTBPA\$ X?YJV^TNP7V:FP=\$ X?,=23QF<
MU""O%,AWUZ:B|B663[D*_WLR3U2'.%!4'J9EA&:Z'16@?.'N+56?;S?>WZ;[*]7*%,7QX-
O6-M^W>U.E:;|XH_6&=WEXID/>43AV\$JI9T;BOM89\$.|+!X/!!WBU%@*-\$&EG5
MW%ZK*S_7RE8A:5ZUYZM2 &|IO5:M:E5*[KYM8>_2 F'^KD3G7P%P#XO,[WI7
M1D6K:JZOCWSN<,U02;TB=6MFP|G_C|XX;#VK\$A?|ACN|_5]?PZH(2O5WEI-2
MHU1%;O:U=^;%KU&J(BC5Z=2716N_8EK=O:->]?8<^YC%6F+5BN|>:R6MEM+O M-
&LQ4J/5=M&JJ72ZM7:RGVA57NVDI;2'_.MUUA5%:PJS66_1SIOU5R|5Z&V
M*YKA'K:R6TIU@_0(L+/J:&J58-Y3!NT:Y)6*J:57FMG1F@-|C*?%#?'JFV
M3_*FW(G|"0JS.)U&;IBTM6:|1:(+"\$,#A_DW79|+Z!2LK9W4K>SJ13-6|OS
MO>^)=E4U|J6U8S|8+F8G3FQ'>K"8I_XX;|VK\$K&UMM)IUE7B:ZS:=FBM>U+G M
>PG5I4WM#9LU9RJQJGMXE2!G?GV%Q;-7?B;^/32^Z%L=K57=\$/(-*?I)|.
MT(JN^V.3IPFH7/U6UU|W7SEI%7;)HE-%<5)!..LH!>HL-9)M\$?:LA7&OZ76-M|;?
WT1IH"0FE4.J\$4B5,(M@|=X|4%.O,\$ A?WW7,R:+^*3TJV'I%[H](5> M:IS>|
=N^;PA"A_BHN0WY)OUHQ9AL79#*;;NHS#ZSJ|Y7./S|<81T;K09
M|J)JZW#5A1_-3?;LJG/W1.EV^LSU66@|,Y5!W|R;#'#SZ*)_7-FZ#38'3P9 M3-_,&>3=
<;60B_-'0->GP,BV3HS7*;;#@/*G>)\$B>|*^WIS197KX2>SBJ^|J M)K^>JLY,*&Z+O<
+6\$"SU!-K-EXPE>E<,W&%L/(O_%[5%NR3X7TQ M)CS82(.F>
(0#HYEQD9_XV/%59|:0W\$*BKC/[S+7UZ;,MF.%|.)BW7&1S-M(W?HS\$P?CP-
FQGV=X1%8"ZQRV1J|=JG\$L%1+@P4#%JIP7H ?|C-!\$SN*Y;@ MZ*XTS|:G6|'3JY#^4
@K&|+/0U4|R)_;3:79[P'8V0+I.8&+0U4+K|825._Z/O8';|NH>N)%B0*/GK MP9/!T0-?
_F@M-L#!?|J|G|K /=7YW+%-&#-X\$)!_JH3.N7H90)01#.:+R> M<<[!..!M=X
MIEJJKNX22+KQP#03M,2_'UU_O"/HR7;#8VW9=M%?D.6"UU=)H:Z_+;U^S!
MXI:@!E#C3IX#.S"[TCAS='K<&AS_J@O,AUN8AJ&#Z|'G|^/-^>C?QR//MV=
MW_S*5/-17;B!08BN<(M'W:9H/5,N-M%&*U&!/|2I|DQ0KD3T>_I#?|<|>;MS/9A>&J)*2,
(T;"?1PT38)5=V:|'A+!9|O6779KFWK,P M^O*8XQJLE>S|#+=4Y6-M2QH!IL!B8#">>
(U6-@C-TW|EX9&.Q=4BL0SI_%,*1:J/\$U|';8/&NL_-
M"NQK^D8<*W:|?!,.)7"\$8!9WP>2!7B|S\$B,OP',"+1UT)2TGY*7L|A@O\$+V+U
M\$4G9A.|FJN&P!J4\$%N-Z?'[LSW\$.',^P@/-X-MALH9M#JCP3PP'.^B?8<_T \$3*#H_=T"M-
&#WFA?,%4P07X>2W/FC|9MH=#R CL/!MN^V&OWG MZD_5<+T_J<;|0%;8^/TJ_PW:++?
7H|JRN_\$%UW|>PA2IN=P23Z3^8^&PKCH+ M?0(2(01)H#-'\$,1)4B)&-
!!S5TY|TSP.)DA>A\$!Y.XPAR?FOQ =B6G:CP'N
MI3RE)16S2|KMNKD<<0TSP,%\$@@>+HR&+V!6-A4B:*(1+|X@SDPAC/F%@?1*YPJ

M8*AIWVE/<\$\$!M\9XL<\$*0T=S%Q')!TPKG;8!<6P]".X)@Q[S;NR7?P8,,M.78X?
J")06UTR\$04.T+'4&O8+1PY=|098ST8)#,,PKQ:=2-U)2RPL-MA-B0+PH'QG%+
(D***>9HG7&7XWW:H@((44Q("-O-IE &BQ-BJ##+"R[JO!:@:MPJSC)2J,^'<:R;VIZC'-
M)%\$)6D*.LJ*!L57GA9BAT1XY@V<":."P(-MENH)VJ3KNS&U6HU++^
"\$[0H1=PjXZ1"0U0>V;,'!(V/8=#X)0Q@)2-SRZ%-MIEW?+(%VOIO
%8]96#,,N\XXL'-'93YR0L"D6013@"5"!P#PU*PSSTJED,=O MH+RSA)P0X",M]/-
H=!W+MIB!|\$)|\$%-3:R#0FS!86 P,BX<3-!JG|+- %JA M3#>(AU\$9"Q)R%FC;|#+
(-.U)6(D5HG3J8E-BK,!%=WW)-G1RJ2=!'^JIN; MH=\$H>H2O/14|1O(+ 'K0K!A|UT&P\$*
|)XDO%D-W('M'DJ>'@/M)VB1"P=GV;!SX\$%:H-ZLN^UL_I\$;9EJ1W9>^.W\$0(,3AH8?
0M@|I MXH0\$41)9M+=X|HXV14^FA!AF#O!|<@J0!8""H:%I
D<.TQ%WJ4((TN0R=^/FD=
FJ8IDWS#S^YQ.B_DGOS5.\$_HP4Y82#L\$G)QS_|'JW%\$_G&GA-,X>|\$.ZQEK
MR%5SQAIR^SIC#;EJG;&&W.O/&"_D<(!:8Z"NO?UFJ;Z.'HYWD;ZV8]P%JPFL
M".001-TCYMB/XN]6IN\$<. ?6JQ2R13#|1J\$&#-^((PK1)H\$_261:/L;,"C5;
M7>3J^7<#QE9S#^#871N.|0_|O2#YUZO+P)S*OVL00SV2ES?VL(V+YRT4^J
MUADL>0S^V=F5>V+E;,*L)0:V5Z;-W#|D75Z+%=J&C5O*CF1;M"MG;-;#6R
M'9Z6M8|67+TBF84&YOY(W|ZO6F',LI6)PW9GG7Z1#1H.NM+;7L"-V:KA7V7X
M]W;7P:&&?PGAWV|OK)!Q#?-2P;^C# 'M%MK|LK3Z^JRY-I;3E4NTQ\$W6V=JRS-M;
|&/1#E757@-WU7=G3K%|8:#!WPY5U5F=&QUBE-5#A|PY5Q5F=&Q6V3|GT,'M?
#E7569T|V*YY|(-OYZK*C(I=J<|'2#JX\$_AP9|.U8+Y; #/Z4D76Q:-M-
FCNK*JJQ7QH05YJUND=Q-MFT)5Z7@1|UJ3+H#ZP+HJJ37IJH%|6(.\8B_-:1?G4BTA# X?
Y!VE6:~#50OD-M;:4_+\$|&7(DTZ8-W2H?
-/9DG.N/;PLXXAZY<-V:\$;V:7."F0+F%MG4&C_=3*M7IDZ815O=KB\$&@.29]JM-KHU!E0:
JJ-5HT!E<:;BT%*HX!|4:_9!A0(CV|
MOJD0.L9SN_05EQ:JDG@VJ&|LU+A8%EPL+@_CX*%>SE65%Q<+ #X%=-3+N:KR
MXN))~8VKQL62X.*@0+Y8WU(H5T#H/=4H.|C'D|/52O;?^=/HK-CC'4JLHM(
M%^D)&F,63JOUU-+J&'UUL*%Y4F-#C0T2&X;=88T--39(,#AIM6MLJ+#!8D._MU2T5-
H1(KS_X*Q/H1"JJ.!17|T4W|/#?8!36|H/QTO|CJ)^+U>UT5&P"&)7;Z MC>8Z"WS|. #
LYLV.5U*C12Y:G#3:-5K4:)&"1+?9.*G1HD:+-%JT&|;+6JT-M2*
%JJ\$K+UI(2^\$G^%>TC_%PZ;VIS_|E*U+ _RVUH+^]CR:GN1/ZLE27I;:<MQ)-
Y|ARI*=:9(0;9_JN9TP6|4GI5V2;S0Z=,J/MD.|Z8<_FLX.OO35QV/ M.ZBB8]-
\$A27[NP=Z.|YAM5J==9_PS1|-E<=^-NS.217G7\$V!X#8.C-5UV,+
MKCH* TQT#WF7C!=@_K?;8 AF6.PQW; &"P8">H9KF E8R<;DG7NN^@:9I<->-K
H!.03,X3+W!XG=R MHN_9Q+%G#"^(+Q)!Q/^|G"E@^#'%-(GG^PVV+)5"/B"
|6S4>QXS#Y<6 M;) M&YH'6-G8D6#*1QCG&2'.50(5|F#C9TAZUN*O?
QFV6X/W;@8A(0H8|(>+QS:& MSU.@*F|=PY\$"20G406!I,*<|@_4;_R7"00/-FQ8VC?
CP&7CF>VXZGH1+\$= M&
Q@9/M;#XD6(L|H|;C_"W\$#PjL=,CO3OPL#X!@X8S."/2FR;4DAA89;-M3!L6!>-
/|3E.OC2Q:6LJHHL;@E?G/L.|C800JS@0AT7X-J"!ZA\$#D|3H'_MJ-%6Q_XB>(#6)D^3
;N":5Q_|'H(-&&IB-EX965)+9+M"/A),/O?S]J'C&- MFZ;,(=>?
W;FJA9_#MK!W^&K85\$M*2-("F4|\$+Y2#I-TWF0(US\$TE:\$M#W,QK7!67;@+
(L.N(>|J68&7|S87#M.WO|];LW3K^MUTHQKO7 MANL9:|A58<8:O%J8M@, MN%|W
WYN,V#TS92J'?#NL;5K-%F |3IE@IM#H|COSZ5K\$^>=?US2EGA|W7 M7WYUJ
Q+J9'M!YZ-&J>5'-BW:%;/^_O2]M;AM)TOX|_A45
MFM:T'0'1/'6TNQU!RY);T|;DD>1W=CJM%(&BB#\$(L'%(XOSZ-S.K"BB-I ZW
M+4)\$;>RN6P105SZ9E9F5F=6U8+-@VSPMRR80U|Y%]>JH,-F9Q|ASON|^T-
M6,TE_H&|"ZO!Q*|/87=+""XY_0;.%M"|?ZP-'6T+9PK|<M.|TU2D=|VE.|TYY?
1V|OHY0'A1W9@))1Y^P"MT_<&H?|+I&G@M MN:|'|>O=N;;BO!C38?))WG3T;9-\$LDO>
<0=>2O&DD/UC?B7D-:= \$DO?|-H"J-MB3|MZE4)_ENS_J8LM|'9RC5,6?
=8QW+%_3|6*EYWG>+M#.;76L\$M%M|BX!&-M(V/[T*Q"&@P_O;QVA.+@
8C8*^U5S,\$U\$A/MXD.N6-|Z!\$1J* YU@6'IU|)%M"G_9G(>FQ*UUG,|!^ESS&T_X>HZJOG#
<|ULP6C#6!(P=H|W;M7" T<*P-'&W& M@X5C7>!XT+7Y#09LJ)308-
Z0MOGI#L_MFOMVIVT#7RT;:%@=YZ#?MVBP:%"R
MH3_8MVBP:%!H&'1W+1HL&C0:.05*F:N17K_QV1/5F"^Z9&GQ(N1MX_|CA|R|
M|/R9^!E=8=_=:QW4]PI| "XMUP8+B1"PL+"Q*E.AU6_L6%A8655CT|'9B8;\$(
MBWZ=I86R%[%|OZ/(F^/O?!2(MR|>+>E?ZX,Z.?4=TE?5NJRTI;+.)FM-M|*/2Q4-
Z,"C|GRQ)_?'<|>2>^J\$GX(>+HWP.(I9.A'P?W|LL3|S'J-H=;+?N6JN&T./2*,Q5B>-&\$9R
M;K-Q'\$T9)G=LLX G*9L+'C_ENGG^M;Z|O.'=W|L+4@?%#^+9W3J%Y)%|!.8

ML>6V3KJ\6M\8R@N%%HQ7+5"J9-QZNJ,YV/GU-?2'4YCDKH+/PPJ'.^_.CX9_M\ R/+X_? V\$|N.'S1\|HADL-)Z)D)/HSF{?,.4 ^N;_F>9;T\VGI=MG?#O\|^77IJ\$JU;JLJ_32"? Q\K8Y"Z)_6#'\@CEES3FE4T1F,@\3W'.N1-58 M<5\$ 'PA@ Q1CHQC\$B\>QRUV&8U\#MM&P4"[VRBZ5C(>NYGXQ5T\>?)5_C(MY;&0C4.+GV >).Q.>9K%/\$A(I@V#0/_AMZU\PJ'><+,%TN\$>Z_7RODU)ZD;3 M&;1,O+UJ7+T\6? N\T&%QR:M\$64:')P+)MPUNF,H%13+!N)_ (SZX^V?F)[\ M=VAYG:549C<"_CN) MKN. NSZ4B2Q_7.ALU+)"TV#\'DPAZV2)=DH\$7JFN&,J M2IH=>0*H.24.M1B,(T LQQ_DS? ((O@20<=#=LA#[G\$"%C;WI771D@.% M+=7+W%0-<"0P5IN&R5,0&J<"T!B+) LP;|L["L453_UK4=IS6^P(0,YNHC@1 M-!P@RURN4Y2(8D3W=YDW;VY:22-V\5DEJU252#K!SA73CA,D4YN># M/.)3_Y?RT*IDZ'>6U+Z1 S"3F,JAG\$0PH9*X0ZU\$X\$^NP._E>^.:>#*EU19 MO2ODFPT0!Q_ZT!V,G9Z91(&"B2<9,\$* <#*,-\$;,(!_1R(48]_%42G.8U/_ MEE1QM844VYO\|YZ^'1*NO?RZ7_VSD+7'.J#YN!\P\@= <^++N)&2DHR\$|_9 MW"5ZH.0L1OV4F)6\(|7#W\;:6Z"1!H\$*0,O_3F;NU\,%:KCL. [E.6N('X/.'Q M=+,NNKZWN*/MRA+IV7=EB?0,NK)\$>@9=62)JUZ\,R* <-5.'6K;;JZK\|^27D MF8>V^JN'Q#\'J4\$YQ(\0JPM^V=I?ZC\$M^|?6F CTIV9:MP0(IT='W5,1\4#+2 MTZ.FT\|P^0;8J&L%FXV7^#^>2Q\ GCGK="WG/)9S_05TX0:O)J?682@6;|! M;\$|FI->_C5MX\|X>'2N+K"QZ*K!U+=@LV#9/R\ (5-FKGHOKW) I\$PHM CLU. ML5L6Z/U3S:+=@=VJ3%6MI_J2T\^S;V VX:3'VGT\%7WS29_KW\?4O_!M._V\|W M(- GZZG>/)7L\1U1>,H+_OK;&_J:830IZCJC4<>_WUP=&>J M3NM.6K*N M/=QI&+F\@_792C6D0,(\K0\!I;DS2+Y\JX\M6L8R?N\|>'R&BG132M>_L&H MZV+U::M/6W+_V"4_L.ITH^B\WUN?/[6&%-A\@A_L656Z403?WUO?|=PU5J2; MX(W^U5?ZL_Q9%L?8;|T:IJQ\K&/U_9TUU\ROG4\L\$0%\NWCOPKK07-C>|_#LX MZHR? KO5M@AH, @)!NQ:|!#0: 8/6H&8(J)%::A,1HZJ MOF |L,D(JOBG5'OL,"KND;JO"MGS\ TL\76,L K%\LK_ZW0\$C5"COGM8\BRH M(4@XZ%DH6"C0L/8&%@L6"W)8^YU=BP6+!2D7\KNUPD*-5/FFI43(2X\,S1\O M9>5L&Z\BS5./[\Z?FS,)UD5B\=JN.1;Z'LV^O"P49!K9V,C!;#_Q2"PL M5L)BT#JPL+"PJ,*BW=JUL+"PJ,*BT\JK+RR4=? "_I77U\|. ^2@0;U^|6*X_ M_UP9T,\OBLZ\Y*.K%1DI2&7<3);V4>EBX?T8%#V/UF2^N.YV2D\H4-/P>| M71J% <8>|UL29)JQ8\1X;|_EO;/#-[W>1#,V3B.IBR="C5C4*/_9GQ.!4Q MJO%XIR%+ (WJ:3OQXX:~#;OQTPFZJMT0H\|C!HK-/9IL"QJ%31UGRCO\UBEQ,_ M84D0W4#CT^A:3&%|_#\'RX%4_9#/H%DN;|BT11'C(=7";.%LRE&|\$YX&(J@=1?1- @48)V"CA4R,QY%<32_V MKPN*@@%[DTX<6I_#:#KCX1PI,.5? <2U3:%FD@!_O!9)BO2AU>25^, 9P"DB M'@O\$J:RW_06U\|F+#+=%RC\$62!2D2#;Y(A-F1@X/+,XBH#=>T/7OV,Q, MQ'@)CF&&PF. >9"Y: <93(0&O@0RKH/ZS,0CP\!7;8'0XG861#\'14;T"G!;" M<("D'BP>"W@6NA/D- +7^/BQN@DLXX8_C\1I"RO,38+P\$FDBDA. LS*8C*3AF M42J%#S5>(-Y/0>? 4I">/ZUOASU\X=W?VPM*RXM2X>,ZM?)-^EG\;>5MHZ M_?)I>6,K+ZQ: <;,HS;*BZVW.JTV6/+0'TYADKN^/@_.V\ S\;_K\$S/+X\ M.O^%|>"&SQ-J= (JNG5"18:7Q3(2<1'=V^X8IA);?V_0_RWQ=ZM'6Z^J\$?W\ M0012+ERU4I<%!6@"^3R>@MRT_ZO5^&VK0044" (5,Y#_G'S!6JX\|= %4RV,_ M_>B/452&%.|">XBW\AO>OWL?#[4Y;(^6\24^_ \$JFD?F M&Z@|UD!??/DEY!D8T,) [M78U;|Q>=?>F/S8&Y.[\6Z\|DQ^>M1TVA8VWP"; M?JU@L_\$2_|=SRP_7Y\BF; M^C\|_N85F?IWU#Z#YR\CKT-H='T;UO^;S+|UUF^J;ZN*W"FZOM9Z7D"5MZ M\N.JL:UU)S^P_:9M"\"L#1S;G7T+1PO'>L"QTW;V>^M3G3>>|O4<58WQV'&Z M72L? +1\K@D>0CYTUJH_V_*=VYS^74ZUYTVA^T+-|WBR:#YPZW69? (WVZ:25QY2WGLS@:~^ZE5K==RDKH\ M8".I&D;RWF\|DKQ))- |SNOOUV6\K0(\FD'RP;|7JAI&\W;9140WU40_J*V5: M_BS+:&RV0@U3UCW6L=ASO\ JK_*_|&5_VN-0+:K9Y%0*,1T+K5#0(UT\|[#1D!::J8#CP1JS M;#>>|/4<57W!:"/%+1QK! <=>U^896CC6!H\|M@_6=ZMN\A1J>"(U*=XUO_JWB M2ST?(RQ>;J=6VB\$-RZG? N&9@_IFX.&_JY%@T4#~#6O7:0\+!HL&A0:NH.^ M18-% PUKX!RT\VN%AAKI\4W+GY#7)YEJOKS1>=NXR_DA-RH\?R9^^*5AZST- MAB'V.JW\APSPQQ*PV"VGV@D%A8K8=%K\2TL+"R\JL-AM\5186%@LPN+ PL+" MH@J+/0PXK2LLE*7P OX=1=XC0+Q\|6*Y+OUS94_ORDZ\Y+^K)2EY6V M7;;);&4? E2X>TH-!V?|D2>J\YV;G\|0//0\$?|9I%, =1S-*)8(?1=;;#8O M/N)!X&@5G?FA&PN>" (JU!ML.NS+2HHUGW1X\P\@PUU3XB^>|_C8\|@BYB^"- MJ,MTXL<>^S/C<2IBM KPCL\670NR*8MNIL,8BP3K@A&9Y97"7(UMYF4QQMXXM M7;;)RF;"QXW8NT6+|K+BI9.8Y>5K//3*-SY;!Q^ M9I\@F;)8)+DEODE378*@2Z#VV\YZ/H\

%%\$F\$D0/X6DD@NB&9!CWPX2Y(L;_M;-Z>JK5B883BCW"7C6(/"@IVXZ<3A@OJ,\$_-
%X"ST9R@=7%TB\$C]Q]_WN]WV MFU"O^V*K]J\$8'MC4;Y#AJ37+WP8@AO!#F;
<1S'B&W JDM1A*;;_%/= 3;!5H M#B3-@?->?;!;AROB9G*J A\$@|P/4!!XD.|-*Z20*U AC*7:2;
1H2[,4 MT*0VT:6#+H:)BZPF*QNEF?Y+BIQ@SL[%# BV"E;:)X:6|.8P,5:(N-&IPI&)
M6V0.&\$K!L@1T D^FO 0-H(KXE|<|"V6B)R"-@0FEGPBS|54^R>IR1!D.5&M*;
<|WX6.KFGW]E.0NBC>(MC5N619D61!*HDYRA(0K*[15D:1-'7E5.\$/G">
M)\$<3)5<6)TTL>;|F,IP=),8LX7E4(J\$J3BC).WLO3\$%EQXX36(6!@U-
\$B8UE4)EK|VH+|0,Y/T(Y'ZO|=3J MDE(+^F<\$^A!O2C(Q;R' #9 WXR#LM08#.'Q=5U?
7D76[[6[_J=|O*5|SRC_9 M?>26|C6CO.7YIE)^,3QOU9H-!HS-EQ>?@EYYOFA%
|5R@2PX+'@L>"QX+'@ ML>|Y1N"140;/\$V7F,W7@->ANUR>;YU2DZ@1|LW-
UEME>@T|?D;RKY>VN| |K@3TJM/5)BACK/;;+7L M=VM@QFM'M8H>G?M#<"-
HG?':>^OK^1U_4BP^10?*'ROC&^E:N-KTFY2KEJ M@LNKGISXLK/.O?95?
=;^":2VM&X,K?OKO ;4DOHI2=W=K05;UTB/:IJ3ZKB: MEOL2|W)?44ZN5:K6P9)6^C:\$U-
V.O6*|2?1^N59?M&7M)R3U&B|3L3ZJVNA6
MG[%@!Y6VP.HS9G43JUD|/4_N|=GMMDGT|O=L\$Z3Z-UU>FU|V\DBG><_D%|M9'J-
%*VF;:'>WU6_;;-UK>|W/>63,_#A|]M/M5B+DMW:9JLMXBRB+*(>BRB
MGBX*S2*J&8C:??+S|=L052-|=^,=BS(!6!<%W_S;V.K'MIC7-SBKC;6Y?A)L
M/L6|3O_@R11%2_\$:4+S3=GK=^IS=K9|&FT_R@;-7(R:OD5*U|4Y\$Z!HOV"%Y
M,EER0X.|:@6O4KCSM/8IF,/V8?NP?=@^;|^;T4>--OF-JYQ43@HO5ESE9!TJ
M:S"VUIH5#<";#Z|UYK94+?UWWQR|_K66|HD>A_4AJPU4K VWHM24;^W7DC
MIE6SUE\$PI39|N?|UWWQR|^KCS%[_^F|^N;N=/4OO!M&|XPS66HJEMHI6TSQ9
MYR))X|Q-,SJMSZ%T?|JZ1
M9M4T%|;02!YDT9CYX;4(TRB>P|C\$;";>;63VKR9RY_N6WU+;4MM2VU'Z>U*Y3-M@'V-
M*RF^:|.2|'66&Z4R4)95(X4?Q>A.|3(WTX(WW-KZA6@Y#2B|4FM*48?|V:<'M|.-
%V2@05?ZIU0VO#Q|VSQGL|JEE957&|S5Q+VD>QKK.H+^VTE,68XW 6*?C
MM'>M(+,@^Y'#WG/V^T|6S/?;,*TY!P|RCRYJ"PI1QF|O;%B^5ZY,^5P?W|
MIA@(C:.D*RI546F*Y?YGV(?G7S,WX\$GRV|;G#^_ ^V*HN4+N|O8P"ZAA/YS")#"&SQ-
&%2=0_&&E<8S\$7(27227,AK^WJ;_669/J\$=;KZL3
M_OW|>3YA3N'?.:G/&#G(HFRV,7;*I1QLDD3IZ=^Z &L?^GMRL"/!/,|]+L0L%=.1
MB%D/9%.WW>T|+)|T(=AA-9SR&K&?^DYOL,MXRMX+5S7>H<9|+7:6Q6P6^Z'KSZ
%M>;84E"0)5TR M+ #P327PR(K';OK/7;>_Y05M?NHZ|?8^_L1=%Q@C35@,W?O7*+5:|!
(F!;W& M@B?X'PMS|9-B6 &.(8W|448B#^>4KT\$T\$S%/Y9?0|SB(;A+FR;AD7+C0#P6;M
H\$F"1.PX-{2)8:U2GWJ*|J/\$Y&R\$73)KJ, QLWC.3R?>|J\$-!>3 O;M-AX7
M8?.7(IZRCQ\$/\$|83=B."/_%)^DD%H(E|D1X62#*5<&Q/2KN U.!R>)8?^HY
MO;U|JPE(/PL-&N#J=|N=@S+,2=S#HODAT)H#%H&(""[XS4|9OX*EQ?4#:9E.
MV*7LI'3UK!% PM+SX_|.\$G9(0#POP((3Z_ ^@T|G;|AE MG.\$3.0N %=[!XVDHZLG1H#D
J35@L.B!3%\$ \$L%W3861YKM5YJ*>'|-2|<|1:'Y|'(<(6(=>&5+!'T%\$AL(T?4-3CDD"
(\$4|G@|P4=9&(@\$A4\$H;| OTN*=;(8E M|&>X;-:K+0Q<)QG9^|
+'>\$1|(T3IPP\$7;IY\$&\$)'C&*XG&B36!MVDN1L.-MX+FA)IL7AF: S!7))?(WS*@?
5@Z#Z2>H;R%CE1P#<,'X.*%T:2#YKRA|_HXN#F.?%-? M|B(J(SU#ZA%, 'C'N7B-
X%4AS+\$9QAHJ'GOA?ATAE(ZD^_|>2N_->M%%6>-%0>
MV@+D)J'U1U!R0/23FM0QM|>71<>YQL2&Y>UK"! (BPIV(>BBD='4BP%7<1Q\$F
M|PSVU)?C|GXUCJ,|_H"W2P6N*UY^;#-\$@'P^:SPZ; Z|Q-(V+|JC)T592O
M"P&JOL>&"F2(/4S_PXH*|Z),?W0GVG*Q+^L2#R3O(>^8NHKQV*UPY%(X0(
M|V"/%ON-RC&92O* XJHR"X#@|CS"#4"^8(>E('JG3-51VM65-M)A38P9\$9?
=+&DE*RW4WU|7!ZFH;@G6Y6;!734%LRMK.0%I%Y4V5..QV6;\$273?.Q'=2L0H(T!/9MEJ?
&2!#"P+4=22:0'?QF/?|=6V/L|(#)=&K*C.OF#L M1MG51*YXL7GM4ZO|V"1^X*);-
,SQ;+D5?JZ*I;N^.|=@L:7:WAJJ%+|+@|4H M=+QBO,OU.|G):0W.WP9#
M(B9A,76J2B#R@"?<@(:.@|9N-(+U)F|3(DT2 |)H|J-5Y\$^G,%!H'UC;P|Y1
MIDA9(1EL)0W&64QS64*+&_ #2^_EV3DU>L/C&/#@BZKQ_<;X\$"\$P#7T0.LI) MIF|P3H
X,.*R/T"NFOYFKI#> 7N M("F50 75_*/O&V\$B!MDGJRQH#L\$T8*;'7 V;%_B_2!7?
4*!W\$M8@|_<8|/M9B|?CM!7.
^05(Q|,REHUJS3Z@ZPLTX+%0KX49"WM|A#T(!C;HUD6|Y;.0N|CQEU6!&XXLC2=?@2^
MIW;M<=>IW4Z3N"B+XIMC.\$HVVUHL5,|8H|Z+ #1
M)|":WM1!*, ^B!AQRV;/#|A1;4HOL;X%AY\$>@/D
MU|!7DK;Z(-^ZWD+*)J;RN.0.CNK!3W\$BK=|(8=75|JS.>|N'+|^WRIF@Y|BA M=|-%6|
<%O5:>| %!L#I| JHU8K1ZU*=V?SK%;K'3"%TZH%33Z8P+.A90|PH0 M%1H86S6JU|'2-?Q
D+"+290%9=?>"= "AQ=|E:1;3 MRV

Y^/"LB\$E8.5M'3S>1_>0%E'TOH4G)\$U[E(L,):6:5.54=K@2(:@G(H|>=<
M%J!8"B,R#,4^0%:ZTW\$76UKP81#2GA 0U)B"&9&4HB.7?W<6:J)-!=(R1OE
MT;D+I8^1)G*N&A8&O?1X0X\$Z)EI<,#09D_1?Y6X7M)I60N5\$DIL|#""7 C&&0
MR:/I7ZRK\$>GR+<2'=9H6-(5&R-B|0>(5.);GWP^EH^@FJR|FZ+.4K;+U_*&
M@#VBPSS84V3P#M+4@T5.!((\$NG@ (BFR"H|9P-L? !9GR6,YNPL#U@:HC9\$.J2
MKB@<,KT_,JXO IQX_GXAVQX0W41&T4_|SNZ@1SXK,S3,7=\$;J/LHSPD\$6R@|ZHY29/
\$S =H/18JM1E.A^2VW#<<4CF,.#H8N9TX^ M/6S:BVDS4BXDXW0B44=_N2Z[>\$SA5\$.
|_B\$12G(0BJ|_/7OI6/D'1T2\$(,U5&F36??.=C05^R;Q:.S_/W= M-
O4ZRV(7ME_I\$4W0XB5'H^2=R.%>OCXP54\KX<"JF|6-; 'WDKF;CL|,\$3
M#1C_GM,^.)#|'|>\$OYQJ*2<5W.*JBN G"6U@W(|%'@?=N!R|5C%^Q8VVZW8WC-MW,+
|5AS+M2_,#YS|O<'=&|+2|NBDN4/FO1%J*R->|JL?-H|0%,1^B,H1^G^'
M,M@9U^1S%/BNUH&/X#M4B1H3SXZ!Y9Z?N%F2Z% O4%>#>>(3?A2N4^_0JF=
MZG"/+)#*"H8N M_(:J/H?"|*Z.#)PTV4BO-0WCOMNT6S%*"YJD^VR.G^@B#
M1!|=)!|_YVK"/&MCD*0&BM&;QY@I9,H M\$?E E'('0FVV""9PSR)PHJ=Y?JQFTW1S>EJ|9
H<0."BI-!IQTB1O@6PXKX)4?(0G MC-*|C>,Y/L2E\$P:-J@NLR ODP*,6&)V^VB^?
(3KQE)7,1U(@569&"S<""A51
M(Z1C7Q_P\$.AL&A4SV##=- (Q+DT)#3K(H|O1(027%SL71H4RN 7SB M)#->#TSQW-2^?
|02ZY+ABA|UTD8 *-D(3 ,&:@3&X9|Q6"H43LFE8F 8^8^3
MV=*@BB@2F*=:Z!E.B_*,\$,2^2X\$523;ZC|1@T?| AWGBUI0JT1@#:T"#X:IO
M+3Q"89Q'&D@|SE3G|,5*^"&&%9 G+ OUF;UI=:.\$?1#8",VJQ8Q@-E^?(GH"7 M
R51U1:G!|=2BE2#!!)0E\$ZC5+">?H1_)9H.ASEF#DW, '?K?U%L,E+ ":FL8
M9-_|F/L|&;>1D#W^1 MD9U'I4U|6.AQ*(8V;N8K5)@*+):.%!3<\$J(VBM|YW&"1D|CM"N-
@8+E|L: I M*POCI?|*.R7O,C6J:JP# 'YI?/M+,8%| #3*ZE)"8?8Z+S#=/39S7+|2MH?Y:- M
C^9"\$|:C"..Z9 H6 BI6.KDBL64Y,C8._XHY>>#2DFPP=TQ0+V)!3BTM2
MVE8#1FD^_BB(/#QQ1^,,:%O),, '*B|=OBW =^CR0"S2+
MZ)25!R7H5Q=WRCTR4M:R1!@F>&<|_ (#W;2D1 &^K+"9<<9^L0N-X5|OK2=46
M7.B+PAQC<94%/):&K3I&J-B8+IWIE:W,:+.M3-JEDT3UV/+QXQS"SZ^*0|09M7
E'#=9_:ZS13FGQSE!CHG>E@7SMP|BOS#>P M8Q#R?
BKYFA(P5%MZUR!!47!C'JTJDV<".JR^F8@0 V'SC("X|_|?C"^G*)5 M4G5HA/4H1(P;+^7
J1|+-3782U3E5"#P'#.I1>B|:K&3I2+D MH=.F"!^,!:!XV-%<^>OU'C6&H6?2>N2S9*+
<%,QDOZY)7W*B.6WH@BKGSY6""@Q0"<8I6H,8&K+JFB4A"A(8-*
M5,'=3|QMO!IES9>YYDKT\$+"K M
S.*SD'%58EZT@FTXDRDH8PL|K6KW#MI*Z)IZ*,Y|J8L&JHWH :,4ZD5|.-> M?RUV|
(VD\$R>"\$H>|T0Z|)5C7MR*V,4@/>TH(I4E=_CG8D|'_NFK1UXF>8ZB
MLK|2|K+SB0FX|D 1_:'Q/DXT+|V|?ZL"#GK"8+5WRPV@|J"T'|D'6.00YKFX
MJOU2XJ|2|U6^Y^=S*.*BI,T%K_5?Y5;9JK?TSIU(;XA8-2)E|_|>Y1#)C4(
M0(Q3!NCRCZDV\$4W^TC0+W06J,CJF.QO*!1\$IU6KLR1JDQ=KA8Z*O#M-1MK:
MDFH@LSSA3B8J!(CB+U\$SE\$Y|4Z20VS# 'KCP>AT|UVK&4532:%CLO9C0%G9EJ
M(JE@ML(SHC\$H5^A&* Y03";P. 9 %H2U=V0 U?,57A,C \$62&M0=-I0!B/+
M14@P"Z^2MHI8|"BAP15ZQ|7OH;&=?R332ZFXWJ.W&AVXH)LB!|JR8JGF0OP##
MM=&_@J8+G>>1ZTS*Q3RC&-,1Z41Z)=KSU+|9E,*.K!2|FV.2!+ #&':H' E
M3:52K,^JTW;#W,=HT0D'B211 MPGM@!I0.6T,6T;YXB!1(CD&(XY?_5IY'2 MPV.
(T*12RD7Y@LQ2\$1B'C<4BKI0F7O"|HIFRW&0A-O@.OI=A|F,2AS&- B%, M%1GU(
>*AL+*M#E*Q/,C|T=+*|P-^:J+:Z-<:TH<
MEX,JY4B2^|9!JE>2%IL_+7*QERT|FC<|S)0N+H..B2M!%Q2P#212%N*#%GM_ M|PB*X
X\$|/4_6V"G%Y!=(5RRDUT0" PM5'CYJ-ZK,,9
MXZ1<4(&V#73;+DT8*#R^N%.\$V)MRU6+TJH|;945R2B5CHK8MC')%|() /<^/
M.0KQ(|M|%=|C3D1I9.5O2DY&_+=0FHH<6)Y69|@3Y9|4!&|+E?=P3YBUCL'U-
W%2PP5Y*%+"R O)*JE5|LM\$))B4KM6 M87\$722.OI+#UZ\$U?-
F^4QVNQ=UH=R:/F#%#3EE&^"JK/!90.9*""|)C #JW M1W?"4"\$'XBO<;-0\$D
ERJD+3PGA7YLG\$7P4IG%K.?\$|!8*,C|HV.Z-OHB.>J MK^&RZ_
T+LB4|ZK0:7>;'N|VJ_2JD* M;X3!_PVT5)QTT-^9@:UI/P!I#Q\$)VX4E+RO-
X+LG|SRKI"Z|,*521P8&,!= M==XK9V;Z=JO^7*=J_-&SPD+?:{683'M\$)E*8S4
M2"GRR)PU8WMUWC=0#>P42=B<8HU@!O0Y2E?)3AKMZ\$--29=*B7)Y|X0|J)->
M%Q1'(#MZ;:QSFI@A>3+JQE ("C:0ETXD|,|H4/)3LJGI#_U2D<.I8,4.I+1
M:1V5)*_221H2G=S9"+\$H"G%N(|&C?|T|(!>5=#' <(-5XEDDJ|0 H101#E! ME).F;
>1^9SHRKUZZ#H9Q7 3H700HJ>L7RNJFQ2T\$MXA0A79T/%7->TI%QI
MQ^'^C<#I4%XN)^TXPHL7B43Y80OI=,|1H|. =+E7UC@GEB56J;QPX>4L/'+*

MM60AT+3HDQHPB/V\$T?2K"^-@6W\$N7%S[W%*A8V769)JY":
M2N"L3">:ZiHL3D5BYP5Z9/ 6?#R2%62P*>+ @H)S!Y; M6BV)0G(P! I/\$V36
QV0%@[6(D%3'SFH|X!1DR)HU2AD36&K&X=I%96#,J.4 MG15'882."MH3-
S|\$IR^UZ85LN>^:(\$>;%:-N2-S8GQ5LYDJEI4@*#BV^9AKR M I43+E3&J.8V(UV4
BR4^(%56Q98_)1F|/+H^,2P",7K+X,1?1F>7IY<
M#B|/_M1&YZ^9_#1_WW^Y.+PX|G%U_.CR[8\W9ETOV:7C^Q|\$E.S^Y^*) M913R+
6*1PM1L)LGNM(DT\;E'/;OL#E=X_F?44F)ZK48Q5A4Z:#R1A)&-Z0+ M4Y8K[%#2IXH7
099@7DP4"X<< T5#4Y3(-3R0-%6JXL#E# VTQ:KY0(,URJ
MRI.:JWXRWF19I_,B&B66Y0'BPB&;YRB7OI1G09O)7C|JYS3+0|T^==@BUECG
MJB1D_^2AO(SBOGMN%K U\$=X5N4&,"#4|9P907>F\ #K*Q6 O6=[.Q"HQY,7| MUX?
#|V682K^,|KKDJ?ZRIO%2XE*<0^+@|ZAHV,=:H8E,G6B\$,14W?0:NM|
M7AP=|%781|H|0;WT6MW\IEJIA5P)>9"+NA&<<1Q@Z=T\$906(KS"VN9^Z>J=AU
IJ6J@E\N_,M*BAO,'MMOQ(/YT|*|_I'A@3XIKOL63(!HV>' M|BTK5#,CPY0\$|1WEXS
RfW#:68+12"8N\$5KGS ME?/2C*Z,DLVXWX|1::AL!X|?BT6\$DQ<58^Q*
(ZPT)!U1*O|/A5*1XS\/'/;' M5<|!SM'S'ZH\;GAK^90&4)-P|2ZT8!-=6.0 M'YKA:&-
+|1UHP.^N=/G1Z8|Q4W*4D=F/8Q=D6^GL;|<|/O&U&*YY<8I=!"Y M2EU-SN4UESER,
@;6I6D+P+&1W@=M2K\$*>=H,#RH*&*NC" 3.Z1H>5%^!.)*
M/W,NPE#J:U5SQ;&8E7G+M.*5V:E6-H_="|=&/W=M')Z=7IZ??;S0?Z-WX_/Y
MV>'1>W1H/+|!(M75U\$\$_|;5W@(-+0AFJ\$J'5_G?R8R|^N^5&IXVL-J@5H%R M^+<7?
_O;K^DH\N9O?TUSA8W"+T&|U|I2&LWH97S7J|2MQ*,>;NJM>*^S3^1
MP^5FYL*:.5+%Q');L3|^4|5&|UU"=<"-/X>%|_2Z(G'!6@Z*AT)&-%OZGPV MT:=,
(+"PYF0K!YPQ&_@W1A+"OY*"KPDGZW465)GSH0Z"I3X!PVN0_|J|.I6_ MY.I7DLTP'3
04YJ'36-80#2/C4I-A:07K&Z)3PXGOABSHU08%BB8X@P+VM%|M?
9YZ5OBGU3.'DA|*M*1D&?*&8<5R=0A"(8X"SUJD4E>JTAZI2JMW(Z!Z7^%Y MAF?IG1|?
Z0Q>"AGUW1EXZJ|";TH=KDC|<48NB3?.P>|/C6K+Z"FVW^W|*I%
MXTTT\$;9>.2NOW:*P,EGDC|(KC=!Q/\$S\$6Q_G6138J?<\$N_#5HOT^P,E;H92
M|53S,PS;R0M+:C*L0@=D>.!01#T_ML68?
I2#*8HNJ|)\$Z3D|UL4(=NU/D3|3+"899|K:\$42E8JR?L.|*OEL/MT|
MFTTS6=A5A*ND*+ "_OV.'& MI1UN_&J%%'|U^\$#:PO9;?N@!;
<&5DU=HLHD*Y\$@0XQ5<*Y M|4-1*MH|/0',L4(5-Z1N|J/ZK1P4|! U)MU&!2
S(1\$NZH#3@ M(.5?12L7X?0A%9P8Z;LOKJFXK;;LC*(D%)N)62.1-# 3RMZF&H2!#,@D-
KB) MJ*>(L@BB&4H'S-8KQ<4AF&2)"59H\$J6&#R/0?>2VTT.S6^0=|C^5=|HD
MOU'3M+B\$@|0L?Q)%5+I+G1;(LI!FJ1.UT&%492_95DO#(D GF8OU_67M*DP|
MI>,7M.Q3,G2O(JST*M5*Y*"BO*3JNPA(:F\$@)PE'Y<(Q:G6H-(CWJ@?
3(^T!|V#"%'45>N/|B'M|'G@H3/(:B;01/J5T&>E/!S,KI MX
D|Y1C+5^W7EQ(\$)=D#;|X9|PAUT;_E 3H:|H6%6;/P_/+|G)R7W'-S^D
M|/+WX_.V/1A^%>7IV|/|D|,-3'Y^M M|YH*X^9V54G(#Z^C0-U_2I5S9\$
BA2=6;KV2E;NK|>@Z6%%N+3HN?=GM/K*N
M^^+E/K1HQU1/#C=.5_KGDPQO)B;)+SRJJ^"Z&^=LT@'H>B!JA1#J270!?4P
M!/P8R_F|(-@H?^|*E890)@|>81P>VKO!>\$?6+)?UXN,K'N9UV+%%\$@#?/@RFC MV-
'QE7C%0""|JUS_6' X5V_I<|D|5R'^5UB^C<(H.88076,|=T>WB |-
=L@=+@|C3/I6E:+ZMGJF\$|+3|Z',U M&;E+H|G"T2F3JF);&%2=%'Y2#S,T: UT>!9N-
4^D+N:*3&;8HTX=#P|O MS|X;
(/Z>:C;ZANJEMX!5E9!0|P)C;)\$ZJ*5VBH(0YEL,Y(23.9WF765AE1= M72?G0/O'6\$RMT|
|Y@R+NEM18AY;;,NSZ#MLQ7="5G^;B41@T|HG'@/ON@2X2_M_:ETB3HY-
6YDW<1E\$3|YEJD, %29"NH2,#DAC%MB,(@3-&\$Z0T=S|)#W3PE?N MFH_*KOC?*,
X'N10%X8YSM!YK-T6JDA.:6Q2F?V4\$"6|=3+(>N|F2=^*LOT
MCDPIS"2GKI7|*KI+|H4",#JE8&YGY;UQVI*)HT1F0KKZ|OB02@!A%0.5/+6!
M3@1#T^GFFLZ7T_.C#R<7H.4?O6<7PX|'%^SLF!W|Z|O)Y?|B@K^8#[4 MZ7OVY>
((R|J|J#RZ12,G0T&@T9"K|7>'QT/OWR|O&!/?I^= O5/3|.|.#1 T
MA>#E@T)/D\$|,5|D0H4_UO/,@E>KYW8-N/'_JW(RRK?SB5_|6/@M/<>.4F6NX M#.=B_-
N6JW|XO)UV!_Y7_>?!3J^|Q4(^A6\$*U_OE4QH'&&R=G(T08V|8QY?P M|;L
%,TMYGN_;;E|>_M;#/96L8-J@|@/_= W9GXGO0XB_NWGX;EO;N-
SKWOM&|JXW>UMLP^04UOO1VZ3|K MK
_N1;-45M20A0ED<)"^BA2/YD'U&0UV.IA2);/.BG*?JH@LF53Z\$^"/G7L^
M<_1WNO@|A3S|H: TLKZ|?V7_!5J|..2DD2-Y&+GCZ>3 K^^+K"|K'PU#RZ MF_/HT?_|?
O+NY/*YQ"D_8GVDRY*;!8_|ME.,363WY?|Z=?V0G*@2*O8|<2IQD.RID1OWNZ=_Sj\$
^FZ%75P5-4)0XEP%A M|WG*4)!\$8.!YTS43|JO5-H*&(6>5|V, >D^UL(ZTSA"X.?V|NA"

[Y+18H MFL/&DN*!!UJ>[D1,>8ZIYT3*P^%'2TJ#E(<|<+5#X:;??L68M6=)V/='QY:P M!F'?
RVN:GSU=/P[?6;H:=/W(1R)XWB3]?'YD26J0|+,LL/GLA7"-650H'2'
MSUCF;;F6_/(-^93A7RF6V0E'VJ4@:<@RXY57-LI>>:Z3RGHU4KLG9XXIHX8N3 M#Z?
#RS74FEE;G(#I>Y'I-I3LGY?"QEC M!U@WTLPL K=-D|&2|GT+%4N=-
&9!4+GTI%3W@PUODUE"(B7W!D\$DJ&=2>I
M09ZEDXB*/3Q|;N\WG+7=5=JUDJ*Z*&,>^*)6)PM_KR\$M)!A7LY#5%JN'/L"1 M?
^?. 'UU"J]YU+F'AP?5R8#SG.>*7:B\$@D#\$X+>M[M8#UZNWT>U=ZSX?
QA>+7!CZ@M>W9CR^+N^S=?S40A[6C96LX|\.GH4!6V?/O:&&'X<7ESM%M-
Y"|.#QY7GEM\EX)XYN%G|\$7Q\$K1QM^GP## M_9UR?%XE6@_ ^0ZWA))T&;_4\$L!
A0#% @ RCMN60W+8LJG!P @#\$ M T (! &5X7S%\W-#\$U.34N:'1M4\$L! A0#% @
RCMN652@P*RY P F | T M (-!1, &5X7S!&T(X+ #,EP %0 @ &" M) 9G1L9BTR,#
(T,#DS,%J)C86PN>&UL4\$L! A0#% @ RCMN69VFTY.? M-0 G'4\$!4 (-!0S &9T;&8M,C R-#
Y,S! ?9&5F+GAM M;%!+ 0(4 Q0 (,H|;EF|_?/_ ,DH *(7! 5 " 15F M
!F=&QF+3(P,C0P.3,P7VQA8BYX;6Q02P\$"% ,4 " #*.VY9PVE\$0JDX M !&UL M4\$L! A0#%
@ RCMN6:4T_>+'\$P\$ _1X1 !0 (-!5ND K &9T;&8R,#(T,#DS,%|Q,'\$N:'1M4\$L%!@*H>0(
\$_J 0 \$! end XML 62 ftlf20240930_10q_hm.xml IDEA: XBRL DOCUMENT 0001374328
2024-01-01 2024-09-30 0001374328 ftlf:AssetsOfMusclepharmCorporationMember
2023-10-10 0001374328 ftlf:AssetsOfMusclepharmCorporationMember
ftlf:BrandsMember 2023-10-10 2023-10-10 0001374328
ftlf:AssetsOfMusclepharmCorporationMember ftlf:InventoryIntangibleAssetsMember
2023-10-10 0001374328 ftlf:AssetsOfMusclepharmCorporationMember 2023-10-10
2023-10-10 0001374328 ftlf:MimisRockCorpMember 2023-01-01 2023-09-30
0001374328 ftlf:MimisRockCorpMember 2024-01-01 2024-09-30 0001374328
ftlf:MimisRockCorpMember 2023-07-01 2023-09-30 0001374328
ftlf:MimisRockCorpMember 2024-07-01 2024-09-30 0001374328
ftlf:MimisRockCorpMember 2023-02-28 0001374328 ftlf:MimisRockCorpMember
2023-02-28 2023-02-28 0001374328 2024-09-30 0001374328 us-
gaap:EmployeeStockOptionMember 2023-01-01 2023-09-30 0001374328 us-
gaap:EmployeeStockOptionMember 2024-01-01 2024-09-30 0001374328 us-
gaap:EmployeeStockOptionMember 2023-07-01 2023-09-30 0001374328 us-
gaap:EmployeeStockOptionMember 2024-07-01 2024-09-30 0001374328 us-
gaap:EmployeeStockOptionMember 2024-08-01 2024-08-31 0001374328 2024-08-01
2024-08-31 0001374328 2024-08-31 0001374328 ftlf:RangeTwoMember 2024-09-30
0001374328 ftlf:RangeTwoMember 2024-01-01 2024-09-30 0001374328
ftlf:RangeOneMember 2024-09-30 0001374328 ftlf:RangeOneMember 2024-01-01
2024-09-30 0001374328 2023-01-01 2023-12-31 0001374328 2023-12-31 0001374328
ftlf:ShareRepurchaseProgramMember 2024-09-30 0001374328
ftlf:ShareRepurchaseProgramMember 2024-01-01 2024-06-03 0001374328
ftlf:ShareRepurchaseProgramMember 2023-01-01 2023-09-30 0001374328
ftlf:ShareRepurchaseProgramMember 2023-03-17 2023-03-17 0001374328
ftlf:ShareRepurchaseProgramMember 2023-03-17 0001374328 us-
gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-09-30 0001374328 us-
gaap:RestrictedStockUnitsRSUMember 2023-07-01 2023-09-30 0001374328 2021-02-
01 2021-02-28 0001374328 us-gaap:RevolvingCreditFacilityMember 2023-12-31
0001374328 us-gaap:RevolvingCreditFacilityMember 2024-09-30 0001374328
ftlf:TermLoanMember 2023-12-31 0001374328 ftlf:TermLoanMember 2024-09-30
0001374328 ftlf:TermLoansMember 2023-10-10 0001374328 ftlf:TermLoanMember
2023-10-10 0001374328 us-gaap:RevolvingCreditFacilityMember 2023-02-23 2023-02-
23 0001374328 ftlf:TermLoanAMember 2024-01-01 2024-03-31 0001374328
ftlf:TermLoanBMember 2023-10-10 2023-10-10 0001374328 ftlf:TermLoanAMember
2023-10-10 2023-10-10 0001374328 2023-10-10 2023-10-10 0001374328
ftlf:TermLoansMember 2023-10-10 2023-10-10 0001374328 us-
gaap:RevolvingCreditFacilityMember 2023-10-10 0001374328 ftlf:TermLoanBMember
2023-10-10 0001374328 us-gaap:RevolvingCreditFacilityMember 2023-02-23
0001374328 ftlf:TermLoanMember 2023-02-23 0001374328 ftlf:TermLoansMember
2023-12-31 0001374328 ftlf:TermLoansMember 2024-09-30 0001374328
ftlf:TermLoanBMember 2023-12-31 0001374328 ftlf:TermLoanBMember 2024-09-30
0001374328 ftlf:TermLoanAMember 2023-12-31 0001374328 ftlf:TermLoanAMember

~~2024-09-30 0001374328 2023-01-01 2023-09-30 0001374328 2023-07-01 2023-09-30
0001374328 2024-07-01 2024-09-30 0001374328 srt:MaximumMember 2024-09-30
0001374328 srt:MinimumMember 2024-09-30 0001374328 us-
gaap:AssetPledgedAsCollateralMember ftlf:FinancingArrangementsMember 2024-09-
30 0001374328 ftlf:InventoryrelatedPurchasesMember us-
gaap:SupplierConcentrationRiskMember ftlf:VendorTwoMember 2024-01-01 2024-09-
30 0001374328 ftlf:InventoryrelatedPurchasesMember us-
gaap:SupplierConcentrationRiskMember ftlf:VendorOneMember 2023-01-01 2023-12-
31 0001374328 ftlf:InventoryrelatedPurchasesMember us-
gaap:SupplierConcentrationRiskMember ftlf:TwoVendorsMember 2024-01-01 2024-09-
30 0001374328 ftlf:InventoryrelatedPurchasesMember us-
gaap:SupplierConcentrationRiskMember ftlf:TwoVendorsMember 2023-01-01 2023-09-
30 0001374328 us-gaap:AccountsPayableMember us-
gaap:SupplierConcentrationRiskMember ftlf:VendorOneMember 2024-01-01 2024-09-
30 0001374328 us-gaap:AccountsPayableMember us-
gaap:SupplierConcentrationRiskMember ftlf:VendorTwoMember 2023-01-01 2023-12-
31 0001374328 ftlf:OneVendorMember us-gaap:AccountsPayableMember us-
gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001374328
ftlf:OneVendorMember us-gaap:AccountsPayableMember us-
gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001374328
ftlf:GNCMember us-gaap:AccountsReceivableMember us-
gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001374328
ftlf:GNCMember us-gaap:AccountsReceivableMember us-
gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001374328
ftlf:GNCMember us-gaap:SalesRevenueNetMember us-
gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0001374328
ftlf:GNCMember us-gaap:SalesRevenueNetMember us-
gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001374328
ftlf:GNCMember us-gaap:SalesRevenueNetMember us-
gaap:CustomerConcentrationRiskMember 2023-07-01 2023-09-30 0001374328
ftlf:GNCMember us-gaap:SalesRevenueNetMember us-
gaap:CustomerConcentrationRiskMember 2024-07-01 2024-09-30 0001374328
ftlf:MusclePharmMember 2024-01-01 2024-09-30 0001374328
ftlf:MusclePharmMember 2024-07-01 2024-09-30 0001374328 ftlf:MRCMember 2023-
01-01 2023-09-30 0001374328 ftlf:MRCMember 2024-01-01 2024-09-30 0001374328
ftlf:MRCMember 2023-07-01 2023-09-30 0001374328 ftlf:MRCMember 2024-07-01
2024-09-30 0001374328 ftlf:LegacyFitLifeMember 2023-01-01 2023-09-30 0001374328
ftlf:LegacyFitLifeMember 2024-01-01 2024-09-30 0001374328
ftlf:LegacyFitLifeMember 2023-07-01 2023-09-30 0001374328
ftlf:LegacyFitLifeMember 2024-07-01 2024-09-30 0001374328 country:US us-
gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2023-
01-01 2023-09-30 0001374328 country:US us-gaap:SalesRevenueNetMember us-
gaap:GeographicConcentrationRiskMember 2024-01-01 2024-09-30 0001374328
country:US us-gaap:SalesRevenueNetMember us-
gaap:GeographicConcentrationRiskMember 2023-07-01 2023-09-30 0001374328
country:US us-gaap:SalesRevenueNetMember us-
gaap:GeographicConcentrationRiskMember 2024-07-01 2024-09-30 0001374328
ftlf:WholesaleSalesMember us-gaap:SalesRevenueNetMember us-
gaap:ProductConcentrationRiskMember 2023-01-01 2023-09-30 0001374328
ftlf:WholesaleSalesMember us-gaap:SalesRevenueNetMember us-
gaap:ProductConcentrationRiskMember 2024-01-01 2024-09-30 0001374328
ftlf:OnlineSalesMember us-gaap:SalesRevenueNetMember us-
gaap:ProductConcentrationRiskMember 2023-01-01 2023-09-30 0001374328
ftlf:OnlineSalesMember us-gaap:SalesRevenueNetMember us-
gaap:ProductConcentrationRiskMember 2024-01-01 2024-09-30 0001374328
ftlf:WholesaleSalesMember us-gaap:SalesRevenueNetMember us-
gaap:ProductConcentrationRiskMember 2024-07-01 2024-09-30 0001374328
ftlf:WholesaleSalesMember us-gaap:SalesRevenueNetMember us-~~

~~gaap:ProductConcentrationRiskMember 2023-07-01 2023-09-30 0001374328~~
~~ftlf:OnlineSalesMember us-gaap:SalesRevenueNetMember us-~~
~~gaap:ProductConcentrationRiskMember 2023-07-01 2023-09-30 0001374328~~
~~ftlf:OnlineSalesMember us-gaap:SalesRevenueNetMember us-~~
~~gaap:ProductConcentrationRiskMember 2024-07-01 2024-09-30 0001374328 us-~~
~~gaap:SeriesAPreferredStockMember 2024-09-30 0001374328 2023-09-30 0001374328~~
~~2022-12-31 0001374328 us-~~
~~gaap:AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMe~~
~~2023-09-30 0001374328 us-gaap:RetainedEarningsMember 2023-09-30 0001374328~~
~~us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001374328 us-~~
~~gaap:CommonStockMember 2023-09-30 0001374328 us-~~
~~gaap:AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMe~~
~~2023-01-01 2023-09-30 0001374328 us-gaap:RetainedEarningsMember 2023-01-01~~
~~2023-09-30 0001374328 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-09-~~
~~30 0001374328 us-gaap:CommonStockMember 2023-01-01 2023-09-30 0001374328~~
~~us-~~
~~gaap:AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMe~~
~~2022-12-31 0001374328 us-gaap:RetainedEarningsMember 2022-12-31 0001374328~~
~~us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001374328 us-~~
~~gaap:CommonStockMember 2022-12-31 0001374328 us-~~
~~gaap:AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMe~~
~~2023-07-01 2023-09-30 0001374328 us-gaap:RetainedEarningsMember 2023-07-01~~
~~2023-09-30 0001374328 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-~~
~~30 0001374328 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001374328~~
~~2023-06-30 0001374328 us-~~
~~gaap:AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMe~~
~~2023-06-30 0001374328 us-gaap:RetainedEarningsMember 2023-06-30 0001374328~~
~~us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001374328 us-~~
~~gaap:CommonStockMember 2023-06-30 0001374328 us-~~
~~gaap:AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMe~~
~~2024-09-30 0001374328 us-gaap:RetainedEarningsMember 2024-09-30 0001374328~~
~~us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001374328 us-~~
~~gaap:CommonStockMember 2024-09-30 0001374328 us-~~
~~gaap:AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMe~~
~~2024-01-01 2024-09-30 0001374328 us-gaap:RetainedEarningsMember 2024-01-01~~
~~2024-09-30 0001374328 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-09-~~
~~30 0001374328 us-gaap:CommonStockMember 2024-01-01 2024-09-30 0001374328~~
~~us-~~
~~gaap:AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMe~~
~~2023-12-31 0001374328 us-gaap:RetainedEarningsMember 2023-12-31 0001374328~~
~~us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001374328 us-~~
~~gaap:CommonStockMember 2023-12-31 0001374328 us-~~
~~gaap:AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMe~~
~~2024-07-01 2024-09-30 0001374328 us-gaap:RetainedEarningsMember 2024-07-01~~
~~2024-09-30 0001374328 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-~~
~~30 0001374328 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001374328~~
~~2024-06-30 0001374328 us-~~
~~gaap:AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMe~~
~~2024-06-30 0001374328 us-gaap:RetainedEarningsMember 2024-06-30 0001374328~~
~~us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001374328 us-~~
~~gaap:CommonStockMember 2024-06-30 0001374328 2024-03-31 0001374328 2024-11-~~
~~13 thunderdome:item iso4217:USD iso4217:USD shares pure utr:Y shares utr:M Q3~~
~~2024 --12-31 false 0001374328 false false false false P5Y 0 0 0 0 http://fasb.org/us-~~
~~gaap/2024#SecuredOvernightFinancingRateSofrMember 2 2 1 1 0 0 10-Q true 2024-~~
~~09-30 false 000-52369 FITLIFE BRANDS, INC. NV 20-3464383 5214 S. 136th Street~~
~~Omaha NE 68137 402-991-5618 Common Stock, par value \$0.01 per share FTLF~~
~~NASDAQ Yes Yes Non-accelerated Filer true false false 4598241 4664000 1139000~~
~~56000 759000 19000 17000 2008000 2046000 86000 162000 10371000 9091000~~

58000 1019000 942000 639000 18099000 14693000 91000 137000 431000 121000
143000 113000 26314000 26309000 13130000 13294000 522000 792000 58587000
55346000 4078000 3261000 957000 1026000 1861000 892000 570000 571000
4500000 4500000 89000 87000 12055000 10337000 9664000 15509000 352000 51000
2358000 2413000 24429000 28310000 0.01 0.01 10000000 10000000 0 0 0.01 0.01
60000000 60000000 4598000 4598000 4598000 4598000 46000 46000 31043000
30699000 3497000 -3417000 -428000 -292000 34158000 27036000 58587000
55346000 15977000 13902000 49456000 39401000 8976000 8206000 27588000
23332000 7001000 5696000 21868000 16069000 1093000 1275000 3647000 3359000
2645000 1897000 7681000 5399000 59000 32000 217000 1519000 22000 22000
85000 64000 3819000 3226000 11630000 10341000 3182000 2470000 10238000
5728000 19000 119000 41000 269000 326000 249000 1085000 598000 21000 -210000
26000 -93000 -286000 -340000 -1018000 -422000 2896000 2130000 9220000 5306000
770000 434000 2306000 1490000 2126000 1696000 6914000 3816000 0.46 0.38 1.5
0.86 0.43 0.35 1.4 0.78 4598000 4446000 4598000 4458000 4965000 4891000
4943000 4901000 2126000 1696000 6914000 3816000 35000 -318000 -136000 -49000
2161000 1378000 6778000 3767000 4598000 46000 30902000 1371000 -463000
31856000 0 141000 0 0 141000 0 0 0 35000 35000 0 0 2126000 0 2126000 4598000
46000 31043000 3497000 -428000 34158000 4598000 46000 30699000 -3417000
-292000 27036000 0 344000 0 0 344000 0 0 0 -136000 -136000 0 0 6914000 0 6914000
4598000 46000 31043000 3497000 -428000 34158000 4446000 44000 30130000
-6593000 269000 23850000 0 21000 0 0 21000 0 0 0 -318000 -318000 0 0 1696000 0
1696000 4446000 44000 30151000 -4897000 -49000 25249000 4507000 45000
30056000 -8713000 0 21388000 -61000 -1000 1000 0 0 0 0 94000 0 0 94000 0 0 0
-49000 -49000 0 0 3816000 0 3816000 4446000 44000 30151000 -4897000 -49000
25249000 6914000 3816000 85000 64000 2000 -17000 -76000 35000 344000 94000
31000 8000 -18000 498000 1223000 -2534000 -270000 -709000 -793000 471000
-72000 -60000 827000 -3570000 -82000 -60000 680000 71000 -2000 -3000 8653000
2772000 10000 60000 -0 17099000 -0 1825000 -10000 -18984000 0 12500000 5875000
1250000 -5875000 11250000 54000 -3000 2822000 -4965000 1898000 13277000
4720000 8312000 1105000 593000 1083000 475000 386000 0

NOTE 1 - DESCRIPTION OF BUSINESS

Summary

FitLife Brands, Inc. (the “Company”) is a provider of innovative and proprietary nutritional supplements and wellness products for health-conscious consumers marketed under the following brand names: (i) NDS Nutrition, PMD Sports, SirenLabs, Core Active, Nutrology, and Metis Nutrition (together, “NDS Products”); (ii) iSatori, BioGenetic Laboratories, and Energize (together, the “iSatori Products”); (iii) Dr. Tobias, All Natural Advice, and Maritime Naturals (together, the “MRC Products”); and (iv) MusclePharm.

The Company distributes the NDS Products principally through franchised General Nutrition Centers, Inc. (“GNC”) stores located both domestically and internationally and, with the launch of Metis Nutrition, through corporate GNC stores in the U.S. The iSatori Products are sold through retail locations, which include specialty and mass, as well as online directly to the end consumer. The Company distributes the MRC Products primarily online through e-commerce platforms, such as Amazon, directly to the end consumer. MusclePharm’s products are sold to both wholesale customers as well as online through various e-commerce platforms directly to the end consumer.

FitLife Brands is headquartered in Omaha, Nebraska. For more information on the Company, please go to www.fitlifebrands.com. The Company's common stock, par value \$0.01 per share ("*Common Stock*"), trades under the symbol "FTLF" on the Nasdaq Capital Market.

0.01

NOTE 2 - BASIS OF PRESENTATION

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation are included. Operating results for the three- and nine-month periods ended September 30, 2024 are not necessarily indicative of the results that may be expected for the year ending December 31, 2024. Although management of the Company believes the disclosures presented herein are adequate and not misleading, these interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the footnotes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Securities and Exchange Commission (the "*SEC*") on March 29, 2024.

NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The Company prepares its financial statements in accordance with accounting principles generally accepted in the U.S. ("*GAAP*"). Significant accounting policies are as follows:

Principles of Consolidation

The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. Intercompany accounts and transactions have been eliminated in the condensed consolidated financial statements.

Foreign Currency Translation

The functional currency of the Company is the U.S. dollar ("*USD*"). The functional currency of the Company's Canadian subsidiaries is the Canadian dollar ("*CAD*"). The assets and liabilities of the Company's foreign subsidiaries are translated into U.S. dollars using end-of-period exchange rates. Changes in reported amounts of assets and liabilities of foreign subsidiaries that occur as a result of changes in exchange rates between foreign subsidiaries' functional currencies and the U.S. dollar are included in foreign currency translation adjustment. Foreign currency translation adjustment is included as a component of stockholders' equity in the accompanying condensed consolidated balance sheets. Revenue and expense transactions use an average rate prevailing

during the period of the related transaction. Transaction gains and losses that arise from exchange rate fluctuations denominated in a currency other than the functional currency of each subsidiary are included in the results of operations as incurred.

Use of Estimates and Assumptions

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect (i) the reported amounts of assets and liabilities, (ii) the disclosure of contingent assets and liabilities known to exist as of the date the financial statements are published, and (iii) the reported amount of net sales and expense recognized during the periods presented.

Those estimates and assumptions include estimates for reserves of uncollectible accounts receivable, allowance for inventory obsolescence, product returns, depreciable lives of property and equipment, allocation of purchase price from business combinations, analysis of impairment of goodwill, realization of deferred tax assets, accruals for potential liabilities and assumptions made in valuing stock instruments issued for services. Management evaluates these estimates and assumptions on a regular basis. Actual results could differ from those estimates.

Revenue Recognition

The Company's revenue is comprised of sales of nutritional supplements and wellness products to consumers.

The Company accounts for revenue in accordance with FASB *ASC 606, Revenue from Contracts with Customers* ("ASC 606"). The underlying principle of ASC 606 is to recognize revenue to depict the transfer of goods or services to customers at the amount expected to be collected. ASC 606 creates a five-step model that requires entities to exercise judgment when considering the terms of contract(s), which includes (1) identifying the contract(s) or agreement(s) with a customer, (2) identifying our performance obligations in the contract or agreement, (3) determining the transaction price, (4) allocating the transaction price to the separate performance obligations, and (5) recognizing revenue as each performance obligation is satisfied. Under ASC 606, revenue is recognized when performance obligations under the terms of a contract are satisfied, which occurs for the Company upon shipment or delivery of products to our customers based on written sales terms. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring the products to a customer.

All products sold by the Company are distinct individual products and consist of nutritional supplements and wellness products. The products are offered for sale solely as finished goods, and there are no performance obligations required post-shipment for customers to derive the expected value from them.

The Company's products are also sold on e-

commerce platforms including Amazon. For these transactions, the Company evaluated principal versus agent considerations to determine appropriateness of recording distribution and platform fees paid to third-party e-commerce companies as an expense or as a reduction of revenue. The Company records distribution and platform fees to cost of goods sold in the condensed consolidated statements of income and comprehensive income. Distribution and platform fees are not recorded as a reduction of revenue because the Company (1) owns the goods before they are transferred to the customer, (2) can direct Amazon, similar to other third-party logistics providers ("*Logistic Providers*"), to return the Company's inventory to any location specified by the Company, (3) has the responsibility to make customers whole following any returns made by customers directly to Logistic Providers and the Company retains the back-end inventory risk, (4) is subject to credit risk (i.e., credit card chargebacks), (5) establishes prices of its products, (6) can determine who fulfills the goods to the customer (Amazon or the Company) and (7) can limit quantities or stop selling the goods at any time. Based on these considerations, the Company is the principal in this arrangement. Advertising fees paid to Amazon are recorded in advertising and marketing expense in the condensed consolidated statements of income and comprehensive income.

The Company disaggregates revenue into distribution channels, geographical regions, and collections of brands (Legacy FitLife and recently acquired brands). The Company determines that disaggregating revenue into these categories achieves the disclosure objective to depict how the nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factors.

Online revenue during the three months ended September 30, 2024 and 2023 was approximately 68% of net revenue for both periods, compared to 32% for the wholesale channel for the same periods. Online revenue during the nine months ended September 30, 2024 and 2023 was approximately 66% and 62% of net revenue, compared to 34% and 38% for the wholesale channel for the same period.

Sales to customers in the U.S. were approximately 95% and 93% during the three months ended September 30, 2024 and 2023, respectively, with the balance of sales for the same respective periods being to customers primarily in Canada. Sales to customers in the U.S. were approximately 96% and 94% during the nine months ended September 30, 2024 and 2023, respectively, with the balance of sales for the same respective periods being to customers primarily in Canada.

The Company provides limited financial performance metrics for three collections of brands—Legacy FitLife (consists of nine brands), MRC (consists of three brands), and MusclePharm (one brand). These collections of brands do not meet the definition of operating segments and are not managed as such.

Table 1: Financial Performance Metrics by Collection of Brands					
	Legacy FitLife	MRC	MusclePharm	Total	
Three months ended September 30, 2024	\$12.5 million	\$3.2 million	\$1.8 million	\$17.5 million	
Three months ended September 30, 2023	\$11.8 million	\$2.9 million	\$1.5 million	\$16.2 million	
Nine months ended September 30, 2024	\$37.2 million	\$9.1 million	\$4.5 million	\$50.8 million	
Nine months ended September 30, 2023	\$35.5 million	\$8.5 million	\$4.2 million	\$48.2 million	

Three months ended

September 30,					
Nine months ended					
September 30,					
2024					
2023					
Legacy FitLife					
\$	6,302				
\$	6,700				
\$	20,065				
\$	21,933				

[illegible]

month periods ended September 30, 2024 and 2023 represent 24% and 34% of total net revenue, respectively. Gross accounts receivable attributable to GNC represented 28% and 30% of the Company's total accounts receivable balance as of September 30, 2024 and December 31, 2023, respectively.

As of September 30, 2024 and December 31, 2023, there was one vendor that accounted for more than 10% of the Company's consolidated accounts payable. During the nine months ended September 30, 2024 and 2023, there were two vendors that each accounted for over 10% of the Company's inventory-related purchases.

Cash and Cash Equivalents

The Company considers all highly liquid investments with an original maturity from the date of purchase of three months or less to be cash equivalents. The Company has approximately \$56 in short-term interest-earning accounts pledged as collateral for financing arrangements at September 30, 2024, currently limited to business credit cards.

Leases

We lease certain corporate office space and office equipment under lease agreements with monthly payments over a period of 36 to 84 months. We determine if an arrangement is a lease at inception. Leased assets are presented as operating lease right-of-use assets and the related liabilities are presented as lease liabilities in our condensed consolidated balance sheets.

Goodwill

The Company has determined that it has a single reporting unit for purposes of performing its goodwill impairment test. The Company reviews goodwill for impairment on an annual basis or whenever events or changes in circumstances indicate the carrying value may not be recoverable. The Company first assesses qualitative factors to determine whether it is more-likely-than-not that the fair value of the reporting unit is less than the carrying amount as a basis for determining whether it is necessary to perform an impairment test. If the qualitative assessment warrants further analysis, the Company compares the fair value of the reporting unit to its carrying value. The fair value of the reporting unit is determined using the market approach. The Company determines the amount of a potential goodwill impairment by comparing the fair value of the reporting unit with its carrying amount. To the extent the carrying value of a reporting unit exceeds its fair value, a goodwill impairment charge is recognized.

As the Company uses the market approach to determine fair value of the reporting unit, the price of its Common Stock is an important component of the fair value calculation. If the Company's stock price experiences significant price

fluctuations, this will impact the fair value of the reporting unit, which can lead to potential impairment in future periods.

Management determined there were no indicators of impairment at September 30, 2024 or December 31, 2023. The Company will perform its next impairment analysis in December 2024.

Intangible Assets

The Company has certain intangible assets that were recorded at their fair value at the time of acquisition. The finite-lived intangible assets consist of client relationships, formulations, and website. Intangible assets with finite useful lives are amortized using the straight-line method over their estimated useful life. Intangible assets with indefinite lives, which consist of brands and trademarks, are not amortized but are tested for impairment annually or when indicators of impairment exist. Factors that management considers in this assessment include macroeconomic conditions, industry and market considerations, overall financial performance (both current and projected), changes in management and strategy, and changes in the composition and carrying amounts of net assets. If this qualitative assessment indicates that it is more likely than not that the fair value of a reporting unit is less than its carrying value, a quantitative assessment is then performed. The Company noted no indicators of impairment for intangible assets as of September 30, 2024, and December 31, 2023.

Acquisitions and Business Combinations

The Company allocates the fair value of purchase consideration to the tangible assets acquired, liabilities assumed, and separately identified intangible assets acquired based on their estimated fair values. The excess of the fair value of purchase consideration over the fair values of these identifiable assets and liabilities is recorded as goodwill. Such valuations require management to make significant estimates and assumptions, especially with respect to intangible assets. Significant estimates in valuing certain intangible assets include, but are not limited to, future expected cash flows from acquired trademarks and trade names, useful lives, and discount rates. Management's estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. During the measurement period, which is the period needed to gather all information necessary to make the purchase price allocation, not to exceed one year from the acquisition date, we may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period, any subsequent adjustments are recorded to earnings.

Income Taxes

Provision for income taxes consists of current and deferred tax expense. Current tax expense is the expected tax payable on the taxable income for the year using tax rates enacted in the countries where the Company and its subsidiaries operate and generate taxable income. The Company accounts for income taxes using the asset and liability method, whereby deferred tax

assets are recognized for deductible temporary differences and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets may also result from unused losses and other deductions carried forward. An assessment of the probability that a deferred tax asset will be recovered is made prior to any deferred tax asset being recognized. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized, or that future deductibility is uncertain.

The income tax provision for interim periods is determined using an estimate of the annual effective tax rate, adjusted for discrete items, if any, that are taken into account in the relevant period. Each quarter, the estimate of the annual effective tax rate is updated, and if the estimated effective tax rate changes, a cumulative adjustment is made. There is potential for volatility of the effective tax rate due to several factors, including changes in the mix of the pre-tax income and the jurisdictions to which it relates. The effective income tax rate was 25% and 28% for the nine months ended September 30, 2024 and 2023, respectively.

Net Income Per Share

Our computation of earnings per share ("**EPS**") includes basic and diluted EPS. Basic EPS is measured as the income available to common stockholders divided by the weighted average common shares outstanding for the period. Diluted EPS reflects the potential dilution, using the treasury stock method, that could occur if securities or other contracts to issue Common Stock were exercised or converted into Common Stock or resulted in the issuance of Common Stock that then shared in the income of the Company as if they had been converted at the beginning of the periods presented, or issuance date, if later. In computing diluted EPS, the treasury stock method assumes that outstanding options and warrants are exercised, and the proceeds are used to purchase Common Stock at the average market price during the period. Options and warrants may have a dilutive effect under the treasury stock method only when the average market price of the Common Stock during the period exceeds the exercise price of the options and warrants. Potential common shares that have an antidilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS.

	Three months ended September 30,	Three months ended September 30,
	2024	2023
Basic	0.00	0.00
Diluted	0.00	0.00

[illegible]

Net income available to common shareholders			
\$	2,126		
\$	1,696		
\$	6,914		
\$	3,816		
Weighted average common shares - basic			
	4,598		
	4,446		
	4,598		

[illegible]

4,943				4,901																																																																																																																																																																																																																																																																																																																																																																																											

[illegible]

1.40			\$	0.78
------	--	--	----	------

Fair Value Measurements

The Company uses various inputs in determining the fair value of its investments and measures these assets on a recurring basis. Financial assets recorded at fair value in the balance sheets are categorized by the level of objectivity associated with the inputs used to measure their fair value. FASB ASC Topic 820, Fair Value, establishes a three-level valuation hierarchy for the use of fair value measurements based upon the transparency of inputs to the valuation of an asset or liability as of the measurement date:

	●	Level 1 – Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.
	●	Level 2 – Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.
	●	Level 3 – Inputs that are both significant to the fair value measurement and unobservable. These inputs rely on management's own assumptions about the assumptions that market participants would use in pricing the asset or liability. The unobservable inputs are developed based on the best information available in the circumstances and may include the Company's own data.

The carrying amounts of financial assets and liabilities, such as cash and cash equivalents, restricted cash, accounts receivable and accounts payable, approximate their fair values because of the short maturity of these instruments. The carrying value of our notes payable approximate their fair value based on the market interest rates of these notes.

Segment

The Company operates in one segment, providing nutritional supplements and wellness products to health-conscious consumers. The Company's chief operating decision maker is the Chief Executive Officer, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company.

Reclassifications

Certain reclassifications have been made in the Company's financial statements. Advertising and marketing expense for the three and nine months ended September 30, 2023 were previously reported as part of selling, general and administrative expense. Advertising and marketing expense is now segregated and reported separately in the accompanying statement of income and comprehensive income to conform to current period presentation. These reclassifications had no impact on earnings or stockholders' equity.

Recently Adopted Accounting Pronouncements

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosure ("ASC 280"), which is intended to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expense categories that are regularly provided to the chief operating decision maker and included in each reported measure of a segment's profit or loss. The update also requires all annual disclosures about a reportable segment's profit or loss and assets to be provided in interim periods and for entities with a single reportable segment to provide all the disclosures required by ASC 280, including the significant segment expense disclosures. This standard became effective for the Company on January 1, 2024. The adoption of this standard did not have a material impact on its results of operations, financial position or cash flows.

Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company's present or future financial statements.

Principles of Consolidation

The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. Intercompany accounts and transactions have been eliminated in the condensed consolidated financial statements.

Foreign Currency Translation

The functional currency of the Company is the U.S. dollar (“USD”). The functional currency of the Company’s Canadian subsidiaries is the Canadian dollar (“CAD”). The assets and liabilities of the Company’s foreign subsidiaries are translated into U.S. dollars using end-of-period exchange rates. Changes in reported amounts of assets and liabilities of foreign subsidiaries that occur as a result of changes in exchange rates between foreign subsidiaries’ functional currencies and the U.S. dollar are included in foreign currency translation adjustment. Foreign currency translation adjustment is included as a component of stockholders’ equity in the accompanying condensed consolidated balance sheets. Revenue and expense transactions use an average rate prevailing during the period of the related transaction. Transaction gains and losses that arise from exchange rate fluctuations denominated in a currency other than the functional currency of each subsidiary are included in the results of operations as incurred.

Use of Estimates and Assumptions

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect (i) the reported amounts of assets and liabilities, (ii) the disclosure of contingent assets and liabilities known to exist as of the date the financial statements are published, and (iii) the reported amount of net sales and expense recognized during the periods presented.

Those estimates and assumptions include estimates for reserves of uncollectible accounts receivable, allowance for inventory obsolescence, product returns, depreciable lives of property and equipment, allocation of purchase price from business combinations, analysis of impairment of goodwill, realization of deferred tax assets, accruals for potential liabilities and assumptions made in valuing stock instruments issued for services. Management evaluates these estimates and assumptions on a regular basis. Actual results could differ from those estimates.

Revenue Recognition

The Company’s revenue is comprised of sales of nutritional supplements and wellness products to consumers.

The Company accounts for revenue in accordance with FASB ASC 606, Revenue from Contracts with Customers (“ASC 606”). The underlying principle of ASC 606 is to recognize revenue to depict the transfer of goods or services to customers at the amount expected to be collected. ASC 606 creates a five-step model that requires entities to exercise judgment when considering the terms of contract(s), which includes (1) identifying the

contract(s) or agreement(s) with a customer, (2) identifying our performance obligations in the contract or agreement, (3) determining the transaction price, (4) allocating the transaction price to the separate performance obligations, and (5) recognizing revenue as each performance obligation is satisfied. Under ASC 606, revenue is recognized when performance obligations under the terms of a contract are satisfied, which occurs for the Company upon shipment or delivery of products to our customers based on written sales terms. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring the products to a customer.

All products sold by the Company are distinct individual products and consist of nutritional supplements and wellness products. The products are offered for sale solely as finished goods, and there are no performance obligations required post-shipment for customers to derive the expected value from them.

The Company's products are also sold on e-commerce platforms including Amazon. For these transactions, the Company evaluated principal versus agent considerations to determine appropriateness of recording distribution and platform fees paid to third-party e-commerce companies as an expense or as a reduction of revenue. The Company records distribution and platform fees to cost of goods sold in the condensed consolidated statements of income and comprehensive income. Distribution and platform fees are not recorded as a reduction of revenue because the Company (1) owns the goods before they are transferred to the customer, (2) can direct Amazon, similar to other third-party logistics providers ("*Logistic Providers*"), to return the Company's inventory to any location specified by the Company, (3) has the responsibility to make customers whole following any returns made by customers directly to Logistic Providers and the Company retains the back-end inventory risk, (4) is subject to credit risk (i.e., credit card chargebacks), (5) establishes prices of its products, (6) can determine who fulfills the goods to the customer (Amazon or the Company) and (7) can limit quantities or stop selling the goods at any time. Based on these considerations, the Company is the principal in this arrangement. Advertising fees paid to Amazon are recorded in advertising and marketing expense in the condensed consolidated statements of income and comprehensive income.

The Company disaggregates revenue into distribution channels, geographical regions, and collections of brands (Legacy FitLife and recently acquired brands). The Company determines that disaggregating revenue into these categories achieves the disclosure objective to depict how the nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factors.

Online revenue during the three months ended September 30, 2024 and 2023 was approximately 68% of net revenue for both periods, compared to 32% for the wholesale channel for the same periods. Online revenue during the nine months ended September 30, 2024 and 2023 was approximately 66% and 62% of net revenue, compared to 34% and 38% for the wholesale channel for the same period.

Sales to customers in the U.S. were approximately 95% and 93% during the three months ended September 30, 2024 and 2023, respectively, with the balance of sales for the same respective periods being to customers primarily in Canada. Sales

to customers in the U.S. were approximately 96% and 94% during the nine months ended September 30, 2024 and 2023, respectively, with the balance of sales for the same respective periods being to customers primarily in Canada.

The Company provides limited financial performance metrics for three collections of brands—Legacy FitLife (consists of nine brands), MRC (consists of three brands), and MusclePharm (one brand). These collections of brands do not meet the definition of operating segments and are not managed as such.

Three months ended		September 30,	
		2024	
2023		2024	
Legacy FitLife			
\$			

[illegible]

[illegible]

an ingredient or ingredients that are subject to a recall by the U.S. Food and Drug Administration ("*FDA*").

A right of return does not represent a separate performance obligation, but because customers are allowed to return products, the consideration to which the Company expects to be entitled is variable. Upon evaluation of returns, the Company determined that product returns are immaterial, and therefore believes it is probable that such returns will not cause a significant reversal of revenue in the future. We assess our contracts and the reasonableness of our conclusions on a quarterly basis.

	0.68	0.68	0.32	0.32	0.66	0.62	0.34	0.38	0.95	0.93	0.96	0.94
Three months ended												
September 30,												
Nine months ended												
September 30,												
2024												
2023												
2024												
2023												

Legacy FitLife

\$

[illegible]

	7,227
	15,977
	\$
	13,902
	\$
	49,456
	\$
	39,401

Customer and Vendor Concentration

Net sales to GNC during the three-month periods ended September 30, 2024 and 2023 represent 23% and 30% of total net revenue, respectively. Net sales to GNC during the nine-month periods ended September 30, 2024 and 2023 represent 24% and 34% of total net revenue, respectively. Gross accounts receivable attributable to GNC represented 28% and 30% of the Company's total accounts receivable balance as of September 30, 2024 and December 31, 2023, respectively.

As of September 30, 2024 and December 31, 2023,

hidden:c457">one vendor that accounted for more than 10% of the Company's consolidated accounts payable. During the nine months ended September 30, 2024 and 2023, there were two vendors that each accounted for over 10% of the Company's inventory-related purchases.</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>0.23 0.30 0.24 0.34 0.28 0.30 0.10 0.10 0.10 0.10<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Cash and Cash Equivalents</i></p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company considers all highly liquid investments with an original maturity from the date of purchase of three months or less to be cash equivalents. The Company has approximately \$56 in short-term interest-earning accounts pledged as collateral for financing arrangements at September 30, 2024, currently limited to business credit cards.</p>56000<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Leases</i></p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We lease certain corporate office space and office equipment under lease agreements with monthly payments over a period of 36 to 84 months. We determine if an arrangement is a lease at inception. Leased assets are presented as operating lease right-of-use assets and the related liabilities are presented as lease liabilities in our condensed consolidated balance sheets.</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>P36M P84M<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Goodwill</i></p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company has determined that it has a single reporting unit for purposes of performing its goodwill impairment test. The Company reviews goodwill for impairment on an annual basis or whenever events or changes in circumstances indicate the carrying value may not be recoverable. The Company first assesses qualitative factors to determine whether it is more-likely-than-not that the fair value of the reporting unit is less than the carrying amount as a basis for determining whether it is necessary to perform an impairment test. If the qualitative assessment warrants further analysis, the Company compares the fair value of the reporting unit to its carrying value. The fair value of the reporting unit is determined using the market approach. The Company determines the amount of a potential goodwill impairment by comparing the fair value of the reporting unit with its carrying amount. To the extent the carrying value of a reporting unit exceeds its fair value, a goodwill impairment charge is recognized.</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">As the Company uses the market approach to determine fair value of the reporting unit, the price of its Common Stock is an important component of the fair value calculation. If the Company's stock price experiences significant price fluctuations, this will impact the fair value of the reporting unit, which can lead to potential impairment in future periods.</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Management determined there were no indicators of impairment at September 30, 2024 or December 31, 2023. The Company will perform its next impairment analysis in December 2024.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Intangible Assets</i></p><p style="font-family:'Times

The Company has certain intangible assets that were recorded at their fair value at the time of acquisition. The finite-lived intangible assets consist of client relationships, formulations, and website. Intangible assets with finite useful lives are amortized using the straight-line method over their estimated useful life. Intangible assets with indefinite lives, which consist of brands and trademarks, are not amortized but are tested for impairment annually or when indicators of impairment exist. Factors that management considers in this assessment include macroeconomic conditions, industry and market considerations, overall financial performance (both current and projected), changes in management and strategy, and changes in the composition and carrying amounts of net assets. If this qualitative assessment indicates that it is more likely than not that the fair value of a reporting unit is less than its carrying value, a quantitative assessment is then performed. The Company noted no indicators of impairment for intangible assets as of September 30, 2024, and December 31, 2023.

Acquisitions and Business Combinations

The Company allocates the fair value of purchase consideration to the tangible assets acquired, liabilities assumed, and separately identified intangible assets acquired based on their estimated fair values. The excess of the fair value of purchase consideration over the fair values of these identifiable assets and liabilities is recorded as goodwill. Such valuations require management to make significant estimates and assumptions, especially with respect to intangible assets. Significant estimates in valuing certain intangible assets include, but are not limited to, future expected cash flows from acquired trademarks and trade names, useful lives, and discount rates. Management's estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. During the measurement period, which is the period needed to gather all information necessary to make the purchase price allocation, not to exceed one year from the acquisition date, we may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period, any subsequent adjustments are recorded to earnings.

Income Taxes

Provision for income taxes consists of current and deferred tax expense. Current tax expense is the expected tax payable on the taxable income for the year using tax rates enacted in the countries where the Company and its subsidiaries operate and generate taxable income. The Company accounts for income taxes using the asset and liability method, whereby deferred tax assets are recognized for deductible temporary differences and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets may also result from unused losses and other deductions carried forward. An assessment of the probability that a deferred tax asset will be recovered is made prior to any deferred tax asset being recognized. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized, or that future deductibility is uncertain.

The income tax provision for interim periods is determined using an

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

0.43			0.35		\$	1.40		\$	0.78
------	--	--	------	--	----	------	--	----	------

2126000 1696000 6914000 3816000
4598000 4446000 4598000 4458000 367000 445000 345000 443000 4965000 4891000
4943000 4901000 0.46 0.38 1.5 0.86 0.43 0.35 1.4 0.78

Fair Value Measurements

The Company uses various inputs in determining the fair value of its investments and measures these assets on a recurring basis. Financial assets recorded at fair value in the balance sheets are categorized by the level of objectivity associated with the inputs used to measure their fair value. FASB ASC Topic 820, Fair Value, establishes a three-level valuation hierarchy for the use of fair value measurements based upon the transparency of inputs to the valuation of an asset or liability as of the measurement date:

			Level 1 – Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.
			Level 2 – Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by

observable market data by correlation or other means.	
--	--

Level 3 – Inputs that are both significant to the fair value measurement and unobservable. These inputs rely on management’s own assumptions about the assumptions that market participants would use in pricing the asset or liability. The unobservable inputs are developed based on the best information available in the circumstances and may include the Company’s own data.

The carrying amounts of financial assets and liabilities, such as cash and cash equivalents, restricted cash, accounts receivable and accounts payable, approximate their fair values because of the short maturity of these instruments. The carrying value of our notes payable approximate their fair value based on the market interest rates of these notes.

Segment

The Company operates in one segment, providing nutritional supplements and wellness products to health-conscious consumers. The Company’s chief operating decision maker is the Chief Executive Officer, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company.

Reclassifications

Certain reclassifications have been made in the Company’s financial statements. Advertising and marketing expense for the three and nine months ended September 30, 2023 were previously reported as part of selling, general and administrative expense. Advertising and marketing expense is now segregated and reported separately in the accompanying statement of income and comprehensive income to conform to current period presentation. These reclassifications had no impact on earnings or stockholders’ equity.

NOTE 4 – INVENTORIES

The Company’s inventory is carried at the lower of cost or net realizable value using the first-in, first-out (“FIFO”) method. The Company evaluates the need to record adjustments for inventory on a regular basis. Company policy is to evaluate all inventories including components and finished goods for all of its product offerings across all of the Company’s operating subsidiaries.

The Company recognizes an allowance for obsolescence for expiring, excess, and slow-moving inventory. To calculate the allowance, the Company analyzes sales projections for each stock-keeping unit

("<i>SKU</i>") relative to the remaining shelf life of the product. The value of any finished goods inventory projected to expire prior to sale is included in the allowance.

The total allowance for expiring, excess and slow-moving inventory items as of September 30, 2024 and December 31, 2023 amounted to \$86 and \$162, respectively. The Company's inventories as of September 30, 2024 and December 31, 2023 were as follows:

	September 30, 2024	December 31, 2023	(Unaudited)
Finished goods	\$9,403	\$8,292	

Components		1,054	961
Allowance for obsolescence		(86	
Total		\$	10,371
		\$	9,091

family: 'Times New Roman'; font-size: 10pt; font-variant: normal; margin: 0pt; "> </p> 86000 162000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;; Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; Times, serif; font-size: 10pt; margin-left: 0pt; border- bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">September 30, 2024</p> </td> <td style="font-family: &quot;Times New Roman&quot;; Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; Times, serif; font-size: 10pt; margin-left: 0pt; border- bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">December 31, 2023</p> </td> <td style="font-family: &quot;Times New Roman&quot;; Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;; Times, serif; font-size: 10pt;"> </td> <td style="font- family: &quot;Times New Roman&quot;; Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">(Unaudited)</p> </td> <td style="font-family: &quot;Times New Roman&quot;; Times, serif; font-size: 10pt;"> </td> <td style="font- family: &quot;Times New Roman&quot;; Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; Times, serif; font-size: 10pt;"> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;; Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; Times, serif; font-size: 10pt; font- variant: normal; margin: 0pt;">Finished goods</p> </td> <td style="width: 1%; font- family: &quot;Times New Roman&quot;; Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; Times, serif; font-size: 10pt; margin-left: 0pt;">\$ </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; Times, serif; font-size: 10pt; margin-left: 0pt;">9,403</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font- family: &quot;Times New Roman&quot;; Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; Times, serif; font-size: 10pt; margin-left: 0pt;">\$ </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; Times, serif; font-size: 10pt; margin-left: 0pt;">8,292</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Components</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; Times, serif; font-size: 10pt;"> </td> <td

1,054			961
Allowance for obsolescence			
			(86
			(162
Total			
			\$
			10,371
			\$
			9,091

9403000 8292000 1054000 961000 86000 162000 10371000 9091000

NOTE

5-PROPERTY AND EQUIPMENT

The Company had property and equipment as of September 30, 2024 and December 31, 2023 as follows:

September 30, 2024					
December 31, 2023					
(Unaudited)					
Equipment					
\$	965		\$	954	
Accumulated depreciation					
			(874		

1%; font-family: "Times New Roman"; Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td style="width: 1%; font-family: "Times New Roman"; Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman"; Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(817</td> <td style="width: 1%; font-family: "Times New Roman"; Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman"; Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman"; Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman"; Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td> <td style="width: 1%; font-family: "Times New Roman"; Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">\$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman"; Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">91</td> <td style="width: 1%; font-family: "Times New Roman"; Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">\$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman"; Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">137</td> <td style="width: 1%; font-family: "Times New Roman"; Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:34pt;">Depreciation expense for the three months ended September 30, 2024 and 2023 was \$15 and \$11, respectively. Depreciation expense for the nine months ended September 30, 2024 and 2023 was \$57 and \$33, respectively. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman"; Times, serif; text-indent: 0px;"> <tbody> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman"; Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman"; Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman"; Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman"; Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman"; Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">September 30, 2024</p> </td> <td style="font-family: "Times New Roman"; Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman"; Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman"; Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman"; Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">December 31, 2023</p> </td> <td style="font-family: "Times New Roman"; Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman"; Times, serif; font-size: 10pt;">

	(Unaudited)	
Equipment	\$	965
Accumulated depreciation		954
Total	\$	

family: "Times New Roman"; Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">91</td> <td style="width: 1%; font-family: "Times New Roman"; Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">\$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman"; Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">137</td> <td style="width: 1%; font-family: "Times New Roman"; Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> 965000 954000 874000 817000 91000 137000 15000 11000 57000 33000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> NOTE 6- NOTES PAYABLE</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Notes payable consisted of the following: </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman"; Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman"; Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman"; Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman"; Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman"; Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman"; Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">September 30, 2024</p> </td> <td style="font-family: "Times New Roman"; Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman"; Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman"; Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman"; Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">December 31, 2023</p> </td> <td style="font-family: "Times New Roman"; Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman"; Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman"; Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman"; Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman"; Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: "Times New Roman"; Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">(Unaudited)</p> </td> <td style="font-family: "Times New Roman"; Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman"; Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman"; Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman"; Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman"; Times, serif; font-size: 10pt;"></td> <td style="font-family: "Times New Roman"; Times, serif; font-size: 10pt;"></td> <td style="font-family: "Times New Roman"; Times, serif; font-size: 10pt;"></td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman"; Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman"; Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: "Times New Roman"; Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Term Loan A</p> </td> <td style="width: 1%; font-family: "Times New Roman"; Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; Times, serif; font-size: 10pt;"> </td>

	\$
\$6,250	
\$10,625	
Term Loan B	
\$8,000	
\$9,500	
Line of Credit	
Unamortized debt issuance costs	
(86)	
(116)	

Total

\$	14,164		\$	20,009
Current	(4,500)		(4,500)	(4,500)
Long term	\$9,664		\$	\$15,509

Credit Agreements – First Citizens Bank

On February 23, 2023, the Company

entered into an Amended and Restated Credit Agreement (the “*Credit Agreement*”) with First Citizens Bank (the “*Bank*”), amending and restating that certain Credit Agreement, dated September 24, 2019, between the Company and the Bank. Pursuant to the Previous Credit Agreement, the Bank provided the Company with a term loan for the principal amount of \$12,500 (“*Term Loan A*”), and a revolving line of credit of \$3,500 (the “*Line of Credit*”), and collectively with the Term Loans, the “*Loan*”). The Company used the proceeds from the Loan to fund the acquisition of MRC (discussed in further detail in Note 8) and for general working capital purposes.

Second Amended and Restated Credit Agreement

On October 10, 2023, the Company entered into a Second Amended and Restated Credit Agreement (the “*Amended Credit Agreement*”) with the Bank, amending and restating the Credit Agreement between the Company and the Bank. Pursuant to the Amended Credit Agreement, the Bank provided the Company with an additional Term Loan (“*Term Loan B*”, and together with Term Loan A, the “*Term Loans*”) for the principal amount of \$10,000 and extended the Line of Credit of \$3.5 million to December 15, 2024. The Company used the proceeds from Term Loan B to fund the acquisition of the MusclePharm assets (discussed in further detail in Note 9) and for general working capital purposes.

Term Loans – Pursuant to the Amended Credit Agreement, the Term Loans accrue interest at a per annum rate equal to 2.75% above the one-month secured overnight financing rate (“SOFR”) published for such day by the Federal Reserve Bank of New York. The Company shall make quarterly payments of principal plus accrued interest on the Term Loans until the principal balances are fully amortized. Quarterly principal payments for Term Loan A and Term Loan B are \$625 and \$500, respectively. During the first quarter of 2024, the Company made a voluntary prepayment on Term Loan A of \$2,500, and as such, Term Loan A will fully amortize in February 2027. Term Loan B will fully amortize in October 2028.

Line of Credit – Also pursuant to the Amended Credit Agreement, outstanding advances under the Line of Credit (“*Advances*”) will accrue interest at a per annum rate equal to 2.75% above the one-month SOFR, and the Company will pay the interest on the Advances monthly, with all principal and any accrued interest on outstanding Advances being due and payable in full on the Line of Credit maturity date. The Company may prepay amounts borrowed under the Loan, in whole or in part with accrued interest to the date of such prepayment on the amount prepaid, by written notice to Bank at least one business day prior to the proposed prepayment.

The Company may prepay amounts borrowed under the Loan, in whole or in part with accrued interest to the date of such prepayment on the amount prepaid, by written notice to Bank at least one business day prior to the proposed prepayment.

The Amended Credit Agreement contains customary events of default (each an “*Event of Default*”), which upon the occurrence of an Event of Default, among other things, interest will accrue at the

~~transform:lowercase;">Applicable <span style="text-
transform:lowercase;">Rate plus 2% per annum, and the Bank may declare all
obligations, with interest thereon, immediately due and payable. The Amended Credit
Agreement further contains customary representations and warranties of the Company;
customary indemnification provisions whereby the Company will indemnify Bank for
certain losses arising out of inaccuracies in, or breaches of, the representations,
warranties and covenants of the Company, and certain other matters; and customary
affirmative and negative covenants, including covenants to maintain a Fixed Charge
Coverage Ratio (as defined in the Amended Credit Agreement) of not less than 1.25 to
1.00 as tested quarterly on a trailing twelve-month basis, starting with the fiscal
quarter ending December 31, 2023, a Funded Debt to EBITDA Ratio (as defined in the
Amended Credit Agreement) of not more than 2.50 to 1.00 as tested quarterly on a
trailing twelve-month basis, starting with the fiscal quarter ending March 31, 2024,
and to the extent the Term Loans still have a balance as of June 30, 2025 and a Cash
Flow Leverage threshold (as defined in the Amended Credit Agreement) of at least 1.15
is not met, the Company will be required to make a prepayment on the Term Loans
equal to 50% of the Excess Cash Flow (as defined in the Amended Credit Agreement).
The Company was in compliance with all covenants as of September 30, 2024 and
December 31, 2023.~~

~~<p style="font-family:'Times New Roman';font-size:10pt;font-
variant:normal;margin:0pt;"></p><p style="font-family:'Times New Roman';font-
size:10pt;font-variant:normal;margin:0pt;"></p><p style="font-family:Times New
Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-
indent:36pt;">The borrowings outstanding on the Term Loans were \$14,250 and
\$20,125 on September 30, 2024 and December 31, 2023, respectively.</p><p
style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-
align:justify;margin:0pt;text-indent:36pt;"></p><p style="font-family: "Times
New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-align:
justify; text-indent: 36pt;">There was <span
style="-sec-ix-hidden:c627">no outstanding balance on the Line of
Credit as of September 30, 2024 and December 31, 2023.</p><p style="font-
family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>~~

September 30, 2024			
		(Unaudited)	
December 31, 2023			

Term Loan A		6,250		10,625
Term Loan B		8,000		9,500
Line of Credit				
Unamortized debt issuance costs				

[illegible]

\$	15,509
----	--------

--

6250000 10625000 8000000 9500000 86000 116000 14164000 20009000 4500000 4500000 9664000 15509000 12500000000 3500000000 10000000 3500000 0.0275 625000 500000 2500000 0.0275 0.02 1.25 2.5 0.000115 0.50 14250000 20125000

NOTE

7-EQUITY

The Company is authorized to issue 60,000 shares of Common Stock, \$0.01 par value per share, of which 4,598 shares of Common Stock were issued and outstanding as of September 30, 2024 and December 31, 2023.

Common Stock Issued for Services

In February 2021, the Company granted an officer an aggregate of 160 restricted share units ("*RSUs*") with a fair value of \$468, which was amortized to stock-based compensation over its vesting term. The Company did not grant or record any stock-based compensation related to RSUs during the three or nine months ended September 30, 2024. The Company recorded \$0 and \$31 of stock-based compensation related to RSUs during the three and nine months ended September 30, 2023, respectively.

Share Repurchase Program

On March 17, 2023, the Board approved the extension of the Company's previously authorized share repurchase program, initially approved by the Board on August 16, 2019, as amended on September 23, 2019, November 6, 2019 and February 1, 2021 ("*Share Repurchase Program*"). Under the extended and amended Share Repurchase Program, the Board authorized management to repurchase up to \$5,000 of the Company's Common Stock over a period of 24 months, at a purchase price equal to the fair market value of the Company's Common Stock on the date of purchase, with the exact date and amount of such purchases to be determined by management (the "*2023 Share Repurchase Program*").

During the nine months ended September 30, 2024 and 2023, the Company did not repurchase any Common Stock under the 2023 Share Repurchase Program. As of September 30, 2024, the Company may purchase \$5,000 of Common Stock under the 2023 Share Repurchase Program.

Information regarding options outstanding as of September 30, 2024 is as follows:

Number of options Weighted average exercise price					Weighted average remaining life (years)				
Outstanding, December 31, 2023					484 \$ 6.82 4.5				

Issued	10	33.20	5.0
Exercised			
Forfeited			

Outstanding, September 30, 2024				
		494		\$
7.36				3.8

Outstanding															
Exercisable															

| | | | | | | | | | | | | | | | |
| | | | |

Exercise price		per share	
Total number		of options	
Weighted		average	
remaining life		(years)	
Weighted		average	
exercise price		Number of	
vested options		exercise price	
Weighted		average	
exercise price		Number of	

[illegible]

[illegible]

bottom: 3px; margin-left: 0pt;"></td><td style="width: 1%; font-family: "Times New Roman"; Times, serif; font-size: 10pt;"></td><td style="width: 1%; font-family: "Times New Roman"; Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"></td><td style="width: 15%; text-align: right; font-family: "Times New Roman"; Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">407</td><td style="width: 1%; font-family: "Times New Roman"; Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"></td><td style="width: 1%; font-family: "Times New Roman"; Times, serif; font-size: 10pt;"></td><td style="width: 1%; font-family: "Times New Roman"; Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">\$</p></td><td style="width: 15%; text-align: right; font-family: "Times New Roman"; Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4.57</td><td style="width: 1%; font-family: "Times New Roman"; Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"></td></tr></tbody></table><p style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; margin: 0pt;"></p><p style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; margin: 0pt;"></p><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The closing stock price for the Company's stock on September 30, 2024 was \$32.74, resulting in an intrinsic value of outstanding options of \$12,554.</p><p style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; margin: 0pt;"></p><p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">In August 2024, the Company granted stock options to purchase 10 shares of common stock to employees. The stock options are exercisable at \$33.20 per share. The stock options expire in five years and vest (i) one fourth immediately on the date of grant, and (ii) in three equal annual installments thereafter. The total fair value of these options at grant date was approximately \$146, which was determined using a Black-Scholes option pricing model with the following assumptions: stock price of \$33.20 per share, expected term of 5 years, volatility of 45%, dividend rate of 0%, and risk-free interest rate of 3.38%. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of measurement corresponding with the expected term of the share option award. The expected term represents the weighted-average period of time that share option awards granted are expected to be outstanding giving consideration to vesting schedules and historical participant exercise behavior. The expected volatility is based upon historical volatility of the Company's Common Stock. The expected dividend yield is based on the fact that the Company has not paid dividends in the past and does not expect to pay dividends in the future.</p><p style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; margin: 0pt;"></p><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">During the three-month periods ended September 30, 2024 and 2023, the Company recognized stock-based compensation of \$141 and \$21, respectively, related to stock options. During the nine-month periods ended September 30, 2024 and 2023, the Company recognized stock-based compensation of \$344 and \$63, respectively, related to stock options. As of September 30, 2024 there is \$542 of unamortized stock-based compensation related to stock options.</p><p style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; margin: 0pt;"></p>60000000 0.01 4598000 160000 468000 0 31000 5000 P24M 5000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman"; Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman"; Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman"; Times, serif; font-size: 10pt;"></td><td style="font-family: "Times New Roman"; Times, serif; font-size: 10pt;"></td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; Times, serif;

Number		of options	
Weighted		average exercise	
price		remaining life	
(years)		484	
Outstanding, December 31, 2023		6.82	
\$		4.5	
Issued			

[illegible]

<p style='font-family: "Times New Roman"; Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;'>Outstanding, September 30, 2024</p>					494			\$	7.36				3.8	

<table><tr><td colspan="16" style='font-family: "Times New Roman"; Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 49%;'><p style="font-family: "Times New Roman"; Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Outstanding</p></td></tr><tr><td colspan="4" style='font-family: "Times New Roman"; Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;'></td></td><td colspan="4" style='font-family: "Times New Roman"; Times, serif; font-size: 10pt; width: 1%;'></td></td><td colspan="6" style='text-align: center; font-family: "Times New Roman"; Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 19%;'><p style="font-family: "Times New Roman"; Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Exercisable</p></td><td colspan="2" style='font-family: "Times New Roman"; Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;'></td></td></tr><tr><td class="finHeading" colspan="4" style='vertical-align: bottom; font-family: "Times New Roman"; Times, serif; font-size: 10pt;'><td colspan="4" style="font-family: "Times New Roman"; Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 7%;"><p style="font-family: "Times New Roman"; Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Exercise price</p><p style="font-family: "Times New Roman"; Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">per share</p></td><td colspan="2" style='font-family: "Times New Roman"; Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;'></td></td><td colspan="2" style='font-family: "Times New Roman"; Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;'></td></td><td colspan="2" style='font-family: "Times New Roman"; Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;'></td></td><td colspan="2" style='font-family: "Times New Roman"; Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;'></td></td><td colspan="2" style='font-family: "Times New Roman"; Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;'></td></td></tr></table>																<p style="font-family: "Times New Roman"; Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Outstanding</p>																</td>				</td>				<p style="font-family: "Times New Roman"; Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Exercisable</p>						</td>		<td colspan="4" style="font-family: "Times New Roman"; Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 7%;"><p style="font-family: "Times New Roman"; Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Exercise price</p><p style="font-family: "Times New Roman"; Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">per share</p>				</td>		</td>		</td>		</td>		</td>	
<p style="font-family: "Times New Roman"; Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Outstanding</p>																																																													
</td>				</td>				<p style="font-family: "Times New Roman"; Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Exercisable</p>						</td>																																															
<td colspan="4" style="font-family: "Times New Roman"; Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 7%;"><p style="font-family: "Times New Roman"; Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Exercise price</p><p style="font-family: "Times New Roman"; Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">per share</p>				</td>		</td>		</td>		</td>		</td>																																																	

	Total number	of options		Weighted average remaining life (years)		Weighted average exercise price		Number of vested options		\$	>0.70
--	--------------	------------	--	---	--	---------------------------------	--	--------------------------	--	----	-------

[illegible]

[illegible]

margin-left: 0pt;"/>\$

4.57	0.7524349000
------	--------------

P3Y8M12D 2.29 349000 2.29 11.55 33.2 145000 P3Y10M24D 19.57 58000 18.49 494000 P3Y9M18D 7.36 407000 4.57 32.74 12554000 10000 33.2 146000 33.2 P5Y 0.45 0 0.0338 141000 21000 344000 63000 542000

NOTE 8

ACQUISITION OF MIMI **S ROCK CORP**

On February 28, 2023, the Company acquired all the equity interests of Mimi's Rock Corp. (*"MRC"*) for the purchase price of \$17,099. MRC is headquartered in Oakville, Ontario, Canada.

The Company accounted for the acquisition as a business combination under *ASC 805, Business Combinations* (*"ASC 805"*). As a result of the MRC acquisition, the Company recorded intangible assets – brands of \$7,630 and goodwill of \$12,764. The goodwill recognized is primarily attributable to anticipated synergies from future growth. The intangible assets, which consist of brands, is not amortized but will be tested for impairment on an annual basis. Goodwill is also not amortized but will be tested for impairment on an annual basis.

The purchase was intended to augment and diversify the Company's product offerings and lineup. Key factors that contributed to the recorded intangible assets and goodwill were the opportunity to complement existing operations of the Company and the opportunity to generate future synergies within the nutritional supplement and wellness business.

The following presents the Company's unaudited pro forma financial information for the nine months ended September 30, 2023, giving effect to the acquisition of MRC as if it had occurred at January 1, 2023. Included in the pro forma information are adjustments to (1) remove non-recurring transaction-related costs related to the acquisition of MRC, (2) remove the interest costs from MRC's debt prior to the closing of the acquisition, and (3) recognize interest expense based on the projected balance of the Term Loan A for the respective periods presented for this pro forma.

Pro Forma Condensed Combined Financial Information (Unaudited, in thousands)	
The following presents the Company's unaudited pro forma financial information for the nine months ended September 30, 2023, giving effect to the acquisition of MRC as if it had occurred at January 1, 2023. Included in the pro forma information are adjustments to (1) remove non-recurring transaction-related costs related to the acquisition of MRC, (2) remove the interest costs from MRC's debt prior to the closing of the acquisition, and (3) recognize interest expense based on the projected balance of the Term Loan A for the respective periods presented for this pro forma.	

September 30, 2023			
		Revenue	\$
		44,455	
Net income			
		5,419	\$

Diluted net income per share

		\$1.09	
--	--	--------	--

The pro forma adjustments do not reflect adjustments for anticipated operating efficiencies that the Company expects to achieve as a result of this acquisition. The pro forma financial information is for informational purposes only and does not purport to present what the Company's results would actually have been had the transaction actually occurred on the dates presented or to project the combined company's results of operations or financial position for any future period.

MRC revenue for the three months ended September 30, 2024 and 2023 was \$7,210 and \$7,202, respectively. MRC revenue for the nine months ended September 30, 2024 was \$22,164 and was \$17,468 for the period from February 28, 2023 (the acquisition date) to September 30, 2023.

17099000 7630000 12764000			
		Nine months ended	
		September 30, 2023	

		\$44,455
		\$5,419
		\$1.09

44455000 5419000 1090.00 7210000 7202000 22164000 17468000

NOTE 9. ACQUISITION OF MUSCLEPHARM ASSETS

On October 10, 2023, the Company acquired substantially all of the assets and assumed none of the liabilities other than *de minimus* cure costs relating to certain assumed contracts of MusclePharm through an asset purchase transaction under Section 363 of the U.S.

~~Bankruptcy Code. Total consideration for the acquisition, including legal expense, amounted to \$18,788.~~

~~The Company accounted for the transaction as an asset acquisition under Accounting Standards Codification (“ASC”) 805. The assets acquired consisted of indefinite life intellectual property – brands of \$18,593 and inventory of \$195. The intangible asset is not amortized and will be tested for impairment on an annual basis.~~

~~The Company accounted for the transaction as an asset acquisition under ASC 805. The assets acquired consist of indefinite life intellectual property – brands with an estimated value of \$18,593 – and inventory of \$195. The intangible assets, which consist of brands, are not amortized but will be tested for impairment on an annual basis.~~

~~18788000 18593000 195000 18593000 195000~~

~~**NOTE**~~

~~**10**~~

~~**COMMITMENTS AND CONTINGENCIES**~~

~~We currently are not involved in any litigation that we believe could have a material adverse effect on our financial condition or results of operations. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of the Company or any of its subsidiaries, threatened against or affecting the Company, our Common Stock, any of our subsidiaries or of the Company’s or our subsidiaries’ officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect.~~

~~**NOTE 11**~~

~~**SUBSEQUENT EVENTS**~~

~~The Company evaluated subsequent events for their potential impact on the condensed consolidated financial statements and disclosures through the date the condensed consolidated financial statements were issued and determined that no subsequent events occurred that were reasonably expected to impact the condensed consolidated financial statements presented herein.~~

~~**ITEM 5. OTHER INFORMATION**~~

~~In the three months ended September 30, 2024,~~

~~no~~

~~directors or officers adopted or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.~~